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Abstract 
Introduction: Acute pancreatitis is an inflammatory disease with a diverse aetiology and variable 
clinical course. The IL-l gene cluster has been implicated in this disease. 
Aims: The aims ofthe study were to investigate polymorphisms of the genes encoded within the IL-
l gene cluster in patients with acute pancreatitis and normal controls and to determine the 
relationship between the polymorphisms and protein levels. 
Methods: Genotype and allele frequencies were determined in controls (n=217) and patients with 
acute pancreatitis (n=137) using the polymerase chain reaction (PCR) followed by digestion with 
restriction endonucleases where applicable. Protein levels were determined using in vitro 
stimulation of PBMCs followed by Enzyme Linked hrununosorbent Assay (ELlS A). Patients were 
categorised according to severity, organ failure scores and aetiology. 
Results: Allele l of the VNTR86 polymorphism in the IL-l RN gene was significantly increased in 
the severe group of patients compared to controls (81.9% vs 63.0%, x2=9.38, p=0.002, Pc=0.004) 
and in the idiopathic group compared to controls (82.4% vs 63.0%, x2=9.33, p=0.002, Pc=0.004). 
The polymorphisms within the genes and between the genes were strongly linked. Significantly 
more of the Mspl-VLP-VNTR86-Sspl 2-3-2-2 haplotype was observed in the control (15.7% vs 
0.1%, x2 =2528.11, p<O.OOOOOOl, Pc<O.OOOOOOI) and patient (14.0% VS 0.1%, x2 =4368.10, 
p<O.OOOOOOl, Pc<0.0000004) populations than expected. Significantly more of the Pstl-Aval-Aiul-
Taql 2-2-2-1 haplotype was observed in controls (27.7% vs 9.7%, x2 =31.39, p<O.OOOOOOl, 
Pc<0.0000005) and patients (12.5% vs 2.0%, x2=53.69, p<O.OOOOOOl, Pc=0.0000007) than 
expected. Preferential combinations of the genotypes existed within controls and patients. The 
median IL-la and IL-lP protein levels from unstimulated PBMCs were significantly increased in 
patients compared to controls: median values (interquartile range). In the IL-la study, significant 
differences were found at 24 hours: 193.5 (127.5-363.5) pg/ml vs 1.0 (0.0-3.0) pg/ml, p=0.005, 48 
hours: 256.5 (171.5-417.0) pg/ml vs 6.5 (2.0-16.0) pg/ml, p=0.006 and at 72 hours: 210.5 (138-427) 
pg/ml vs 0.5 (0-7) pg/ml, p=0.005. In the IL-l P study, significant differences were found at 24 
hours: 663 (507-782) pg/ml vs 12 (5-53) pg/ml, p=0.004, 48 hours: 620 (570-1080) pg/ml vs 14.5 
(11-36) pg/ml, p=0.004 and at 72 hours: 545.5 (442-771) pg/ml vs 12.5 (2-43) pg/ml, p=0.006. 
Conclusion: Polymorphisms of the IL-l gene cluster are associated with susceptibility to and /or 
severity of the acute pancreatitis. Polymorphisms within the IL-l gene cluster are in linkage 
disequilibrium. Unstimulated PBMCs from patients with acute pancreatitis secrete significantly 
more IL-la and IL-IP protein levels compared to those from controls. The (AC)n, Alu I and 
VNTR86 polymorphisms do not correspond to differences in functional protein levels. 
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CHAPTER 1: THE PANCREAS AND ACUTE PANCREATITIS 
Despite its first description more than lOO years ago (Fitz, 1889), acute pancreatitis 
(AP), an acute inflammatory disease of the pancreas remains a potentially fatal disease. It 
is characterized by diverse aetiologies, poorly understood pathophysiology, variable 
clinical course and managed largely by supportive treatment regimes. 
1.1 The Normal Pancreas 
1.1.1 Anatomy 
The pancreas (Gk. pan-all, kreas-flesh) is a soft, lobulated gland which is located in 
the epigastric and left hypochondriac regions. It is 12-15cm in length and extends 
obliquely across the posterior abdominal wall behind the peritoneum from the curve of the 
duodenum to the hilum of the spleen. For purposes of description, the gland is divided into 
4 parts: the head, neck, body and tail (Moore, 1996). 
The pancreas develops from 2 endodermal buds, a small ventral bud and large 
dorsal bud (Sadler, 1990). These buds arise from the 2nd part of the duodenum in the 41h 
week of gestation and their resulting parenchyma and ducts later fuse to form a single 
gland. The main pancreatic duct (of Wirsung) is formed from the distal part of the dorsal 
pancreatic duct and the entire ventral pancreatic duct. It begins in the tail of the pancreas 
and runs through the substance of the gland near its posterior surface receiving exocrine 
secretions from interlobular ducts all along its length. The main pancreatic duct unites with 
the common bile duct ("the common channel") to form a small chamber, the ampulla of 
Vater that opens into the second part of the duodenum on the major duodenal papilla. A 
layer of Gircular muscle surrounds the ampulla of Vater to form the sphincter of Oddi. This 
sphincter reacts to neuronal and hormonal stimuli at the time of food ingestion and 
regulates the amount of pancreatic juice that enters the duodenum. The accessory duct (of 
Santorini) is formed from the proximal part of the dorsal pancreatic duct and drains the 
upper part of the head. It communicates with the main pancreatic duct to open on the major 
duodenal papilla but also opens separately into the duodenum on the minor duodenal 
papilla, superior to the major duodenal papilla. 
1.1.2 Histology and Physiology 
Septa extend from the fibrous capsule that surrounds the pancreas and subdivide 
the parenchyma into lobules. Each lobule contains both exocrine and endocrine tissue. The 
exocrine portion consists of clusters of acini and secretory ducts and is concerned with the 
production of enzymes used in the digestion of protein, fat and carbohydrate. The 
endocrine portion consists of islets of Langerhans with specialist cells that produce 
hormones such as insulin and glucagon. Acute pancreatitis is a disease that affects the 
exocrine pancreas and therefore only the histology and physiology of this part of the gland 
will be discussed. 
The acini (singular: acinus) are composed of spherical groups of acinar cells that 
secrete digestive proenzymes into a network of ducts that meet to form the main pancreatic 
duct. Acinar cells have a broad base and narrow apical surface covered by short microvilli. 
The basal half of the cell contains basophilic rough endoplasmic reticulum (RER), while 
the apical half close to the lumen contains eosinophilic zymogen granules that store the 
proenzymes synthesised by the cell. Acinar cells also have many mitochondria indicating 
that they are highly active cells. The proenzymes are synthesized by the RER and 
transferred to the Golgi complex that packages them into granules (Figure 1.1) (Stevens 
and Lowe, 1992). 
Each acinus is drained by a small ductule called an intraacinar duct that is formed 
by centroacinar cells that are located at the centre of each acinus. These intraacinar ducts 
empty into intercalated ducts, then intralobular ducts and finally into interlobular ducts, 
which run in the septa between the pancreatic lobules. The interlobular ducts join the main 
pancreatic duct that runs longitudinally from the tail of the pancreas to its head and empty 
into the duodenal lumen at the ampulla of Vater. 
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Figure 1.1 The Acinar Cell 
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Pancreatic acinar cells have a broad base and narrow apical surface covered by short 
microvilli. The basal half of the cell contains basophilic RER, while the apical half close 
to the lumen contains eosinophilic zymogen granules that store the proenzyrnes 
synthesized by the ce11. Acinar cells also have many mitochondria indicating that they are 
highly active cells. The proenzymes are synthesized by the RER and transferred to the 
Golgi complex that packages them into granules. The enzymes then migrate towards the 
apical cell membrane where they are secreted from the cell by exocytosis. 
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The pancreatic juice produced by the exocrine gland consists of 2 main components: 
digestive enzymes released by acinar cells and bicarbonate secreted by the ductal cells. The 
premature activation of the digestive enzymes is important in the pathogenesis of acute 
pancreatitis. 
1.1.2.1 Pa11creatic e11zymes 
Acinar cells secrete many different digestive enzymes including proteases, lipases, 
arnylases, nucleases and trypsin inhibitors. With the exception of amylase and lipase, these 
enzymes are capable of attacking pancreatic cell membranes and are therefore secreted as 
the inactive proenzymes trypsinogen, chymotrypsinogen, proelastase 2, proprotease E, 
procarboxypeptidase A and B, prophospholipase A2 and procolipase. Amylase and lipase 
are not harmful to the pancreas and are therefore secreted in their active forms. 
In order for the proenzymes to be able to cleave their substrates they first require 
activation. This is carried out by trypsin which itself has to be activated from its own 
proenzyme trypsinogen. Activation of trypsinogen to trypsin is usually performed by 
enterokinase, an enzyme located in the brush border of the duodenum, however, trypsin 
also has the ability to activate trypsinogen. Enterokinase activates trypsinogen by the 
cleavage of the trypsinogen activation peptide (TAP). Once in its active form, trypsin can 
activate the other proenzymes during a process known as the "pancreatic enzyme cascade" 
(Rinderknecht, 1988). 
1.1.2.2 E11zyme sy11tlresis a11d secretio11 
As with all eukaryote proteins, digestive enzymes and lysosomal hydrolases are 
synthesized on ribosomes attached to the RER. They then migrate within membrane-
enclosed compartments to the Golgi complex, where lysosomal hydrolases are packaged 
into lysosomes and digestive enzymes into zymogen granules. 
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The zymogen granules migrate towards and fuse with the apical plasma membrane where 
the enzymes are released into the lumen during a process known as exocytosis. This is a 
complex process that is dependent on the hydrolysis of membrane polyphosphoinositides 
by phospholipase C to inositol 1,4,5 trisphosphate and diacylglycerol and subsequent 
activation of protein kinase C (Steer and Meldolesi, 1987). 
1.1.2.3 Control of enzyme secretion 
Pancreatic enzyme secretion IS controlled through hormonal and neuronal 
pathways. The thought, sight, smell and taste of food during the cephalic phase of 
digestion and distension of the stomach during the gastric phase control pancreatic 
secretion via the parasympathetic vagal nerve. During the intestinal phase, fat and amino 
acids present in the duodenum cause the release of cholecystokinin (CCK) from cells in the 
mucosa of the duodenum. This CCK binds to its receptor on the membrane of the acinar 
cell and also interacts with the parasympathetic vagal nerve that releases acetylcholine and 
leads to the discharge of zymogen granules from the acinar cell by exocytosis. Acinar cells 
also have receptors for gastrin, VIP and secretin on their cell membranes, however, these 
are only weak stimulants of pancreatic enzyme secretion (V ander et al, 1990). 
1.1.2.4 Protective mechanisms 
The pancreas is protected from autodigestion by a variety of safety mechanisms 
that occur within the acinar cell, the lumen of the pancreatic duct and duodenum (Lankisch 
and Banks, 1998a). 
In the acinar cell: 
1. Digestive enzymes capable of attacking pancreatic cell membranes are synthesized and 
stored as inactive zymogens 
2. Lysosomal hydrolases and digestive enzymes travel within membrane-bound vesicles 
and mature along different pathways 
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3. Trypsin inhibitor within zymogens (Pancreatic Secretory Trypsin Inhibitor) prevents 
premature activation of trypsinogen from trypsin 
4. Acid pH within the zymogens inactivates any trypsin that might be prematurely 
activated from trypsinogen 
In the pancreatic duct: 
1. Low Ca2+ concentrations in duct lumen discourage trypsinogen activation 
2. Any activated trypsin is inhibited by trypsin inhibitor in alkaline pH of duct lumen 
In the duodenum: 
I. Enterokinase, which activates trypsinogen is located in the duodenum rather than the 
pancreas 
1.2 Pancreatitis 
Pancreatitis IS an inflammatory disease of the pancreas that exists m acute or 
chronic forms. Acute pancreatitis is distinguished from chronic pancreatitis by the absence 
of continuing inflammation, irreversible structural changes and permanent impairment of 
exocrine and endocrine function (Mergener and Baillie, 1998). For the purpose of this 
thesis, only acute pancreatitis will be considered. 
1.2.1 Classification of acute pancreatitis 
The heterogeneity of acute pancreatitis has made it difficult to classify. A number 
of international symposia were held between 1963 and 1988 in an attempt to categorize the 
disease. However, due to a lack of clinical information and morphological description, 
these were of limited use to the clinician attempting to diagnose and manage the condition 
(Banks, 1994). To provide a more comprehensive classification system, a symposium was 
held in Atlanta in 1992 which was based on information obtained by CT scannmg 
(Bradley, 1993). The definitions that were derived from this symposium were: 
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"Acute pancreatitis is an acute inflammatory process of the pancreas with variable 
involvement of other regional tissues or remote organ systems." 
"Severe acute pancreatitis is associated with organ failure and or local complications such 
as necrosis, abscess or pseudocyst." 
"Mild acute pancreatitis is associated with minimal organ dysfunction and an uneventful 
recovery and it lacks the features of severe acute pancreatitis". 
"Acute fluid collections occur early in the course of acute pancreatitis, are located in or 
near the pancreas and always lack a wall of granulation or fibrous tissue." 
" Pseudocyst is a collection of pancreatic juice enclosed by a wall of fibrous or granulation 
tissue, which arises as a consequence of acute pancreatitis, trauma or chronic pancreatitis." 
"Pancreatic abscess is a circumscribed intra-abdominal collection of pus usually in 
proximity top the pancreas, containing little or no pancreatic necrosis, which arises as a 
consequence of acute pancreatitis or pancreatic trauma." 
"Pancreatic necrosis is a diffuse or focal area (s) of non viable pancreatic parenchyma 
which is typically associated with peripancreatic fat necrosis." 
1.3 Epidemiology 
1.3.1 Incidence 
The incidence of acute pancreatitis varies considerably between different countries 
and between different regions within countries. The incidence is low in England and the 
Netherlands with figures of 11.7 and 10.2 per 100,000 population respectively (Giggs et al, 
1988; Tran and Van Schilfgaarde, 1994); intermediate in Scotland and Germany with 
figures of 24.2 and 15.6 per 100,000 population respectively {Thomson et al, 1987; 
Assmus et al, 1996); and high in the United States of America and Finland where reported 
figures are as high as 79.8 and 73.4 per 100,000 population (Go, 1994; Jaakkola and 
Nordback, 1993). Many of these studies were performed over a long period of time and 
show the incidence of acute pancreatitis is increasing. In Britain alone there are as many as 
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10,000 new cases each year (Kingsnorth, 1997). The increase maybe due to improved 
diagnosis and increased awareness rather than due to a true increase in the number of cases 
(Larvin, 1996). An increase in males has been strongly correlated with increased alcohol 
consumption (Tran and Van Schilfgaarde, 1994; Jaakkola and Nordback, 1993). 
1.3.2 Mortality rates 
There is also a wide variation in mortality rates ranging from 6.1% to 19.6% (De 
Beaux et al, 1995; Corfield et al, 1985). In addition, there is disagreement regarding trends 
in mortality rates. Whilst some have suggested the mortality rates have remained constant 
despite the changing incidence of acute pancreatitis (Larvin, 1996), others suggest 
mortality rates are decreasing (De Beaux et al, 1995; Wilson and Imrie, 1990; McKay et a!, 
1999). The latter may be due to a number of factors including increased diagnosis of mild 
cases, a better understanding of the clinical course and improved diagnostic and 
management strategies (Cartmell and Kingsnorth, 2000). 
1.4 Aetiology 
A number of aetiological factors are known to cause acute pancreatitis and these 
can be divided into 4 main groups: gallstones (40%}, alcohol (30%}, idiopathic (20%) and 
'other' causes (I 0%). 'Other' causes include trauma, drugs, infection, metabolic disorders, 
obstruction, ischemia, cystic fibrosis and hereditary pancreatitis. 
1.4.1 Gallstones 
Acute pancreatitis associated with gallstones is the most common form of the 
disease accounting for 40% of all cases (Lankisch et al, 1997), however, the risk of an 
individual with gallstones developing acute pancreatitis is low (3.4%) (Moreau et al, 
1988). The diameter, number, shape and weight of the gallstone are important risk factors. 
(Diehl et al, 1997; Houssin et al, 1983). 
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1.4.1.1 Theories explaini11g the patlroge11etic mechanism of gallstone-i11duced acute 
pa11creatitis 
The association between gallstones and acute pancreatitis was first reported by 
Opie in 1901 (Opie, 1901). He suggested 2 theories for the pathogenesis of acute 
pancreatitis based on his findings at two post-mortems: Theory I: "The impaired flow 
hypothesis": Impaired pancreatic secretion due to an impacted gallstone at the duodenal 
papilla caused acute pancreatitis. Theory 2: "The common channel with bile reflux 
hypothesis": A common channel was created between the pancreatic duct and the common 
bile duct when a gallstone became impacted at the duodenal papilla. This common channel 
allowed bile to reflux from the biliary duct into the pancreatic duct to initiate acute 
pancreatitis. 
"The duodenal reflux hypothesis" was suggested by Seidel (Seidel, 191 0) and later 
by Pfeffer et a! (Pfeffer et a!, 1957). It was based on the principle that gallstones passing 
through the sphincter of Oddi caused sphincter insufficiency allowing duodenal juice 
containing activated enzymes to reflux back through the sphincter into the pancreatic duct 
to initiate acute pancreatitis. This was demonstrated in dogs using a closed duodenal loop 
model of acute pancreatitis created by ligating the duodenum above and below the ampulla 
of Vater. Duodenal juice containing activated enzymes was forced through the sphincter of 
Oddi and was found to induce acute pancreatitis. Although the duodenal reflux hypothesis 
was successfully demonstrated in animal models, passage of gallstones through the 
duodenal papilla in humans has been shown to produce stenosis of the sphincter and not 
sphincter insufficiency (Lankisch and Banks, 1998b ). 
Another theory that was suggested was "the combined bile and pancreatic duct 
obstruction hypothesis". To determine whether bile duct obstruction or bile reflux were 
important factors in gallstone-induced acute pancreatitis, Senninger et a!, ligated the 
common bile duct (bile reflux possible), separate pancreatic and bile duct (bile reflux 
impossible), pancreatic duct (bile reflux possible) and bile duct (controls) of American 
opossums. They found that bile obstruction alone did not cause acute pancreatitis, 
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pancreatic duct obstruction alone caused mild acute pancreatitis while obstruction of both 
pancreatic duct and bile duct caused severe acute pancreatitis. From these results they 
concluded that pancreatic duct obstruction and bile duct obstruction but not bile reflux 
were important in severe acute pancreatitis (Senninger et al, 1986). Lerch et al, also used 
the opossum model to evaluate the severity of acute pancreatitis after ligation of the 
pancreatic duct, pancreatic and bile ducts and common bile duct. In contrast to findings by 
Senninger et al, they found that severe acute pancreatitis developed in all models 
regardless of whether bile reflux occurred. They concluded that neither bile duct 
obstruction or bile reflux caused acute pancreatitis or increased severity of the disease, but 
that acute pancreatitis was caused by pancreatic duct obstruction alone (Lerch et al, 1993). 
It is now widely accepted that gallstone-induced acute pancreatitis is due to a 
transient blockage of the ampulla by migrating gallstones which causes hypertension in the 
pancreatobiliary duct system. This hypothesis is called "the transient obstruction 
hypothesis" and is based largely on findings by Acosta et al, who carried out a study on 78 
patients with gallstone-induced acute pancreatitis admitted to hospital within 48 hours of 
the onset of symptoms. Sixty-three percent of patients were found to have gallstones at the 
ampulla of Vater implying that impaired pancreatic outflow due to obstruction was 
important in gallstone-induced acute pancreatitis. It was suggested that the absence of 
ampullary obstruction in some patients was due to the early migration of the gallstone into 
the duodenum. Furthermore, the decrease in the incidence of ampullary obstruction 
correlated with the presence of gallstones in faeces. Acosta et al, also found that the degree 
of pancreatic damage was directly related to the duration of ampullary obstruction. The 
longer the impaction time, the more severe the disease. They suggested that the gallstones 
in patients with mild acute pancreatitis migrated within 48 hours of the onset of symptoms 
and caused minimal pancreatic damage, however, in patients with severe disease migration 
occurred later resulting in irreversible pancreatic lesions. This study demonstrated that 
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early removal of the gallstones with the restoration of pancreatic outflow was important in 
preventing severe acute pancreatitis (Acosta et al, 1980). 
1.4.2 Alcohol 
Alcohol-induced acute pancreatitis is the second most common form of the disease 
and accounts for 30% of all cases (Lankisch et al, 1997). Since only 5% of alcoholics 
develop alcoholic acute pancreatitis, other factors related to the host must be important in 
susceptibility to the disease (Meier, 1995). The risk of developing the disease increases 
with the duration and amount of alcohol consumed (Mergener and Baillie, 1998; Lankisch 
and Banks, l998c). Although binge drinking in the chronic alcoholic can cause acute 
pancreatitis, episodes of acute pancreatitis in the non-alcoholic binge drinker are rare 
(Meier, 1995; Robles-Diaz and Gorelick, 1997). Young males tend to be most at risk of 
developing alcohol-induced acute pancreatitis due to the social pressures placed upon them 
to consume excessive amounts of alcohol. 
It remains controversial as to whether alcoholic acute and chronic pancreatitis are 
separate disease entities or whether acute pancreatitis reflects underlying chronic 
pancreatitis. Ammann and Muellhaupt have suggested that "true" alcoholic acute 
pancreatitis does exist in a small number of patients, however, in the majority of cases it 
reflects underlying alcoholic chronic pancreatitis (Ammann and Muellhaupt, 1994). 
Diagnosis of acute pancreatitis presumes that the pancreas is structurally and functionally 
normal prior to the attack, however, in most cases the condition of the pancreas is largely 
unknown. Generally, the disease is considered to be alcoholic acute pancreatitis unless 
there is evidence of chronic pancreatitis e.g. calcifications. The mechanism by which 
alcohol initiates acute pancreatitis remains unknown. 
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1.4.2.1 Theories explaining the pathogenetic mecha1rism of a/co/rol-induced acute 
pancreatitis 
"The large duct obstruction hypothesis" postulates that alcohol causes contraction 
of the sphincter of Oddi that obstructs the pancreatic duct in a similar manner to Opie's 
first hypothesis for gallstone-induced acute pancreatitis. A variation of this theory is that 
contraction of the sphincter of Oddi caused by alcohol creates "a common channel" in 
much the same way as Opie's second theory for gallstone-induced acute pancreatitis. An 
alternative hypothesis based on Pfeffer's closed loop model and demonstrated by Goff 
implies that instead of causing contraction of the sphincter of Oddi, alcohol causes it to 
relax allowing duodenal contents with activated enzymes to reflux back into the pancreas 
to initiate acute pancreatitis (Goff, 1993). In addition to its effects on the sphincter of Oddi, 
studies on cats have shown that alcohol increases the pancreatic duct permeability allowing 
large molecules including activated pancreatic enzymes to enter the parenchyma to initiate 
acute pancreatitis (Wedgwood et al, 1986). 
"The small duct obstruction hypothesis" suggests that alcohol causes the 
development of "protein plugs" in the small pancreatic ducts. These plugs cause 
obstruction resulting in increased pancreatic pressure and the extravasation of activated 
pancreatic enzymes into the pancreatic tissue. This has been supported by findings from 
Guy et al, who demonstrated elevated levels of protein plugs in the pancreatic juice of 
patients with alcoholic pancreatitis compared to controls (Guy et al, 1983). These protein 
plugs may form as a result of decreased lithostathine levels (pancreatic stone protein) that 
inhibit protein plug formation (Multigener et al, 1985; Schenker and Montalvo, 1998). 
However, it has been shown that mRNA levels of lithostathine in the rat pancreas are 
actually increased after 4 weeks of ethanol exposure (Apte et al, 1996). 
The third theory is "the toxic-metabolic hypothesis". Alcohol and its metabolites, 
acetaldehyde and fatty acid ethyl esters (F AEEs) may have direct toxic effects on 
pancreatic acinar cells. Xanthine oxidase oxidizes ethanol and acetaldehyde with the 
release of oxygen free radicals (OFRs). Increased OFR levels and reduced antioxidants in 
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animal models of acute pancreatitis results in oxidative stress which causes lipid 
peroxidation and increased acinar cell membrane permeability (Braganza and 
Rinderknecht, 1988; Iimuro et a!, 1996; Nordback et a!, 1991 ). Ethanol administered to rats 
has also been shown to increase the mRNA and protein levels of digestive (trypsinogen, 
chymotrypsinogen and lipase) and lysosomal enzymes (cathepsin B) (Apte et a!, 1998). 
Moreover, the pancreas of a rabbit incubated with a 3% concentration of ethanol over a 2 
hour period was found to have increased concentrations of a amylase, trypsinogen and 
chymotrypsinogen but decreased levels of the protective trypsin inhibitor compared to 
controls (Steer et a!, 1979). F AEEs extracted from the pancreas of intoxicated humans and 
infused into rats at concentrations comparative to those found in human plasma caused 
pancreatic edema, trypsinogen activation and vacuolization of acinar cells (Werner et a!, 
1997a). In addition, FAEEs added directly to rat pancreatic lysosomes were found to 
increase their fragility (Haber et a!, 1993). 
It is likely that alcohol-induced acute pancreatitis is mediated at least in part by 
increased acinar cell membrane permeability, increased pancreatic enzyme synthesis and 
their release from fragile zymogen and lysosomal compartments. Furthermore, ethanol 
may reduce pancreatic blood flow suggesting a role for ischemia-reperfusion injury in 
alcoholic acute pancreatitis (Toyama et a!, 1997). 
1.4.3 Idiopathic 
Idiopathic aetiology accounts for 20% of cases (Lankisch et a!, 1997). It has been 
suggested that the majority of these cases are caused by biliary sludge and microlithiasis 
(Lee et a!, 1992; Ros et a!, 1991 ). 
1.4.4 Other causes 
The remaining 10% of cases of acute pancreatitis are due to rare causes such as 
trauma of the pancreas due to accidental abdominal injuries (Ryan et a!, 1994) or following 
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medical/surgical procedures such as endoscopic retrograde cholangiopancreatography 
(ERCP), endoscopic sphincterotomy (ES) (Gottlieb and Sherman, 1998), biliary tract 
surgery (Vemava et al, 1987) and cardiopulmonary bypass (Ohri et al, 1991). Drugs may 
also be associated with the development of acute pancreatitis. (McArthur, 1996). 
Acute pancreatitis may also be caused by a number of infectious agents such as 
parasites (Toxoplasma, Cryptosporidium, Ascaris), bacteria (Mycoplasma, Legionella, 
Leptospira, Salmonella), fungi (Aspergillus) and viruses (Mumps, Coxsackie, Hepatitis B, 
Cytomegalovirus, Varicella-zoster virus, Herpes simplex virus) (Parenti et al, 1996). 
Patients infected with the human immunodeficiency virus (HIV) are particularly at risk of 
developing the disease (Dassopoulos and Ehrenpreis 1999; Manocha et al, 1999). It has 
been suggested however, that this may be due to opportunistic infections such as 
cytomegalovirus, drugs or neoplasm associated with AIDS rather than the HIV itself 
(Lankisch and Banks, l998c). 
Metabolic disorders such as hyperlipidemia (Fortson et al, 1995) and 
hypercalcemia (Prick et al, 1995), and obstructive disorders such as by pancreatic tumors 
(Lin and Feller, 1990), duodenal diverticula (Griffen et al, 1968) and pancreas divisum 
(Bemard et al, 1990) have also been shown to be causative. Furthermore, since the 
pancreas has a very abundant blood supply it is particularly susceptible to diseases that 
cause ischemia (Sakorafas et al, 2000). 
Recent research in the field of pancreatitis has focussed on the role of cystic 
fibrosis and hereditary pancreatitis as possible causes. Although both have been implicated 
in acute pancreatitis, most studies have been performed in patients with chronic 
pancreatitis. 
1.4.4.1 Cystic fibrosis (CF) 
Cystic fibrosis is the most common inherited disease of the exocrine pancreas and 
is caused by a defective cystic fibrosis transmembrane conductance regulator (CFTR) 
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protein. When the CFTR is defective there is reduced water and ion transport across the 
apical membrane of ductal cells resulting in the production of highly viscous secretions 
that obstruct the ducts of the pancreas. Mutations of the CFTR gene have been associated 
with chronic idiopathic pancreatitis (Cohn et al, 1998; Sharer et al, 1998), however, to date 
there have been no reports of an association between CFTR gene mutations and acute 
pancreatitis. 
1.4.4.2 Hereditary Pancreatitis (HP) 
Hereditary pancreatitis is a rare form of the disease and since its description in 1952 
by Comfort and Steinberg, only 100 kindreds have been reported worldwide. HP is an 
autosomal dominant disorder with 80% penetrance characterized by recurrent attacks of 
acute pancreatitis with onset typically at 5-10 years of age. It is caused by specific 
mutations in the cationic trypsinogen (CAT) gene which has been mapped to chromosome 
7q35 (Whitcomb et al, 1996a). Two important mutations known as Rl17H and N21I have 
been identified in the gene which define 2 types of HP: type I hereditary pancreatitis 
(Rll7H) and type 11 hereditary pancreatitis (N21 I) (Gates et al, 1999). 
Whitcomb et al, identified a G to A mutation in exon 3 of the CAT gene which 
involved the substitution of arginine for histidine at codon 117 (R 117H). The arginine acts 
as a hydrolysis site (cleavage site) whereby trypsin is degraded and inactivated (Whitcomb 
et al, 1996b ). Overactivation of trypsin is prevented by trypsin hydrolysis and the trypsin 
inhibitor, PSTI. The R117H mutation prevents hydrolysis of the trypsin and this leads to 
the second protective mechanism (PSTI) becoming overwhelmed leading to uncontrolled 
trypsin production and subsequent activation of other proenzymes (Whitcomb et al, 
1996b)(Figure 1.2). This intermittent overwhelming of PSTI in the presence of Rll7H 
explains why these individuals experience attacks of acute pancreatitis. 
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Figure 1.2: Mechanism for the development of Hereditary Pancreatitis 
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Normally inactive trypsinogen is converted to active trypsin with the cleavage of TAP by two mechanisms: 1) enterokinase in the duodenum 2) 
autoactivation by trypsin itself. The pancreas has 2 protective mechanisms to prevent trypsin from being overactivated: 1) trypsin hydrolysis 2) trypsin 
inhibitor, PSTI. 
HP is caused by a G to A mutation in the cationic trypsinogen gene that causes the substitution of arginine for histidine at codon 117 (Rll7H). The arginine 
acts as a hydrolysis site (cleavage site) whereby trypsin is degraded and inactivated. When the Rll7H mutation is present the arginine hydrolysis site is 
replaced with histidine and trypsin hydrolysis is prevented. The second protective mechanism, PSTI can only inactivate 20% of trypsin and becomes 
overwhelmed at times leading to uncontrolled trypsin production and subsequent activation of other proenzymes. This intermittent overwhelming of PSTI in 
the presence of Rll7H explains why individuals experience attacks of acute pancreatitis. 
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Gorry et al, have described a N21I substitution in exon 2 in HP patients without the Rll7H 
mutation. The molecular basis for HP in these patients is unknown although the presence 
of isoleucine may inhibit access to the hydrolysis site of trypsin (Gorry et al, 1997). 
Studies have shown that patients with type I hereditary pancreatitis (R 117H mutation) have 
a more severe form of the disease in terms of age of onset and requirement for surgery than 
those with type II hereditary pancreatitis (N21I mutation)(Creighton et al 2000; Gorry et 
al, 1997). 
Other mutations have been identified in the CAT gene. An Al6V substitution in 
exon 2 has been found to affect the first amino acid of the trypsinogen molecule and 
therefore the cleavage site of the signal peptide (Witt et al, 1999). A K23R substitution 
occurs in exon 2 that has been found to alter the structure of PSTI binding site (Ferec et al, 
1999) and a -28deiTCC has been shown to increase transcription of trypsinogen (Ferec et 
al, 1999). 
The recurrent attacks of acute pancreatitis caused by a mutated CAT gene and 
overwhelmed PSTI subsequently lead to chronic pancreatitis. This further substantiates 
reports by Ammann and Muellhaupt, which suggested a progression of acute to chronic 
pancreatitis. 
The pathogenetic mechanism involved in HP suggests a role for excess trypsin 
activation in the pathogenesis of other forms of acute pancreatitis. Furthermore, a study by 
Creighton et a!, demonstrated that 19% of patients referred to a clinic with idiopathic 
chronic pancreatitis showed mutations in the CAT gene suggesting that HP could be an 
undetected cause of idiopathic chronic pancreatitis (Creighton et al, 1999). This may also 
be the case for patients with idiopathic acute pancreatitis. 
The pathophysiology of acute pancreatitis will be discussed in Chapter 3. 
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1.5 Pathology 
Two main forms of acute pancreatitis are recognized pathologically: acute 
edematous pancreatitis (80%) and acute necrotizing pancreatitis (20%)(Banks, 1994). 
Acute edematous pancreatitis, which corresponds clinically to mild acute pancreatitis, is 
characterised by interstitial edema, limited peripancreatic fat necrosis and an absence of 
organ dysfunction. Acute necrotizing pancreatitis, which corresponds clinically to severe 
acute pancreatitis, is characterised by pancreatic parenchyma! necrosis, extensive 
peripancreatic and intrapancreatic fat necrosis, and the development of organ failure/local 
complications. This form of the disease may also be associated with hemorrhage in which 
case it is called acute necrotizing hemorrhagic pancreatitis (Krumberger, 1993). 
1.6 Clinical Presentation 
Patients with acute pancreatitis generally present with a sudden onset of severe 
epigastric pain, nausea and vomiting. In 50% of patients, the pain radiates through to the 
back and is frequently confused with the pain of myocardial infarction (Mergener and 
Baillie, 1998). Clinical signs of acute pancreatitis include fever with temperatures reaching 
38.5°C, dehydration due to episodes of vomiting, confusion due to hypoxia, abdominal 
tenderness and guarding. There may also be signs of hypovolemic shock and jaundice in 
gallstone-induced acute pancreatitis. In less than 5% of severe cases bruising occurs 
around the umbilicus (Cullen's sign) or flanks (Grey Turner's sign) and represents the 
spread of the retroperitoneal inflammatory infiltrate (Sargen and Kingsnorth, 1998). These 
skin associated features of acute pancreatitis have been associated with poor prognosis and 
fatal outcome in 35% of cases (Dickson and Imrie, 1984). 
1.7 Natural History 
The natural history of acute pancreatitis is variable. The majority of patients (80%) 
suffer from mild acute pancreatitis, a self-limiting disease that responds to conservative 
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treatment. Up to 20% of patients with acute pancreatitis, however, proceed to a clinically 
severe form with the systemic inflammatory response syndrome (SIRS) and organ 
complications (Mergener and Baillie, 1998). Prognosis following an attack of acute 
pancreatitis depends largely on whether the necrotic pancreas becomes infected with 
bacteria. 40-70% of patients with severe disease will develop infection and up to 50% will 
die (Lemaire et al, 1997). 
1.8 Complications 
Acute pancreatitis is often associated with local and systemic complications. Most 
early deaths from acute pancreatitis occur within the first week and are due to systemic 
complications, in particular respiratory complications (Neoptolemos et al, 1998). Deaths 
that occur after the first week are largely due to septic complications. 
1.8.1 Local complications 
Local complications that affect the pancreas or peripancreatic tissue include: acute 
fluid collections, pseudocyst, pancreatic necrosis and pancreatic abscess (as previously 
defined in Section 1.2.1 ). 
1.8.2 Systemic complications 
Systemic complications are those which involve failure of organ systems distant 
from the pancreas. The most common systemic complications are respiratory, renal, 
cardiovascular, haematologic and metabolic complications (Gross et al, 1993). Failure of 
more than 1 organ system results in a potentially fatal condition known as multiple organ 
dysfunction syndrome (MODS). 
MODS is defined as "a syndrome of progressive but potentially reversible organ failure, 
involving two or more systems remote from the original insult" (Neoptolemos et al, 1998). 
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CHAPTER 2: IMMUNOLOGY AND THE ACUTE INFLAMMATORY PROCESS 
Acute pancreatitis is an example of an acute inflammatory response. This response 
forms part of the non-specific natural immune system. 
2.1 Components of the acute inflammatory response 
The acute inflammatory response is a complex biological process that involves the 
interaction of many different components including plasma mediator systems (coagulation, 
fibrinolytic, kinin and complement), specific cells (neutrophils, monocytes/macrophages, 
endothelial cells) and cell-derived mediators (PAF, arachidonic acid metabolites, oxygen 
free radicals, nitric oxide, cytokines). The role of each of these components in acute 
pancreatitis is discussed in Chapter 3. 
2.1.1 Plasma mediator systems 
The coagulation, fibrinolytic, kinin and complement systems are a series of plasma 
enzyme cascades that eo-activate and interact with each other during inflammation. 
Activation of Hageman factor (Factor XII) by foreign agents such as bacteria is central to 
the activation of these plasma mediator systems. Activated Hageman factor results in the 
activation of thrombin and conversion of fibrinogen to fibrin and the conversion of 
plasminogen to plasmin. Plasmin degrades fibrin and these products are chemotactic for 
neutrophils and cause activation of the complement system. In addition, activated 
Hageman factor induces the conversion of kininogen to bradykinin by kallikrein in the 
kinin system. Kallikrein amplifies Hageman factor production and therefore acts as a 
positive feedback loop. Bradykinin and other kinins are vasoactive peptides that cause 
increased vascular permeability, vasodilatation and the release of arachidonic acid 
metabolites. The complement system is a group of plasma proteins that are involved in the 
control of inflammation, the activation of phagocytes and the lytic attack on cell 
membranes. The products of complement component C3 cleavage have important roles in 
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inflammation. C3a and C5a cause the degranulation of mast cells with the release of 
histamine. C5a is chemotactic for phagocytes and causes the release of prostaglandins and 
leukotrienes. C3b is an opsonin which binds to the antigen surface and facilitates 
phagocytosis while C5b-C9 are important in cell lysis by the formation of membrane 
attack complexes (MAC) that form pores in target cell membranes and cause cell death 
(Bumett, 1997). 
2.1.2 Cell mediators 
The main cells that are involved m inflammation are neutrophils, 
monocytes/macrophages and endothelial cells. 
2.1.2.1 Neutropllils 
Neutrophils are large cells (diameter: 12-14~-Lm) with a multi-lobed nucleus whose 
neutral cytoplasmic granules are poorly stained with haematoxylin and eosin 
(neutrophilic). They are derived from the myeloid cell lineage and account for 40-75% of 
leucocytes. Their function is to carry out phagocytosis (Section 2.2.5). 
2.1.2.2 Mmwcytes/macroplrages 
Monocytes are large cells (diameter: 20~-Lm) with a kidney bean shaped nucleus that 
circulate briefly in the bloodstream before migrating to the tissues to differentiate into 
macrophages. They are derived from the myeloid cell lineage and account for 1-5% of 
leucocytes. Their function is to perform phagocytosis and to act as antigen presenting cells. 
2.1.2.3 Endotlrelial cells 
Endothelial cells are elongated cells whose function during the acute inflammatory 
response is to allow the migration of leucocytes from the blood to the site of tissue injury. 
This process is mediated by adhesion molecules that are present on the surface of both 
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leucocytes and endothelial cells. There are 3 types of adhesion molecules that are 
sequentially activated during a process known as "the adhesion cascade" (Adams and 
Nash, 1996). First, selectins such as E (endothelium) selectin, P (platelet) selectin and L 
(leucocyte) selectin; second, integrins such as CD 18 and CD 11 and third, intercellular 
adhesion molecules such as ICAM-1 and VCAM-1. The expression of adhesion molecules 
is upregulated on endothelial cells in response to inflammatory mediators such as 
cytokines (IL-l, IL-6, IL-8, TNFa) during a process known as "endothelial cell activation" 
(Hunt and Jurd, 1998). Because of their central role in mediating leucocyte migration into 
damaged tissues, adhesion molecule interactions represent a therapeutic target for 
inflammatory diseases (Serafini and Rosemurgy, 2000). The role of adhesion molecules in 
inflammation is explained in more detail in Section 2.2.3. 
2.1.3 Cell-derived mediators 
1.1.3.1 Platelet activating factor (PAF) 
P AF (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) IS a biologically active 
phospholipid that is released from cell membranes by the action of phospholipase A2 
(lmaizumi et al, 1995). It is produced by a variety of cells including endothelial cells, 
monocytes, macrophages and neutrophils and may be synthesised by 2 pathways: the de 
novo pathway and the remodeling pathway. The de novo pathway maintains normal 
physiological intracellular PAF levels in organs such as the brain and kidney, while the 
remodeling pathway occurs in neutrophils, monocytes and endothelial cells that are 
stimulated during pathological conditions by other inflammatory mediators such as 
cytokines or OFRs (Johnson, 1999). P AF has many biological effects that are mediated 
through its binding to its specific PAF receptor on target cells. The receptor is G protein-
coupled and subsequent binding of PAF leads to elevated intracellular calcium levels 
followed by production of inflammatory mediators such as IL-l and TNFa and to changes 
in vascular permeability. The main pathological effect of P AF during inflammation is to 
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cause the migration of activated leucocytes from the blood vessels into the interstitium of 
organs and the release of substances such as proteolytic enzymes, elastase, cathepsin B and 
superoxide ions that cause tissue damage (Kingsnorth, 1996). Blockade of the P AF 
receptor using PAF antagonists such as Lexipafant™ has been shown to have beneficial 
effects in acute pancreatitis (Kingsnorth et a!, 1995). 
2.1.3.2 Arachido11ic acid nretabolites 
Arachidonic acid is released as a side product of PAF production by the action of 
phospholipase A2 during the remodeling pathway (Johnson, 1999). Arachidonic acid is 
oxidized further by 5-lipoxygenase to produce leukotrienes e.g. LTB4, whilst oxidation by 
cyclooxygenase produces prostaglandins e.g. PGh and thromboxanes e.g.TXA2 (Figure 
2.1 ). These metabolites have different effects in inflammation. Leukotrienes cause 
increased vascular permeability, whilst prostaglandins cause vasodilatation and pain, and 
thromboxanes cause vasoconstriction and platelet aggregation. L TB4 is an important 
leukotriene since it attracts leucocytes particularly neutrophils to sites of inflammation 
(Bumett, 1997). 
2.1.3.3 Oxyge11Jree radicals (OFRs) 
OFRs (e.g 0 2-•, oH•, o•) are a group of highly reactive oxygen species that are 
produced as a side product of normal oxidative metabolism and by phagocytes during the 
respiratory burst of phagocytosis. OFRs have an unpaired electron and cause damage to 
other molecules when they transfer the unpaired electron to them. Cells have antioxidant 
mechanisms to protect themselves against the harmful effects of the OFRs and these 
include enzymes such as superoxide dismutase (SOD), catalase, glutathione peroxidase 
and endogenous free radical scavengers such as vitamins E, C and p carotene (Sweiry and 
Mann, 1996). 
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Figure 2.1: Production ofPAF and arachidonic acid from cell membranes 
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During the remodeling pathway Phospholipase A2 (PLA2) acts on cell membranes with the 
release of PAF. Arachidonic acid is formed as a side product. Further oxidation by 5 
lipoxygenase produces leukotrienes whereas further oxidation by cyclooxygenase produces 
prostaglandins and thromboxanes. 
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Excess production of OFRs or failure of the protective antioxidant mechanisms results in 
oxidative stress. The OFRs attack lipids in cell membranes (lipid peroxidation), causing 
increased membrane permeability and subsequent cell death. In addition to their direct 
toxic effect on cells, OFRs also cause the production of chemotactic factors and the 
production ofP AF and arachidonic acid metabolites. 
2.1.3.4 Nitric Oxide (NO) 
Nitric oxide is produced by endothelial cells and macrophages. Its function is to 
regulate blood vessel tone and microvascular permeability. NO is synthesized from the 
amino acid L-arginine by the family of enzymes known as nitric oxide synthase (NOS). 
There are 2 main types of NOS known as constitutive cNOS (calcium dependent) and 
inducible iN OS (non-calcium dependent). Synthesis of NO by endothelial cells cNOS has 
a protective and anti-inflammatory function, whilst production of NO by iNOS can lead to 
the sustained production of high concentrations of NO leading to vasodilatation, tissue 
edema, and stimulation of immune cells to produce cytokines (Anggard 1994). 
2.1.3.5 Cytoki11es 
Cytokines are a diverse group of low molecular weight signalling proteins that are 
produced by a wide variety of stimulated cells. They control the amplitude and duration of 
immune and inflammatory responses by affecting the activity, proliferation and 
differentiation of immune cells and therefore represent potential therapeutic targets (Cohen 
and Cohen, 1996). They act at low concentrations (picomolar concentrations) in an 
autocrine, paracrine or endocrine manner by binding to specific cell surface receptors on 
target cells to cause altered gene expression. Cytokines also exhibit pleiotropy (a cytokine 
may have multiple effects on a target cell) and redundancy (different cytokines can induce 
the same effect in a particular target cell). Furthermore, they do not act alone but interact in 
a "cytokine network". A particular cytokine may increase/decrease the production of 
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another cytokine (cytokine cascade), block (antagonism) or amplify (synergism) its effect 
or increase/decrease the expression of its cytokine cell surface receptors (receptor 
transmodulation)(Vilcek, 1998). 
There are many different types of cytokine and the number continues to rise. For 
the purpose of this study, cytokines will be classified into interleukins, TNFa, interferons, 
colony stimulating factors and TGF~. The cell origin and immunological function of 
selective cytokines are shown in Table 2.1. 
2.1.3.5.1 Chemokines 
Chemokines are a group of chemotactic cytokines that are involved in the 
activation and migration of inflammatory cells from the blood into damaged tissues. They 
are structurally related proteins each containing 4 cysteine residues in the mature protein 
(with the exception of lymphotactin) and are subdivided into 4 families (a, ~. 6 and y 
chemokines) on the basis of the relative position of the cysteine residues (Luster, 1998). a 
chemokines (CXC) contain a single amino acid between the first two cysteine residues. 
These are further subdivided into ELR and non-ELR a chemokines according to the 
presence or absence of a glutamic acid-leucine-arginine (ELR) sequence immediately 
preceding the first cysteine residue. a chemokines attract neutrophils and lymphocytes and 
examples include IL-8, GROa, GRO~. GROy and MIG. ~ chemokines (CC) contain 
adjacent cysteine residues. They are also subdivided into 2 families: the monocyte 
chemoattractant protein-eotaxin family and "other ~ chemokines". The monocyte 
chemoattractant protein-eotaxin family includes the MCPl-5 and eotaxin and examples of 
"other ~ chemokines" include MIP-la, M1P-l~ and RANTES. ~ chemokines attract 
lymphocytes, monocytes, eosinophils and basophils. 6 chemokines (CXXXC) contain 3 
amino acids between the first two cysteines and examples include neurotactin and 
fractalkine. The only y chemokine (C) identified to date is lymphotactin (IL-16) which 
only contains 2 cysteines in the mature protein. 
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Table 2.1: Selected cytokines, cell origin and immunological functions 
Cytokine Immune cells Other cells Immunological function 
IL-la/!3 Monocytes/macrophages Endothelial, epithelial and neuronal Activation ofT and B cells, macrophages and endothelium 
cells, fibroblasts Stimulation of acute phase response 
IL-2 T cells - Proliferation and/or activation ofT, B and NK cells 
IL-3 T cells, mast cells, thymic Keratinocytes, neuronal cells Proliferation of pluripotent stem cells 
epithelium Production of various blood cell types 
IL-4 T and B cells, macrophages, mast - Activation of B cells. 
cells and basophils, bone marrow Differentiation ofTh2 cells and suppression ofThl cells 
stroma 
IL-5 T cells, mast cells - Development, activation and chemoattraction of eosinophils 
IL-6 T cells, monocytes or macrophages Fibroblasts, hepatocytes, Activation of haematopoietic stem cells. 
endothelial and neuronal cells Differentiation ofB and T cells. 
Production of acute phase response 
IL-7 Bone marrow stroma - Growth of B cell precursors. 
Proliferation and cytotoxic activity ofT cells 
IL-8* T cells, monocytes, neutrophils Endothelial and epithelial cells, Chemoattraction of neutrophils, T cells, basophils 
fibroblasts Activation of neutrophils 
IL-9 T cells - Development of erythroid precursors 
IL- Interleukin *also classed as a chemok:ine 
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Table 2.1 continued 
Cytokine Immune cells Other cells Immunological function 
IL-10 T and B cells, macrophages Keratinocytes Suppression of macrophage functions and Th 1 cells 
Activation ofB cells 
IL-11 Bone marrow stroma Trophoblasts Stimulation ofhaemopoietic precursors 
Production of actute phase proteins 
IL-12 B cells, macrophages - Differentiation ofThl cells. 
Activation ofNK cells and T cells 
IL-13 T cells - Activation ofB cells. 
Inhibition of monocytes or macrophages 
IL-14 T cells - Proliferation of activated B cells but inhibition of 
immunoglobulin secretion 
IL-15 T cells - Proliferation ofT cells 
IL-16* T cells - Chemotaxis 
Increased expression of class II :MHC cytokine synthesis, 
suppress antigen induced proliferation 
IL-17 T cells - Activation of macrophages and neutrophils 
IL-18 Macrophages Keratinocytes, adrenal cortical Induces IFNy production in T cells and NK cells 
cells, osteoblasts 
IL-Interleukin *also classed as a chemokine 
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Table 2.1 continued 
Cytokine Immune ceUs Other ceUs Immunological function 
TNFa Macrophages, lymphocytes, Astrocytes, endothelium, smooth Activation of macrophages, granulocytes, cytotoxic cells 
neutrophils muscle and endothelium. 
Enhanced HLA class I expression 
Stimulation of acute phase response 
Antitumour effects 
IFNa,p T and B cells, monocyte or Fibroblasts Antiviral activity 
macrophages Stimulation of macro phages and NK cells 
Enhanced HLA class I expression 
IFNy T and NK cells - Antiviral activity 
Stimulation of macrophages and endothelium 
Enhanced HLA class I and class II expression 
Suppression of Th2 cells 
G-C SF T cells, macrophages, neutrophils Fibroblasts, endothelium Development and activation ofneutrophils 
M-CSF T cells, macrophages, neutrophils Fibroblasts, endothelium Development and activation of monocytes/macrophages 
GM-CSF T cells,macrophages, mast cells, Fibroblasts, endothelium Differentiation of pluripotent stem cells 
neutrophils, eosinophils Development of neutrophils, eosinophils and macrophages 
TGFP T cells, monocytes Chondrocytes, osteoblasts, Inhibition ofT and B cell proliferation and NK cell activity 
osteoclasts, platelets, fibroblasts 
TNF Tumour necrosis factor; IFN Interferon; CSF Colony stimulating factor; TGF Transforming growth factor 
(Adapted from Reeves and Todd, 1996) 
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The action of chemokines is mediated through their binding to specific G-protein coupled cell 
surface receptors on target cells. Four families of human chemokine receptor have been 
identified: CXC (CXCR1-CXCR4), CC (CCR1-CCR8), CXXXC (CX3CRI) and C 
(XCR 1 )(Rossi and Zlotnik, 2000). 
Chemokine production is stimulated by a variety of factors including the pro-
inflammatory cytokines IL-l and TNFa. During inflammation they provide signals to convert 
low affinity selectin mediated interactions into higher affinity integrin-mediated interactions 
that leads to extravasation of leucocytes. Furthermore, once inside the tissue leucocytes 
migrate along a chemotactic gradient created by chemokines to the exact site of injury by a 
process known as chemotaxis (Luster, 1998). Because of their central role in pathological 
processes such as inflammation, chemokines and their receptors represent a target for 
therapeutic intervention. A recent example of this has been demonstrated in the field of AIDS 
research. NSC 651016, a ditamycin analog has been found to inhibit HIV-1 replication by 
downregulating CCR5 and CXCR4 chemokine receptor expression and preventing HIV cell 
entry (Howard et al, 1998). Cytokines that are particularly important in the pathophysiology of 
acute pancreatitis include: IL-l, IL-lra, IL-2, IL-6, IL-8, IL-10, IL-12 and TNFa and their 
involvement in the disease is reviewed in Chapters 3 and 4. 
Having described the different components of the immune system that are involved in 
the acute inflammatory response, the sequence of events that occur during the process will 
now be explained. 
2.2 Events in the acute inflammatory response 
The function of the acute inflammatory response is to contain and control infection or 
injury, to eliminate pathogens and to initiate healing and tissue repair. Acute inflan1mation is 
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characterised by 5 main events: vasodilatation, increased vascular permeability, leucocyte 
migration, chemotaxis and phagocytosis. 
2.2.1 Vasodilatation 
This is caused by a variety of inflammatory mediators including histamine, serotonin, 
prostaglandins e.g. PGE2, NO and bradykinin and leads to increased blood pressure and blood 
flow to the area. 
2.2.2 Increased vascular permeability 
Histamine, serotonin, leukotrienes e.g. L TD4, NO, P AF, cytokines e.g. IL-l, 
bradykinin and complement C3a and C5a (via histamine) are responsible for the increased 
permeability of blood vessel walls that occurs during inflammation. This allows inflammatory 
exudate rich in neutrophils and plasma proteins (antibodies, fibrinogen and other components 
of the plasma mediator systems) to enter the tissue. The exudate is responsible for the swelling 
and in part, the pain and has several important functions in the inflammatory process. 
2.2.3 Leucocyte migration 
Leucocyte migration involves the adherence of leucocytes to the endothelium 
(margination/pavementing) which then "crawl" between the endothelial cells into the tissue. 
This process has 4 stages collectively known as "the adhesion cascade" and is mediated by 
adhesion molecules present on the surface of the leucocytes and endothelial cells (Adams and 
Nash, 1996)(Figure 2.2). The first stage of the adhesion cascade is known as "rolling". This 
involves the leucocytes rolling along the blood vessel wall which become slowly tethered by 
low affinity selectins. 
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Figure 2.2: Leucocyte migration, chemotaxis and phagocytosis 
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Leucocyte migration has 4 stages collectively known as "the adhesion cascade". "RolLing" involves the leucocytes rolling along the blood vessel 
wall which become slowly tethered by low affinity selectins. "Triggering" involves the upregulation of integrins on the surface of leucocytes 
following their activation by P AF, cytokines and chemoattractants. "Strong adhesion" is where integrins on the surface of leucocytes bind strongly 
to intercellular adhesion molecules on the surface of the endothelial cells causing the leucocytes to be fixed to the endothelium. "Extravasation" 
involves the migration of the leucocytes through the intercellular spaces between the endothelial cells into the tissue. Once inside the tissue, the 
leucocytes migrate towards the exact site of injury by following an increasing concentration gradient of chemotactic factor (chemotaxis). When the 
leucocytes reach the exact site of injury, they engulf microorganisms, damaged cells or tissue debris during phagocytosis. This process is enhanced 
if the particle is opsonised. The particle is destroyed by lysosomal enzymes and/or OFRs formed during the respiratory burst. 
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"Triggering" is the second stage and involves the upregulation of integrins on the surface of 
leucocytes following their activation by PAF, cytokines e.g. IL-l and chemoattractants e.g. IL-
8, LTB4, C5a. The third stage is called "strong adhesion" whereby integrins on the surface of 
leucocytes bind strongly to intercellular adhesion molecules on the surface of the endothelial 
cells causing the leucocytes to be fixed to the endothelium. "Extravasation" (diapedesis/ 
transendothelial migration) is the final stage of the adhesion cascade and involves the 
migration of the leucocytes through the intercellular spaces between the endothelial cells into 
the tissue. 
2.2.4 Chemotaxis 
Once inside the tissue, the leucocytes migrate towards the exact site of injury by 
following an increasing concentration gradient of chemotactic factor e.g L TB4, CS a, P AF and 
IL-8 during a process called chemotaxis. 
2.2.5 Phagocytosis 
When the leucocytes for example, neutrophils reach the exact site of injury, they 
engulf microorganisms, damaged cells or tissue debris during a process known as 
phagocytosis. This process is enhanced if the particle e.g. microorganism is coated with either 
antibody (IgG) or complement C3b during a process called opsonisation. The opsonised 
microorganism becomes attached to the neutrophil membrane receptors for the opsonin and 
engulfment occurs. The opsonised particle is internalized into the cell within a membrane 
bound vesicle called a phagosome. The phagosome fuses with lysosomes to fom1 a 
phagolysosome. Fusion of the lysosomes with the phagosome allows the discharge of 
lysosomal enzymes into the phagolysosome, which degrade the dead microorganism. 
Activation of the phagocyte also triggers the respiratory (oxidative) burst in which the 
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membrane-bound NADPH-oxidase produces oxygen intermediates such as superoxide 
radicals, hydrogen peroxide, hypochlorous acid and cholamines that are toxic to 
. . 
m1croorgamsms. 
2.3 Polymornhisms and the acute inflammatory response 
It is well known that different allelic forms or polymorphisms are known to exist in the 
genes coding for proteins. These are normal variations within the human genome, which occur 
more frequently in a given population than abnormal mutations. Polymorphisms within the 
exons of a gene can affect the structure of expressed protein, whilst variation within the 
introns and promoter region can modify the expression of the gene. These variations may 
predispose an individual to an inflammatory disease or a more severe form of the disease. 
Even if a polymorphism does not have a functional effect, it maybe in linkage disequilibrium 
with a functional polymorphism and may still act as a marker for disease susceptibility or 
severity. 
The IL-l gene cluster has a central role in a number of inflammatory diseases as 
discussed in Chapter 4. Polymorphisms in members of this gene complex may affect the 
amplitude and duration of an inflammatory response. Since acute pancreatitis is an 
inflammatory disease, they may also be involved in this disease. 
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CHAPTER 3: PATHOPHYSIOLOGY OF ACUTE PANCREATITIS 
Information regarding the pathophysiology of acute pancreatitis is limited since 
clinical and post-mortem studies of the early stages of the disease are almost impossible to 
obtain. The current understanding is therefore based on experimental animal models, the 
relevance of which is questionable. 
3.1 Experimental models of acute pancreatitis 
There are a variety of in vivo and in vitro experimental models used to study acute 
pancreatitis, however, none of these models exactly mimics the human disease and they all 
have limitations (Banerjee et al, 1994). The 5 most commonly used in vivo models are 
shown in Table 3.1. 
3.2 Pathophysiology of acute pancreatitis 
Following initiation of the disease by for example gallstones or alcohol, the 
pathophysiological process is thought to occur in 3 phases: a local inflammatory response 
of the pancreas, a systemic inflammatory response that can result in organ failure or 
multiple organ failure and sepsis with the translocation of bacteria from the gut 
(Kingsnorth, 1997). 
3.2.1 The local inflammatory response 
3.2.1.1 Normal pa11creas 
Normally, digestive enzymes and lysosomal hydrolases are synthesized on 
ribosornes attached to the RER and then migrate to the Golgi complex, where lysosomal 
hydrolases for example, cathepsin B are packaged into lysosornes and separated from 
digestive enzymes which are packaged as zymogen granules. During exocytosis, the 
zymogen granules migrate towards and fuse with the apical membrane where the enzymes 
are released into the duct lumen and pass to the duodenum to be activated by enterokinase 
(Figure 3.1). 
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Table 3.1: Experimental in vivo models of AP 
Model Agent Administration 
Secretagogue Cerulein* Intraperitoneal, Intravenous, Subcutaneous 
Diet CDEDiet 
Duct injection Bile/Taurocholate 
Duct ligation -
Microvascular Microspheres 
* Cerulein is a cholecystokinin (CCK) analogue 
CDE Choline-deficient ethionine-supplemented 
Oral 
Pancreatic duct 
-
Pancreatic artery 
Animal Type of pancreatitis 
Rat, Dog Edematous 
Mouse Necrotizing 
Mouse (Female) Necrotizing !Hemorrhagic 
Rat, Dog Edematous/Necrotizing 
Rat, Opossum, Dog Necrotizing!Hemorrhagic 
Rat Edematous/Necrotizing!Hemorrhagic 
Edematous pancreatitis corresponds clinically to mild acute pancreatitis while necrotizing pancreatitis corresponds clinically to severe acute pancreatitis 
(Adapted from Banerjee et al, 1994) 
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Figure 3.1: Pathophysiology of acute pancreatitis 
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Blockage of zymogen secretion by for example gallstones or alcohol leads to the accumulation of zymogen granules within the acinar cell. This 
allows the colocalisation of zymogen granules and lysosomes within large vacuoles to occur ("crinophagy"). The lysosomal hydrolases activate the 
digestive enzyme precursor trypsinogen to trypsin, which in turn activates the pancreatic enzyme cascade and leads to autodigestion of the gland. 
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(Adapted from Lankisch and Banks. 1998a and 1998b) 
A number of safety mechanisms protect the pancreas from autodigestion (Section 1.1.2.4), 
however, during acute pancreatitis these protective mechanisms fail and there is premature 
activation of pancreatic enzymes within the acinar cell that leads to autodigestion of the 
gland. 
3.2.1.2 Acute pancreatitis 
The cellular injury that occurs during acute pancreatitis is the result of a blockage 
in the secretion of zymogen granules from acinar cells and their subsequent accumulation 
within the acinar cell. Once this blockage occurs, the zymogen granules undergo abnormal 
fusion with lysosomes a process known as "crinophagy". This results in the formation of 
large vacuoles that contain both digestive enzyme and lysosomal hydrolase. The lysosomal 
hydrolase then activates the digestive enzyme precursor trypsinogen to trypsin, which in 
turn activates the pancreatic enzyme cascade and leads to autodigestion of the gland 
(Figure 3.1)(Watanabe et a!, 1984; Saito et a!, 1987; Steer and Meldolesi, 1987; Saluja et 
al, 1989). 
An alternative theory has been proposed whereby in the presence of calcium and 
low pH trypsinogen is autoactivated to trypsin with the subsequent activation of other 
zymogens within the acinar cell (Whitcomb, 1999; Leach et al, 1992, Bettinger and 
Grendell, 1991). The recent identification of two mutations in the CAT gene that renders 
trypsin resistant to degradation in patients with HP supports a role for the premature 
activation of trypsinogen in acute pancreatitis (Gorry et a!, 1997; Whitcomb et al, 1996b) 
(Section 1.4.4.2). 
Whichever mechanism of trypsinogen activation is involved, the result is that 
protease secretion occurs at the basolateral membrane of the acinar cell into the 
interstitium of the pancreas, rather than at the apical membrane (Fernandez del Castillo et 
al, 1993 ). The activated enzymes damage the cells and cause the release of cytokines and 
activation of the complement system (Kame and Gorelick, 1999). These molecules cause 
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the migration of leucocytes (neutrophils and macrophages) from the blood into the 
pancreatic interstitium due to an upregulation of receptors on both leucocytes and 
endothelium. The leucocytes release inflammatory mediators including cytokines and 
OFRs that induce the local pancreatic inflammation (Kingsnorth, 1997). 
Despite the central role of enzymes in the pathogenesis of acute pancreatitis, 
clinical trials using protease inhibitors such as Aprotonin (Cox, 1977; Imrie et al, 1978) 
and Gabexate mesilate (Buchler et al, 1993; Andrulli et al, 1998) and antisecretory agents 
such as Somatostatin (Gjorup et al, 1992) and Ocreotide (Uhl et al, 1999) have been 
disappointing. 
3.2.2 The systemic inflammatory response syndrome (SIRS) 
Loss of control of local pancreatic inflammation results in the systemic 
inflammatory response syndrome (SIRS). As defined at the American College of Chest 
Physicians/Society of Critical Care Medicine Consensus Conference of 1991: 
"SIRS is a systemic inflammatory response to a variety of severe clinical insults. The 
response is manifest by two or more of the following criteria: Temperature > 38°C or < 
36°C; Heart rate > 90 beats/minute; Respiratory rate > 20 breaths/minute or PaC02 < 
4.3kPa and WBC count >12000 cells/mm3, < 4000 cells/mm3 or >10% immature cells" 
(Bone et al, 1992). 
High levels of macrophage-derived pro-inflammatory cytokines are released from 
the damaged pancreas into the general circulation. These cytokines activate systemic 
leucocytes and cause the upregulation adhesion molecule expression on neutrophils and 
endothelial cells. This increases cell adhesion and allows leucocytes to migrate from the 
blood into the parenchyma of distant organs in particular lungs, heart and kidneys where 
they release more inflammatory mediators such as cytokines, PAF, proteases and OFRs 
that cause tissue damage (Kingsnorth, 1997). 
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The systemic inflammatory response syndrome (SIRS) is one of 2 main components that 
are activated following tissue injury. The other component is the compensatory anti-
inflammatory response syndrome (CARS). (An intermediate mixed antagonist response 
syndrome (MARS) also exists). SIRS that occurs when there is a systemic spillover of pro-
inflammatory mediators and CARS that occurs when there is a systemic spillover of anti-
inflammatory mediators act as opposing forces in a balance (Bone, 1996a). SIRS (and 
CARS) occurs in 3 stages (Figure 3.2)(Bone, 1996b). Stage I (Local response): The 
pancreas produces pro-inflammatory mediators whose function is to cause an inflammatory 
response, promote wound repair and recruit phagocytes. Anti-inflammatory mediators are 
also released to downregulate this process. If the pro-inflammatory and anti-inflammatory 
mediators balance locally homeostasis is restored. Stage 2 (Systemic spillover): If 
homeostasis is not restored in stage I, small quantities of pro-inflammatory and anti-
inflammatory mediators are released into the systemic circulation to recruit cells to the 
pancreas. This continues until the pancreatic damage is resolved and homeostasis is 
restored. Stage 3: (SIRS or CARS): If the balance between the pro-inflammatory and anti-
inflammatory mediators is not restored and homeostasis is not reestablished after stage 2, 
SIRS due to a massive release of pro-inflammatory mediators or CARS due to massive 
release of anti-inflammatory mediators will develop. 
When SIRS and CARS are unbalanced a variety of clinical sequelae occur 
depending on whether SIRS or CARS predominates. These have been termed CHAOS 
(Cardiovascular shock (SIRS predominates), Homeostasis (SIRS and CARS balance), 
Apoptosis (SIRS predominates), Organ dysfunction (SIRS predominates) and immune 
Suppression (CARS predominates) (Bone, 1996c). The systemic inflammatory state of an 
individual patient must be determined in order to administer the correct treatment. If the 
pro-inflammatory SIRS predominates, anti-inflammatory therapy will be required, 
however, if the anti-inflammatory CARS predominates agents that stimulate the immune 
system such as G-CSF and IL-2 will be beneficial (Davies and Hagen, 1997). 
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Figure 3.2: Development of the systemic inflammatory response syndrome (SffiS) 
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Stage 1 (Local response): The J:Xlncreas produces pro-inflammatory mediators whose function is to cause an 
inflammatory response. Anti-inflammatory mediators are also released to downregulate this process. lf the 
pro-inflammatory and anti-inflammatory mediators balance locally homeostasis is restored. 
Stage 2 (Systemic spiUover): lf homeostasis is not restored in stage I, small quantities of pro-inflammatory 
and anti-inflammatory mediators are released into the systemic circuJation to recruit cells to the J:XlOCreas. 
This continues until the pancreatic damage is resolved and homeostasis is restored. 
Stage 3 (SIRS or CARS): If the balance between the pro-inflammatory and anti-inflammatory mediators is 
not restored and homeostasis is not reestablished after stage 2, SfRS due to a massive release of pro-
in.flanmtatory mediators or CARS due to massive release of anti-inflammatory mediators wiU develop. One 
of the sequelae that occurs wlten SIRS predominates is organ dysfunction. Failure of more than one organ 
results in a condition known as multiple organ dysfunction syndrome (MODS). 
(Adapted from Davies and Hagen. 1997) 
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One of the sequelae that occurs when SIRS predominates is organ dysfunction. Failure of 
more than one organ results in a condition known as multiple organ dysfunction syndrome 
(MODS). As defined by the American College of Chest Physicians/Society of Critical Care 
Medicine Consensus Conference of 1991: 
"Multiple organ dysfunction syndrome is the presence of altered organ function in an 
acutely ill patient such that homeostasis cannot be maintained without intervention" (Bone 
et a!, 1992). 
A common sequence of organ failure is found to be respiratory failure, then renal 
failure, then cardiovascular failure and finally coagulation failure (Larvin, 1996). The 
mortality rate is directly related to the number of organ systems involved with 1, 2, 3 and 4 
organ system failures corresponding to 18%, 54%, 90%, 100% mortality respectively 
(Larvin, 1996). The outcome of MODS can be explained by the "two hit" hypothesis. The 
"first hit" in severe acute pancreatitis is the initial pancreatic insult that leads to SIRS and 
MODS. Resolution occurs in most patients with MODS provided there is no "second hit" 
such as a chest infection. A "second hit" superimposed on MODS, however, often results 
in death (Brady et al, 1999). 
3.2.3 Sepsis 
As discussed above, SIRS can occur as a result of massive activation of pro-
inflammatory mediators by severe tissue trauma. SIRS can also occur or be enhanced by 
bacterial infection of the pancreatic necrosis, a condition known as sepsis. As defined at 
American College of Chest Physicians/Society of Critical Care Medicine Consensus 
Conference of 1991: 
"Sepsis is SIRS in response to infection. This systemic response is manifested by two or 
more of the criteria for SIRS as a result of infection" (Bone et a!, 1992). 
The extent of bacterial infection is related to the degree of pancreatic necrosis 
which inturn correlates with disease severity (Schmid et al, 1999). Once the necrotic 
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pancreas is infected, cytokines and bacterial toxins are released into the blood circulation 
and pass to distant organs for example the lungs, where they initiate inflammatory 
reactions and cause the SIRS which can lead to MODS and death (Lemaire et a!, 1997). 
The bacteria that infect the necrotic pancreas originate from the gut by a process known as 
"bacterial translocation". They include gram-negative bacteria such as Escherichia coli, 
Pseudomonas spp, Proteus spp, Klebsiella spp and gram-positive bacteria such as 
Staphylococcus aureus, Streptococcusfaeca/is, Enterococcus. Occasionally fungi may also 
be present in the pancreas (Schmid et a!, 1999). 
3.2.3.1 Bacterial tra11slocation 
"Bacterial translocation is defined as the passage of microbes and endotoxin across 
the intestinal barrier" (Lemaire et al, 1997) and has demonstrated in different animal 
models of acute pancreatitis. These include opposums (Runkel et a!, 1990, Runkel, et al, 
1995), dogs (Kazantsev et al, 1994), rats (Medich et al, 1993; Runkel, et al, 1991) and cats 
(Widdison et al, 1994). Bacterial translocation from the intestinal lumen to extraintestinal 
sites including pancreatic necrosis may occur via the lymphatic, blood circulation or direct 
transperitoneal route. The route of bacterial translocation is dependent on the animal 
model. In opposums with duct ligation-induced acute pancreatitis and dogs with 
taurocholate-induced acute pancreatitis bacteria spread via lymphatics (Runkel et al, 1990, 
Runkel et al, 1995; Kazantsev et a!, 1994). In rats with cerulein-induced acute pancreatitis 
the bacteria spread transperitoneally (Medich et a!, 1993) while in cats with duct perfusion-
induced acute pancreatitis translocation occurred via the blood circulation and 
transperitoneally (Widdison et a!, 1994). Bacterial translocation is caused by 3 factors: I) 
disruption of the intestinal microflora, 2) loss of intestine wall barrier function and 3) 
impaired host defence (Runkel, 1996). 
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3.2.3.1.1 Disruptio11 ofi11testi11al microjlora 
During acute pancreatitis there is an imbalance in the gram-negative and gram-
positive bacteria in the intestine skewed towards the gram-negative bacteria. This shift in 
intestinal microflora is believed to be due to reduced gut motility. The link between 
reduced gut motility, disrupted intestinal microflora and bacterial translocation has been 
demonstrated in rats using morphine as a depressant of gut motility (Runkel et a!, 1993) 
and in a time course study in rats with duct ligation-induced acute pancreatitis (Muncy et 
al, 1993). 
3.2.3.1.2 Loss oji11testine wall barrier junctio11 
Loss of mucosal barrier function of the intestine wall results in leakage of bacteria 
and endotoxin from the gut lumen. Increased intestinal permeability in acute pancreatitis 
has been shown in dogs using plasmid-labelled E. coli (Kazantsev et al, 1994), a clinical 
strain of E. coli in cats (Widdison et al, 1994) and by fluorescent beads (Medich et al, 
1993). The mechanism of increased intestinal permeability remains unknown, however, it 
may be caused by reduced gut motility or intestinal ischemia (Runkel, 1996). 
3.2.3.1.3 Impaired lrost defense 
There is evidence to suggest that the host defense system is impaired during acute 
pancreatitis. Curley et al, found that the proportion of circulating levels of CD4+ cells was 
reduced during the disease and correlated inversely with translocating endotoxin (Curley et 
al, 1993). Widdison et al, showed that the local clearance of E. coli from the pancreas was 
impaired in cats with duct perfusion-induced acute pancreatitis indicating a loss of 
phagocytic function. Furthermore, administration of the imrnunostimulant drug, 
LevimasoleTM was found to improve phagocytic function and reduce pancreatic infection 
(Widdison et a!, 1992). 
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3.3 Plasma mediator systems of inflammation 
The most extensively studied plasma mediator systems in acute pancreatitis are the 
kinin and complement systems. 
3.3.1 Tbe kinin system 
Elevated levels of bradykinin have been found in dogs with severe acute 
pancreatitis (Satake et al, 1985), whilst bradykinin administered to rabbits with cerulein-
induced acute pancreatitis was found to significantly reduce pancreatic blood flow and 
increase disease severity compared to controls (Y otsumoto et al, 1993). 
Experiments using bradykinin antagonists have provided conflicting results. 
Hoffinann et al, demonstrated that the bradykinin antagonists, HOE140 and CP-0597 
improved pancreatic microcirculation in an ischemia-reperfusion model of acute 
pancreatitis in rats compared to untreated controls (Hoffmann et al, 1996a; Hoffmann et al, 
l996b). HOE140 also improved survival in taurocholate-induced acute pancreatitis in rats 
(Kanbe et al, 1996) and prevented edema formation in cerulein-induced acute pancreatitis 
in rats (Griesbacher et al, 1993). In addition, Closa et al, found that HOE140 inhibited 
bradykinin-mediated NO generation and thromboxane release and improved the disease 
severity in taurocholate-induced acute pancreatitis in rats (Closa et al, 1995). 
In contrast, Lerch et al, found no beneficial effect ofHOE140 on the survival rates 
in 4 different models of acute pancreatitis (Lerch et al, 1995). Furthermore, in one study 
HOE140 actually increased the severity of disease (Weidenbach et al, 1995). Cicardi et al, 
have demonstrated that pretreatment with Cl inhibitor plasma concentrate, a kallikrein 
inhibitor may offer benefit to patients at high risk of developing acute pancreatitis 
following ERCP. Patients pretreated with Cl inhibitor showed reduced levels of amylase 
compared to the untreated patients. Since the Cl inhibitor has to be administered before 
acute pancreatitis is induced, it is probably only of benefit to patients with ERCP-induced 
acute pancreatitis (Cicardi et al, 1994). 
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3.3.2 The complement system 
Decreased levels of serum C3 and increased levels of complement products 
implicate the complement system in acute pancreatitis (Seelig et al, 197S; Horn et al, 1982; 
Roxvall et al, 1990). Acute pancreatitis was induced in CS sufficient mice (Hc1Hc1) and in 
mice with a mutant He gene that were genetically deficient in circulating CS (Hc0Hc0). All 
mice developed the disease, however, the mice deficient in CS had significantly reduced 
pancreatic inflammation compared to those with CS (Merriam et al, 1997). 
Vesentini et al, have shown that rats with taurocholate-induced acute pancreatitis 
pretreated with Cl esterase inhibitor, an inhibitor of both kallikrein and complement had 
improved survival compared to untreated rats (Vesentini et al, 1993). Combined treatment 
of Cl esterase inhibitor and antithrombin Ill, an inhibitor of the coagulation system given 
either prophylactically or therapeutically was also shown to improve the survival of rats 
with taurocholate-induced but not cerulein-induced acute pancreatitis (Yamaguchi et al, 
1997). In contrast, Niederau et al, showed no beneficial effect of Cl esterase in 3 different 
models of the disease (Niederau et al, 199S). In a clinical study, C I esterase inhibitor 
administered therapeutically to 2 children with severe acute pancreatitis following 
allogeneic hematopoietic stem cell transplantation was found to improve pancreatic 
inflammation and prevented MODS (Schneider et al, 1999). 
In other studies, soluble complement receptor type 1 (sCRl), another complement 
inhibitor administered to rats with cerulein-induced acute pancreatitis failed to reduce local 
or systemic complications (Weiser et al, 1996; Acioli et al, 1997). 
Guice et al, demonstrated that cerulein-induced acute pancreatitis in rats produced 
lung injury with neutrophil sequestration and increased lung permeability. The lung injury 
was ameliorated by the induction of neutropenia, complement depletion or by scavenging 
OFRs. They suggested that the local and systemic injury that occurs during acute 
pancreatitis is the result of complement activation with the production of CSa and C3a 
leading to neutrophil activation and the production of OFRs (Guice et al, 1989). 
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3.4 Cell mediators of inflammation 
3.4.1 Neutrophils 
Overactivation of neutrophils occurs during acute pancreatitis (Widdison and 
Cunningham, 1996). Serum levels of neutrophil elastase were found to be elevated during 
the disease and correlated with severity (Gross et a!, 1990; Uhl et a!, 1991; Mora et a!, 
1997). Administration of ON0-5046, a neutrophil elastase inhibitor prevented lung injury 
in 2 animal models, but had no effect on pancreatic inflammation (Imamura et a!, 1998; 
Guo et at, 1995). The neutrophil elastase inhibitor R-020 also prevented sepsis-induced 
lung and liver damage in rats (Murata et al, 1994). Combined treatment of a neutrophil 
elastase inhibitor and pancreatic elastase inhibitor in a rat model of acute pancreatitis with 
septic challenge significantly reduced mortality, however, individual administration of 
either inhibitor did not offer any benefit. This suggests that neutrophil and pancreatic 
elastase may have a synergistic action in acute pancreatitis (Y amano et a!, 1998). 
Neutrophil depletion studies have also implicated neutrophils in acute pancreatitis. 
Methotrexate, a neutropenia-inducing drug administered to a rat model caused a reduction 
in pancreatic injury (Fujimoto et al, 1997). Also Urge-8, an anti-neutrophil monoclonal 
antibody given after pancreatitis induction prolonged survival in rats (Han et al, 1996). 
Neutrophil depletion has been found to promote apoptosis not necrosis of pancreatic acinar 
cells during acute pancreatitis. This shift towards apoptosis may be the mechanism by 
which neutrophil depletion reduces the severity of acute pancreatitis (Sandoval et al, 1996). 
Neutrophils activated during acute pancreatitis are also involved with the associated 
lung injury. Pretreatment with anti-neutrophil serum was found to prevent the development 
of lung injury in animal models (Bhatia et al, 1998; Guice et al, 1989). In addition, 
prophylactic treatment of rats with a polyclonal anti-rat neutrophil antibody to cause 
neutropenia and therapeutic treatment with an anti-rat monoclonal antibody to prevent 
neutrophil adherence to the endothelium prolonged survival and prevented lw1g injury 
associated with the disease (Inoue et a!, 1995). 
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3.4.2 Monocytes/macrophages 
Serum neopterin levels, a marker of macrophage activation were found to be 
increased in acute pancreatitis and correlated with severity (Uomo et al, 1996; Mora et al, 
1997). 
A recent study has demonstrated that Zymosan, a macrophage stimulant caused 
pancreatic barrier dysfunction in a dose and time dependent manner. Pretreatment with 
NAC, an OFR scavenger showed that the pancreatic barrier damage was mediated at least 
in part by OFRs released from the macrophages (Andersson et al, 1997). Furthermore, 
administration of CN1493, a macrophage-pacification compound to rats with acute 
pancreatitis decreased pancreatic disease severity via a reduction in TNFa levels (Yang et 
al, 1998a) and reduced hepatocellular injury by down regulating TNFa and IL-1P 
expression (Y ang et al, 1998b ). 
Monocyte phagocyte function may determine the outcome of acute pancreatitis. 
Patients with severe disease showed impaired monocyte phagocyte function, which lead to 
a decreased rate of clearance of protease-anti protease complexes (Larvin et al, 1993; Liras 
and Carballo, 1996). In addition, mice with CDE-induced acute pancreatitis fed glucan, a 
chemical that enhances macrophage function had reduced disease severity and improved 
survival rates (Browder et al, 1987). HLA-DR expression, an indicator of monocyte 
function was also found to be reduced in patients with acute pancreatitis and correlated 
with outcome (Richter et al, 1999). 
Widdison and Cunningham have suggested that monocyte function is overwhelmed 
not impaired during acute pancreatitis. They implied that phagocytes have only limited 
capacity to phagocytose bacteria and protease-antiprotease complexes and that systemic 
release of proteases during acute pancreatitis saturates the phagocytes causing the reduced 
rate of clearance (Widdison and Cunningham, 1996). 
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3.4.3 Endothelial cells and adhesion molecules 
3.4.3.1 Endothelial cells 
Endothelin is released from vascular endothelial cells in response to a variety of 
stimuli and causes vasoconstriction, increased permeability and increased neutrophil 
chemotaxis (Todd et al, 1997). It mediates its action via 2 surface receptors known as 
endothelin ETa and ETb that have both been located on pancreatic acinar cells (Hildebrand 
et a!, 1993). Administration of endothelin to rats with acute pancreatitis was found to 
increase capillary permeability in the pancreas, whilst blockade of the endothelin receptor 
reduced capillary permeability (Eibl et a!, 2000). Endothelin antagonism using PD145065 
also reduced the severity of both local and systemic manifestations of acute pancreatitis in 
mice with CDE-induced disease (Todd et a!, 1997). In contrast, an earlier experiment 
showed that endothelin protected rats against cerulein-induced acute pancreatitis, while an 
endothelin antagonist BQ-123 increased disease severity (Kogire et a!, 1995). 
3.4.3.2 Adlresio11 molecules 
Circulating levels of ICAM-1 were found to be elevated in patients with severe 
acute pancreatitis and levels correlated with disease severity (Kaufrnann et al, 1996). This 
association between ICAM-1 levels and disease severity was also demonstrated in a rat 
model. Furthermore, treatment with a monoclonal antibody against ICAM-1 at the time of 
acute pancreatitis induction was found to reduce the local pancreatic injury and systemic 
lung injury (Wemer et al, 1999). It has also been demonstrated that gut endothelial 
dysfunction associated with severe acute pancreatitis in rats was decreased by the injection 
of monoclonal antibodies against ICAM-1 and a PAF antagonist reducing the systemic 
inflammatory response (Wang et a!, 1999). In another study, ascitic fluid from rats with 
acute pancreatitis caused an increase in the expression ofiCAM-1 and VCAM-1 molecules 
in human umbilical vein endothelial cells (HUVECs) suggesting a possible role for ICAM-
1 in the systemic manifestations of acute pancreatitis (Masamune et al, 1999). 
50 
In another study, pancreatitis was induced in mice that were either deficient in ICAM-1, 
deficient in neutrophils or both. The severity of pancreatitis and pancreatitis-associated 
lung injury was significantly reduced in mice deficient in ICAM-1 and mice deficient in 
neutrophils compared to controls, however, there was no additive protective effect of mice 
deficient in ICAM-1 and neutrophils (Frossard et al, 1999). 
Some studies have shown that events that lead to inflammation occur in a particular 
sequence. Lundberg et al, showed in mice with CDE-induced acute pancreatitis that the 
disease is associated initially with systemic release of inflammatory cytokines, followed by 
increased expression of pulmonary ICAM-1 and VCAM-1, followed by neutrophil 
infiltration which subsequently lead to lung injury (Lundberg et al, 2000a). The same 
group also demonstrated this sequence of events with selectins whereby there was an 
increase in inflammatory cytokines, followed by an increase in P and E selectin, followed 
by increased infiltration of leucocytes and lung tissue damage (Lundberg et a!, 2000b). 
Folch et al, also demonstrated that in the lungs of rats with taurocholate-induced acute 
pancreatitis there was increased P selectin which caused increased leucocyte infiltration. 
They expanded the study to show that P se lectin or ICAM -1 neutralisation prevented 
infiltration ofneutrophils into the lung. In addition, they found that xanthine oxidase levels 
increased during acute pancreatitis and that inhibition of XOD prevented the increase of P 
selectin in the lung and neutrophil infiltration (Folch et al, 1999). 
Pretreatment with IS-741, a carboxamide derivative has been shown to reduce 
neutrophil infiltration into the pancreas in rats with cerulein-induced acute pancreatitis by 
inhibiting the upregulation of integrin CD 11 b (Y amauchi et al, 1999). The same drug has 
been shown to prevent pancreatitis-associated lung injury following septic challenge in rats 
with cerulein-induced acute pancreatitis (Y amaguchi et al, 1999a). 
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3.5 Cell-derived mediators of inflammation 
3.5.1 Platelet activating factor (PAF) 
Isolated pancreatic lobules have been found to synthesize PAF (Soling and Fest, 
1986) and pancreatic P AF levels were elevated in both cerulein-induced rat models 
(Konturek et al, 1992; Zhou et al, 1993; Zhou et al, 1994) and in human acute pancreatitis 
(Kingsnorth, 1996). In addition, the injection of PAF has been found to induce acute 
pancreatitis in animal models (Emanuelli et al, 1989; Jancar et al, 1988). Yotsumoto et al, 
also showed that the simultaneous administration of PAF with cerulein to rabbits 
exacerbated the detrimental effects of this secretagogue model (Yotsumoto et al, 1994). 
P AF given intraperitoneally caused similar changes in pancreatic histopathology to acute 
pancreatitis induced by cerulein (Konturek et al, 1992). P AF levels were also increased in 
lung tissue and were associated with the lung injury seen in acute pancreatitis (Zhou et al, 
1992). PAF is inactivated by the enzyme platelet activating factor acetylhydrolase (PAF-
AH). Therapeutic administration of this enzyme to an animal model has been found to 
protect against acute pancreatitis and its associated lung injury (Hofbauer et al, 1998). 
P AF antagonists have been found to reduce the severity of acute pancreatitis and its 
complications. There are a variety of P AF antagonists: BN-52021, CV6209, WEB2170, 
TCV309 and BB-882. BN-52021 administered prophylactically to rats with immune 
complex-induced (Jancar et al, 1988), cerulein-induced (Jancar et al, 1995), bile-induced 
(Zhou et al, 1992) and taucholate-induced acute pancreatitis (Dabrowski et al, 1995) was 
found to reduce severity of the disease. A similar reduction in severity was also achieved 
with CV6209 pretreatment in a cerulein-induced rat model (Fujimura et al, 1992). 
The role of PAF in the systemic complications of acute pancreatitis was 
demonstrated in a bile-induced rat model using pretreatment with WEB2170. There was a 
reduction in pulmonary inflammatory mediators, vascular permeability and leucocyte 
infiltration compared to controls (Zhou et al, 1992). Similarly, pretreatment with TCV309 
reduced the severity of cerulein-induced and P AF injection-induced acute pancreatitis in 
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rats (Tomaszewska et a!, 1992) and was found to prevent the activation ofbronchoalveolar 
macrophages in cerulein-induced rats with septic challenge (Y amaguchi et a!, 1999b ). 
Furthermore, BB-882, also known as LexipafantrM, administered therapeutically in a 
microembolisation-induced rat model caused significant reduction in pancreatic 
inflammation (Formela et al, 1994) and pulmonary capillary permeability (Galloway and 
Kingsnorth, 1996). In contrast, a study performed by Rivera et al, demonstrated that BB-
882 did not improve the survival or decrease disease severity in rats with cerulein plus 
bile-induced acute pancreatitis (Rivera et a!, 1998). BB-882 administered prior to acute 
pancreatitis induction has also been found to prevent intestinal barrier dysfunction and 
reduce bacterial translocation in taurocholate-induced rat model and further proves that 
PAF plays a role in systemic manifestations of the disease (Andersson et a!, 1998; Wang et 
a!, 1999; Liu et a!, 1999). 
Lexipafant™ is the only PAF antagonist to have been studied in clinical trials. Two 
randomised double-blind placebo-controlled phase Il trials have been conducted to assess 
the efficacy of Lexipafant™ as a therapy for human acute pancreatitis (K.ingsnorth et al, 
1995; McKay et a!, 1997). In both studies, patients who received Lexipafant™ had 
improved survival and decreased organ failure score compared to those receiving placebo. 
A subsequent phase III multicentre double-blind placebo-controlled clinical trial showed 
that patients treated with Lexipafant™ had fewer local complications, a more rapid 
resolution of systemic complications and reduced mortality (Kingsnorth, 1998). 
Furthermore, patients who had received the treatment within 48 hours of onset of 
symptoms showed significantly reduced mortality, suggesting that Lexipafant™ ts 
particularly effective if administered early. Although these clinical trials showed that 
Lexipafant™ has therapeutic potential, this maybe due to the relatively small numbers of 
patients involved in the studies. This theory is supported by a larger multicentre study 
involving both Europe and the USA which has shown that LexipafantTM does not reduce 
organ failure or mortality in severe acute pancreatitis (Bhatia et al, 2000). 
53 
3.5.2 Arachidonic acid metabolites 
Studies implicating arachidonic acid metabolites in acute pancreatitis are limited 
and often conflicting. 
3.5.2.1 Leukotrienes 
Leukotrienes are the 5-Iipoxygenase metabolites of arachidonic acid. LTB4 levels 
were found to be elevated in rats with taurocholate-induced acute pancreatitis (Zhou et al, 
1994; Folch et al, 1998a}, while LTC4 and LTD4 levels were increased in two acute 
pancreatitis models in pigs (Vollmar et al, 1989). A study using AA861, a 5-lipoxygenase 
inhibitor provided evidence that leukotrienes may cause acute pancreatitis in rats by 
enhancing amylase secretion from pancreatic acinar cells (Sato et al, 1988). In addition, 
pretreatment with the leukotriene receptor antagonist, pranlukast hydrate was found to 
protect against the histological features which occur in the pancreas during cerulein-
induced acute pancreatitis in rats (Hirano, 1997). 
3.5.2.2 Tllromboxanes 
Thromboxanes and prostaglandins are the cycloxygenase metabolites of 
arachidonic acid. Zhou et al, found that TXB2 (metabolite of TXA2) was significantly 
decreased in rats with taurocholate-induced acute pancreatitis (Zhou et al, 1994), however, 
other studies using the same animal model have demonstrated that levels of TXB2 were 
significantly increased (Van Ooijen et al, 1988; Closa et al, 1993). Pretreatment of rats 
with taurocholate-induced acute pancreatitis using a TXA2 synthesis inhibitor called OKY-
046 reduced disease severity by decreasing thromboxane levels and significantly improved 
survival compared to untreated controls (Iida et al, 1998). Other studies involving 
experimental acute pancreatitis have demonstrated that TXB2 levels were reduced by 
pretreatment with HOE, a bradykinin inhibitor (Closa et al, 1995) or pretreatment with 
Verapamil, a calcium channel blocker (Closa et al, 1996). 
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3.5.2.3 Prostaglandins 
Zhou et al, found that the levels ofPOD2, POE2 and 6 keto POFta (a metabolite of 
PO h) were decreased in a rat model of acute pancreatitis (Zhou et al, 1994), whereas it had 
previously been demonstrated that 6 keto POF1a levels were significantly increased in dogs 
with the disease (Kiviniemi et al, 1987). 
PGI2, POE1 and POE2 have been shown to have therapeutic potential in acute 
pancreatitis. Treatment with the POh analogue, OP2507 was found to have no effect in rats 
with taurocholate-induced acute pancreatitis (Iida et al, 1998), however, iloprost, another 
POh analogue was beneficial in rats with cerulein-induced acute pancreatitis, particularly 
in pancreas regeneration (Jurkowska et al, 1996). Treatment with the POEt analogues, 
Misoprostol and MR356 was also found to be therapeutic in rats with acute pancreatitis 
(Buscail et al, 1990; Sakai et al, 1992). Interestingly, Poszar et al, found that optimum 
POEt ameliorated the disease in rats with closed loop duodenal acute pancreatitis, 
however, higher doses increased disease severity (Pozsar et al, 1996). Other studies have 
shown that PGE2 and not POEt had a beneficial effect on rats with acute pancreatitis 
(Manabe et a!, 1993; Hirano et a!, 1993) and the effect was more pronounced when 
combined with ON0-3307 a protease inhibitor (Hirano et al, 1992). 
The protective effect of prostaglandins in acute pancreatitis maybe due to their 
ability to stabilise cellular and subcellular organelles such as zymogen granules, lysosomes 
and mitochondrial membranes thereby preventing the colocalisation of lysosomal 
hydrolases and zymogens that is known to cause acute pancreatitis (Manabe et a!, 1993). 
3.5.3 Oxygen Free Radicals 
Superoxide and hydrogen peroxide free radicals directly injure isolated rat 
pancreatic acini, whilst SOD and catalase suppress the damage caused by them. OFRs 
released from the damaged pancreas into the bloodstream also damage vascular 
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endothelium at distant sites contributing to the complications associated with acute 
pancreatitis (Tamura et al, 1992). 
Levels of the oxidants, xanthine oxidase (XOD) and lipid peroxides (LPO) were 
significantly increased in animal models of acute pancreatitis, whilst levels of SOD were 
decreased suggesting that oxidative stress occurs in acute pancreatitis (Nonaka et al, 1989; 
Dabrowski and Gabryelewicz, 1992). This oxidative stress has also been shown in human 
acute pancreatitis with increased superoxide and LPO levels and decreased levels of an 
OFR scavenger in patients compared to controls (Braganza et at, 1995; Tsai et at, 1998). 
The oxidative stress was found to correlate with severity of the disease (Tsai et al, 1998) 
and it has been suggested that oxidative stress can be used as a prognostic marker in 
disease (Wereszczynska-Siemiatkowska et al, 1998). 
Oxidative stress can be improved by either decreasing the OFR level or increasing 
the antioxidants/OFR scavengers levels to restore the imbalance. 
3.5.3.1 Decreasing OFR levels 
Since the main source of OFRs in acute pancreatitis is from the XOD system 
(Sanfey et al, 1985) and neutrophils (Gough et al, 1990), methods that inhibit the XOD 
system or neutrophil function/infiltration may be therapeutic. Studies using allopurinol, a 
XOD inhibitor, have produced conflicting results. Pretreatment with allopurinol was found 
to reduce the severity of acute pancreatitis in some animal models (Sanfey et al, 1984; 
Wisner and Renner, 1988), but not in others (Lankisch et al, 1989; Creagh et al, 1993). 
Neutropenia induced by nitrogen mustard was found to reduce the level of superoxide 
anion and improve the severity in a cerulein-induced rat model (Ito et at, 1996). 
Pretreatment with catalase, SOD and monoclonal antibody anti-ICAM-1 in experimental 
rat models was found to be effective in reducing tissue damage, neutrophil infiltration and 
OFR production (Inoue et al, 1996; Poch et a!, 1999). Furthermore, oxypurinol, a XOD 
inhibitor administered to rats with acute pancreatitis was found to prevent neutrophil 
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infiltration in the lungs (Folch et al, 1998b). Also, the inhibition of neutrophils and 
neutrophil superoxide anion generation using a polyclonal antineutrophil antibody was 
found to diminish pulmonary neutrophil accumulation in rats (Murakami et al, 1995). 
3.5.3.2 Increasing antioxidant/OFR scavenger levels 
The most common studies of antioxidants in acute pancreatitis involve SOD and 
catalase. Pretreatment with SOD and catalase has shown to be beneficial in some animal 
models (Sanfey et al, 1984; Schoenberg et al, 1994; Schoenberg et al, 1990; Steer et al, 
1991; Niederau et al, 1992; Furukawa et al, 1994), but not in others (Niederau et al, 1992; 
Furukawa et al, 1994), suggesting that different models of acute pancreatitis have different 
degrees and mechanisms of OFRs. A recent study has shown that when transgenic Cu/Zn 
SOD mice and control mice were given cerulein to induce acute pancreatitis, the transgenic 
mice which over express SOD had reduced inflammation compared to control mice 
(Kikuchi et al, 1997). 
Other studies using the free radical scavengers, melatonin (Qi et al, 1999), 
desferrioxamine (DFX) alone/in combination with a P AF antagonist ginkgo biloba (GB) 
(Soybir et al, 1999) and CV3611 (Nonaka et al, 1991), and the antioxidant N-acetyl-L-
cysteine were all found to improve severity of acute pancreatitis in animal models (Wang 
et al, 1995). 
3.5.4 Nitric Oxide 
The role of NO in diseases such as acute pancreatitis can be determined by 
manipulating NO levels using NO donors and NO inhibitors. The role of NO in the 
pathophysiology of acute pancreatitis is uncertain since studies have produced conflicting 
results. Some show a protective effect for NO donors whilst others show a protective effect 
for NO inhibitors. 
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3.5.4.1 Protective effects of NO donors 
NO has a protective role in the pancreas and distant organs that are involved in the 
systemic complications of acute pancreatitis. Endogenous NO is involved in the regulation 
of exocrine pancreatic secretion in rats (Konturek et a! 1994; Molero et al, 1995) and 
pancreatic blood flow (Satoh et a!, 1994). Furthermore, inhibition of NOS was found to 
reduce exocrine and endocrine pancreatic secretion in humans (Konturek et a!, 1997). 
NO donors have been shown to reduce pancreatic inflammation in rat models of 
acute pancreatitis (Wemer et a!, 1997b; Wemer et a!, 1998; Molero et a!, 1995). In 
addition, blocking the action of NOS using the NOS inhibitor, L-NAME was found to 
increase the inflammation (Molero et a!, 1995). 
Pancreatic microcirculation was improved following the administration of the NO 
donor, L-arginine in a rat model (Dobosz et a!, 1996). Furthermore, inhibition of NOS was 
found to aggravate rat acute pancreatitis by reducing pancreatic capillary blood flow 
(Dobosz et a!, 1998; Dobosz et al, 1999). 
Exogenous administration of NO by sodium nitroprusside, a NO donor inhibited 
lung injury associated with a rat model. Furthermore, inhibition of NO using L-NAME 
actually increased the pulmonary injury suggesting that NO has a protective role against 
pancreatitis-induced lung injury possibly by inhibiting neutrophil influx (0' Donovan et al, 
1995). This is supported by another study which showed that NO decreased neutrophil 
accumulation in the pancreas and liver in cerulein rats, while rats pretreated with the NO 
synthase inhibitor (L-NNA) had increased levels of neutrophils in the pancreas and liver 
(Inagaki et al, 1997a). 
Endothelial-leucocyte adherence is an important aspect of inflammatory diseases 
such as acute pancreatitis. The presence of endogenous NO reduces endothelial-leucocyte 
adherence during acute pancreatitis and impairment of NO production leads to leucocyte 
adhesion and emigration (Kubes et al, 1991; Masamune et a!, 2000). 
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3.5.4.2 Protective effects of NO i11hibitors 
In contrast to the studies by Kubes et al, and Masamune et al, Chen et al, have 
shown that pancreatic NO levels directly correlate with the amount of leucocytes adherent 
to the endotheliwn suggesting that NO could have an adverse role in the microcirculation 
(Chen et al, 1998). This is supported by a study which showed that pancreatic edema was 
reduced by L-NAME in rats with acute pancreatitis (Abe et al, 1995). 
A recent study using a rat model showed that during acute pancreatitis there was 
induction of iNOS, raised NO levels and increased inflammation (AI-Mufti et al, 1998). 
Furthermore, Satoh et al, have shown that iNOS expression occurred in a severe model but 
not in a mild model of rat acute pancreatitis. They suggested that in severe disease excess 
NO is produced because iNOS is expressed and that this does not occur in mild forms of 
the disease (Satoh et al, 1998). 
NO levels were found to be increased in cerulein-induced pancreatitis in mice 
pretreated with LPS but not in those without LPS. This rise in NO was subsequently 
inhibited by the NOS inhibitor (L-NNA), suggesting that NO maybe an important mediator 
of systemic effects of endotoxemia in acute pancreatitis (Kikuchi et al, 1996). In another 
study, NO released from alveolar macrophages was found to contribute to lung injury 
associated with the disease and administration of the NOS inhibitor, L-NMMA protected 
against it (Tsukahara et al, 1996). 
3.5.5 Cytokines 
The first association between cytokines and the pathophysiology of acute 
pancreatitis was suggested in 1988 by Rinderknecht who hypothesized that acute 
pancreatitis occurred as a result of excessive stimulation of leucocytes (Rinderknecht, 
1988). Since then much evidence has accwnulated to support the role of these proteins in 
the disease. The role of the IL-l gene cluster in acute pancreatitis is reviewed in Chapter 4. 
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3.5.5.1 Interleukin-2 (IL-2) 
IL-2 is an immunomodulatory cytokine that is produced by CD4+ T helper cells. 
Decreased IL-2 production or a decrease in the number of CD4+ T helper cells is 
associated with impaired cellular immunity and increased susceptibility to infection. 
Curley et al found that IL-2 production was decreased in a CDE diet-induced murine 
model of acute pancreatitis and that the decrease was exacerbated by a subsequent 
endotoxin challenge resulting in high levels of mortality. Furthermore recombinant IL-2 
administered to the mice soon after the endotoxin challenge improved IL-2 secretion and 
was shown to be protective, suggesting a potential role for IL-2 as therapy in acute 
pancreatitis and sepsis (Curley et al, 1996). 
Levels of CD4+ T helper cells have also been found to be decreased during acute 
pancreatitis reflecting an impaired cellular immune function (Curley et al, 1993; Widdison 
and Cunningham, 1996). In addition, serum soluble interleukin-2 receptor (siL-2R) levels 
which are a marker of the activation of lyrnphocytes are increased in acute pancreatitis and 
are useful predictors of disease severity (Pezzilli et al, 1994; Salomone et al, 1996). 
3.5.5.2 Interleukin-6 (IL-6) 
IL-6 is a pro-inflammatory cytokine that is produced by monocytes, macrophages 
and endothelial cells which is involved in the synthesis of acute phase proteins such as C-
reactive protein (CRP) from the liver. Recent studies have shown that serum IL-6 levels 
are increased in patients with acute pancreatitis and that the levels correlate with severity 
of the disease (Leser et al, 1991; McKay et al, 1996; Inagaki et al, 1997b ). Furthermore, 
IL-6 concentrations appear to be more useful early predictors of disease severity and 
mortality than CRP due to the fact that circulating levels of IL-6 peak 24-48 hours before 
those ofCRP (De Beaux et al, 1996; Ikei et a!, 1998; Pezzilli et al, 1998; Chen et al, 1999). 
Determination of serum IL-6 levels therefore allows the selection of appropriate treatment 
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in the early stages of disease to prevent the progression from mild to severe acute 
pancreatitis. 
3.5.5.3 llrterleuki11-8 (/L-8) 
IL-8 is an a chemokine (CXC) that has the ability to attract and activate neutrophils 
and to upregulate cell adhesion molecule expression. It is secreted by a variety of cells 
including monocytes/macrophages, neutrophils and endothelial cells (Baggiolini et a!, 
1989). Serum IL-8 levels are elevated in patients with acute pancreatitis and correlate with 
levels of neutrophil elastase, a marker of neutrophil activation (Gross et a!, 1992; McKay 
et a!, 1996). IL-8 is the earliest cytokine to appear in the serum of patients with AP 
(Kingsnorth et al, 1995) and is believed to be responsible for attracting neutrophils into the 
parenchyma of the pancreas and lung early in the course of the disease. Similar to IL-6 
levels, IL-8 levels have been found to correlate with severity of the disease (Gross et a!, 
1992; McKay et al, 1996; Berney et a!, 1999). 
Further evidence supporting a role of IL-8 m acute pancreatitis comes from 
experiments involving the administration of sodium fusidate (Osman et a!, 1998a), and 
hydrocortisone (Osman et a!, 1999) to rabbit models of the disease. These studies showed a 
reduction in IL-8 levels and mortality rates. Similarly, phase II clinical trials with 
Lexipafant™, a PAF antagonist in human acute pancreatitis have shown a reduction in the 
levels of IL-8 with beneficial effects on disease severity and mortality (Kingsnorth et a!, 
1995). Furthermore, studies using a neutralising monoclonal antibody (WS-4) against IL-8 
activity have reduced disease severity and mortality in a rabbit model of bile-induced 
pancreatitis. Serum concentrations of IL-8 were found to be decreased, adhesion molecule 
expression was down regulated and lung injury was reduced (Osman et a!, 1998b). A 
similar reduction in lung injury was observed following the administration of an anti-
human IL-8 antibody to rats (Mulligan et al, 1993). 
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3.5.5.4llrterleukin 10 (IL-10) 
IL-10 is a macrophage-derived anti-inflammatory cytokine which has a protective 
role in acute pancreatitis by inhibiting the secretion of pro-inflammatory cytokines such as 
IL-l, IL-6 and TNFa from monocytes, macrophages and Th I cells (Fiorentino et al, 1991 ). 
Normally IL-l 0 is not detectable in the serum of healthy individuals, however, during 
acute pancreatitis levels are significantly elevated on the first day of illness and 
progressively decrease in the following days. Furthermore, IL-10 levels inversely correlate 
with severity of the disease being significantly higher in patients with mild disease 
compared to those with severe disease on the first day of illness (Pezzilli et al, 1997; 
Galloway and Kingsnorth, 1996). This secretory profile differs to that of the 
proinflammatory cytokines that are significantly higher in severe acute pancreatitis patients 
compared to mild acute pancreatitis patients. The low levels of serum IL-l 0 in severe acute 
pancreatitis may reflect an inadequate anti-inflammatory mechanism to counteract and 
down regulate the inflammatory response initiated by pro-inflammatory cytokines in 
patients with severe disease. 
It has recently been demonstrated that administration of IL-10 before and after the 
induction of experimental acute pancreatitis is able to decrease the severity of the disease. 
V an Laethem et al, administered recombinant IL-10 intraperitoneally before and during 
cerulein-induced acute pancreatitis in mice and found that in treated animals there was a 
decrease in disease severity which was probably due to reduced serum IL-6, IL-l p and 
TNFa levels (Van Laethem et al, 1995). Administration ofiL-10 to a cerulein-induced rat 
model (Rongione et al, 1995) and a CDE diet-induced mouse model (Kusske et al, 1996) 
have also shown that IL-10 reduced the severity of the pancreatitis. Similar protective 
effects ofiL-1 0 were seen in animal models of sepsis whereby its administration protected 
against lethal endotoxemia in mice (Howard et al, 1993) and sublethal endotoxin in 
primates (V an der Poll, et a!, 1997). 
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Experiments using IL-10 knockout mice have shown that IL-l 0 is protective against lung 
injury in acute pancreatitis. Lung injury was more severe in the IL-l 0 knockout mice 
compared to controls (Gloor et al, 1998). Moreover, pretreatment with IT9302, a synthetic 
IL-l 0 agonist has been found to reduce lung injury in rabbits with acute necrotising 
pancreatitis and to improve mortality rates (Osman et al, 1998c ). Furthermore, Denham et 
al, have successfully transfected the human IL-l 0 gene into the mouse pancreas using a 
plasmid/liposome vector. The gene was functional and was found to improve mortality and 
severity of cerulein-induced acute pancreatitis (Denham et al, 1998a). 
3.5.5.5 Interleukin 12 (/L-12) 
IL-12 is a heterodirneric cytokine composed of 2 sub units known as IL-12 p35 and 
p40 that is produced by macrophages and is responsible for the differentiation of a naive 
CD4+ T cell into a Th1 cell rather than a Th2 cell (Adorini, 1999). Pezzilli et al, 1999 
investigated the levels of total IL-12 heterodimer and the two subunits p70 and p40 in the 
serum of patients with acute pancreatitis. The levels of total IL-12 heterodimer and the p40 
subunit were found to be significantly increased during days 1 to 6 following admission, 
while the level of the p70 subunit was significantly increased on day 1 but subsequently 
decreased on days 2, 3 and 4 of illness. Increased levels of the p40 subunit were also 
associated with increased susceptibility to infection (Pezzilli et al, 1999). 
Experiments involving ceru1ein-induced acute pancreatitis in control, nude 
(athymic) and CD4+ T cell depleted mice have indicated a role of CD4+ T cells in 
experimental acute pancreatitis. In the control mice, CD4+ T cells were present in the 
pancreas during acute pancreatitis and correlated with severity, however, in the nude and 
CD4+ T cell depleted mice the characteristic pancreatic features of severe acute pancreatitis 
were absent. Subsequent transfer of T cells into the nude mice partially restored the 
severity of acute pancreatitis and demonstrated that CD4+ T cells are involved in the 
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development of tissue injury during acute experimental pancreatitis in mice (Demo is et a!, 
2000). 
3.5.5.6 Tumour Necrosis Factor Alpha (TNFa) 
TNFa is a macrophage derived pro-inflammatory cytokine that is capable of 
inducing the secretion of other cytokines including IL-l, IL-6, IL-8 and IL-10 (Tracey and 
Lowry, 1990). Serum TNFa levels are elevated in patients with sepsis and correspond to 
disease severity (Damas et al, 1989). Since acute pancreatitis shares many clinical 
characteristics with sepsis, several clinical studies have been carried out to demonstrate a 
correlation between serum TNFa levels and disease severity in acute pancreatitis, 
however, the results are conflicting. Early studies showed that serum TNFa levels were not 
a reliable indicator of disease severity (Banks et a!, 1991; Paajanen et a!, 1995; De Beaux 
et a!, 1996). TNFa is not always detectable in the serum of pancreatitis patients because it 
is rapidly removed from the circulation by the liver (Grewal et a!, 1994a). In contrast, a 
more recent attempt to correlate serum TNFa levels with severity has found that they were 
significantly elevated in severe patients compared to mild patients on days 1-3 following 
admission, but this trend did not continue on days 4-7 (Chen et a!, 1999). 
Isolated peripheral blood monocytes from 26 patients with moderate to severe acute 
pancreatitis and stimulated with LPS showed that TNFa secretion was significantly 
increased in patients with systemic complications compared to patients with an 
uncomplicated course (McKay et a!, 1996). De Beaux et a!, however, showed that in a 
similar experiment with a mixed PBMCs culture containing both monocytes and 
lymphocytes taken from 58 patients, TNFa levels were similar to those of controls 
following stimulation with the same mitogen (De Beaux et a!, 1996). 
TNFa mediates its actions through its binding to 2 membrane bound surface 
receptors on the target cells known as p55 and p75. Following exposure to TNFa, the 
target cells downregulate their response to TNFa by shedding these receptors into the 
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circulation (Van der Poll and Lowry, 1995). Studies have shown that the soluble receptors 
appear to be better indicators of disease severity and increased levels predict organ failure 
in patients with acute pancreatitis (De Beaux et a!, 1996; Heresbach et a!, 1998; Kaufinan 
et a!, 1997). Furthermore, Spinas et a!, demonstrated a significant correlation between peak 
serum TNFa and sTNFR55 in human volunteers after intravenous administration of E. coli 
endotoxin suggesting that sTNFR55 may reflect the degree of TNFa-induced 
inflammation and may reflect severity of disease (Spinas et a!, 1992). Experiments using 
germ-free rats have shown that TNFa levels rise in the pancreas despite the absence of 
endotoxin indicating a primary role of TNFa in the disease (Hughes et a!, 1995). Vaccaro 
et a!, have recently shown that acinar cells that are stressed also produce TNFa during 
acute pancreatitis (Vaccaro et a!, 2000). 
Although TNFa does not induce acute pancreatitis, TNFa levels are toxic to acinar 
cells and induce apoptosis in cerulein-induced model in rats suggesting that acinar cells do 
not only die from necrosis or autodigestion during acute pancreatitis (Gukovskaya et al, 
1997; Norman et a!, 1997a). Furthermore TNFa receptor gene knockout animals have 
shown that acinar cells unable to respond to TNFa do not undergo apoptosis during acute 
pancreatitis (Norman et al, 1997a). The TNFa-induced apoptosis correlates with severity 
ofthe disease (Gukovskaya et al, 1997; Norman et a!, 1997a). 
Neutralization of TNFa with an anti-TNFa polyclonal antibody in a rat model of 
bile-induced acute pancreatitis showed a decrease in pancreatic severity, improved 
pulmonary complications and survival (Grewal et al, 1994b; Hughes et al, 1996a). In 
contrast, an earlier experiment carried out by Guice et al, showed that the administration of 
an anti-TNFa antibody to a cerulein-induced rat model actually increased edema in both 
the pancreas and lung (Guice et a!, 1991). 
Norman et al, used a recornbinant type I TNFa receptor to antagonise TNFa both 
prophylactically and therapeutically in a CDE-induced mouse model of acute pancreatitis. 
65 
Both methods of treatment resulted in improved survival and a decrease in severity with 
reduced levels of IL-l and IL-6, however, the effect was more pronounced in mice that had 
received the treatment therapeutically demonstrating that the timing of treatment is 
important in outcome (Norman et al, 1996a). 
Methods that interfere with the synthesis and release of TNFa may have 
therapeutic potential. As with many genes, TNFa expression is controlled by transcription 
factors such as nuclear factor KB (NFKB). Pretreatment with amobarbital, a drug which 
blocks the activation of the transcriptional factor showed that both NFKB activation and 
TNFa expression were prevented with a decreased severity in a pancreatic duct-ligation 
acute pancreatitis model in rats (Dunn et al, 1997). In addition an inhibitor of p38 map 
kinase which is also involved in TNFa production has prevented pancreatitis-associated 
lung injury in bile-induced model in rats (Yang et al, 1999). Calcium has a role in TNFa 
release and pretreatment with a calcium channel blocker called diltiazem was found to 
inhibit its release in acute pancreatitis and ameliorate severity of the disease in a bile-
induced rat model (Hughes et a!, 1996b) 
Another method of inhibiting TNFa and IL-l production is by macrophage 
inhibition using CNI-1493, a small organic molecule that inhibits the translation of mRNA 
to protein. IL-l and TNFa production in the pancreas and lungs were found to be 
decreased in animals treated with CNI-1493 and there was a decrease in severity (Denham 
et al, 1997a). A later study has shown that CNI-1493 is capable of preventing many of the 
sequelae of experimental pancreatitis. Hepatocellular production of IL-l and TNFa and 
hepatocellular injury during acute pancreatitis are also attenuated in animals treated with 
CNI-1493 (Yang et all998b). 
Other methods of reducing TNFa levels that have been shown to improve the 
severity of acute pancreatitis and its complications include: pretreatment with 
propentoxyfylline, a xanthine derivative in rats with cerulein-induced acute pancreatitis 
and endotoxemia (Sugita et al, 1997); octreotide treatment administered simultaneously 
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with iaucm)late 'induction in ·'rats (Martpn, :et · al, 1998) and. :administration .. of :anti-
in"flammatocy- :c)itokines such as, Th-fO and 'IL-li"a. (Derihafu: et :al, J.998a; Kl!sske et aH 
CHAPTER 4: THE INTERLEUK.IN-1 GENE CLUSTER AND ITS ROLE IN 
ACUTE PANCREATITIS 
4.1 Introduction to the Interleuk.in-1 Gene Cluster 
The interleukin-1 gene cluster describes a collection of genes that are located on the 
long arm of chromosome 2 (2q13-2q21) which are concerned with the synthesis and 
regulation of the pro-inflammatory cytokine, interleukin-1 (IL-l) (Webb et al, 1986; 
Lafage et al, 1989; Lennard et al, 1992; Nicklin et al, 1994). IL-IA and IL-IB code for the 
2 forms of the agonist interleukin-1 alpha (IL-Ia) and interleukin-1 beta (IL-lp) 
respectively, while IL-IRN codes for the receptor antagonist (IL-lra). The intron-exon 
organisation of these genes suggests duplication of a common gene more than 350 million 
years ago (Dinarello, 1994). IL-l has many biological actions that are mediated through its 
binding to the two IL-l receptors known as Type I IL-l receptor (IL-IRI) and Type II IL-l 
receptor (IL-l RII). The genes for these receptors have also been mapped to the same 
region of chromosome 2 (Sims et al, 1995; Dale and Nicklin, 1999)(Figure 4.1 ). 
4.2 Interleukin-1 alpha and lnterleukin-1 beta 
The first form of human IL-l to be identified was IL-l p. Its cDNA sequence was 
cloned in 1984 from peripheral blood monocytes by Auron et al. This cDNA sequence was 
translated to form a 269 amino acid precursor which could be cleaved into a mature protein 
comprising 153 amino acids with a molecular weight of l7kDa (Auron et al, 1984). The 
cDNA sequence for human IL-l a was cloned in 1986 from a library of human macrophage 
cDNA (March et al, 1985) and was found to be homologous to the murine IL-Ia cDNA 
sequence (Lomedico et al, 1984). Translation of the human IL-Ia cDNA sequence 
produced a 271 amino acids precursor, which could be cleaved into a mature form of 159 
amino acids with a molecular weight of 17kDa (March et al, 1985). 
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Figure 4.1: Map of the Interleukin-1 gene cluster and lnterleukin-1 receptor genes 
Centromere IL-lRII IL-lRI Telomere 
The interleukin-1 gene cluster describes a collection of genes that are located on the long arm of chromosome 2 (2q 13-2q21) which are concerned with 
the synthesis and regulation of the pro-inflammatory cytokine, interleukin-1 (IL-l). IL-lA and IL-lB code for the 2 forms ofthe agonist interleukin-1 
alpha (IL-l a) and interleukin-1 beta (IL-l p) respectively, while IL-l RN codes for the receptor antagonist (IL-lra). IL-l has many biological actions 
that are mediated through its binding to the two IL-l receptors known as Type I IL-l receptor (IL-lRI) and Type II IL-l receptor (IL-lRII). The genes 
for these receptors have also been mapped to the same region of chromosome 2. 
(Adapted from Nick:in et al., 1994 and Dale and Nicklin, L999) 
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The complete genomic sequences of human IL-1A and IL-lB have also been determined 
(Furutani et al, 1986; Clark et al, 1986). These genes each contain 7 exons and share 45% 
homology in their nucleotide sequences (Gubler et al, 1986). IL-1A is 7.8kb long, while 
IL-1B is 10.5kb long. Both genes give rise to proteins that form a 13-pleated sheet tertiary 
structure (Murzin et al, 1992) and which exhibit 26% homology at the amino acid level 
(Gubler et al, 1986). 
Many different cell types, in particular monocytes and macrophages produce IL-l 
(Dinarello, 1991). Transcription can be induced by a wide variety of microbial (endotoxin) 
and non-microbial stimulants. Non-microbial stimulants include stress factors (e.g. 
ischemia-reperfusion), neuroactive substances (e.g. Substance P), inflammatory substances 
(e.g. complement components), cell matrix components (e.g. collagen), clotting factors 
(e.g. thrombin), lipids (e.g. PAF) and cytokines (e.g. IL-l, TNFa, IL-2, IL-3, IL-12, GM-
CSF) (Dinarello, 1996). Despite the similarity in gene and protein structure, the two forms 
of IL-l are synthesized in different ways. 
4.2.1 Synthesis oflnterleukin-1 alpha 
Following stimulation by an inducing agent such as endotoxin, the monocyte starts 
to synthesize the 31 kDa pro IL-l a precursor in association with microtubules (Stevenson et 
al, 1992; Rubartelli et al, 1990). This precursor comprises 2 subunits, a 16kDa propiece 
and a 17kDa unit that eventually forms the mature IL-l a protein. Because the 31 kDa 
pro IL-l a lacks a leader peptide, it is not secreted and remains in the cytosol. This 
intracellular pro IL-l a is fully active and exerts a direct autocrine effect on the cell by 
binding to the nuclear DNA (Mosley et al, 1987). Approximately 10% to 15% of the 
31 kDa pro IL-l a, however, undergoes a post-translational modification known as 
myristoylation (addition of fatty acids) that facilitates its passage to the cell membrane 
(Stevenson et al, 1993). This myristoylated proiL-la is then transported to the cell 
membrane to which it becomes attached. This membrane bound IL-Ia is biologically 
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active and serves as a paracnne messenger to adjacent cells. Alternatively, the 
myristoylated proiL-la may be cleaved into the 17kDa mature IL-la by the calcium-
dependent membrane-associated cysteine proteases called calpains with the release of the 
16kDa IL-l a propiece (Kobayashi et al, 1990). 
After cleavage, this 17kDa mature IL-la is released into the extracellular 
compartment while the 16kDa IL-la propiece, like the intracellular 3lkDa proiL-la binds 
to the nuclear DNA and acts as an autocrine messenger (Stevenson et a!, 1992) (Figure 
4.2). 
4.2.2 Synthesis of Interleukin-1 beta 
Following stimulation by an inducing agent, the inactive 31 kDa pro IL-l P is 
synthesized by polysomes in the cytosol and associated with microtubules (Rubartelli et a!, 
1990). Like the proiL-la, the proiL-lP is comprised of a 16kDa IL-IP propiece and a 
17kDa unit that eventually forms the mature IL-l p protein. Simultaneously, interleukin-1 P 
converting enzyme (ICE) is translated in the rough endoplasmic reticulum as an inactive 
precursor (proiCE). This proiCE is converted to its active heterodimer form by active ICE 
present in the cytosol. After activation, the active ICE heterodimer molecules accumulate 
at the inner surface of the cell membrane where they combine with each other to form ICE 
tetramers. Each ICE tetramer associates with 2 molecules of the 3lkDa proiL-lP and 
causes cleavage that results in the formation of the 17kDa mature IL-l P and 16kDa IL-l P 
propiece (Wilson et a!, 1994; Walker et a!, 1994). The 17kDa mature IL-l p is secreted into 
the extracellular compartment through a membrane channel while the 16kDa IL-l p 
propiece becomes distributed both inside and outside the cell (Higgins et a!, 1994). A small 
amount of 31kDa pro IL-l p may be transported into the extracellular space via the 
membrane channel. 
71 
Figure 4.2: Synthesis ofiL-la. and IL-1J3 by monocytes 
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Stimulated monocytcs synthesize the 3lkDa proiL-Ia. and proiL-lP precursors that comprise a 16kDa propiece and a 17kDa mature protein. ProiL- la. binds to the nuclear 
DNA and acts as an autocrine messenger. 10%-15% of the proiL-la. becomes myristoylated and transported to the cell membrane to which it becomes attached and acts as 
a paracrine messenger. This myristoylated proiL-la. may also be cleaved into the 17k.Da mature IL-l a. by calpain with the release of the 16k:Da IL-l a. propiece. Tite 17kDa 
mature IL-Ia. is secreted while the 16kDa IL-la. propiece acts as an autocrine messenger. During IL-lP production, inactive ProiCE is simultaneously produced and is 
converted to its active heterodimer form by active ICE. Two ICE heterodimers combine to form ICE tetramers. Each ICE tetramer associates with 2 molecules of the 3lk.Da 
proiL-lP to cause cleavage that results in the formation of the 17k.Da mature IL-lP and 16k.Da IL-lP propiece. The 17k.Da mature IL-l P is secreted through a membrane 
channel while the 16kDa IL-lP propiece becomes distributed both inside and outside the cell. A small amount of 3lk.Da proiL-l P may also be secreted from the cell via the 
memhrane channel. 
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When ICE activity within the cell is inhibited, increased proiL-1 P is found in the 
extracellular compartment where it can bind to soluble type II IL-1R (Sims et al, 1994; 
Symons et al, 199l)(Figure 4.2). 
4.2.2.1 lnterleukilr-1 beta converting enzyme (ICE) 
ICE also known as Caspase 1, is an intracellular cysteine protease that cleaves 
inactive pro IL-l P at aspartic acid position 116 to its mature active IL-l P form. A second 
ICE cleavage site in pro IL-l p is located at aspartic acid position 27 and accounts for the 
22kDa form of IL-l p found in monocyte cell supernatants. The importance of ICE in the 
processing of IL-l p is demonstrated in ICE-deficient mice whose macrophages do not 
release mature IL-IP upon stimulation in vivo (Kuida et al, 1995). ICE is specific for 
pro IL-l p and does not cleave pro IL-l a (Ho ward et al, 1991 ), however, it has also been 
found to cleave proiL-18 into mature IL-18, a new member of the IL-l family (Gu et al, 
1997). 
The cDNA sequence for ICE was isolated in 1992 and was found to encode a 
45kDa precursor form of ICE known as ProiCE (Ceretti et al, 1992; Thornberry et al, 
1992). The gene for ICE designated ILlBC has also been identified. It is 10.5kb long, 
consists of 9 introns and 10 exons and is located on chromosome 11 (q22.2-q22.3) 
(Cerretti et al, 1994). ICE is synthesized in a 45kDa precursor form (proiCE) which is 
cleaved internally twice by itself to its mature heterodimer form which consists of a I OkDa 
and a 20kDa chain containing the active site (Wilson et al, 1994; Gu et al 1995). Two 
molecules of the ICE heterodimer are required to form a tetramer with 2 molecules of 
pro IL-l p in order for cleavage to occur (Wilson et al, 1994). The activity of ICE is 
regulated by a competitive inhibitor that reduces maturation and secretion of IL-l p and 
encourages the accumulation of proiL-11} within the cell (Thornberry et al, 1992). 
Furthermore, ICE has 5 isoforms resulting from alternative splicing ofmRNA. ICEa is the 
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most active whereas ICEE is inactive and can have an inhibitory effect on the enzyme 
activity (Wu et al, 1995). 
The ICE gene is homologous to the ced-3 gene of the nematode Caenorhabditis 
elegans that has a role in apoptosis (Y uan et al, 1993). Overexpression of the ICE gene 
leads to increased apoptosis in cells transfected with the gene suggesting a role for IL-l 
and ICE in apoptosis (Miura et al, 1993; Faucheu et al, 1995). It is important to know 
whether ICE and IL-l play a role in apoptosis since therapies aimed at inhibiting ICE and 
hence reducing IL-l production are being investigated at present and could have a 
secondary effect on inhibiting apoptosis and prolonging the survival of malignant cells. 
4.3 Interleukin-1 receptor antagonist 
Interleukin-1 receptor antagonist (IL-lra) is a naturally occurring inhibitor of IL-l 
that competes for occupancy of the IL-l receptors but does not induce a signal (Dripps et al 
1991; Granowitz et al, 199la). The gene that encodes IL-lra known as IL-IRN consists of 
4 exons with 2 alternative first exons that give rise to the 2 main forms of IL-l ra: a 
secreted form (siL-l ra) and an intracellular form iciL-lra (Lennard et al, 1992). When the 
secretory promoter (exonls) is used, the protein possesses a signal peptide and is secreted 
(siL-lra), however, when the intracellular promoter (exonlic) is used there is no signal 
peptide and the protein remains intracellular (iciL-1 ra)(Haskill et al, 1991; Butcher et al, 
1994). 
4.3.1 Secretory lnterleukin-lreceptor antagonist (siL-lra) 
The secreted form of IL-l ra was first reported as an IL-l inhibitor binding activity 
of 22kDa in the supematant of human monocytes cultured on adherent IgG (Arend et al, 
1985). The cDNA for tllis form of the antagonist sequence was subsequently isolated from 
a monocyte library and was translated to form a 17kDa unglycosylated protein consisting 
of 177 amino acids. Cleavage of a 25 amino acid leader peptide followed by a variable 
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degree of glycosylation resulted in the mature protein comprising of 152 amino acids with 
a molecular weight of 22-25kDa (Hannum et al, 1990; Eisenberg et al, 1990). IL-l ra shares 
26% amino acid homology with IL-l~ and 19% homology with IL-l a (Eisenberg et al, 
1990; Carter et al, 1990). Despite having a similar ~ pleated sheet tertiary structure to the 
agonists (Vigers et al, 1994), IL-lra does not initiate a signal on binding to the IL-l 
receptors. Cells known to produce the secretory form of the antagonist include monocytes, 
macrophages and neutrophils (Arend et al, 1998). siL-lra can also be produced by the liver 
following stimulation by IL-l or IL-l and IL-6 in much the same way as C reactive protein 
(CRP) and therefore it has been suggested that IL-lra is an acute phase protein (Gabay et 
al, 1996). 
4.3.2 Intracellular Interleukin-lreceptor antagonist (iciL-lra) 
The cDNA for the intracellular form (iciL-1 ra) was first isolated from keratinocytes 
and digestive epithelial cells and was translated to form a 159 amino acid non-glycosylated 
protein with a molecular weight of 18kDa (Haskill et al, 1991; Hammerberg et al, 1992). 
iclL-lra is expressed constitutively by these cells and in a large excess over IL-Ia. Unlike 
the secreted form of IL-l ra, the intracellular form is not normally found in plasma but may 
be released from cells when they are damaged to counteract the eo-released IL-l. Epithelial 
cells such as keratinocytes are exposed to the external environment and are therefore 
particularly at risk from insults. In addition, iciL-lra may also have a role in inhibiting the 
intracellular binding of IL-l a to nuclear receptors and hence preventing its action as an 
autocrine messenger (Haskill et al, 1991; Arend. 1993). iciL-lra production can also be 
induced in monocytes and fibroblasts (Arend et al, 1998). More recently, a second form of 
iciL-lra known as 16kDa non-glycosylated iciL-lra type II that is generated by alternative 
translation initiation of the mRNA has been described in neutrophils, monocytes and 
hepatic cells (Mal yak et al, 1998). The function of this form of iciL-1 ra remains unknown 
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but it may act as an IL-lra reservoir that is released upon cell death to help the secreted 
form to limit inflammation. 
Transcription of IL-l ra can be stimulated by a wide variety of cytokines (IL-l, IL-
2, IL-3, IL-4, IL-6, IL-10, IL-13, IFNy, GM-CSF, TGFp) and other stimuli including LPS, 
adherent lgG, acute phase proteins (APP) and immune complexes (Arend et al, 1998). 
4.3.3 Synthesis oflnterleukin-1 receptor antagonist 
During the first 24 hours following stimulation the monocyte uses the siL-l ra 
promoter. The primary transcript is pro(s)IL-lra that is translated in the endoplasmic 
reticulum and transported to the Golgi. Following cleavage of the leader sequence, siL-l ra 
is secreted from the cell (Arend, 1993). After 48 hours, the monocyte exhibits macrophage 
characteristics and uses the iciL-lra promoter to transcribe iciL-lra. Since iciL-lra lacks a 
leader sequence, it is not secreted but remains intracellular (Andersson et al, 1992) (Figure 
4.3). 
4.4 Tbe Interleukin-1 receptor family 
The IL-l receptor family consists of 3 molecules: 2 true receptors called IL-l type I 
(IL-lRI) and IL-l receptor type I1 (IL-lRll) and IL-l receptor accessory protein (TL-IR-
AcP). The receptors belong to the immunoglobulin superfamily and exist in membrane and 
soluble forms. They have 3 domains, an extracellular domain, a transmembrane domain 
and a cytoplasmic domain however, the lengths of these domains varies between the 2 
types of receptors. 
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Figure 4.3: IL-l ra synthesis by monocytes 
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During the first 24 hours following stimulation the monocyte uses the siL- l ra 
promoter. The primary transcript is pro(s)IL-1 ra that is translated in the 
endoplasmic reticulum and transported to the Golgi. Following cleavage of the 
leader sequence, siL-l ra is secreted from the cell. After 48 hours, the monocyte 
exhibits macrophage characteristics and uses the iciL-1 ra promoter to transcribe 
iclL-1 ra. Since iclL-1 ra lacks a leader sequence, it is not secreted but remains 
intracellular. 
(Adapted from Dinarello, 1996) 
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4.4.1 Membrane receptors 
4.4.1.1 Type I receptor 
IL-1RI is an 80kDa glycoprotein expressed at the surface of numerous types of 
cells including endothelial cells, fibroblasts, chondrocytes smooth muscle cells and T 
lymphocytes. The extracellular, transmembrane and cytoplasmic domains of this receptor 
contain 316, 20 and 213 amino acids, respectively (Sims et al, 1988). IL-1RI is the only 
one of the 2 receptors that is capable of transmitting a signal when it is occupied by IL-l 
(Stylianou et al, 1992; Sims et al, 1993). IL-l is a very potent cytokine and requires only 
50-200 receptors per target cell to transmit a signal (Shirakawa et al, 1987). Because IL-
1RI is involved in signal transduction, its expression can affect the activity of IL-l. 
Increased expression of this receptor causes increased IL-l activity. Agents known 
to increase the expression ofiL-lRI include phorbol esters, PGE2, dexamethasone, vitamin 
D3, IL-2 and IL-4 (Dinarello, 1994). IL-l itself can also upregulate or downregulate IL-
1RI expression depending on whether the cell produces PGE2• In cells producing PGE2 it 
increases IL-lRI expression (Takii et al, 1992), but in cells that do not produce PGE2 it 
reduces IL-l RI expression (Takii et al, 1994). 
4.4.1.2 The interleukin-1 receptor accessory protein 
The interleukin-1 receptor accessory protein (IL-lR-AcP) is required for signal 
transduction following the binding of IL-l to IL-l RI. The process of signal transduction is 
described in Section 4.5. Unlike the genes for the "true" IL-l receptors which are located 
on chromosome 2 (Sims et al, 1995), the gene which codes for IL-lR-AcP has been 
mapped to 3q38 (Dale et al, 1998). 
4.4.1.3 Type 11 receptor 
The second receptor is a 68kDa glycoprotein that is found on B lymphocytes, 
neutrophils and bone marrow cells. The extracellular, transmembrane and cytoplasmic 
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domains are 336, 26 and 29 amino acids long respectively (McMahan et al, 1991). Due to 
the short cytoplasmic domain, IL-l Rll does not transmit a signal but acts as a "decoy 
receptor" and is a negative regulatory factor for IL-l which remains trapped on the 
receptor which prevents it from inducing a signal (Colotta et al, 1993). It has been 
suggested that the function of the membrane bound type II receptor is to serve as the 
precursor for a soluble IL-l binding factor that can be shed under appropriate 
circumstances to antagonize and modulate IL-l activity (Sims et al, 1993). Because IL-
lRll is a "decoy receptor", increased expression inhibits IL-l activity. Agents known to 
increase the expression of IL-lRll include dexamethasone, IL-4 and IL-13 (Colotta et al, 
1993; Re et al, 1994; Colotta et al, 1996) and IL-l itself (Dinarello, 1996). IL-lRI has a 
higher affinity for IL-l a and IL-l ra whereas the IL-l Rll has a higher affinity for IL-l p. 
4.4.2 Soluble receptors 
The soluble forms of the 2 receptors result from the cleavage of the extracellular 
portion of the membrane receptors and exhibit 28% amino acid homology. These receptors 
are found in both healthy (Sims et al, 1994; Symons et al, 1991) and diseased subjects 
(Arend et al, 1994). Like the membrane IL-l receptors, the soluble receptors exhibit 
preferential binding. The soluble extracellular domain of IL-lRI (siL-lRI) binds IL-
l ra>IL-1 a> IL-l p, while the soluble extracellular domain of IL-lRII (siL-lRII) binds IL-
lP>proiL-lP>IL-la>IL-lra. Since the membrane receptors act as a source of soluble 
receptors, agents that increase the expression of the membrane forms also increase the 
levels of the soluble forms. Increased levels of siL-l RI preferentially bind IL-l ra and 
hence increase IL-l activity whereas increased siL-l Rll preferentially bind IL-l p and 
decrease IL-l activity. Because of their inhibitory effect on IL-l activity, siL-l RII exhibit 
therapeutic potential. 
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4.5 Signal transduction 
IL-l binds to the extracellular domain of either type I {IL-l RI) or type 11 {IL-l RII) 
receptors on the target cell. IL-l RI has a higher affinity for IL-l a whereas IL-l RII has a 
higher affinity for IL-l~. IL-l binds to IL-lRI with its two receptor binding sites to form a 
low affinity binding complex (IL-1/IL-1 RI). This causes a structural change in the 
cytoplasmic domain of the receptor which allows the IL-l R accessory protein (IL-l R-AcP) 
to combine with the low affinity binding complex (IL-1/IL-lRI) to form a high affinity 
heterodimer complex (IL-lRI/IL-1/IL-lR-AcP) with the initiation of signal transduction 
(Greenfeder et al, 1995). The cytoplasmic domains of the IL-l RI and IL-lR-AcP contain 
areas of GTPase activity. When the IL-1/IL-lRI and IL-lR-AcP form the heterodimer 
complex they are in close proximity and there is hydrolysis of GTP by intrinsic GTPase 
activity of the cytoplasmic domains. This leads to a signal transduction phosphorylation 
cascade and to activation of NF-KB regulated transcription. Because IL-lRil lacks a 
cytoplasmic domain when IL-l binds to it no signal is transduced. IL-lRII therefore acts as 
a decoy receptor for IL-l (Dinarello, 1998). IL-lra binds to IL-lRI with only one receptor 
binding site (Evans et al, 1995) and therefore does not result in a structural change of the 
receptor. This means that IL-lR-AcP does not form a high affinity complex with the IL-
1/IL-lRI so no signal is transduced and there is no biological response (Dripps et al, 
199l)(Figure 4.4). 
The binding of IL-l to its receptor on a target cell and the subsequent signal 
transduction, affects the expression of a wide range of genes within the cell. Genes whose 
expression is increased include those that encode enzymes such as cyclooxygenase 
(production of prostaglandins and thromboxanes), phospholipase A2 (production of PAF 
and leukotrienes, prostaglandins and thromboxanes) and inducible nitric oxide synthase 
(production of NO). The expression of cytokines such as IL-l, TNFa, IL-6, and IL-8 and 
adhesion molecules such as ICAM-1, ELAM and VCAM-1 are also increased. 
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Figure 4.4: Cell receptors for IL-l 
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IL-l binds to IL-lRI with its two receptor binding sites to form a low affinity binding complex. This causes a structural change in the cytoplasmic 
domain of the receptor which allows IL-lR-AcP to combine with the low affinity binding complex to form a high affinity heterodimer complex. 
The close proximity of the two GTPase leads to hydrolysis, a signa] transduction phosphorylation cascade and to activation of NF-KB regulated 
transcription. Because IL-lRII lacks a cytoplasmic domain when IL-l binds to it no signal is transduced. IL-lRII therefore acts as a decoy receptor 
for IL-l . IL- l ra binds to IL-l RI with only one receptor binding site and therefore does not result in a structural change of the receptor. This means 
that IL-IR-AcP does not form a high affinity complex with the IL-1/IL-lRI so no signal is transduced and there is no biological response. 
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Genes whose expression is decreased following IL-l receptor binding include genes for 
albumin and cytochrome p450 (Dinarello, 1996). 
The administration of IL-l to humans with certain solid tumours causes both local 
manifestations such as localised pain and edema and systemic manifestations such as 
hypotension, fever and systemic pain that are caused by the products of the upregulated 
gene expression. IL-l, TNFa, IL-6 and P AF activate leucocytes, IL-8 and L TB4 are 
chemotactic for the activated leucocytes and ICAM-1, ELAM, and VCAM-1 are involved 
in leucocyte migration. Furthermore, leukotrienes and NO increase vascular permeability 
allowing the inflammatory exudate to accumulate in the damaged tissue causing the local 
edema, while prostaglandins are responsible for pain and fever. Prostaglandins and NO 
also cause vasodilatation leading to hypotension (Dinarello, 1997). 
4.6 Biological actions of Interleukin-1 
IL-l is a pleiotropic cytokine that shares a wide variety of biological actions with 
TNFa. These actions can be classified as non-immunological, immunological and 
hematopoietic (Figure 4.5). IL-l may act alone or in synergy with other cytokines. 
4.6.1 Non-immunological actions 
IL-l acts on the central nervous system to induce fever (Dinarello and Woolf, 
1982), slow wave sleep (Dinarello, 1988a) and the release of the hormones corticotropin-
releasing factor (CRF) and adrenocorticotropin (ACTH) that cause steroidogenesis in the 
adrenal glands (Sapolsky et at, 1987). IL-l also acts directly on the adrenal glands to 
induce steroidogenesis (Lee et at, 1988). Small doses of IL-l have been shown to induce 
insulin production, whereas larger doses are cytotoxic to p cells of the pancreas and may 
therefore be implicated in the pathogenesis of diabetes (Mandrup-Poulsen et at, 1986). 
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Figure 4.5: Biological actions of IL-l 
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IL-l has many biological actions that can be divided into non-immunological, immunological and hematopoietic. 
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Another important action of IL-l is to cause the acute phase response in the liver resulting 
in an increase in hepatic protein synthesis and a decrease in albumin production (Ramadori 
et al, 1985). IL-l also induces prostaglandin synthesis in endothelial cells and smooth 
muscle cells. These substances cause vasodilatation and are responsible for the 
hypotension associated with IL-l (Dinarello, 1988b; Dejana et al, 1987). In addition, IL-l 
exhibits catabolic effects that include the induction of collagenase production in synovial 
cells, chondrocytes and osteoclasts (Dayer et al, 1986; Eastgate et al, 1988). These 
catabolic properties of IL-l in cartilage and bone are involved in the pathogenesis of 
diseases such as rheumatoid arthritis and osteoarthritis. 
4.6.2 Immunological actions 
IL-l causes T cell activation resulting in the increased IL-2 production and 
expression ofiL-2 receptors (Kaye and Janeway, 1984) and induces the production of IL-4 
and GM-CSF from activated T cells (Herrmann et al, 1988). In B cells it causes activation 
and increased immunoglobulin synthesis (Abbas et al, 1987; Lipsky et al, 1983). IL-l acts 
on monocytes and macrophages inducing its own synthesis and the production of TNFa 
and IL-6 (Lovett et al, 1986; Navarro et al, 1989). Furthermore, IL-l synergizes with other 
cytokines such as IL-2 to activate NK cells (Ben Aribia et al, 1987) and produce LAK cells 
(Kovacs et al, 1989). Since these cells have tumoricidal effects, IL-l indirectly promotes 
anti-tumour activity. In vitro studies using tumour cell lines have demonstrated that IL-l is 
also directly toxic to tumour cells, however, the response of the tumours to IL-l appears to 
be clonal dependent. Some cell lines such as human ovarian carcinoma are killed by IL-l 
(Kilian et al, 1991), whereas others such as human astrocytoma are not susceptible to IL-l 
and actually proliferate more in its presence (Lachman et al, 1987). Furthermore, it has 
been shown that mice with subcutaneous B 16 melanoma tumours that are known to 
produce IL-l benefited from IL-lra treatment (McKenzie et al, 1996). IL-l therapy would 
therefore not be applicable to this type of malignancy. IL-l has been implicated in the 
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pathogenesis of leukemia (Rambaldi et al, 1991; Wetzler et al, 1994) and therefore it is 
important to emphasize that IL-l treatment for solid tumours may increase the risk of 
developing leukemia. 
4.6.3 Hematopoietic actions 
IL-l causes the production of hematopoietic growth factors such as CSF from a 
variety of cells. Furthermore, it synergizes with CSF or IL-3 to promote the growth of 
primitive hematopoeitic stem cells (Stanley et al, 1986). Levels of IL-l are important in the 
pathogenesis of hematopoietic diseases such as leukaemia and bone marrow failure states. 
Increased levels of IL-l have been described in patients with leukaemia (Rambaldi et al, 
1991; Wetzler et al, 1994) whereas decreased levels have been found in bone marrow 
failure states such as aplastic anaemia (Nakao et al, 1989). Patients with leukaemia would 
therefore benefit from IL-l ra therapy, whereas patients with aplastic anaemia would 
benefit from IL-1 therapy. Furthermore, because of its role in promoting hematopoeisis, 
IL-l can also be used in combination with chemotherapy and after bone marrow 
transplants to accelerate bone marrow recovery (Dinarello, 1996). 
4.7 Interleukin-1 and Interleukin-lreceptor antagonist in health and disease 
With the exception of skin keratinocytes, other epithelial cells, ovarian granulosa 
cells and certain cells of the central nervous system, the cells of healthy individuals do not 
produce IL-l. During pathological conditions such as infection, however, the transcription 
of IL-l is upregulated in a wide variety of cells particularly monocytes and macrophages. 
Increased IL-l production has been reported in a number of diseases including: 
Alzheimer's disease (Griffin et al, 2000); AP (Chen et al, 1999); IBD (Nakamura et at, 
1992; Ligumsky et al, 1990); sepsis (Cannon et al, 1990); rheumatoid arthritis (Eastgate et 
al, 1988); acute myelogenous leukaemia (Rambaldi et al, 1991); chronic myelogenous 
leukaemia (Wetzler et al, 1994); IDDM (Mandrup-Pou1sen et al, 1986); tuberculosis 
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(Fujiwara et a!, 1986); leprosy (Watson et a!, 1984); meningococcemia (Girarddi et a!, 
1988) and atherosclerosis (Galea et a!, 1996). 
In contrast to IL-l, IL-lra circulates at low levels in healthy individuals (Hurme 
and Santilla, 1998). During disease these IL-lra levels increase dramatically in an attempt 
to counteract the rise in IL-l levels. Despite the elevation of IL-l during disease, levels 
often remain low and are difficult to detect. Consequently IL-lra levels have proven to be 
a better indicator of disease than IL-l. Elevated levels of IL-lra have been detected in a 
variety of human diseases (Table 4.1 ). 
It has been suggested that the IL-l ra: IL-l ratio is important in the pathogenesis of 
disease (Dinarello and Wolff, 1993). The amount of IL-lra that is required to block the 
action of IL-l is very high despite relatively low plasma levels of IL-l. Granowitz et al, 
found that a 100 fold excess in vitro and 1000 fold excess in vivo ofiL-lra relative to IL-l 
was required to block the action of IL-l in models of endotoxemia (Granowitz et al, 
199lb). The reason why so much IL-lra is required to block IL-l activity when IL-l levels 
are relatively low is not fully understood and a number of theories have been postulated. 
These include: an underestimation of IL-l production during disease; high potency of IL-
l/high sensitivity of IL-l type I receptors to IL-l; binding of IL-l ra to the soluble type I 
receptor; poor tissue penetration of IL-l ra; short plasma half-life of IL-l ra and rapid 
clearance of IL-lra from the body by the kidneys. 
Diseases are thought to occur when the IL-lra: IL-l ratio is decreased. The 
increased production of IL-l relative to IL-lra disturbs this balance favouring the pro-
inflammatory state and there is insufficient IL-lra to counteract the action of IL-l. This 
was demonstrated in experimental endotoxemia in human volunteers where despite there 
being an 100 fold excess of IL-l ra relative to IL-l, the balance remained in favour ofiL-1 
activity resulting in shock (Granowitz et al, 1991 b). 
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Table 4.1: Increased levels of IL-lra in buman disease 
Disease 
Inflammatory diseases 
Periodontitis 
Idiopathic pulmonary fibrosis 
Sarcoidosis 
Myocardial infarction 
Subarachnoid hemorrhage 
Cerebral infarction 
Hemophagic lymphohistiocytosis 
Thermal injury 
Poliomyositis/dermatomyositis 
Ulcerative colitis 
Acute hepatitis 
Pars Planitis and Behcet Disease 
Infectious diseases 
HIV infection 
Sepsis 
Experimental endotoxemia 
Pediatric sepsis syndrome 
Neonatal sepsis 
Autoimmune diseases 
SLE 
Relapsing/remitting multiple sclerosis 
Juvenile chronic arthritis 
Rheumatoid arthritis 
Neurological diseases 
Depression 
Schizophrenia 
Maligna11t diseases 
Hodgkins disease 
Glioblastoma 
Pituitary adenoma 
Gynaecological cancer 
Bronchogenic carcinoma 
Ot/rer 
Pre-eclampsia 
Asthma 
Chronic renal failure 
Ishihara et al, 1997 
Smith et al, 1995 
Reference 
Rolfe et al, 1993; Chensue et al, 1992 
Shibata et al, 1997 
Mathiesen et al, 1997 
Beamer et al,l995 
Henter et al, 1996 
Mandrup-Poulsen et al 1995; En do et al, 1996 
Gabay et al, 1994 
Hyams et al1994 
Sekiyama et al, 1994 
Benezra et al, 1997 
Thea et al, 1996; Rimaniol et al, 1997 
Fischer et al, 1992; Pruitt et al, 1996 
Granowitz et al, 1991b 
Samson et al, 1997 
DeBont et al, 1995 
Suzuki et al, 1996; Chang, 1997 
Nicoletti et al, 1996 
Prieur et al, 1987; De Benedetti et al, 1995; 
Muller et al, 1997 
Malyak et al, 1993; Chikanza et al, 1995 
Maes et al, 1995 
Maes et al,1996 
Gruss et al, 1992 
Tada et al,1994 
Sauer et al, 1994 
Fujiwaki et al,1997 
Smith et al, 1993 
Kimya et al, 1997 
Yoshida et al, 1996 
Pereira et al, 1994 
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Despite many studies detecting elevated levels of IL-l or IL-l ra in disease as discussed 
above, relatively few have measured both proteins and demonstrated an imbalance 
between them. Low IL-lra: IL-l ratios have been associated with acute myelogenous 
leukaemia (Rambaldi et al, 1991), chronic myelogenous leukaemia (Wetzler et al, 1994), 
hairy cell leukaemia (Barak et al, 1994), Lyme arthritis (Miller et al, 1993), rheumatoid 
arthritis (Firestein et al, 1994; Chomarat et al, 1995, Chikanza et al, 1995), psoriasis 
(Kristensen et al, 1992; Corradi et al, 1995), smokers versus non-smokers (Janson et al, 
1993), illD (Casini-Raggi et al, 1995; Nishiyama et al, 1994; Hyams et al, 1995; Dionne et 
al, 1998; Ishizuka et al, 2001), severe acute pancreatitis (Mayer et al, 2000; Powell et al, 
2001), chorionarnnionitis (Baergen et al,1994), newly diagnosed IDDM (Netea et al, 
1997), periapical lesions (Shimauchi et al, 1998), sarcoidosis and idiopathic pulmonary 
fibrosis (Mikuniya et al, 1997), nonbacterial prostatitis (Nishimura et al, 1998), chronic 
hepatitis due to hepatitis C virus (Gramantieri et al, 1999), pediatric astrocytomas and 
ependymomas (Ilyin et al, 1998), head and neck squamous cell carcinoma (Von Biberstein 
et al, 1996) and increased risk of acute renal allograft rejection (Teppo et al, 1998). 
The variation in IL-l and IL-lra protein levels may be genetically determined. A 
number of polymorphisms are known to exist in the genes that encode IL-l a, IL-l P and 
IL-l ra. It has been shown that polymorphisms in other cytokine genes such as IL-l 0, IFN-y 
and TNFa determine functional protein levels (Eskdale et al, 1998, Pravica et al, 1999, 
Pociot et al, 1993). 
4.7.1 The Interleukin-1 gene cluster polymorphisms 
The members of the interleukin-1 gene cluster are highly polymorphic. There are 
several different types of polymorphisms, however, for the purpose of this study only 4 
types will be considered. 
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Single Nucleotide Polymorph isms (SNP) 
Single nucleotide polymorphisms involve the substitution of one nucleotide for 
another with the creation of 2 alleles. Restriction endonucleases that recognize and cleave 
specific sequences within the DNA strand can be used to detect these nucleotide changes 
provided the substitution creates or destroys the restriction endonuclease cleavage site. 
However, in the majority of cases SNPs cannot be detected by restriction endonucleases. 
An example of a single nucleotide polymorphism is: 
Allele 1 
Allele 2 
cCGA 
-!, 
rCGA 
Taq I restriction endonuclease recognizes and cleaves the sequence T+CGA (+ represents 
the position of cleavage). In the example above, the substitution of a Thvmine for a 
Cvtosine creates a Taq I site. If the polymorphism is present on both chromosomes, 2 
bands are visible on the agarose gel (homozygous), if the polymorphism is present on 
neither chromosome, only I band is visible (homozygous) and if the polymorphism is 
present on I chromosome only, 3 bands are visible (heterozygous). 
Dinucleotide repeat polymorphisms 
These polymorphisms consist of continuous repeating units of a dinucleotide repeat 
sequence, for example (AC)n. The different number of dinucleotide repeats correspond to 
different alleles. An example of a dinucleotide polymorphism is: 
Allele I ACAC 
Allele 2 ACACAC 
Allele 3 ACACACAC 
Allele 4 ACACACACAC 
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2 repeats 
3 repeats 
4 repeats 
5 repeats 
Variable number of tandem repeat polymorplrisms (VNTR) 
These polymorphisms are similar to dinucleotide repeat polymorphisms because 
they consist of repeating units of a given number of base pairs, however, the repeating 
sequences are longer e.g. 86 base pairs (bp) long and are interrupted by non-repeating 
sequences. An example of a variable number of tandem repeat polymorphism is: 
Allele 1 -86bp--86bp--86bp--86bp---
Allele 2 -86bp--86bp---
Allele 3 -86bp--86bp--86bp--86bp--86bp---
Allele 4 -86bp--86bp--86bp---
4 repeats 
2 repeats 
5 repeats 
3 repeats 
Allele 5 -86bp--86bp--86bp--86bp--86bp--86bp--- 6 repeats 
86bp =a set number of base pairs non-repeating sequence 
Variable Length Polymorphisms (VLP) 
A variable length polymorphism occurs when the distance between 2 points on the 
gene (X and Y) varies in length, each length variation creating a different allele. An 
example of a variable length polymorphism is: 
Allele 1 
Allele 2 
Allele 3 
x--------------------Y 
x------ y 1.45kb 
x-- y 1.3kb 
1.55kb 
The following polymorphisms of the IL-l gene cluster are discussed in the order in which 
they appear on the long arm of chromosome 2 relative to the centromere. 
4. 7.1.1/L-JRI Gene 
At least six single nucleotide polymorphisms have been described in the 5' 
untranslated region of the IL-l RI gene. A T to C substitution has been identified at 
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position 131(T ~C131 ) in exon 1B which created a Pst I restriction endonuclease site, while 
aCto T substitution at position 157 (C~T157) in the same region did not create or destroy 
a restriction endonuclease site (Bergholdt et al, 1995). Sitara et al, found an A to G 
substitution in intron 1B at position 52 (A~G52) that created a Msp I restriction 
endonuclease site (Sitara et al, 1999) and a single nucleotide polymorphism was identified 
in exon 1 C at position 97 (G~A 97) which created Sty I restriction site (Sitara et al, 2000). 
An A toT substitution was also reported at position 140 (A~T140) in exon 1C, however, 
this did not create or destroy a restriction endonuclease site (Sitara et al, 1999). 
Furthermore, a Hinjl single nucleotide polymorphism has recently been characterised and 
found to be associated with IL-l RI plasma levels (Bergholdt et al, 2000). 
4. 7.1.2 IL-JA Gene 
Single nucleotide polymorphisms also exist in the promoter region of the IL-l A 
gene at position -889 (C~1889) and in exon 5 at position +4845 (G~T+4845) which create 
Nco I and Fnu 4HI endonuclease restriction sites respectively (McDowell et al, 1995; V an 
den Velden and Reitsma, 1993). The Fnu 4HI polymorphism, which causes the 
substitution of a serine for an alanine at position 114 is 100% linked with Nco I 
polymorphism (Jouvenne et al, 1999). An (AC)n repeat polymorphism has been identified 
at position 7695 within intron 5 which consists of 6 alleles (Todd and Naylor, 1991) or 7 
alleles (Epplen et al, 1994). In addition, a variable number of tandem repeats (VNTR) 
polymorphism has been found at position 8912 in intron 6 which consists of 7 alleles 
corresponding to between 5 and 18 copies of a 46 base pair sequence (VNTR46). Allele I 
(800bp, 9 repeats), allele 2 (1220bp, 18 repeats), allele 3 (760bp, 8 repeats), allele 4 
(940bp, 12 repeats), allele 5 (620bp, 5 repeats), allele 6 (1080bp, 15 repeats) and allele 7 
(660bp, 6 repeats). The repeat region is flanked at the 5' end by a poly (dA-dC) and at the 
3' end by a poly (dG-dT) and the repeats are conserved except for a nucleotide change (A 
to G) at position 8925 and a 4-nucleotide deletion (TAGG) at position 9128. Each 46bp 
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repeat contains 3 potential transcription factor-binding sites: SPl, viral enhancer element 
and glucocorticoid-responsive element (GRE) (Bailly et al, 1993). The presence of these 
transcription factor-binding sites implies that the polymorphism may be involved in IL-l a 
gene regulation. A recent study has shown that there was an inverse relationship between 
the number of repeats and IL-Ia. production, suggesting that the polymorphism had a 
negative regulatory role on IL-Ia gene expression (Bailly et al, 1996). 
4.7.1.3 IL-JB Gene 
Single nucleotide polymorphisms have been identified in the promoter of the IL-lB 
gene at positions 1423 (C~T1423) and 1903 {T~C1903) which destroy Ava I and Alu I 
restriction endonuclease sites respectively (Guasch et a!, 1996). The c~ T polymorphism 
at position 1423 is identical to the previously-described C to T transition polymorphism at 
position -511 (C~T"511 ) (Di Giovine et al, 1992). Allele 2 of this polymorphism has been 
associated with high IL-l p secretion (Nemetz et al, 1999). The T ~c polymorphism at 
position 1903 is identical to the Alu I polymorphism described in the promoter region at 
position -31 (El-Omar et al, 2000). In exon 3 at position 3263 there is a C to T substitution 
(C~T3263) which does not create or destroy a restriction endonuclease site (Langdahl et al, 
2000). Furthermore, single nucleotide polymorphisms at position 5810 (G~A5810) in 
intron 4 and at position 5887 (C~T5887) in exon 5 create BsoFI and Taq I restriction sites 
respectively (Guasch et a!, 1996). The nucleotide substitution in exon 5 is identical to the 
previously described Taq I polymorphism at position +3953 (C~T+3953)(Pociot et a!, 
1992). Allele 2 of this polymorphism has been associated with high IL-l p secretion 
(Pociot et al, 1992). A recently described Aci I restriction site created by a G to A 
substitution at position 3877 (G~A3877) in intron 4 has been found to be identical to the 
BsoFI described by Guasch et al (Langdahl et al, 2000). 
92 
4. 7.1.4 IL-JRN Gene 
A G-4A nucleotide substitution has been identified in the promoter of the IL-l RN 
gene at position 1731 (G-4A1731 )(Clay et a!, 1996). As discussed in Section 4.3, the IL-
lRN gene has 2 first exons: exonlic codes for intracellular IL-1ra and exonls codes for 
secretory IL-l ra. Single nucleotide polymorphisms have been described in ex on l ic at 
positions 1812 (G-4A1812), 1868 (A-401868), 1887 (G-4C1887) (Clay et a!, 1996) and 1934 
(T -4C1934) (Langdahl et a!, 2000). Nucleotide substitutions have also been found at 
positions 8006 (T -4C8006) in exon 2 and 8061 (C-4 T8061 ) in intron 2 which create Msp I 
and destroy Mwo I restriction sites respectively (Guasch et a!, 1996). A variable length 
polymorphism (VLP) has been identified in intron 2 at position 190 (Genbank: M63099) 
that consists of 3 alleles. Each allele corresponds to a different length of DNA: allele I 
(l.55kb), allele 2 (1.45kb) and allele 3 (l.3kb)(Steinkasserer et a!, 1991). A variable 
number of tandem repeats (VNTR) polymorphism is also known to exist in intron 2 at 
position 8902 that consists of 5 alleles corresponding to between 2 and 6 copies of an 86 
base pair sequence (VNTR86). Allele 1 (410bp, 4 repeats), allele 2 (240bp, 2 repeats), allele 
3 (500bp, 5 repeats), allele 4 (325bp, 3 repeats), and allele 5 (595bp, 6 repeats). Each 
repeat contains 3 potential protein-binding sites: an a-interferon silencer A, a ~-interferon 
silencer B and an acute phase response element (Tarlow et a!, 1993). Studies regarding an 
association between this polymorphism and functional IL-l ra protein levels are conflicting. 
One study suggests that allele 2 (2 x 86bp repeats) correlates with low IL-l ra protein level. 
(Tarlow et a!, 1993), whilst another study has reported that allele 2 corresponds to high IL-
l ra protein levels (Danis et a!, 1995). Single nucleotide polymorphisms are also described 
at positions 9589 (A-4 T9589) in intron 3 and Ill 00 (T -4C11100) in ex on 4 which create Ssp 
I and MspAJI restriction sites respectively (Guasch et al, 1996). Tables 4.2A-C show 
positive and negative associations between these polymorphisms and human disease. 
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Table 4.2A: Positive and negative associations between polymorphisms in the IL-l 
gene cluster and inflammatory diseases 
Gene Polymorphism +!- Population Disease association Reference 
IL-IA Ncor American Periodontitis Gore et al, 1998 
IL-IA Nco 1-889 British Single and multivessel Francis et al, 1999 
IL-IA Nco I-889 British 
coronary artery disease 
Ulcerative colitis Mansfield et al, 1994 
IL-IA Nco I-889 British Crohn's disease Mansfield et al, 1994 
IL-IA Fnu 4HJ'4845 American Silicosis Yucesoy et al, 200 I 
IL-IB Ava r 511 + Hungarian Ulcerative colitis Nemetz et al, 1999 
IL-IB Ava r 511 + Hungarian Crohn's disease Nemetz et al, 1999 
IL-IB Ava r 511 + Japanese Alcoholic liver disease Takamatsu et al, 2000 
IL-IB Ava f 511 French Crohn's disease Heresbach et al, 1997 
IL-IB Ava r 511 French Ulcerative colitis Heresbach et al, 1997 
IL-IB Ava r 511 American Periodontitis Gore et al, 1998 
IL-IB Ava r 511 British Single and multivessel Francis et al, 1999 
IL-IB Ava r511 Japanese 
coronary artery disease 
Chronic obstructive Ishii et al, 2000 
Taq }'3953 
pulmonary disease 
IL-IB + Japanese Alcoholic liver disease Takamatsu et al, 2000 
IL-IB Taq 1+3953 + American Periodontitis Galbraith et al, 1999a 
IL-IB Taq r3953 + American Periodontitis Gore et al, 1998 
IL-IB Taq r3953 + British Early-onset periodontitis Parkhill et al, 2000 
IL-IB Taq r3953 Hungarian Ulcerative colitis Nemetz et al, 1999 
IL-IB Taq r3953 British Ulcerative colitis Mansfield et al, 1994 
IL-IB Taq 1+3953 French Ulcerative colitis Heresbach et al, 1997 
JL-IB Taq r3953 Hungarian Crohn's disease Nemetz et al, 1999 
IL-IB Taq r3953 British Crohn's disease Mansfield et al, 1994 
IL-IB Taq tl95J French Crohn's disease Heresbach et al, 1997 
IL-IB Taq t 3953 British Acute pancreatitis Powell et al, 200 I 
JL-IB Taq 1+3953 British Single and multi vessel Francis et al, 1999 
coronary artery disease 
IL-IB Taq r3953 American Silicosis Yucesoy et al, 200 I 
IL-IRN VNTR86 + Dutch Ulcerative colitis Bioque et al, 1996 
IL-IRN VNTR86 + Jewish Ulcerative colitis Duerr and Tran, 1995 
IL-IRN VNTR86 + British Ulcerative colitis Mansfield et al, 1994 
IL-IRN VNTR86 + Jewish Ulcerative colitis Tountas et al, 1999 
IL-IRN VNTR86 + Spanish Ulcerative colitis Papo et al, 1999 
(pAN CA) 
IL-IRN VNTR86 + Japanese Alcoholic liver disease Takamatsu et al, 1998 
(hepatic fibrosis) 
IL-IRN VNTR86 + American Vulvar vestibulitis Jeremias et al, 2000 
IL-l RN VNTRs6 + British Single coronary artery Francis et al, 1999 
disease 
IL-IRN VNTR86 + S. African Asthma Pillay et al, 2000 
IL-IRN VNTR86~AI)- + British Early-onset periodontitis Parkhill et al, 2000 
Taq t 395 \A I) 
IL-l RN VNTR 6 British Ulcerative colitis Louis et al, 1996 
IL-IRN VNTR86 Spanish Ulcerative colitis Garcia-Parades et al, 1996 
IL-IRN VNTR86 German Ulcerative colitis Hacker et al, 1997 
IL-IRN VNTR86 French Ulcerative colitis Heresbach et al, 1997 
IL-l RN VNTR86 Non-Jewish Ulcerative colitis Tountas et al, 1999 
IL-IRN VNTR86 British Crohn's disease Louis et al, 1996 
IL-l RN VNTR86 Spanish Crohn's disease Garcia-Paredes et al, 1996 
IL-IRN VNTR86 Dutch Crohn's disease Bioque et al, 1996 
IL-IRN VNTR86 British Crohn's disease Mansfield et al, 1994 
IL-IRN VNTR86 French Crohn's disease Heresbach et al, 1997 
IL-IRN VNTR86 Jewish Crohn's disease Tountas et al, 1999 
IL-IRN VNTR86 Non-Jewish Crohn's disease Tountas et al, 1999 
IL-IRN VNTR86 British Acute pancreatitis Powell et al, 200 I 
IL-IRN VNTRs6 Italian Ischemic heart disease Manzoli et al, 1999 
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IL-IRN VNTR86 Japanese Polymyositis Son et al, 2000 
IL-IRN VNTRs6 Japanese Dermatomyositis Son et al, 2000 
IL-l RN VNTRs6 British Multivessel coronary Francis et al, 1999 
artery disease 
IL-IRN VNTRs6 Japanese Chronic obstructive Ishii et al, 2000 
pulmonary disease 
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Table 4.28: Positive and negative associations between polymorphisms in the IL-l 
gene cluster and autoimmune diseases 
Gene Polymorphism +/- Population Disease association Reference 
IL-l RI Pst 1131 + Danish IDDM Pociot et al, 1994 
IL-IRI Pst I 131 + Danish IDDM Bergholdt et al, 1995 
IL-IRI Pst I 131 + British IDDM Metcalfe et al, 1996 
IL-IRI Pst I 131 Danish Nephropathy (IDDM) Tamow et al, 1997 
IL-IRI Pst I 131 Irish Nephropathy (IDDM) Loughrey et al, 1998 
IL-IA Nco r 889 + Norwegian Juvenile chronic arthritis McDowell et al, 1995 
IL-IA Nco r 889 + French Chronic polyarthritis Jouvenne et al, 1999 
IL-IA Nco rss9 Irish Nephropathy (IDDM) Loughrey et al, 1998 
IL-IA Nco r 889 British Juvenile chronic arthritis Donn et al, 1999 
IL-IA Nco 1-889 French Spondylarthropathies Djouadi et al, 200 I 
IL-IA Nco r 889 British Autoimrnune thyroid Hunt et al, 2000 
disease 
IL-IA Nco r 889 Finnish Multiple sclerosis Luomala et al, 2001 
IL-IA Fnu 4Hr"'845 + French Chronic polyarthritis Jouvenne et al, 1999 
IL-IA F nu 4 Hr"'845 American Graves' disease Cuddihy and Bahn, 1996 
IL-IA Fnu 4Hr"'845 Italian Polymyalgia rheurnatica Boiardi et al, 2000 
IL-IA (AC)n7695 German Rheumatoid arthritis Gomolka et al, 1995 
IL-IA (AC)n7695 British Juvenile chronic arthritis Donn et al, 1999 
IL-IA VNTR46 French Rheumatoid arthritis Bailly et al, 1995 
IL-LB Ava r 511 + British Rheumatoid arthritis Di Giovine et al, 1994 
IL-IB Ava 1"511 British Multiple sclerosis Feakes et al, 2000 
IL-IB Ava 1"511 Finnish Multiple sclerosis Luomala et al, 200 l 
IL-IB Ava 1"511 British Autoimrnune thyroid Hunt et al, 2000 
disease 
IL-IB Ava 1"511 French Rheumatoid arthritis Cantagrel et al, 1999 
!L-IB Ava 1"511 Italian Polymyalgia rheumatica Boiardi et al, 2000 
IL-LB Taq r'"3953 + Irish Nephropathy (IDDM) Loughrey et al, 1998 
IL-LB Taq ['"3953 + American Alopecia areata Galbraith et al, 1999b 
(with KM) 
IL-IB Taq 1+3953 + American Multiple sclerosis Kantarci et al, 2000 
IL-IB Taq r'"3953 + Swedish Myasthenia gravis Huang et al, 1998 
!L-IB Taq r'"3953 + French Rheumatoid arthritis Cantagrel et al, 1999 
!L-LB Taq t+3953 + British Primary biliary cirrhosis Donaldson et al, 200 I 
!L-IB Taq t+3953 Italian Polymyalgia rheumatica Boiardi et al, 2000 
IL-IB Taq t+3953 French Spondylarthropathies Djouadi et al, 2001 
IL-IB Taq t3953 Dutch Multiple sclerosis Schrijver et al, 1999 
IL-IB Taq r'"3953 Finnish Multiple sclerosis Luomala et al, 200 I 
IL-IB Taq t 3953 Swedish Wegeners Huang et al, 2000 
granulomatosis 
IL-IB Taq t+3953 British Autoimrnune thyroid Hunt et al, 2000 
disease 
IL-IB Taq r'"3953 Danish Nephropathy (IDDM) Tamow et al, 1997 
IL-IB Taq t+39S3 British/ American Type I autoimmune Cookson et al, 1999 
hepatitis 
!L-IB Taq 1+3953 British Primary sclerosing Donaldson et al, 2000 
cholangitits 
IL-IRN VNTRs6 + African Nephropathy (IDDM) Freedman et al, 1997 
American 
IL-IRN VNTR86 + British Nephropathy (IDDM) Blakemore et al, 1996 
IL-IRN VNTRs6 + Chinese IgA nephropathy Liu et al, 1997 
(recurrent gross 
hematuria) 
IL-IRN VNTR86 + Chinese lgA nephropathy Shu et al, 2000 
IL-IRN VNTRs6 + Chinese Henoch-Schonlein Liu et al, 1997 
purpura nephritis 
IL-IRN VNTR86 + British Graves' disease Blakemore et al, 1995 
IL-IRN VNTRs6 + British Alopecia areata Tarlow et al, 1994 
IL-IRN VNTRs6 + British/German Psoriasis learl~ onseQ Tarlow et al, 1997 
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IL-IRN VNTR86 + British Lichen sclerosus Clay et al, 1994 
IL-IRN VNTR86 + British SLE Blakemore et al, 1994 
IL-IRN VNTR86 (with + Swedish SLE Tjernstrom et al, 1999 
HLA-
DRI7,DQ2) 
IL-IRN VNTRs6 + French Sjogren's syndrome Perrier et al, 1998 
IL-l RN VNTR86 + Italian Polyrnyalgia rheumatica Boiardi et al, 2000 
IL-IRN VNTRs6 + Dutch Multiple sclerosis Crusius et al, 1995 
IL-1RN VNTRs6 + American Multiple sclerosis Kantarci et al, 2000 
IL-1RN VNTRs6 + Italian Multiple sclerosis Sciacca et al, 1999 
IL-l RN VNTR86(with + Spanish Multiple sclerosis (RIR) De la concha et al, 1997 
HLA-
DRB1*1501) 
IL-l RN VNTR86 + American Juvenile idiopathic Rider et al, 2000 
inflammatory 
myopathies 
IL-l RN VNTR86 + British Primary biliary cirrhosis Donaldson et al, 2001 
IL-l RN VNTRs6 African Non-diabetic ESRD Freedman et al, 1997 
American 
IL-l RN VNTRs6 Danish Nephropathy (IDDM) Tarnow et al, 1997 
IL-l RN VNTRs6 Irish Nephropathy (IDDM) Loughrey et al, 1998 
IL-l RN VNTRs6 Australian SLE Danis et al, 1995 
IL-1RN VNTRs6 Swedish Multiple sclerosis Huang et al, 1996 
IL-1RN VNTRs6 French Multiple sclerosis Semana et al, 1997 
IL-l RN VNTRs6 Dutch Multiple sclerosis Schrijver et al, 1999 
IL-l RN VNTRs6 British Multiple sclerosis Feakes et al, 2000 
IL-l RN VNTR86 Finnish Multiple sclerosis Luomala et al, 200 I 
IL-l RN VNTRs6 Swedish Myasthenia gravis Huang et al, 1998 
IL-IRN VNTRs6 British/ American Type I autoimmune Cookson et al, 1999 
IL-l RN VNTRs6 British 
hepatitis 
Primary sclerosing Donaldson et al, 2000 
cholangitis 
IL-IRN VNTR86 British Corneal melting McKibbin et al, 2000 
(systemic vasculitis) 
IL-l RN VNTRs6 French Rheumatoid arthritis Cantagrel et al, 1999 
IL-l RN VNTRs6 French Rheumatoid arthritis Perrier et al, 1998 
IL-l RN VNTRs6 French Spondylarthropathies Djouadi et al, 2001 
IL-l RN VNTRs6 American Graves' disease Cuddihy and Balm, 1996 
IL-l RN VNTRs6 German Graves' disease Muhlberg et al, 1998 
IL-l RN MspAII 11100 British Autoimmune thyroid Hunt et al, 2000 
disease 
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Table 4.2C: Positive and negative associations between polymorpbisms in the IL-l 
gene cluster and infectious, metabolic, malignant and neurological diseases 
Gene Polymorphism +/- Population Disease association Reference 
INFECTIOUS 
IL-IA (AC)n African Tuberculosis Bellamy et al, 1998 
IL-IB Ava 1"511 + Finnish EBV Hurme and Helminen, 1998a 
IL-IB Ava 1"511 + British Meningococcal disease Read et al, 2000 
IL-IB Ava 1"511 African Tuberculosis W ilkinson et a!, 1999 
IL-IB Ava 1"511 African Tuberculosis Bellamy et al, 1998 
IL-IB Taq t 3953 AI+ - + African Tuberculosis W ilkinson et a!, 1999 
VNTR86A2- (Tuberculous pleurisy) 
IL-IB Taq I+3953 German Severe sepsis Fang et al, 1999 
IL-IRN VNTR86 + German Severe sepsis Fang et al, 1999 
IL-l RN VNTR86 + African Tuberculosis Bellamy et al, 1998 
IL-IRN VNTR86 + African Tuberculosis Wilkinson et a!, 1999 
(Manteux response) 
IL-IRN VNTR86 + Finnish EBV Hurme and Helminen, 1998a 
IL-IRN VNTR86 + Finnish CMV Hurme and Helroinen, 1998b 
IL-IRN VNTR86 + Brazilian Ureaplasma urealyticum Jeremias et al, 1999 
IL-IRN VNTR86 African 
vaginal colonisation 
Severe malaria Bellamy et a!, 1998 
METABOLIC 
IL-IB Ava 1"511 Danish Osteoporotic fractures Langdahl et a!, 2000 
IL-IB Aci I3887 Danish Osteoporotic fractures Langdahl et a!, 2000 
IL-IB Taq I+3953 + German Osteoarthritis Moos et al, 2000 
IL-IB Taq I+3953 Danish Osteoporotic fractures Langdahl et al, 2000 
IL-IRN VNTR86 + British Postmenopausal bone loss Keen et a!, 1998 
IL-l RN VNTR86 + Danish Osteoporotic fractures Langdahl et a!, 2000 
IL-IRN VNTR86 + German Osteoarthritis Moos et a!, 2000 
IL-l RN VNTR86 Hungarian Bone mineral density Bajnok et a!, 2000 
IL-IRN MspAII'''oo Danish Osteoporotic fractures Langdahl et a!, 2000 
MALIGNANT 
!L-IB Ava r 511 + British/Polish Gastric cancer El-Omar et al, 2000 
!L-IB Alu r 3' + British/Polish Gastric cancer EI-Omar et a!, 2000 
!L-IB Taq f3953 + British/Polish Gastric cancer El-Omar et al, 2000 
IL-IB Taq 1'3953 + British 
(protective) 
Pancreatic cancer Barber et a!, 2000 
IL-IB Taq I+3953 Swedish Multiple myeloma Zheng et a!, 2000 
IL-IRN VNTR86 + British/Polish Gastric cancer El-Omar et al, 2000 
IL-IRN VNTR86 German Hematopoietic Demeter et a!, I996 
malignancies 
IL-IRN VNTR86 Swedish Multiple myeloma Zheng et al, 2000 
IL-IRN VNTR86 British Secondary acute myeloid Langabeer and Linch, 1998 
leukemia 
NEUROLOGICAL 
IL-IA Nco r 889 + British/ American Alzheimer's disease Nicoll et a!, 2000 
IL-IA Nco I-889 + American Alzheimer's disease Du et al, 2000 
IL-IA Nco r889 + Italian Alzheimer's disease Grimaldi et a!, 2000 
IL-IA Nco I-889 Japanese Temporal lobe epilepsy Kanemoto et a!, 2000 
IL-IB Ava r 511 + Italian Alzheimer's disease Grimaldi et a!, 2000 
IL-IB Ava r 511 + Japanese Temporal lobe epilepsy Kanemoto et a!, 2000 
!L-IB Ava r511 Japanese Schizophrenia Tatsumi et a!, 1997 
IL-IB Taq I+3953 + British/American Alzheimer's disease Nicoll et a!, 2000 
IL-IB Taq I+3953 French Schizophrenia Laurent et a!, 1997 
IL-IB Taq f3953 Japanese Temporal lobe epilepsy Kanemoto et a!, 2000 
IL-IRN VNTR86 + Italian Alzheimer's disease Grimaldi et a!, 2000 
IL-IRN VNTR86 Japanese Temporal lobe epilepsy Kanemoto et al, 2000 
IL-IB- Aval(AI)- + Finnish Schizophrenia Katila et a!, 1999 
IL-IA- Ncoi(A2)-
IL-IRN VNTR86(AI) 
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4.7.2 Differential Regulation 
Another explanation as to why there may be an imbalance in the IL-l ra/IL-1 
system is that gene expression and synthesis of IL-l and IL-l ra are differently regulated 
within the same cell (Poutsiaka et a!, 1991; Arend et a!, 1991 ). Some stimuli such as LPS, 
IL-l and TNFa induce the transcription of both IL-l and IL-lra, while others induce the 
transcription of one but not the other. Stimuli inducing IL-l ra but not IL-l include immune 
complexes and adherent IgG, while those that induce IL-l but not IL-l ra include the 
complement component C5a and Borrelia burgdorferi. Furthermore, cytokines such as IL-
4, IL-l 0, IL-13 and TGF~ increase the production of IL-l ra but simultaneously decrease 
the production of IL-l (Dinarello, 1996). In addition IL-l and IL-l ra have different 
expression kinetics. IL-l is produced before IL-l ra both in vivo and in vitro peaking at I 
hour compared to 2 hours for IL-lra in vivo (Granowitz et al, 199lb) and at 2 hours 
compared to 4 hours for IL-l ra in vitro (V annier et a!, 1992). 
The IL-l gene cluster has been implicated in many diseases as discussed above and 
shown in Tables 4.2 A-C and its role in acute pancreatitis will now be reviewed. 
4.8 The Interleukin-1 gene cluster and acute pancreatitis 
Despite several reports of elevated serum levels of IL-l, IL-6 and TNFa in 
experimental animal models (Norman et al 1994; Grewal et a! 1994a), until recently there 
had been no reports of plasma IL-l~ in patients with acute pancreatitis. Serum IL-l~ levels 
are known to increase 1 hour after the initiation of experimental pancreatitis and it has 
been suggested that its absence in the serum of acute pancreatitis patients may be due to 
the fact that IL-l~ levels have already peaked and declined before the patients have been 
admitted to hospital. IL-l~ is however an inducer of other cytokines such as IL-6, and IL-8 
which peak later and are therefore easier to measure in the serum of patients on admission. 
Chen et al, have recently measured serum IL-l~ levels from 50 patients on days 1-7 
following admission and found that they were significantly higher in patients with severe 
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compared to mild disease with a median peak occurring on day I (Chen et al, 1999). 
McKay et al, had failed to show this difference in IL-l secretion in an in vitro model which 
involved the LPS stimulation of isolated monocytes taken from 26 patients with moderate 
to severe disease (McKay et al, 1996). More recently, 2 studies have shown that there is an 
imbalance between IL-lra and IL-l beta levels in patients with severe acute pancreatitis 
(Mayer et al, 2000; Powell et al, 2001). 
Studies have demonstrated that IL-l and TNFa are initially produced in the 
pancreas parenchyma within 30 minutes of induction of experimental pancreatitis and are 
produced later in distant organs in particular the lungs, liver and spleen (Norman et al, 
1997b ). The subsequent rise in inflammatory cytokines in these organs is linked to specific 
organ disorders. Elevations of IL-l and TNFa in the lungs for example are associated with 
the development of ARDS (Parsons et al, 1992). The production of IL-l and TNFa in the 
pancreas is due to the infiltrating macrophages and neutrophils and experiments that 
involve the depletion of specific leukocyte populations have demonstrated that 
macrophages are primarily responsible for production of IL-l and TNFa during 
experimental acute pancreatitis (Fink and Norman, 1996). 
There is evidence to suggest that although IL-l~ and TNFa are produced in the 
pancreas during acute pancreatitis they do not cause the disease. Firstly, isolated human 
pancreas perfused with IL-l and TNFa does not induce acute pancreatitis (Denham et al, 
1998b) and secondly, the treatment of isolated acinar cells with IL-l and TNFa does not 
cause colocalisation of zymogen granules and lysosomes or the activation of digestive 
enzymes (Fink et al, 1997). 
The role of IL-l in acute pancreatitis has also been demonstrated by experiments 
involving IL-l antagonism. These include recombinant IL-l ra administration, IL-l 
receptor gene knockout mice and inactivation ofiCE. IL-l ra administered prophylactically 
or therapeutically to bile-induced rat model (Tanaka et a!, 1995), cerulein-induced rat 
model (Norman et a!, 1995a) and CDE-induced mouse model (Norman et a!, 1995b) have 
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all shown a reduction in pancreatic damage, lung injury and mortality. Interestingly, 
therapeutic treatment proved to be more beneficial than prophylactic treatment (Norman et 
al, 1995a; Norman et al, 1995b ). IL-l ra does not appear to act directly on acinar cells since 
adminstration does not directly reduce disease severity. Rather the effect appears to be due 
to an indirect mechanism that interrupts interactions between acini and leucocytes possibly 
by the downregulation ofTNFa and IL-6 (Fink et al, 1997). In addition to recombinant IL-
lra, another cytokine suppressive agent (FR167653) has recently shown to improve the 
survival of rats with closed duodenal loop-induced acute pancreatitis (Hirano, 1999). 
Although the experimental studies show that IL-lra could have potential therapeutic value 
in acute pancreatitis, clinical studies have been disappointing. Phase ill trials on 893 
patients with sepsis, a disease which shares many clinical features with acute pancreatitis 
have shown that treatment with recombinant human IL-lra has no clinical benefits 
compared to placebo (Fisher et al, 1994). 
IL-l receptor gene 'knockout' mice are deficient in IL-l receptor and cannot 
recognise or respond to IL-l. When cerulein is administered intraperitoneally to these 
mice, acute pancreatitis still occurs, however, it is less severe than in control mice. This 
indicates that IL-l does not cause acute pancreatitis but is necessary for the progression 
and severity (Norman et al, 1996b). Furthermore, knockout mice deficient in TNF type I 
receptor, IL-l type I receptor or both showed that an identical beneficial effect on severity 
and mortality was obtained with blocking either receptor but no additional beneficial effect 
was achieved by blocking both receptors together. This suggests that that IL-l~ and TNFa 
make an equivalent contribution to the severity of acute pancreatitis (Denham et al, l997b ). 
As previously mentioned in Section 4.2.2, the Interleukin-1 p converting enzyme (ICE) 
cleaves IL-l P into its active form before it leaves the cell. Any method of inhibiting or 
eliminating this enzyme will therefore prevent the secretion of this cytokine. Mice 
pretreated with VE-13045 (an ICE inhibitor) prior to induction of acute pancreatitis by bile 
injection and transgenic mice with a disrupted ICE gene fed a CDE-diet showed decreased 
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severity and mortality compared to controls. In these experiments there was no alteration 
in IL-l mRNA levels, however, IL-l and TNFa protein levels were significantly reduced 
(Norman et a!, 1997c). 
4.9. Summary 
It has been suggested that acute pancreatitis may have a genetic component since 
the natural history and aetiology of the disease are diverse and may be related to impaired 
host defense. The majority of patients develop only mild disease with minimum organ 
dysfunction and without complications, however, there is a significant proportion who 
develop severe disease with both local and systemic complications. Furthermore, 
individuals with gallstone disease or alcoholism do not inevitably develop acute 
pancreatitis. Only 3.4% of patients with gallstones (Moreau et a!, 1988) and 5% of 
alcoholics develop the disease (Meier, 1995). 
The interleukin-1 gene cluster has been implicated in the pathogenesis of acute 
pancreatitis. Serum IL-l levels have been found to be elevated in both humans (Chen et a!, 
1999) and in experimental animals models with the disease (Norman et al, 1994). 
Furthermore, studies that reduce the level of IL-l by preventing its production ( e.g the ICE 
inhibitor, VE-13045) (Norman et al, 1997c), manipulating IL-l receptor expression (e.g. 
IL-l receptor gene "knockout" mice) (Norman et al, 1996b) or preventing the binding of 
IL-l to its receptor (e.g. recombinant IL-lra) (Tanaka et al, 1995; Norman et al, l995a) 
have been shown to decrease the severity and mortality of acute pancreatitis and further 
implicate the cytokine in the disease. More recently an IL-l ra: IL-l imbalance has been 
reported in patients with severe acute pancreatitis (Mayer et al, 2000; Powell et al, 2001 ). 
In conclusion, there is compelling evidence to suggest that the IL-l gene cluster may 
contribute to the susceptibility to and/or severity of acute pancreatitis, and this may be 
determined by polymorphisms within the genes. 
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4.10 Aims of the study 
The aims of this study were to: 
I) investigate polymorphisms of the genes coding for the IL-l gene cluster (IL-l A, IL-
lB, IL-IRN) and IL-l receptors (IL-IRI and IL-IRII) in patients with acute 
pancreatitis and normal healthy controls 
2) determine any functional relationship between the IL-l gene cluster polymorphisms 
and protein levels. 
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CHAPTER 5: MATERIALS AND METHODS 
5.1 Subjects 
The characteristics of the subjects used in the study are shown in Table 5.1. 
5.1.1 Controls 
Two hundred and seventeen Caucasian cord bloods obtained following healthy 
obstetric delivery at Derriford Hospital in Plymouth were used as healthy controls for the 
DNA study. In addition, ten healthy Caucasian adults were used as controls for the protein 
study. These controls were comprised of 4 males and 6 females with an age range from 24-
48 years and a median age of 27 years. The controls were sex and ethnically matched with 
the acute pancreatitis patients. 
5.1.2 Patients 
The patient cohort consisted of one hundred and thirty seven patients with acute 
pancreatitis who were admitted to Derriford Hospital in Plymouth. This group comprised 
66 males and 71 females with an age range from 21-86 years and a median age of 58 years. 
The criteria for diagnosis of acute pancreatitis were: 
1) A clinical presentation consistent with the disease (Table 5.2) 
2) Radiological evidence (Table 5.3) 
3) Hyperamylasaemia >660units/l (Hitachi 911, Hitachi Corporation, Japan; normal level 
<220units) 
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Table 5.1: Characteristics of the controls and patients used in the genetic study 
Normal AP Mild Severe 
Controls Patients AP AP OFS=O OFS:!:l OFS:!:l 
n =217• n=137• n=99 n=38 n=89 n=48 n=35 
Age 
Range NIA 21-86 21-86 26-78 21-81 26-86 26-84 
(years) 
Median 
Age NIA 58 56 65.5 54 64 66 
(years) 
Sex 
(M:F) 98:119 66:71 49:50 17:21 44:45 22:26 17:18 
AP Acute pancreatitis 
n represents the number of subjects in each group 
M male 
F female 
Mild and severe disease severity groups are according to the Atlanta convention classification 
OFS organ failure scores according to Kingsnorth et a!, I 995 
A Alcoholic pancreatitis - if daily consumption of ~80g alcohol per day for 6 months 
G Gallstone pancreatitis - if radiological or ERCP evidence of cholelithiasis 
I Idiopathic pancreatitis - if no identifiable aetiology 
NI A Age not applicable to controls as taken from a bank of cord bloods 
A I G 
OFS:!:3 OFS:!:4 AP AP AP 
n=19 n=12 n=21 n=36 n=80 
26-78 26-76 28-62 25-84 21-86 
66 65.5 43 60.5 60 
11:8 7:5 20:1 20:16 26:54 
• Although the controls and patients used in the different studies were taken from the same populations, the numbers differ in each study because results 
were not obtained for all subjects. 
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Table 5.2 Clinical presentation of acute pancreatitis 
CLINICAL PRESENTATION 
Symptoms 
Signs 
Abdominal pain +/- radiating through to the back 
Nausea 
Vomiting 
Fever (38.5°C} 
Dehydration 
Confusion (secondary to hypoxia) 
Abdominal tenderness 
Hypovolemic shock 
Jaundice (10-20%) 
Grey-Turner/Cullen sign (<5%) 
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The patient population was subdivided into groups according to severity, organ failure 
scores and aetiology. 
5.1.2.1 Classification accordi11g to severity 
Patients were classified as having mild disease (n=99) or severe disease (n=38) 
according to criteria defined by the Atlanta convention classification on the basis of 
physiological, biochemical and hematological measurements (Table 5.4). 
5.1.2.2 Classification according to organ failure scores 
Patients were classified according to the organ failure scores OFS=O (n=89), 
OFS~l (n=48), OFS~ (n=35), OFS~3 (n=l9) and OFS~4 (n=l2) as described by 
Kingsnorth et al, 1995 (Table 5.5). 
5.1.2.3 Classificatioll accordi11g to aetiology 
Patients were considered to have alcoholic pancreatitis if their daily admitted 
consumption was greater than 80g alcohol per day for a period of time exceeding 6 months 
(Wilson et al, 1985)(n=21 ); gallstone pancreatitis if they had radiological or ERCP 
evidence of cholelithiasis or gallstones (n=79); or idiopathic if no cause could be identified 
(n=37) (Table 5.6). Patients with chronic pancreatitis were excluded from the study and CT 
or ERCP was used to ensure that a case of alcoholic acute pancreatitis was not chronic 
pancreatitis. 
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Table 5.4 Classification of acute pancreatitis according to severity 
CATEGORY CRITERIA 
Mild acute pancreatitis Minimal organ dysfunction 
Severe acute pancreatitis Organ failure and /or local complications 
Predicted severe disease APACHE ll Score ~ 8 
Organ Failure: 
Cardiovascular Systolic blood pressure <90mmHg 
DIC Platelets :SI 00,000 per mrn3 Fibrinogen <1 g/1 
Gastrointestinal 500ml of blood loss in 24 hours 
Metabolic Serum calcium :Sl.87mrnolll. 
Renal Serum Creatinine> 177umol/l (after rehydration) 
Respiratory p02<60mmHg {8Kpa) 
Local Complications: 
Acute fluid collection Lacks a wall of granulation or fibrous tissue; 
Located in or near the pancreas 
Pseudocyst Collection of pancreatic secretion bound by fibrous 
or granulation tissue wall 
Abscess Circumscribed collections of pus 
Necrosis Diffuse or focal nonviable pancreatic parenchyma 
DIC Disseminated Intravascular Coagulopathy 
mmHg millimetres of mercury 
Kpa Kilopascals 
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(Adapted from Bradley, 1993). 
Table 5.5 Classification of acute pancreatitis according to organ failure scores 
SYSTEM 
Pulmonary 
Pa02/Fi02 (mmHg) 
Renal 
Creatinine (mg/lOOml) 
Creatinine (umoUl) 
Cardiovascular 
SBP(mmHg) 
Lactate (mmoUl) 
CNS 
GCS 
Coagulation 
Platelets (xl09/l) 
0 
Normal 
:2:400 
::>1.5 
::>133 
:2:90 
15 
:2:120 
I 
Abnormal 
BOOto<400 
>1.5 to $2.0 
>133 to::>l69 
<90 
Responsive to fluid 
13-14 
:!:80 to <120 
Organ failure score was the sum of the score obtained in each system 
Pa02= arterial partial pressure of oxygen; 
Fi02 Fraction of inspired oxygen; 
SBP= systemic blood pressure; 
GCS= Glasgow Coma Score; 
ARDS= Acute respiratory distress syndrome 
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2 
Mild 
~00 to <300 
Acute lung injury 
>2.0toB.6 
> 169 to:S3 10 
<90 
Unresponsive to fluid 
10-12 
:!:50 to <80 
Clinically significant 
3 
Moderate 
:!:lOO to <200 
ARDS 
>3.6 to:SS.O 
> 310 to:SMO 
2-5 
6-9 
~Oto<SO 
4 
Severe 
<lOO 
Severe ARDS 
>5.0 
>440 
>5 
::>5 
<20 
(Adapted from Kingsnorth et al, 1995) 
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5.2 Collecting Samples 
Following Local Ethical Committee approval, peripheral venous blood samples 
were collected by venepuncture from all patients. Blood for DNA extraction was collected 
in 5% disodium ethylene diamine tetra-acetic acid (Na2EDT A) and stored at -20°C in 
sterile polypropylene Falcon tubes until use. Blood for cell culture was collected in sodium 
heparin tubes and was used immediately for protein analysis. 
5.3 Materials 
5.3.1 Water 
All general purpose, specialized and stock solutions were reconstituted usmg 
distilled tap water obtained from a Millipore water dispenser (Millipore Ltd, Watford, 
UK). Sterile bottled water (Baxter Healthcare, Thetford, UK) was used for PCR and 
restriction digestion reactions. 
5.3.2 Reagents 
All reagents used were analytical grade or molecular biology grade or equivalent. 
5.3.2.1 General purpose reage11ts 
Acetic acid, hydrochloric acid, magnesium chloride 6 hydrate, orthoboric acid, 
sodium chloride and sodium hydroxide were purchased from BDH Laboratory Supplies-
Merck Limited (Lutterworth, UK). Chloroform, ethanol, industrial methylated spirit and 
methanol were supplied by Rathbum Limited (Walkerbum, UK). Ammonium persulfate, 
disodium ethylenediamine tetra-acetic acid (Na2-EDTA), ethidium bromide (2,7-diamino-
1 0-ethyl-9-phenyl-pheanthridinium), formamide, glycerol, sucrose, Tris (hydroxymethyl) 
arninomethane, Triton X-100, trypan blue and xylene cyanol were obtained from Sigma 
Chemicals (Poole, UK) and orange G from Fischer Scientific (Loughborough, UK). 
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5.3.2.2 Specialised reagents, enzymes and materials 
"Expand™" high-fidelity PCR system, molecular weight markers, multi-purpose 
agarose, restriction endonucleases and restriction endonuclease buffers were purchased 
from Roche Diagnostics (Germany). Deoxynucleoside 5'-triphosphates (dNTPs), 
radioactivity (l2P), stop solution, and T4 polynucleotide kinase (T4 PNK) were supplied 
by Amersham Pharmacia Biotech (Sweden). "Super Taq" polymerase and 10 X "Super 
Taq" buffer were provided by HT Biotechnology (Cambridge, UK). The oligonucleotide 
amplimers were obtained from MWG Biotechnology (Germany). Repelcote (2% solution 
of dimethyldichlorosilane in octamethylcyclotetrasiloxane), Sequagel® concentrate, 
diluent and buffer were provided by Flowgen Instruments Ltd (Lichfield, UK). 
"Lymphoprep™", phosphate buffered saline (PBS), RPMI 1640 without L-glutamine, 
penicillin/streptomycin and foetal calf serum were supplied by Gibco GRL (Paisley, UK). 
Temed, L-glutamine and Lipopolysaccharide 0127:B8 were supplied by Sigma (Poole, 
UK) and "Quick-Precip™" was purchased from Advanced Biotech Corps (USA). DNA 
extraction kits and IL-1A, IL-1B and IL-1ra ELISA kits were purchased from Scotlab 
(Coatbridge, UK) and Rand D Systems Europe (Abingdon, UK) respectively. 
5.3.3 Stock solutions 
Tris/borate electrophoresis buffer (TBE) 
10 X: 0.89mM Tris(hydroxymethyl)aminomethane base, 0.89M orthoboric acid 
2mM EDT A (pH 8.0) 
Etl1idium bromide 
lOmg mr 1 in H20 
Orange G loading buffer 
0.25% orange G, 10% v/v glycerol in 10 X TBE 
Xyle11e cya11olloading buffer 
0.25% w/v xylene cyanol, 10% v/v glycerol in 10 X TBE 
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Reage11t A (Nucleoli DNA Extractio11 kit) 
10mM Tris HCI, 320mM sucrose, 5mM MgCh, 1% Triton X-100, Adjusted to pH 8.0 
using 40% NaOH 
5.3.4 Autoclaving 
All solutions, glassware and plastics used in the techniques of DNA and protein 
analysis were autoclaved at a temperature of 121 oc and pressure of 15psi for 30 minutes in 
a PriorClave autoclave (PriorClave Ltd, Woolwich, UK). 
5.4 Extraction of High Molecular Weight DNA 
High molecular weight DNA was extracted from whole blood using a Nucleon® 
BACC (blood and cell culture) genomic DNA extraction kit (Scotlab, Coatbridge, UK.) 
which consisted of Reagents A and B, sodium perchlorate, and Nucleon® resin. 1 0-20mls 
of peripheral venous blood were collected by venepuncture from all subjects in 5% 
ethylenediaminetetracetic acid (EDT A) vacutainer tubes (Becton Dickinson, Oxford, UK) 
and stored at -20°C in 50ml sterile polypropylene Falcon tubes (Phillip Harris Scientific, 
Cardiff, UK) prior to subsequent DNA extraction. The stored blood was thawed at room 
temperature and 10mls aliquoted into fresh 50ml Falcon tubes. Four times the amount by 
volume of Reagent A (1 OmM Tris-HCl, 320mM sucrose, 5mM MgCh, 1% Triton X-1 00, 
pH to 8.0) was then added to the blood and the mixture was shaken for 4 minutes using a 
Luckham R100/TW Rotatest shaker. Next the contents of the 50ml Falcon tube were 
centrifuged in a MSE Mistral 1000 centrifuge (MSE Scientific Instruments, Leicester, UK) 
at 1300g for 4 minutes, after which time the supematant containing lysed red cells was 
discarded leaving a pellet containing PBMCs. 2 mls of Reagent B (400mM Tris HCl, pH to 
8.0, 60mM EDTA, 150mM NaCl, 1% SDS) were then added to the pellet which was 
resuspended by vortexing briefly. Following this, the pellet suspension was incubated in a 
37°C waterbath (Grant, Cambridge, UK) for 10-15 minutes enabling nuclear membrane 
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disruption to occur, after which time, it was transferred to a 15ml sterile polypropylene 
Falcon tube (Phillip Harris Scientific, Cardiff, UK). Next 500f.ll of 5M sodium perchlorate 
(Scotlab, Coatbridge, UK) were added to the 15ml Falcon tube and the tube was inverted 
10-15 times. Then 2mls of chloroform (-20°C}(Rathburn Ltd. Walkerburn, UK) were 
added to the 15ml Falcon tube to emulsify the 2 phases which was inverted and centrifuged 
at 1300g for 3 minutes. Next 200f.ll ofNucleon® silica resin were added to the 15ml Falcon 
tube without disturbing the phases and the contents of the Falcon tube were centrifuged 
again at 1300g for 3 minutes. The resulting upper aqueous phase containing the DNA was 
transferred to a clean 15ml Falcon tube ensuring the interphase with silica resin and 
underlying organic phase were not disturbed. The aqueous phase was then centrifuged for 
1 minute at 1300g to pellet any residual silica and after centrifugation, the supernatant was 
transferred to a clean 15ml Falcon tube and twice the amount by volume of 100% ethanol 
(-20°C} (Rathburn Ltd, Walkerburn, UK) was added to it to precipitate out the DNA. The 
15ml Falcon tube was inverted 10 times and the resulting DNA 'strand' was hooked out 
using a sterilized glass rod. Finally, the DNA 'strand' was washed in 70% ethanol, 
dissolved in 500f.ll sterile bottled water and kept in the fridge at 2-8°C for 24 hours (Figure 
5.1). 
5.5 Quantification of High Molecular Weight DNA 
The extracted DNA was diluted 1:5 using sterile, bottled water to give 1 00-500ng 
of DNA per micro litre of dilute solution. The concentration of DNA was confirmed on a 
sample of specimens using a Cecil 5500 spectrophotometer (Cecil Instruments, Cambridge, 
UK). 
5.6 Detection of Polymorph isms 
All polymorphisms studied in this thesis were analyzed using PCR followed by 
analysis of the PCR product by gel electrophoresis (Figure 5.2). 
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Figure 5.1: Summary of the technique for DNA Extraction 
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vacutainer 
SOml Falcon tube 
1 Oml blood 
15ml Falcon tube 
Add 4X Reagent A 
~ 
JOml blood 
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~ Centrifuge 1300g 4mins Discard supernatant Add 2 ml Reagent B 
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Figure 5.2: The Polymerase Chain Reaction {PCR) Process 
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Region 
Genomic DNA 5' 
( A \ r 
"' 
_, 5' 
5' l ..,, .) 
Denaturation (94°C) 
r 5' 
5' l J' 
Annealing (50-65°C) 
... 5' 
·' l 
5' 
--· 
.) 
Extension (72°C) 
"' .) 5' 
PCR is a process during which the polymorphic region of a strand ofDNA is amplified 
(replicated). It involves the use of amplimers that are designed to flank the polymorphic 
region and which in conjunction with Taq DNA polymerase enzyme, synthesize new 
DNA from dNTPs on the opposite strands of DNA. The process consists of repetitive 
cycles comprising denaturing, annealing and extension steps that take place in a thermal 
cycler. A typical reaction consists of 30 repetitions. The PCR product is then separated 
using gel electrophoresis. 
(Adapted from Connor, 1995) 
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5.6.1 Amplimer Design and Production 
In each study, the appropriate gene sequence was obtained from Genbank using 
the website address: http://www.ncbi.nlm.nih.gov/entrez/nucleotide. Amplimers were then 
designed for both strands of DNA. The forward amplimer was complementary to the DNA 
template, whereas the reverse amplimer was both complementary and reversed. All 
amplimers were designed so that they were approximately 24 bases long, with a GC 
content of at least 50%. Care was taken to avoid poly G, C, A and T sequences since these 
may result in primer dimers where the amplimers bind to each other rather than to the 
DNA template or hairpin loops which occur when the primers bind to themselves. In 
addition, dinucleotide repeat regions within the amplimer sequence were avoided since 
these may be polymorphic. All amplimers were manufactured at a scale of O.OlJ.U11ol and 
supplied in lyophilized form by MWG Biotechnology (Germany). The lyophilized 
amplimers were re-suspended initially in lml and then diluted to lOpmoVfll using sterile 
water (Baxter Healthcare, Thetford, UK). 
5.6.2 PCR Optimisation 
Following dilution to 1 OpmoV~-tl, the optimum conditions for each set of amplimers 
were determined. This was achieved using different magnesium chloride titrations (1.5-
6.5mM) at different annealing temperatures (50°C-65°C). Figure 5.3 shows the effect of 
increasing magnesium chloride concentrations on 2 different genomic DNA samples A and 
B. The reaction volume was 30fll and PCR conditions consisted of 30 cycles of 94°C for 
30 seconds, 62°C for 2 minutes and 72°C for 2 minutes. 
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Figure 5.3: Effect of increasing magnesium chloride concentration on PCR amplification. 
1 2 3 4 5 6 7 8 9 10 11 12 13 
~ 72bp 
._603bp 
._872bp 
PCR reactions were performed using various magnesium chloride concentrations (1.5-6.5mM) 
to demonstrate the effect on the amplification of an 860bp fragment. Each lane contains 1 Oj.!l 
of PCR product. 
Lane 1 - Subject A - 1.5mM MgCh 
Lane 2 - Subject B - 1.5mM MgClz 
Lane 3 - Subject A - 2.5mM MgCh 
Lane 4- Subject B - 2.5mM MgCh 
Lane 5- Subject A- 3.5mM MgCh 
Lane 6- Subject B- 3.5mM MgClz 
Lane 7 - Subject A - 4.5mM MgCh 
Lane 8 - Subject B - 4.5mM MgCh 
Lane 9- Subject A- 5.5mM MgCh 
Lane 10 - Subject B - 5.5mM MgCh 
Lane 11 - Subject A - 6.5mM MgCh 
Lane 12- Subject B- 6.5mM MgCh 
Lane 13- Molecular weight marker IX (72bp-1353bp) 
The optimum magnesiwn chloride concentration for this reaction was 2.5mM (Lanes 3 and 4) 
since this concentration produced a single band on the gel, the size of which was determined 
using the molecular weight marker in lane 13. 
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5.6.3 PCR Reaction 
Each PCR reaction mixture consisted of 100-SOOng of genomic DNA, lOpmol of 
each amplimer pair, 2J.!I 1 OX "Super Taq" buffer (SOmM Tris-HCI, pH 9, 1.5mM MgC)z, 
250mM KCI, 1% Triton X-1 00, 0.1% (w/v) gelatin), 1-2mM MgC)z, O.l25mM of each 
dNTP and 0.8 units of Taq DNA polymerase. All PCR reactions were carried out in 30J.!I 
volumes in 0.2ml thin-walled microtubes (Advanced Biotechnology, Epsom, UK) in a 
Cyclogene thermocycler (Techne Ltd, Cambridge, UK). The samples were then stored at 
4°C until analysis by gel electrophoresis. 
5.7 Single Nucleotide Polymorphism Analysis 
5. 7.1 Restriction endonuclease digestion 
Six nucleotide polymorphisms were analyzed using restriction endonucleases in 
this study. The amplimers used in each assay are shown in Table 5.7. The polymorphic 
region of DNA was amplified using the polymerase chain reaction and the PCR products 
were checked prior to digestion by running a 5J.!l sample with l.5J.!I orange G loading 
buffer on a 1% agarose gel for 30 minutes hour at 200 volts. Following this, 5-l OJ.lg of 
DNA was digested using 10 units of the appropriate restriction endonuclease (Roche 
Diagnostics, Germany), and 3J.!I of endonuclease buffer (Roche Diagnostics, Germany). 
The reactions were carried out in 30Jll volume in 0.5ml tubes. The contents of the tube 
were then centrifuged briefly in a Biofuge 13 microfuge (Heraeus Sepatech, Germany) and 
then incubated in a 37°C or 65°C waterbath (Grant, Cambridge, UK) for 1 hour, 3 hours or 
overnight depending on the endonuclease (Table 5.7). The digestion products were 
analyzed by agarose gel electrophoresis on a 3% gel run at I 00 volts for 1 hour. 
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Table 5.7: Amplimer sequences, PCR conditions and digestion conditions used in the single nucleotide polymorphism studies 
Restriction Gene Amplimer Sequence PCR Conditions• Digestion Conditions 
endonuclease 
Hot start: 94 °C, 4 mins 37°C, I hour 
Pstl IL-1RI Pst 1: 5 TfG GAG GAT GGC CC A TGA AGA CO' Denaturation: 94°C, 30 secs 
C.J..TGCAG Pst 11: 5 'CTG TT A CGC GCC CGG ATG AAA AA1. Annealing: 59°C, 2 mins 
Extension: 72°C. 2 mins 
Hot start: 94°C, 4 mins 37°C, overnight 
Aval IL-18 Aval:s·GGCAGA GCTCATCTGGCATTGATO' Denaturation: 94°C, 30 secs 
C.J..T/CCGNGG Avail: S"GTA TCT GCC AGTTTCTCC CTC GO' Annealing: 59°C, 2 mins 
E:\1ension: 72°C, 2 mins 
Hot start: 94°C, 4 mins 37°C, 3 hours 
Alu I IL-18 Alu 1: s·GTG AAA TCA GGT ATT CAA CAG Am· Denaturation: 94°C, 30 secs 
AG.J..CT Alu 11: 5 TTC CCT TAG CAC CTA GTT GTA AGW. Annealing: 57°C, 2 mins 
Extension: 72°C, 2 mins 
Hot start: 94°C, 4 min 65°C, 3 hours 
Taql IL-18 Taq 1: 5 "GAC CTG AAG CTG G.M CCC ATG TO. Denaturation: 94°C, 30secs 
T.J..CGA Taq 11: 5 TGC TCC AGC ACT CTT GTT TC A GC3. Annealing: 60°C, 2 mins 
E:\1ension: 72°C, 2 mins 
Hot start: 94°C, 4 mins 37°C, 1 hour 
Mspl IL-1RN Mspl: 5"CAT GTG GTT AGT GGC CAC CCT ATT GJ' Denaturation: 94°C, 30 secs 
c.J..cGG Msp 11:5'(' AT ATG TGC CCT TC A GT A GCC AGG 0. Annealing: 61 oc, 2 mins 
E:\1ension: 72°C. 2 mins 
Hot start: 94 °C, 4 mins 37°C, 1 hour 
Ssp! IL-1RN Sspl: 5'TTG TGG GGA CCA GGG GAG AD' Denaturation: 94°C, 30 secs 
AAT.J..ATT Sspll: 5'AGC CTG GCA CTC TGC TGA AD' Annealing: 58°C, 2 mins 
E:\1ension: 72°C. 2 rnins ..... 
•30 cycles of denaturation, annealing and extension. Amplimers supplied by MWG Biotechnology, Germany. Restriction endonucleases supplied by 
Roche Diagnostics, Germany (,[,cleavage site). 
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5.7.2 Agarose gel electrophoresis 
To prepare a 1% agarose gel, 1g of multi-purpose agarose (Roche Diagnostics, 
Germany) was added to a 250ml Duran bottle and dissolved in 1 OOml 0.5 x TBE by 
boiling. In order to visualize the DNA, 10J.d of a lOmg/ml ethidium bromide solution was 
then added to the gel to make a final concentration ofO.l% w/v. The contents of the Duran 
bottle were then poured into a lOOml (14 x 11cm) UV light transparent perspex tray sealed 
at both ends with masking tape (Gibco GRL, Paisley, UK) and two 14 plastic tooth combs 
were added to form the wells. The gel was allowed to set at room temperature for 30 
minutes, after which time the gel was transferred to a horizontal gel electrophoresis system 
(Gibco GRL, Paisley, UK) which contained 0.5 x TBE buffer. 10J.Ll ofPCR products were 
then added to 1 Jll of orange G loading buffer (Fischer Scientic, Loughborough, UK) on a 
multi well plate. Orange G dye unlike xylene cyanol migrates with the amplimer in front of 
the PCR fragments and therefore does not obscure the bands when visualized. Next using a 
Gilson Pipetman (Anachem Ltd, Luton, UK) the PCR product/orange G mixture was added 
to the wells in the agarose gel and the gel was run at 200 volts for 30 minutes to 1 hour 
using a E452 power pack (Flowgen Instruments Ltd, Lichfield, UK). Molecular weight 
markers (Roche Diagnostics, Germany) were added to the end well on each gel so the size 
of the DNA fragments could be determined. The choice of molecular weight marker 
depended on the size range of the PCR fragments. The gel was then visualized using a 
UVP computer software package (Vision Works 3.0) (UVP International, Cambridge, UK) 
and UVP UV transilluminator (UVP International, Cambridge, UK), and a photograph of 
the samples was taken using a Sony video graphic printer on UPP-11 OHA Sony 
photographic paper (Sony Corporation, Japan). For each 1% increase in the gel thickness, 
an additional 1g of multi-purpose agarose was added to the lOOm! of0.5 x TBE. 
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5.7.3 Automated sequencing 
A single nucleotide polymorphism which destroyed an Ava I site was identified at 
nucleotide 1423 in the IL-lB DNA sequence by Clark et a/, 1986 (Genbank accession 
number: X04500). Automated sequencing carried out on homozygotes for alleles 1 and 2 
using a Li-Cor L-4200-L2 automated sequencer (MWG Biotechnology, Gennany), 
confirmed the presence of a C to T substitution which destroyed the Ava I polymorphic 
site. This is identical to the previously described Ava I C~T transition polymorphism 
reported at position -511 in the IL-lB DNA sequence by (Di Giovine et a/, 1992). 
5.8 Dinucleotide repeat. VLP and VNTR Analysis 
The polymorphic region of the gene was amplified using the polymerase chain 
reaction and the PCR products were separated using either agarose or polyacrylamide gel 
electrophoresis. Amplimers used for the assays are shown in Table 5.8. The forward 
amplimer used in the (AC)n repeat study was 5' end labelled with y32P ATP (Amersham 
Pharrnacia Biotech, Sweden) using T4 polynucleotide kinase (T4 PNK). 
5.8.1 5'-end labelling of the (AC)n amplimers 
50pmol ofthe forward amplimer to be labelled was added to a tube containing 8-10 
units of T4 PNK, which had been reconstituted in 25f!l sterile water (Baxter Healthcare, 
Thetford, UK). lf.ll of y2P ATP (lOf!Ci/f.ll) (Amersham Pharrnacia Biotech, Sweden) and 
l9f.ll of sterile water were then added to the tube to make the total volume 50f.ll. The tube 
was then centrifuged for 30 seconds in a Biofuge 13 microfuge (Heraeus Sepatech, 
Gennany) before being incubated at 37°C for 30 minutes. Following incubation, 5.5f!l of 
SM sodium chloride (BDH laboratory supplies-Merck Ltd, Lutterworth, UK), 2111 of 
"Quick-Precip™" (4°C)(Advanced Biotech Corps, USA) and 165f.ll of 100% ethanol (-
200C) (Rathburn Ltd, Walkerburn, UK) were added to the tube to precipitate the DNA 
which was then vortexed to mix the contents. 
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Table 5.8: Amplimer sequences, PCR conditions and method of gel electrophoresis used in the dinucleotide repeat, VNTR and VLP polymorphism 
studies 
Polymorphism Gene Amplimer Sequence PCR conditions Gel electrophoresis 
Hot start: 94°C, 4 mins Polyacrylamide 
(AC)n (2bp) IL-IA Forward: r2P-5. GGT ATT TAC ACC ATA GGTGGG GAC 3" Denaturation: 94°C, 30secs 6%gel 
Reverse: 5. GC A CCC A TG TC A AA T TIC ACT GG 3. Annealing: 56°C, 2 mins 
Extension: 72°C, 2 mins 
Hot start: 94°C, 4 mins Agarose 
VNTR(46bp) IL-IA Forward: 5"GCCTCT AGT CTC ATA G.M CTT AGT c:;· Denaturation: 94°C, 30 secs 2% 
Reverse: 5'GTG AGG TCA GGC CAT TGC ACT m· Annealing: 62°C, 2 mins 
Extension: 72°C, 2 mins 
Elongation: 72°C, 45 secs • 
VLP IL-l RN Forward: 5"GTT GCT GGA TAC TTG CAA GGA CCA3. Hot start: 94°C, 4 mins Agarose 
Reverse: 5TCC TCC ATG GATTCC CAA GAl\ CAG1" Denaturation: 94°C, 30 secs I% 
Annealing: 64°C, 2 mins 
Ex1ension: 72°C, 2 mins 
Hot start: 94°C, 4 mins Agarose 
VNTR(86bp) IL-l RN Forward: 5'CCC TCAGCA ACACTC CTA TTG AD. Denaturation: 94°C, 30 secs 2% 
Reverse: 5 'TC A TC'T TCC TGG TCT GC A GGT AAJ. Annealing: 60°C. 2 mins 
Ex1ension: 72°C. 2 mins 
•Expand™ High Fidelity PCR System (Roche Diagnostics, Germany) was used to amplify the DNA. This method requires an additional elongation step 
of72°C, 45secs (I cycle) 
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Next the tube was centrifuged again at 13,000 rpm for 3 minutes in the microfuge to pellet 
out the DNA, after which time the supernatant was discarded. 165J.1l of 70% ethanol were 
then added and the contents of the tube were centrifuged again for 30 seconds. Following 
centrifugation, the supernatant was discarded leaving a pellet. Residual ethanol was 
allowed to evaporate and the pellet was re-suspended in 50J.1l of sterile water. 
5.8.2 Polyacrylamide gel electrophoresis (PAGE) 
A 30cm x 50cm Sequi-Gen™ GT electrophoresis cell (BioRad Laboratories, Hemel 
Hempstead, UK) consists of front and back plates*, 2 red spacers, 2 black electrodes 
clamps, a gel caster, a support, a buffer chamber, top and bottom electrode connectors, a 
syringe with rubber tubing and a 30cm comb. Whilst laying in a horizontal position, the 
front and back plates of the cell were cleaned with 70% industrial methylated spirit 
(Rathburn Ltd, Walkerburn, UK). Repelcote (BDH Laboratory supplies-Merck Ltd, 
Lutterworth, UK) was then applied to the back plate and allowed to dry. Following this, the 
two red spacers, which had been coated in a thin layer of petroleum jelly to help them 
adhere, were placed on the sides of the back plate. The front plate of the cell was then 
placed on the top of the back plate and was held in place using the 2 black electrode 
clamps which were attached either side of the cell so the 2 plates were flush with each 
other. Next the gel rig was positioned vertically in the gel caster and was held in place 
using clips attached to the gel caster. The cell was then positioned horizontally on the 
bench so the gel could be added. A 6% polyacrylamide gel was then used to analyze the 
(AC)n repeat polymorphism of the IL-IA gene. This consisted of: 36mls Sequagel® 
concentrate (237.5g acrylamide, 12.5g methylene bisacrylamide, 500g urea), l5mls 
Sequagel® buffer (50% urea in lM Tris borate, 20mM EDTA buffer pH8.3), 99mls 
Sequagel® diluent (500g 8.3M urea) (National Diagnostics, Atlanta, USA), and l2mls 
10% formamide (Sigma Chemicals, Poole, UK). 
• The back plate comprises 2 glass plates separated by a well 
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70!-ll Temed (Sigma Chemicals, Poole UK) and I500!li I 0% ammonium persulfate were 
then added to polymerize the gel (4°C) (BDH laboratory supplies-Merck Ltd, Lutterworth, 
UK). Using the syringe and rubber tubing, the gel mixture was injected into the cell 
through the injection port in the gel caster between the front and back plates until it had 
completely covered the surface of the glass plates. Care was taken to avoid air bubbles and 
buffer leakage, since these may lead to sparking and short-circuiting when the voltage is 
applied. A 30cm 49-well vinyl sharkstooth comb with a 0.4mm spacer set (BioRad 
Laboratories, Hemel Hempstead, UK) was then positioned upside down at the top of the 
cell between the front and back plates to form a straight edge. The gel was allowed to set 
for I hour after which time the syringe and gel caster were removed. The cell was then 
positioned vertically in the buffer chamber which contained 1 X TBE to a depth of 
approximately I inch and was held in position with the support. I X TBE was then added 
to the cell into the well provided which separates the 2 layers of the back plate and the top 
and bottom electrode connectors were attached. The gel was pre-heated to 50°C by running 
it at 2000 volts for 45 minutes using a PC3000 powerpac 3000 power supply (BioRad 
Laboratories, Hemel Hempstead, UK). The PCR products were then prepared for loading. 
61-11 of each PCR product was added to 3!-ll of stop solution containing formamide (98% 
deionised formamide, I OmM EDT A pH8, 0.025 xylene cyanol, 0.025% bromophenol 
blue)(Amersham Pharmacia Biotech, Sweden) in a multi-well plate. When the cell had 
reached its optimum temperature, the comb was inverted so the teeth made wells in the gel, 
and the PCR product/stop solution mixture were added to each well using a IO!ll 
Drummond sequencing pipette (Drummond Laboratories USA). The gel was then run at 
1500-2000 volts for 4 hours maintaining the temperature at 50°C. The temperature was 
continually monitored using a temperature indicator attached to the front plate of the cell. 
After 4 hours, the electrodes were disconnected and the 1 X TBE drained out of the well 
between the 2 layers of the back plate via the drain port. The cell was laid horizontally on 
the bench and the black electrode clamps were removed. Using a wedge to break the seal 
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between the front and back plate, the back plate was slowly lifted offthe front plate. Since 
the back plate was covered in Repelcote, the gel remained attached to the front plate. The 
front plate was then transferred to a tray and was covered with 10% methanol/acetic acid 
solution (Rathburn Ltd, Walkerburn, UK) to fix the gel. The front plate was then gently 
agitated for approximately 5 minutes to detach the gel. When it had become totally 
detached a piece of 3MM filter paper 25cm X 50cm (Phillip Harris Scientific, Cardiff, UK) 
was laid rough side down on top of the gel. The top left-hand corner of the filter paper had 
been cut so the gel could be orientated later. Light pressure was applied to the paper to 
encourage the gel to adhere to the filter paper and then the gel was carefully lifted off the 
front plate attached to the filter paper. The radioactive region of the gel was then 
determined using a radioactivity counter and the filter paper was reduced in size to aid 
drying. The gel attached to the filter paper was then covered with "Saran Wrap™" and 
dried using a Sue 300 gel dryer (Heto Laboratory Equipment, Germany) at 80°C for 1-2 
hour. After the gel was dry, it was transferred to a Cronex photographic cassette between 
Cronex lighting and intensifying screens. In a dark room it was covered with a 25cm x 
SOcm piece of Kodak XLSS X ray film (Scientific lmaging Systems Ltd, Cambridge, UK) 
and cassette firmly closed. The film was exposed overnight at a temperature of -80°C after 
which time it was defrosted and developed in Kodak X ray developer (Anachem, Luton, 
UK) for 2 minutes, then indicator stop bath solution (Anachem, Luton, UK) for 30 seconds 
and finally liquid fixer (Anachem, Luton, UK) for 2 minutes. The film was then rinsed 
with tap water and allowed to air dry. Allele scoring was then carried out independently by 
2 observers. 
5.9 Isolation of peripheral blood mononuclear cells (PBMCs) from whole blood 
30mls of peripheral venous blood was collected from all subjects by venepuncture 
in sodium heparin vacutainer tubes (Becton Dickinson, Oxford, UK) and transferred to two 
SOml sterile polypropylene Falcon tubes (Phillip Harris Scientific, Cardiff, UK). The blood 
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was then diluted 1: 1 using Dulbecco's PBS (Gibco GRL, Paisley, UK) which had been 
warmed to 37°C. Next 7mls of "Lymphoprep™" (Gibco GRL, Paisley, UK) were added to 
eight different 15ml universal tubes and 7mls of the blood/PBS solution was carefully 
added to it dropwise using a Pasteur pipette (Richardsons of Leicester, Leicester, UK) 
being careful not to break the "Lymphoprep™" surface. The contents of the tubes were 
then centrifuged at 2000rpm for 30 minutes in a MSE Mistral centrifuge, producing a 4-
layered mixture, a top layer of serum, followed by a layer of lymphocytes, then a layer of 
Ficoll and finally a bottom layer of red cells. The top layer of serum was discarded to allow 
access to the layer of lymphocytes that were removed using a Pasteur pipette and 
transferred to a clean 15ml universal tube. Four times the amount by volume of PBS was 
then added to the cells to wash them and they were centrifuged at 1400rpm for 10 minutes 
after which time the supernatant was removed. The cells were then washed again in 4 times 
the amount by volume ofRPMI 1640 without L-glutamine (Gibco GRL, Paisley, UK) and 
centrifuged at 1400rpm for 10 minutes. Following centrifugation, the supernatant was 
removed, and the pellet was re-suspended in 1ml RPMI 1640 supplemented with 5% 
penicillin/streptomycin (Gibco GRL, Paisley, UK), 10% foetal calf serum (Gibco GRL, 
Paisley, UK) and 5% L-glutarnine (Sigma Chemicals, Poole, UK) by gently sucking it up 
and down using a Pasteur pipette. 
5.9.1 Calculating cell number 
In order to standardize the cell culture experiments the number of cells present per 
ml of cell suspension was determined. 50J.1l of cell suspension was mixed with 50J.1l of 
trypan blue solution (Sigma Chemicals, Poole, UK) in an Eppendorf and a drop of this cell 
suspension/trypan blue solution was then placed on a Neubauer Haemocytometer. The 
number of cells present in 4 small squares was then determined on X 40 magnification. 
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If for example, the number of cells in 4 squares was 360, to calculate the number of cells 
per 1 ml of cell suspension: n x 4 x 2 x 1 04= 106 
(number of cells in 4 small squares x 4 x 1 in 2 dilution with trypan blue x 104) 
360 x 4 x 2x 104 = 30 X 106 cells per ml 
The lml of cell suspension was then transferred to a clean 50rnl Falcon tube and 
29ml of culture medium was added to it (1 :30 dilution) to adjust the cell concentration to 
lx106 cetlsperml (Figure 5.4). 
5.9.2 Culturing peripheral blood mononuclear cells 
Optimum cell culture conditions for maximal protein secretion were found to be I x 
106 cells per ml, stimulated with 51Jg/ml LPS for 72 hours (Appendix 1). Four time points 
were used in this experiment to provide a more accurate representation of an individual's 
secretory profile. lml of cell suspension was added to 2 Eppendorfs labelled OJ.lg/ml LPS 
time 0 hours and 51Jg/ml LPS time 0 hours. 51Jg/ml LPS was added to the Eppendorf 
labelled 51Jg/ml LPS, while the cell suspension in the Eppendorf labelled 01Jg/ml remained 
unstimulated. The 2 Eppendorfs were then centrifuged in a Heraeus Sepatech microfuge 
for 30 seconds to pellet out the cells and the supematant was transferred to a fresh 
Eppendorf and stored immediately at -20°C. 4 m is of the cell suspension was then added 
to each well on a 6-well flat-bottomed tissue culture plate (Fischer Scientific, 
Loughborough, UK) labelled 01Jg/ml LPS (AI) 24 hours, 51Jg/ml LPS 24 hours (A2), 
OJ.lg/ml LPS 48 hours (Bl) 51Jg/ml LPS 48 hours (B2), Of.lg/ml LPS 72 hours (Cl) and 
51Jg/ml LPS 72 hours (C2) seeding cells at 1 x 106 cells per ml. The cells in wells A2-C2 
were stimulated with 51Jg/ml LPS (E.coli 0127:B8) for 24, 48 and 72 hours respectively 
while cells in the wells A 1-Cl remained unstimulated (Figure 5.5). The plates were then 
placed in a plastic box containing 1 OOmls of sterile water and 4 drops of "Sigma clean ™" 
water bath treatment (N-alkyldimethylbenzylamrnonium chloride, ethyl alcohol, methyl 
alcohol) (Sigma Chemicals, Poole, UK) to prevent evaporation from the plates. 
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Figure 5.4: Summary of the technique for isolating PBMCs 
50ml Falcon tube 
Collect 30mls 
blood in 
sodium heparin 
vacutainers 
PBMCs 
15ml blood 
Dilute blood 1:1 
using PBS 
~ 
1--+-~ Centrifuge 2000rpm 30mins 
layer of PBMCs 
Add 4X PBS to wash 
PBS 
Centrifuge 1400rpm lOmins 
Discard supernatant 
Add 4X wash RPMI 
JO,U trypau blu• 45ml EPf"odoif ~ 
~cell suspension 
PBMCs 
Dilute to lxl06 cells per ml 
RP!vfl medium 
1 m/ cell suspension 
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15ml PBS 
Invert 20X I Aliquot into 8x15ml 
• tubes containing 
7ml "LymphoprepnA" 
1 5ml Universal 
tube 
7ml blood/PES 
mixture 
7ml "Ly mphoprep ""' 
Centrifuge 1400rpm lOmins 
Discard supernatant 
Resuspend pellet in 
lml RPMI medium 
/m/ RPM! medium (with 
5% penlstrep, 10% FCS 
5% L-glutamine) 
pellet (PBMCs) 
Figure 5.5: Layout of each 6 well flat-bottomed cell culture plate 
A 
B 
1 
0!-ig/ml LPS 
24 hours 
5!-!g/ml LPS 
24 hours 
2 
0!-ig/ml LPS 
48 hours 
5!-ig/ml LPS 
48 hours 
3 
0!-!g/ml LPS 
72 hours 
5!-ig/ml LPS 
72 hours 
Each well on the cell culture plate contains 4mls cell suspension at a concentration of 
lxl06 cells per m!. The cells in row B are stimulated with Sj.lg/ml LPS E. coli 0127:B8, 
while those in row A remain unstinmlated. All cells are then incubated for 24, 48 and 72 
hours at 37°C, 5% C02. 
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The lid of the box was perforated to allow C02 to reach the cells, but also minimize 
evaporation. All cells were incubated at 37°C in 5% C02 in a Leec incubator (Jencons-
PLS, Leighton Buzzard, UK.). After 24, 48 and 72 hours, the supematant from each well 
was removed, centrifuged to pellet out the cells and the supematant was transferred to a 
clean Eppendorf and stored at -20°C for batch cytokine assay. The amount of protein 
present was determined using a Quantikine® ELISA kit (R & D Systems Europe, 
Abingdon, UK). Cell viability was confirmed at each time point by adding 20f.ll of trypan 
blue to the cells attached to the culture plate and then observing them under a microscope 
to ensure that the cell membranes were intact. 
5.10 Quantification of protein levels 
Each Quantikine® ELISA kit consisted of a microplate, conjugate, standard, 
calibrator diluent, wash buffer concentrate, colour reagent A, colour reagent B, stop 
solution and plate covers. All reagents were brought to room temperature before use. The 
optimisation experiment indicated that the stimulated supematants needed to be diluted 
1:10 using RPMI without L-glutamine to ensure the measurements would not exceed the 
absorbance-protein concentration graph plotted by the microplate reader while the 
unstimulated supematants were used 1: 1. 
5.1 0.1 Preparation of the standards 
To prepare the standards, 3ml of the calibrator diluent RD5 was added to the 
standard, inverted and allowed to stand for 15 minutes. 500f.ll of neat calibrator diluent 
RD5 was then added to 6 Eppendorfs labelled 1000, 500, 250, 125, 62.5 and 31.2pg/ml. 
Next 500f.ll of the undiluted standard (2000pg/ml) was added to the Eppendorf labelled 
1 OOOpg/ml to give a 112 dilution and the contents of the tube were mixed by inversion. 
SOOJ.ll of the 112 dilution was then added to the tube labelled 500pg/ml to give a l/4 
dilution. 500f.l1 of the 114 dilution was then transferred to the tube labelled 250pg/ml to 
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gtve a 1/8 dilution and so on. The undiluted standard served as the high standard 
(2000pg/ml) and the calibrator diluent RD5 served as the zero standard (Opg/ml). 
5.10.2 Quantifying protein levels 
200111 of the 8 standards (2000, 1000, 500, 250, 125, 62.5, 31.2 and Opg/ml) were 
added in duplicate to columns I and 2 on the ELISA microplate. Next 200111 of neat 
calibrator diluent RD5 was added to column 3 to act as blanks. 200111 of the samples were 
then added in duplicate to columns 4-12 on the ELISA plate. The microplate was then 
covered with the plate cover and the samples were incubated at room temperature for 2 
hours. After incubation, the samples were discarded, and the wells were washed with 
200111 wash buffer three times', blotting the plate onto paper after each wash. 200111 of 
conjugate was then added to each well and the microplate was covered again with a plate 
cover and incubated for 1 hour' at room temperature. After I hour, the conjugate was 
discarded and the wells were washed 3 times' with 200!11 wash buffer blotting onto paper 
after each wash as before. Next equal volumes of the colour reagents A and B were mixed 
into a sterile bottle to make up the substrate solution. 200111 of the substrate solution was 
then added to each well and the microplate was covered with a plate cover and allowed to 
incubate for 20 minutes at room temperature. After 20 minutes, 50!11 of stop solution was 
added to each well causing a colour change from blue to yellow. The optical density and 
hence the amount of protein in each well was then determined within 30 minutes using a 
Dias microplate reader (Dynal, UK) set to 450nm and corrected to 570nm to avoid optical 
imperfections in the plate (Figure 5.6). To determine the amount of protein in each well, a 
log-log graph was plotted of absorbance vs protein concentration by the microplate reader. 
• 4 times (IL-lra study);' 2 hours (IL-lra study) 
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Figure 5.6: Summary of the Quantikine® ELISA protocols 
Prepare reagents and standards 
Add 2001J.l standard or sample to each well 
Incubate 2 hours. Room temperature 
ll - lra 11...-IJ 
Aspirate and wash 4X 
Add 200tJ.l IL-l ra 
conjugate to each well 
Incubate 2 hours 
Room temperature 
Aspirate and wash 4X 
Aspirate and wash 3X 
Add 200tJ.I IL-l f3 
conjugate to each well 
Incubate 1 hour 
Room temperature 
D 
Aspirate and wash 3X 
Add 200tJ.} substrate solution to each well 
Incubate 20 minutes. Room temperature 
Add 501J.I Stop solution to each well 
Read at 450nm within 30 minutes 
A. correction 570nm 
11 I 
Aspirate and wash 3X 
Add 2001J.l IL- l a 
conjugate to each well 
Incubate 1 hour 
Room temperature 
D 
Aspirate and wash 3X 
(Adapted from the Quantikine® Human IL-lra, IL-lP and IL- la Immunoassay booklets) 
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5.11 Analysis of the data 
The genotype data obtained for each study was recorded on Microsoft® Excel 7 
spreadsheets so statistical analysis could be carried out within the same application or in 
applications into which Excel spreadsheets could be imported. 
5.11.1 Allele and genotype frequencies 
The occurrence of each allele was expressed as a percentage of the total number of 
alleles present in the population to give an allele frequency. Homozygotes represented 2 
copies of a given allele whereas heterozygotes represented only I copy. The number of 
individuals carrying a particular genotype was also calculated as a proportion of the total 
number of genotypes in the population to give a genotype frequency. Comparison of allele 
and genotype frequencies between controls, patients and patient subgroups were made in 2 
x 2 contingency tables using the x2 test. The statistics were performed on the Statca/c 
program of the computer software package Epi Info6 (World Health Organisation, 
Switzerland). P values were then corrected (Pc) for the number of comparisons made using 
the Bonferroni inequality method (Tiwari and Terasaki, 1985). Statistical significance was 
obtained when Pc<O.OS. Correcting p values is necessary to show that the results are more 
likely to be significant and less likely to be due to chance. 
5.11.2 Hardy-Weinberg equilibrium 
This is a statistical test that shows whether a polymorphism conforms to normal 
distribution within a population. For a biallelic polymorphism the expected genotype 
frequencies are calculated using the equation 1 = p2 + q2 + 2 (pq) where p and q are the 
frequencies of the 2 alleles within the population. Hardy-Weinberg equilibrium occurs if 
the expected frequency does not differ significantly (p<O.OS) from the observed frequency. 
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5.11.3 Haplotype analysis and linkage disequiUbrium 
In addition to analysing the genotypes for each gene, the genotypes of different 
genes were also combined to give haplotypes and analysed to determine whether the genes 
were linked and hence influence each other's expression. Individuals were considered for 
haplotype analysis provided they were not heterozygous at more than 1 locus. Double 
heterozygote& were omitted from the study since the 2 different haplotypes were possible 
on each chromosome. This subjective removal of the heterozygotes may introduce a bias if 
a large number of double heterozygotes are present, however, since the bias is likely to be 
consistent in both controls and patients the 'error' is not significant. The haplotype data 
were analysed using the Epitable program of the computer software package Epilnfo6 
(World Health Organisation, Switzerland). Linkage disequilibrium occurs when alleles at 2 
loci appear more frequently than could be expected by random association. Expected 
frequency of an allelic association between 2 loci was calculated by multiplying the 
frequency of 1 of the alleles with the other. Expected and observed frequencies were 
compared using x2 test. Linkage was apparent ifp<0.05. 
5.11.4 Combined genotype analysis 
The genotypes of the different genes were also combined for each subgroup of the 
patient population to determine whether the genotypes were preferentially expressed in a 
given group. Haplotype analysis could not be used in this case, since the number of 
subjects in each patient subgroup would become too small following elimination of the 
double heterozygote& that statistical significance could not be obtained. In this type of 
analysis double heterozygotes were included. The same analysis was carried out on the 
control population. 
5.11.5 ELISA analysis 
The ELISA data were analysed by the Mann-Whitney U test (Statgraphics Plus2.1) 
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CHAPTER 6: RESULTS 
The following results are discussed in the order in which the polymorphisms occur 
on the long rum of chromosome 2 relative to the centromere, beginning with Pst I 
polymorphism in the IL-l RI gene and ending with the Ssp I polymorphism in the IL-l RN 
gene. For each study, comparisons of the genotype and allele frequencies were made 
between the: 
I) controls and patients 
2) controls and subgroups of the patient population (mild, severe, OFS=O, OFS~I,2,3,4, 
alcoholic, idiopathic, gallstone) 
3) mild group and severe group 
4) OFS=O group and OFS~ I ,2,3,4 groups 
5) different combinations of the aetiological groups 
using the x2 test and 2 x 2 contingency tables. All of the significant data are discussed, 
however, only the data that are significant following correction for the number of 
comparisons involved are included in the tables. All polymorphisms conformed to the 
Hardy-Weinberg equilibrium. Figure 6.1 illustrates the interleuk:in-1 gene cluster and 
location of the polymorphisms studied in this thesis. 
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Figure 6.1: Map of the Interleukin-1 gene cluster and Interleukin-1 receptor genes illustrating the positions of polymorphisms investigated in this study 
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... , ........... · 
N ucleotides are numbered in accordance with Bergholdt et al, 1995 ~Genbank: S81 089) 
7695 Intron 5 (AC)n (Todd and Naylor, 1991 ); 8912 Intron 6 VNTR (Bailly et a!, 1993) 
Nucleotides are numbered in accordance with Furutani et al, 1986 (Genban.k: X03833) 
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Telomere 
(Adapted from Nickin et al, 1994 and Dale and Nicklin, 1999) 
6.1 DNA Studies 
6.1.1 IL-lRI 
6.1.1.1 Pst I polymorphism 
Figure 6.1 illustrates the location of the Pst I polymorphism in the IL-l gene 
cluster. Digestion of PCR products amplified by Pst I and // amplimers with Pst I 
generated fragments of 349bp and 97bp, 252bp for alleles 1 and 2. These gave rise to three 
possible genotypes: 1,1; I ,2; 2,2. The T ~C131 SNP creates a Pst I restriction site. 
Homozygotes for allele I (349bp) occur when the SNP is not present on either 
chromosome. Homozygotes for allele 2 (97bp, 252bp) occur when the SNP is present on 
both chromosomes. Heterozygotes (97bp, 252bp, 349bp) occur when the SNP is present on 
one chromosome only (Figure 6.2). 
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Figure 6.2: 3% agarose gel illustrating the genotypes detected at the Pst I locus 
1 2 3 4 5 6 7 8 
~ X 97bp 
~ 252bp 349bp 
Two alleles were detected: allele 1 (349bp ), allele 2 (97bp,252bp ). Band X is an artefact. 
Lanes 1,5,6,7,8 and 9- 2,2 
Lanes 2,4,10,11 and 12- 1,2 
Lane 3- 1,1 
Lane 13- Molecular weight marker XIII (50bp ladder) 
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Table 6.1A: Frequency of IL-l RI Pst 1 genotypes in controls, patients and patient subgroups 
Mild Severe A I G 
Genotype Controls Patients AP AP OFS=O OFS~I OFS~ OFS~ OF~4 AP AP AP 
% % 0/o 0/o % % % % % % % % 
I , I 7.I 3.0 3.I 2.7 4.5 0.0 0.0 0.0 0.0 4.8 2.9 2.6 
(12) (4) (3) (1) (4) (0) (0) (0) (0) (1) (1) (2) 
I , 2 43.2 36.6 38.1 32.4 37.5 34.8 36.4 36.8 33.3 33.3 45;7 33.3 
(73) (49) (37) (12) (33) (16) (12) (7) (4) (7) (16) (26) 
2,2 49.7 60.4 58.8 64.9 58.0 65.2 63.6 63.2 66:7 61.9 51.4 64.I 
(84) (81) (57) (24) (51) (30) (21) (12) (8) (13) (18) (50) 
Total (n) I69 134 97 37 88 46 33 19 12 21 35 78 
This table shows the frequency of the 3 genotypes of the Pst I polymorphism in the IL-l RI gene in controls and patient subgroups. n represents the number 
of genotypes in each group. The number in brackets is the actual number of subjects with a particular genotype. Comparisons were made between the 
control and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for 
each genotype using the x2 test and 2 x 2 contingency tables. No significant differences were found. 
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Table 6.1B: Frequency of IL-l RI Pst I aUeles in controls, patients and patient subgroups 
Mild Severe A I G 
Allele Controls Patients AP AP OFS=O OFS~1 OFS~ OF~ OFS~4 AP AP AP 
o;o % % % o;o % o;o % % % o;o % 
1 28.7 21.3' 22.2 18.9 23.3 17.4b 18.2 18.4 16.7 21.4 25.7 19.2< 
(97) (57) (43) (14) (41) (16) (12) (7) (4) (9) (18) (30) 
2 71.3 78.78 77.8 81.1 76.7 82.6b 81.8 81.6 83.3 78.6 74.3 80.8< 
(241) (211) (151) (60) (135) (76) (54) (31) (20) (33) (52) (126) 
Total (o) 338 268 194 74 176 92 66 38 24 42 70 156 
This table shows the frequency of the 2 alleles of the Pst /polymorphism in the IL-lRl gene in controls and patient subgroups. n represents the number 
of alleles in each group. The number in brackets is the actual number of subjects with a particular allele. Comparisons were made between the control 
and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for each 
a1lele using the x2 test and 2 x 2 contingency tables. 
a= patients vs controls (Allele 1:21.3% VS 28.7%, X2=4.35, p=0.037 (1df), Pc=0.037, Allele 2:78.7% VS 71.3%,x2=4.35, p=0.037 (1df), Pc=0.037) 
b= OFS~l vs controls (Allele 1: 17.4% VS 28.7%, x2=4.77, p=0.029 (1df), Pc=0.029; Allele 2: 82.6% vs 71.3%, x2=4,77, p=0.029 (1df), Pc=0.029) 
c =gallstones vs controls (Allele 1: 19.2% vs 28.7%, x2=5.0l, p=0.025 (ldf), Pc=0.025; Allele 2: 80.8% vs 71.3% x2=5.01, p=0.025 (ldf), Pc=0.025) 
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Summary of the results obtained from the Pst /locus 
Genotype frequency 
Controls vs patients/ controls vs patient subgroups/ mild group vs severe group, OFS=O 
group vs OFS~,2,3,4 groups/ differellt combinations oft/re aetiological groups 
There were no significant differences in the Pst I genotype frequencies between the 
controls, patients or patient subgroups. 
Allele frequency 
Controls vs patients 
Comparisons of the Pst I allele frequencies between the control group and patient group 
showed that allele I was significantly decreased in patients compared to controls (21.3% vs 
28.7%, x2=4.35 p=0.037, Pc=0.037), whereas allele 2 was significantly increased between 
the two groups (78.7% VS 71.3%, x2= 4.35, p=0.037, Pc=0.037). 
Cotrtrols vs patietrt subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology, and comparisons made between the different subgroups and controls, allele I 
was found to be significantly decreased in the OFS;;:>:I group compared to controls (17.4% 
vs 28.7%, x2=4.77, p=0.029, Pc=0.029), whereas allele 2 was significantly increased 
between the same two groups (82.6% vs 71.3%, x2=4.77, p=0.029, Pc=0.029). In addition, 
allele 1 was significantly decreased in the gallstone group compared to controls (19.2% vs 
28.7%, x2=5.0I, p=0.025, Pc=0.025), while allele 2 was significantly increased between 
the two groups (80.8% vs 71.3%, x2=5.0I, p=0.025, Pc=0.025). 
Mild group vs severe group, OFS=O group vs OFS~,2,3,4 groups, differetrt 
combitrations oft/re aetiological groups 
No significant differences in the Pst I allele frequencies were found when comparisons 
were made between the mild and severe groups, between the OFS=O group and 
OFS~ 1 ,2,3,4 groups or between different combinations of the aetiological groups. 
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Figure •6..1: .iliusttates:,the location of the (.AG)n: :repeat polymo!'Phism in the ILc 1 
I , • - • -
gerte chist~r. Ni~e difier~_nt. :alJeies. :(a)leles Oc8): were detected each :corresponding to a: 
: ' ' - - - . - - - . . . 
. . . 
~iff'e~enl nwnlm 'Of: copies iOf the AG' dinucleotide repeat. Twenty tw.o. genotypes were 
I 
·observed (Figure 6i3). 
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Figure 6.3: 6% polyacrylamide gel illustrating the genotypes observed at the {AC)n repeat locus. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1718 19 20 21 22 
Nme alleles were detected: alleles 0-8. Allele 1 was the most common allele. 
Lanes 1 and 8- 1,5 
Lanes 2,10 and 11 - 1,1 
Lanes 3,9,14,15,17,19 and 21- 1,2 
Lane 4- 0,1 
Lanes 5,7 and 18 - 2,4 
Lane 6- 1,8 
Lane 12-2,2 
Lane 13 - 1,6 
Lane 16- 1,4 
Lane 20- 2,7 
Lane 22- 3,4 
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Table 6.2A: Frequency of IL-lA (AC)n repeat genotypes in controls, patients and 
patient subgroups 
Mild Severe A I G 
Grr Control Patients AP AP OFS=O OFS~l OFS~ OFS:8 OFS~4 AP AP AP 
s % 0/o % 0/o % % 0/o 0/o 0/o 0/o % 
% 
0,1 4.0 1.5 1.0 2.6 2.2 0.0 0.0 0.0 0.0 0.0 2.8 1.3 
(6) (2) (I) (I) (2) (0) (0) (0) (0) (0) (I) (I) 
0,2 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(I) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
1 ' 1 12.0 12.4 11.1 15.8 14.6 8.3 11.4 21.1 25.0 14.3 5.6 15.0 
(18) (17) (11) (6) (13) (4) (4) (4) (3) (3) (2) (12) 
1,2 23.3 28.5 25.3 36.8 21.3 41.7 45.7"< 42.1 41.7 19.0 30.6 30.0 
(35) (39) (25) (14) (19) (20) (16) (8) (5) (4) (11) (24) 
1 '3 2.0 0.7 1.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 
(3) (1) (1) (0) (I) (0) (0) (0) (0) (0) (0) (I) 
1 '4 14.7 13.1 16.2 5.3 15.7 8.3 5.7 5.3 8.3 9.5 13.9 13.8 
(22) (18) (16) (2) (14) (4) (2) (I) (I) (2) (5) (!I) 
1 '5 2.7 3.6 3.0 5.3 1.1 8.3 8.6 10.5 8.3 4.8 2.8 3.8 
(4) (5) (3) (2) (1) (4) (3) (2) (I) (I) (I) (3) 
1 '6 0.7 0.7 0.0 2.6 0.0 2.1 2.9 0.0 0.0 0.0 0.0 1.3 
(I) (1) (0) (I) (0) (I) (1) (0) (0) (0) (0) (I) 
1,7 0.7 0.7 1.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 
(I) (I) (I) (0) (I) (0) (0) (0) (0) (0) (0) (I) 
1 '8 2.0 0.7 1.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 
(3) (I) (I) (0) (1) (0) (0) (0) (0) (0) (0) (I) 
2,2 12.7 10.2 8.1 15.8 6.7 16.7 17.1 10.5 8.3 0.0 13.9 11.3 
(19) (14) (8) (6) (6) (8) (6) (2) (1) (0) (5) (9) 
2,3 2.7 1.5 1.0 2.6 2.2 0.0 0.0 0.0 0.0 4.8 0.0 1.3 
(4) (2) (1) (I) (2) (0) (0) (0) (0) (I) (0) (I) 
2,4 12.0 13.9 17.2 5.3 14.6 12.5 5.7 5.3 0.0 33.3b 16.7 7.Sd 
(18) (19) (17) (2) (13) (6) (2) (1) (0) (7) (6) (6) 
2,5 1.3 3.6 4.0 2.6 5.6 0.0 0.0 0.0 0.0 0.0 2.8 s.o 
(2) (5) (4) (I) (5) (0) (0) (0) (0) (0) (1) (4) 
2,6 0.0 0.7 1.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 
(0) (I) (1) (0) (1) (0) (0) (0) (0) (0) (0) (1) 
2,7 0.7 1.5 2.0 0.0 2.2 0.0 0.0 o.o 0.0 0.0 5.6 0.0 
(I) (2) (2) (0) (2) (0) (0) (0) (0) (0) (2) (0) 
2,8 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(1) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
3,4 2.7 3.6 4.0 2.6 5.6 0.0 0.0 0.0 0.0 9.5 2.8 2.5 
(4) (5) (4) (I) (5) (0) (0) (0) (0) (2) (I) (2) 
3,5 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(2) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
4,4 1.3 0.7 1.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 
(2) (1) (1) (0) (l) (0) (0) (0) (0) (0) (0) (I) 
4,5 2.0 0.7 1.0 0.0 1.1 0.0 0.0 0.0 0.0 4.8 0.0 0.0 
(3) (1) (I) (0) (l) (0) (0) (0) (0) (l) (0) (0) 
4,6 0.0 1.5 1.0 2.6 1.1 2.1 2.9 5.3 8.3 0.0 2.8 1.3 
(0) (2) (1) (1) (1) (1) (1) (I) (I) (0) (1) (I) 
Total (n) ISO 137 99 38 89 48 35 19 12 21 36 80 
146 
This table shows the frequency of the 22 genotypes of the (AC)n polymorphism in the IL-
l A gene in controls and patient subgroups. n represents the number of genotypes in each 
group. The number in brackets is the actual number of subjects with a particular genotype. 
Comparisons were made between the control and patient groups, controls and patient 
subgroups, mild and severe, OFS=O and OFS~I,2,3,4 groups and different patient 
aetiologies for each genotype using the x2 test and 2 x 2 contingency tables. 
"= OFS~ vs controls (45.7% vs 23.3%, x2=7.12, p=0.008 (ldf), Pc=0.04) 
b =Alcoholics vs controls (33.3% vs 12.0%, x2=6. 72, p=O.Ol (Idf), Pc<0.05) 
c = OFS~ vs OFS=O (45.7% vs 21.3%, x2=7.36, p=0.007 (ldf), Pc=0.035) 
d =Gallstone vs alcoholics (7.5% VS 33.3%, x2=9.9, p=0.002 (ldf), Pc=O.Ol) 
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Table 6.2B: Frequency ofiL-lA (AC)n repeat aUeles in controls, patients and patient subgronps 
Mild Severe A I G 
Allele Controls Patients AP AP OFS=O OFS~ OFS~ OFS~ OFS:2:4 AP AP AP 
% % % 0/o 0/o 0/o % % % 0/o % % 
0 2.3 0.7 0.5 1.3 1.1 0.0 0.0 0.0 0.0 0.0 1.4 0.6 
(7) (2) (1) (1) (2) (0) (0) (0) (0) (0) (1) (1) 
1 37.0 37.2 35.4 42.1 36.5 38.5 42.9 50.0 54.2 31.0 30.6 41.9 
(111) (102) (70) (32) (65) (37) (30) (19) (13) (13) (22) (67) 
2 33.3 35.0 33.3 39.5 30.3 43.8 42.9 34.2 29.2 28.6 41.7 33.8 
(100) (96) (66) (30) (54) (42) (30) (13) (7) (12) (30) (54) 
3 4.3 2.9 3.0 2.6 4.5 0.0 0.0 0.0 0.0 7.1 1.4 2.5 
(13) (8) (6) (2) (8) (0) (0) (0) (0) (3) (1) (4) 
4 17.0 17.2 20.7 7.9 20.2 11.5 7.1 7.9 8.3 28.6 18.1 13.8 
(51) (47) (41) (6) (36) (11) (5) (3) (2) (12) (13) (22) 
5 3.7 4.0 4.0 3.9 3.9 4.2 4.3 5.3 4.2 4.8 2.8 4.4 
(11) (11) (8) (3) (7) (4) (3) (2) (1) (2) (2) (7) 
6 0.3 1.5 1.0 2.6 1.1 2.1 2.9 2.6 4.2 0.0 1.4 1.9 
(1) (4) (2) (2) (2) (2) (2) (1) (1) (0) (1) (3) 
7 0.7 1.1 1.5 0.0 1.7 0.0 0.0 0.0 0.0 0.0 2.8 0.6 
(2) (3) (3) (0) (3) (0) (0) (0) (0) (0) (2) (1) 
8 1.3 0.4 0.5 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0 0.6 
(4) (1) (1) (0) (1) (0) (0) (0) (0) (0) (0) (1) 
Total (n) 300 274 198 76 178 96 70 38 24 42 72 160 
This table shows the frequency of the 9 alleles of the (AC)n polymorphism in the IL-lA gene in controls and patient subgroups. n represents the number 
of alleles in each group. The number in brackets is the actual number of subjects with a particular allele. Comparisons were made between the control 
and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS<::l,2,3,4 groups and different patient aetiologies for each 
allele using the x2 test and 2 x 2 contingency tables. No significant differences were found. 
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Summary of the results obtained at the (AC)n repeat locus 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Genotype frequency: 
To make the genotype analysis easier, genotypes were divided into 1,1; 1,2; 1,4; 2,2; 2,4 
and "other". 
Controls vs patients 
There were no significant differences in genotype frequencies between the patient group 
compared to the control group. 
Controls vs patient subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with controls, the 1,2 genotype was significantly 
increased in the OFS;;::t group compared to controls (41.7% vs 23.3%, x) =6.09, 
p=0.014*). The 1,2 genotype was significantly increased in the OFS;;::2 group compared to 
controls (45.7% vs 23.3%, x2=7.12, p=0.008, Pc=0.04). The 2,4 genotype was significantly 
increased in the alcoholic group compared to controls (33.3% VS 12.0%, x2=6.72, p=O.Ol, 
Pc<0.05). 
Mild group vs severe group 
No significant differences in genotype frequency were found between mild group and 
severe group. 
OFS=O group vs OFS8,2,3,4 groups 
Analysis of the genotype data with respect to organ failure scores showed the l ,2 genotype 
was significantly increased in the OFS~l group compared to the OFS=O group (41.7% vs 
21.3%, x2=6.32, p=O.Ol2•). The 1,2 genotype was significantly increased in the OFS~2 
group compared to the OFS=O group (45.7% vs 21.3%, x2=7.36, p=0.007, Pc=0.035). 
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Different combinati011s of tile aetiological groups 
When the data was analysed with respect to aetiology, the 2,4 genotype was significantly 
decreased in the gallstone group compared to the alcoholic group (7.5% vs 33.3%, x.2= 9.9, 
p=0.002, Pc=O.Ol). 
Allele frequency: 
C011trols vs patients 
No significant differences in allele frequency were found between the control and patient 
groups. 
Controls vs patient subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with controls, allele 4 was significantly decreased in 
the severe group compared to controls (7.9% vs 17.0%, x.2 =3.91, p=0.048*) while allele 6 
was significantly increased between the same two groups (2.6% vs 0.3% x.2 =4.05, 
p=0.044*). Allele 3 was significantly decreased in the OFS21 group compared to controls 
(0.0% vs 4.3%, x.2 =4.30, p=0.038*). Allele 4 was also significantly decreased in the 
OFS22 group compared to controls (7.1% vs 17.0%, x.2=4.29, p=0.038*) while allele 6 
was significantly increased between the same groups (2.9% vs 0.3%,x.2=4.5, p=0.034*). 
Allele 6 was also significantly increased in the OFS24 group compared to controls (4.2% 
vs 0.3%, x.2 =5.32, p=0.021 *). 
Mild group vs severe group 
Analysis of the data with respect to severity showed allele 4 was significantly decreased in 
the severe group compared to the mild group (7.9% vs 20.7%, x.2=6.34, p=O.OI2•). 
OFS=O group vs OFS~1,2,3,4 groups 
When the data was analysed with respect to organ failure scores allele 2 was significantly 
increased in the OFS2l group compared to the OFS=O group (43.8% vs 30.3%, x.2=4.93, 
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p=0.026•) whereas allele 3 was significantly decreased between the same groups (0.0% vs 
4.5%, x2=4.44, p=0.035•). Allele 4 was significantly decreased in the OFS;::2 group 
compared to the OFS=O group (7.1% vs 20.2%, x2=6.23, p=O.Ol3•). 
Different combinations of the aetiological groups 
Comparisons of the allele frequencies between the different aetiological groups showed 
allele 4 was significantly decreased in the gallstone group compared to the alcoholic group 
(13.8% VS 28.6%, x2=5.22, p=0.022*). 
• p value became non-significant following correction for the number of comparisons 
made. 
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6.1.2.2 VNTR46 polymorphism 
Figure 6.1 illustrates the location of the VNTR46 polymorphism in the IL-l gene 
cluster. Five different alleles (alleles 1-4 and 6) were observed corresponding to 9 (800bp), 
18 (1220bp), 8 (760bp), 12 (940bp) and 15 (1080bp) copies of the 46bp repeat sequence. 
These gave rise to 12 different genotypes. Alleles 5 and 7 corresponding to 5 (620bp) and 6 
(660bp) copies of the repeat sequence were not detected (Figure 6.4). 
!52 
Figure 6.4: 3% agarose gel showing tbe genotypes detected at tbe IL-lA VNTR46 1ocus. 
1 2 3 4 5 6 7 8 9 
760bp/800bp/940bp ~ 
1080bp/1220bp ~ 
10 11 12 13 
._ IOObp 
._ SOObp 
._ IOOObp 
._ 2642bp 
Five different alleles (alleles 1-4 and 6) were detected corresponding to: 9(800bp), 18(1220bp), 8(760bp), 12(940bp) and 15(1080bp) copies of the 46bp repeat sequence. Alleles 5 and 7 
corresponding to 5 ( 620bp) and 6 ( 660bp) cop1es of the repeat sequence were not detected. 
Lanes 1,6 and 12- 1,2 
Lanes 2 and 11 - 2,2 
Lane 3- 1,6 
Lanes 4,7,8, and 9- 1,3 
Lane 5- 1,1 
Lane 10- 1,4 
Lane 13 - Molecular weight marker XIV ( 1 OObp ladder) 
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Table 6.3A: Frequency of IL-IA VNTR46 genotypes in controls, patients and patient 
subgroups 
Mild Severe A I G 
Grr Controls Patients AP AP OFS=O OFS<!:l OFSC!:l OFS<!:J OFS<!:4 AP AP AP 
•;. % % 0/o % "/o % % •;. •;. % % 
1 ' 1 31.6 25.0 24.2 27.0 29.2 17 20.6 26.3 25.0 28.6 19.4 26.6 
(59) (34) (24) (10) (26) (8) (7) (5) (3) (6) (7) (21) 
1 '2 29.9 33.8 34.3 32.4 31.5 38.3 38.2 31.6 33.3 38.1 44.4 27.8 
(56) (46) (34) (12) (28) (18) (13) (6) (4) (8) (16) (22) 
1,3 12.8 14.7 15.2 13.5 15.7 12.8 14.7 15.8 16.7 23.8 5.6 16.5 
(24) (20) (15) (5) (14) (6) (5) (3) (2) (5) (2) (13) 
1 '4 2.7 2.9 3.0 2.7 3.4 2.1 2.9 0.0 0.0 0.0 2.8 3.8 
(5) (4) (3) (I) (3) (I) (1) (0) (0) (0) (1) (3) 
1 '6 3.7 3.7 5.1 0.0 2.2 6.4 2.9 0.0 0.0 0.0 2.8 5.1 
(7) (5) (5) (0) (2) (3) (1) (0) (0) (0) (I) (4) 
2,2 7.5 4.4 5.1 2.7 3.4 6.4 5.9 0.0 0.0 4.8 5.6 3.8 
(14) (6) (5) (1) (3) (3) (2) (0) (0) (I) (2) (3) 
2,3 6.4 11.8 11.1 13.5 11.2 12.8 8.8 15.8 16.7 0.0 16.7 12.7 
(12) (16) (11) (5) (10) (6) (3) (3) (2) (0) (6) (10) 
2,4 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(4) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
3,3 1.6 2.9 2.0 5.4 3.4 2.1 2.9 5.3 8.3 4.8 2.8 2.5 
(3) (4) (2) (2) (3) (1) (1) (1) (1) (I) (1) (2) 
3,4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(1) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
4,6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(1) (0) (0) (0) (0) (O) (0) (0) (0) (0) (0) (0) 
6,6 0.5 0.7 0.0 2.7 0.0 2.1 2.9 5.3 0.0 0.0 0.0 1.3 
(I) (I) (0) (1) (0) (I) (I) (I) (0) (0) (0) (I) 
Total (n) 187 136 99 37 89 47 34 19 12 21 36 79 
This table shows the frequency of the 12 genotypes of the VNTR46 polymorphism in the IL-
lA gene in controls and patient subgroups. n represents the number of genotypes in each 
group. The number in brackets is the actual number of subjects with a particular genotype. 
Comparisons were made between the control and patient groups, controls and patient 
subgroups, mild and severe, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies 
for each genotype using the x2 test and 2 x 2 contingency tables. No significant differences 
were found. 
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Table 6.3B: Frequency of IL-lA VNTR46 alleles in controls, patients and patient 
subgroups 
Mild Severe A I G 
Allele Controls Patients AP AP OFS=O OFS~l OFS~ OFS<!:J OFS~4 AP AP AP 
% % % % 0/o % % % % % 0/o % 
1 56.1 52.6 53.0 51.4 55.6 46.8 50.0 50.0 50.0 59.5 47.2 53.2 
(210) (143) (105) (38) (99) (44) (34) (19) (12) (25) (34) (84) 
2 26.7 27.2 27.8 25.7 24.7 31.9 29.4 23.7 25.0 23.8 36.1 24.1 
(lOO) (74) (55) (19) (44) (30) (20) (9) (6) (10) (26) (38) 
3 11.5 16.2 15.2 18.9 16.9 14.9 14.7 21.1 25.0 16.7 13.9 17.1 
(43) (44) (30) (14) (30) (14) (10) (8) (6) (7) (10) (27) 
4 2.9 1.5 1.5 1.4 1.7 1.1 1.5 0.0 0.0 0.0 1.4 1.9 
(11) (4) (3) (1) (3) (0) (I) (0) (0) (0) (I) (3) 
5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
6 2.7 2.6 2.5 2.7 1.1 5.3 4.4 5.3 0.0 0.0 1.4 3.8 
(10) (7) (5) (2) (2) (5) (3) (2) (0) (0) (I) (6) 
7 0.0 0.0 0.0 0.0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
Total (n) 374 272 198 74 178 94 68 38 24 42 72 158 
This table shows the frequency of the 7 alleles of the VNTR46 polymorphism in the IL-l A 
gene in controls and patient subgroups. n represents the number of alleles in each group. The 
number in brackets is the actual number of subjects with a particular allele. Comparisons 
were made between the control and patient groups, controls and patient subgroups, mild and 
severe, OFS=O and OFS~ 1 ,2,3,4 groups and different patient aetiologies for each allele using 
the X) test and 2 x 2 contingency tables. No significant differences were found. 
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Summary of the results obtained at the IL-lA VNTR46 1ocus 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Genotype frequency 
To make the genotype analysis easier, genotypes were divided into 1,1; 1,2; 1,3; 2,2; 2,3 
and "other". 
C011trols vs patie11ts 
No significant differences in the genotype frequencies were found between the control and 
patient groups. 
C01rtrols vs patie11t subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with controls, the 1,1, genotype was significantly 
decreased in the OFS~1 group compared to controls (17.0% vs 31.6%, x2=3.88, 
p=0.049•). The 2,3 genotype was significantly increased in the idiopathic group compared 
to controls (16.7% vs 6.4%, x2=4.27, p=0.039•). 
Mild group vs severe group IOFS=O group vs OFS;d,2,3,4 groups 
No significant differences in genotype frequency were found between mild group when 
compared with the severe group or between the OFS=O group and OFS~1,2,3,4 groups. 
Differellt aetiological groups 
Analysis of the data with respect to aetiology showed the 1,3 genotype was significantly 
decreased in the idiopathic group compared to the alcoholic group (5.6% vs 23.8%, 
x2=4.1 ,p=0.043• ), while the 2,3 genotype was significantly increased between the two 
groups (16.7% VS 0.0%, x2=3.91, p=0.048*). 
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Allele frequency: 
C01rtrols vs patients/ Controls vs patient subgroups/ mild group vs severe group 
No significant differences in allele frequency were found between these groups. 
OFS=O group vs OFS~,2,3,4 groups 
Analysis of the data with respect to organ failure scores showed allele 6 was significantly 
increased in the OFS~l group compared to the OFS=O group (5.3% vs l.l%, x2=4.32, 
p=0.038•). 
Different combinatio11s of the aetiological groups 
No significant differences were found in allele frequencies between the different 
aetiological groups. 
• p value became non-significant following correction for the number of comparisons 
made. 
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Figure 6.5: 3% agarose gel displaying the genotypes observed at the Ava I locus. 
1 2 3 4 
203bp ____. 
514bp 
=t 717bp 
Two alleles were detected: allele 1 (203bp,514bp ), allele 2 (717bp ). 
Lanes 1 and 6 - 2,2 
Lanes 2,5,9 and 10 - 1,2 
Lanes 3,4,7,8,11 and 12 - 1,1 
Lane 13 -Molecular weight marker XN (1 OObp ladder) 
5 6 7 
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Table 6.4A: Frequency of IL-lB Ava I genotypes in controls, patients and patient subgroups 
Mild Severe A I G 
Genotype Controls Patients AP AP OFS=O OFS~1 OFS~ OF~ OF~4 AP AP AP 
% % % % % % % % % o;o % o;o 
1 '1 42.4 43.4 42.4 45.9 47.2 36.2 38.2 36.8 41.7 42.9 50.0 40.5 
(92) (59) (42) (17) (42) (17) (13) (7) (5) (9) (18) (32) 
1,2 39.6 47.1 46.5 48.6 42.7 55.3 55.9 57.9 58.3 57.1 41.7 46.8 
(86) (64) (46) (18) (38) (26) (19) (11) (7) (12) (15) (37) 
2,2 18.0 9.6 11.1 5.4 10.1 8.5 5.9 5.3 0.0 0.0 8.3 12.7 
(39) (13) (11) (2) (9) (4) (2) (1) (0) (0) (3) (10) 
Total (n) 217 136 99 37 89 47 34 19 12 21 36 79 
This table shows the frequency of the 3 genotypes of the Ava I polymorphism in the IL-lB gene in controls and patient subgroups. n represents the number 
of genotypes in each group. The number in brackets is the actual number of subjects with a particular genotype. Comparisons were made between the 
control and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS;?:l,2,3,4 groups and different patient aetiologies for each 
genotype using the x2 test and 2 x 2 contingency tables. No significant differences were found. 
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Table 6.4B: Frequency ofiL-lBAva I aUeles in controls, patients and patient subgroups 
Mild Severe A I G 
AUele Controls Patients AP AP OFS=O OF~l OFS~ OF~ OFS::!:4 AP AP AP 
% % % % % % % % % % % % 
1 62.2 66.9 65.7 70.3 68.5 63.8 66.2 65.8 70.8 71.4 70.8 63.9 
(270) (182) (130) (52) (122) (60) (45) (25) (17) (30) (51) (101) 
2 37.8 33.1 34.3 29.7 31.5 36.2 33.8 34.2 29.2 28.6 29.2 36.1 
(164) (90) (68) (22) (56) (34) (23) (13) (7) (12) (21) (57) 
Total (n) 434 272 198 74 178 94 68 38 24 42 72 158 
This table shows the frequency of the 2 alleles of the Ava /polymorphism in the IL-lB gene in controls and patient subgroups. n represents the number 
of alleles in each group. The number in brackets is the actual number of subjects with a particular allele. Comparisons were made between the control 
and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for each 
allele using the x_2 test and 2 x 2 contingency tables. No significant differences were found. 
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Summary of the results obtained at the Ava I locus 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Genotype frequency 
Co11trols vs patie11ts 
Comparisons of the Ava I genotype frequencies between patients and controls showed the 
2,2 genotype was significantly decreased in the patient group compared to controls (9.6% 
VS 18.0%, X2=4.71, p=0.03*). 
Controls vs patie11t subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology, and the subgroups compared with controls, the 1,2 genotype was significantly 
increased in the OFS~l group compared to controls (55.3% vs 39.6%, x2=3.89, p=0.049•). 
The 2,2 genotype was significantly decreased in the alcoholic group compared to controls 
(O.O% vs 18.0%, x2 = 4.51, p=0.034•). 
Mild group vs severe group/ OFS=O group vs OFS~,2,3,4 groups/ different 
combinatio11s of tile aetiological groups 
No significant differences in genotype frequency were found when the mild group was 
compared with the severe group, OFS=O group compared with the OFS~l,2,3,4 groups or 
between different combinations of the aetiological groups. 
Allele frequency 
Co11trols vs patielltslcolltrols vs patient subgroups/ mild group vs severe group/ OFS=O 
group vs OFS~,2,3,4 groups/ different combinatio11s of tile aetiological groups 
No significant differences were found between the Ava I allelic frequencies in controls and 
patients or between subdivisions of the patient group. 
* p value became non-significant following correction for the number of comparisons 
made. 
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:6.H3l2 A.iu J:polymorph'ism 
F:igille .6>Ji ;jJhistrates ·the lopatipn 9_ftlie Alw /• polymol]lhism in the :JL-1 gene: 
:clllster, Pigc;:stion QfP(::R'prodl,lcts with Alw'/ :gave fragments' of 5'7bp,. l44bp 1 and 20t:l)p: 
'· . ' 
for:alides:Ii •and: 2:respectively, These two: alleles gave:rise to three :genotypes: l,,f; I ,2; 2;2. 
:i'he: !f4C1?03 SNP':destroys an Alu. /.restriction site. Homozygotes for :alleie. :li :(),?bp, 
'1'44bp) OCCUf when ·the ~NP ismot .present· on either· chromosome:. Homozygotes for allele 2·. 
:~201bp} occm when. the !SNP is• present on iboth: chromosomes .. Heterozygotes :(5.7,bp, 
144bp,,201 bp). occm when ,the!SNP.Is:present ori:orily'oile. chromosome (Figure 6:6). 
,.; .. ·: 
f 
I 
,--------
Figure 6.6: 3% agarose gel illustrating the genotypes detected at the Alu I locus. 
57bp 
144bp 
20lbp 
1 2 3 4 5 
Two alleles were detected: allele 1 (57bp,144bp), allele 2 (201bp). 
Lanes 1,2,4 and 7- 1,2 
Lane 3-2,2 
Lanes 5,6,8,9,10,11 and 12- 1,1 
Lane 13- Molecular weight marker XIII (50bp ladder) 
6 7 
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Table 6.5A: Frequency of IL-lB Alu I genotypes in controls, patients and patient subgroups 
Mild Severe A I G 
Genotype Controls Patients AP AP OFS=O OFS~1 OFS~ OFS~ OF~4 AP AP AP 
% 0/o % % % % % % 0/o % % % 
1 '1 40.8 41.8 40.2 45.9 44.3 37.0 39.4 36.8 41.7 38.1 51.4 38.5 
(69) (56) (39) (17) (39) (17) (13) (7) (5) (8) (18) (30) 
1,2 39.6 48.5 48.5 48.6 45.5 54.3 54.5 57.9 58.3 61.9 40.0 48.7 
(67) (65) (47) (18) (40) (25) (18) (11) (7) (13) (14) (38) 
2,2 19.5 9.78 11.3 5.4 10.2 8.7 6.1 5.3 0.0 0.0 8.6 12.8 
(33) (13) (11) (2) (9) (4) (2) (1) (0) (0) (3) (10) 
Total (n) 169 134 97 37 88 46 33 19 12 21 35 78 
This table shows the frequency of the 3 genotypes of the Alu I polymorphism in the IL-lB gene in controls and patient subgroups. n represents the number 
of genotypes in each group. The number in brackets is the actual number of subjects with a particular genotype. Comparisons were made between the 
control and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for 
each genotype using the x2 test and 2 x 2 contingency tables. 
"=patients vs controls (9.7% vs 19.5%, x2=5.6, p=0.018 (ldf), Pc=0.036) 
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Table 6.5B: Frequency ofiL-lB Alu I alleles in controls, patients and patient subgroups 
Mild Severe A I G 
Allele Controls Patients AP AP OFS=O OF~1 OFS~ OFS~ OFS~ AP AP AP 
% % % % % % 0/o % % % o;o % 
1 60.7 66.0 64.4 70.3 67.0 64.1 66.7 65.8 70.8 69.0 71.4 62.8 
(205) (177) (125) (52) (118) (59) (44) (25) (17) (29) (50) (98) 
2 39.3 34.0 35.6 29.7 33.0 35.9 33.3 34.2 29.2 31.0 28.6 37.2 
(133) (91) (69) (22) (58) (33) (22) (13) (7) (13) (20) (58) 
Total (n) 338 268 194 74 176 92 66 38 24 42 70 156 
This table shows the frequency of the 2 alleles of the Alu I polymorphism in the IL-l B gene in controls and patient subgroups. n represents the number 
of alleles in each group. The number in brackets is the actual number of subjects with a particular allele. Comparisons were made between the control 
and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for each 
allele using the x2 test and 2 x 2 contingency tables. No significant differences were found. 
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Summary of tbe results obtained at tbe Alu I locus 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Genotype frequency 
Co11trols vs patie11ts 
Comparisons of the Alu I genotype frequencies between patients and controls showed the 
2,2 genotype was significantly decreased in the patient group compared to controls (9.7% 
vs 19.5%, x2 =5.6, p=O.Ol8, Pc=0.036). 
C01rtrols vs patie11t subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology, and the subgroups compared with controls, the 2,2 genotype was significantly 
decreased in the severe group compared to controls (5.4% vs 19.5%, x2 =4.29, p=0.038*). 
The 2,2 genotype was significantly decreased in the alcoholic group compared to controls 
(0.0% VS 19.5%, X2=4.96, p=0.026*). 
Mild group vs severe group/ OFS=O group vs OFS~,2,3,4 groups/ different 
combitrati01rs of the aetiological groups 
No significant differences in genotype frequency were found when mild group was 
compared with the severe group, the OFS=O group compared with OFS~1,2,3,4 group or 
between different combinations of the aetiological groups. 
Allele frequency 
Controls vs patie~rts/contro/s vs patie11t subgroups/ mild group vs severe group/ OFS=O 
gro11p vs OFS~,2,3,4 groups/ different combinations oft/re aetiological groups 
No significant differences were found between the Alu I allelic frequencies in controls and 
patients or between subdivisions of the patient group. 
* p value became non-significant following correction for the number of comparisons 
made. 
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6.1.3.3 Taq I polymorphism 
Figure 6.1 illustrates the location of the Taq I polymorphism in the IL-l gene 
cluster. Taq I digestion of the PCR fragment amplified by amplimers Taq I and II detected 
fragments of 218bp, 522bp and 740bp for alleles I and 2 respectively. Three genotypes 
were observed: 1,1; 1 ,2; 2,2. The C~ T5887 SNP creates a Taq I restriction site. 
Homozygotes for allele 1 (218bp, 522bp) occur when the SNP is present on both 
chromosomes. Homozygotes for allele 2 (740bp) occur when the SNP is not present on 
either chromosome. Heterozygotes (218bp, 522bp, 740bp) occur when the SNP is present 
on only one chromosome (Figure 6. 7). 
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Figure 6.7: 3% agarose gel showing the genotypes detected at the Taq I locus. 
1 2 3 4 5 6 7 8 9 10 
218bp ~ 
522bp ~ 
740bp ~ 
Two alleles were detected: allele 1 (218bp,522bp ), allele 2 (7 40bp ). (The 2,2 genotype is not shown). 
Lanes 1 ,2,4,8 and 10 - 1,2 
Lanes 3,5,6,7,9,11 and 12- 1,1 
Lane 13 - Molecular weight marker XN (1 OObp ladder) 
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Table 6.6A: Frequency of IL-lB Taq I genotypes in controls, patients and patient subgroups 
Mild Severe A I G 
Genotype Controls Patients AP AP OFS=O OFS~1 OFS~ OFS~ OFS~4 AP AP AP 
0/o 0/o % % % % % % % % % O/o 
1 '1 67.6 63.2 66.7 55.6 70.6 52.2 48.5 50.0 41.7 72.2 56.3 64.1 
(115) (72) (52) (20) (48) (24) (16) (9) (5) (13) (18) (41) 
1 '2 31.2 35.1 32.1 41.7 26.5 47.8b 51.5•• 50.0 58.3 27.8 43.8 32.8 
(53) (40) (25) (15) (18) (22) (17) (9) (7) (5) (14) (21) 
2,2 1.2 1.8 1.3 2.8 2.9 0.0 0.0 0.0 0.0 0.0 0.0 3.1 
(2) (2) (I) (1) (2) (0) (0) (0) (0) (0) (0) (2) 
Total (n) 170 114 78 36 68 46 33 18 12 18 32 64 
This table shows the frequency of the 3 genotypes of the Taq I polymorphism in the IL-l B gene in controls and patient subgroups. n represents the number 
of genotypes in each group. The number in brackets is the actual number of subjects with a particular genotype. Comparisons were made between the 
control and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS;;::I,2,3,4 groups and different patient aetiologies for each 
genotype using the x2 test and 2 x 2 contingency tables. 
"= OFS~ vs controls (51.5% vs 31.2%, x2 =5.06, p=0.024 (ldf), Pc=0.048) 
b= OFS;;::I vs OFS=O (47.8% vs 26.5%, x2=5.49, p=O.Ol9 (ldf), Pc=0.038) 
c = OFS;;::2 vs OFS=O (51.5% vs 26.5%, x2=6.15, p=O.Ol3 (Idf), Pc=0.026) 
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Table 6.6B: Frequency ofiL-lB Taq I aUeles in controls, patients and patient subgroups 
Mild Severe A I G 
AUele Controls Patients AP AP OF~ OF~1 OFSC!:l OFS~ OF~4 AP AP AP 
% 0/o o;o % 0/o % 0/o 0/o 0/o % % % 
1 83.2 80.7 82.7 76.4 83.8 76.1 74.2 75.0 70.8 86.1 78.1 80.5 
(283) (184) (129) (55) (114) (70) (49) (27) (17) (31) (50) (103) 
2 16.8 19.3 17.3 23.6 16.2 23.9 25.8 25.0 29.2 13.9 21.9 19.5 
(57) (44) (27) (17) (22) (22) (17) (9) (7) (5) (14) (25) 
Total (n) 340 228 156 72 136 92 66 36 24 36 64 128 
This table shows the frequency of the 2 alleles of the Taq I polymorphism in the IL-l B gene in controls and patient subgroups. n represents the number 
of alleles in each group. The number in brackets is the actual number of subjects with a particular allele. Comparisons were made between the control 
and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for each 
allele using the r..2 test and 2 x 2 contingency tables. No significant differences were found. 
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Summary of tbe results obtained at tbe Taq I locus 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Genotype frequency 
Controls vs patients 
No significant differences m genotype frequency were present between controls and 
patients. 
Controls vs patient subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with controls, the 1,2 genotype was significantly 
increased in the OFS~1 group compared to controls (47.8% VS 31.2%, x2=4.43, p=0.035•). 
The 1, I genotype was significantly decreased in the OFS~2 group compared to controls 
(48.5% vs 67.6%, x2=4.43, p=0.035•), while the 1,2 genotype was significantly increased 
between the same groups (51.5% vs 31.2%, x2=5.06, p=0.024, Pc=0.048). 
Mild group vs severe group 
No significant differences in genotype frequencies were found between the mild group and 
severe group. 
OFS=O group vs OFS~1,2,3,4 groups 
Analysis of the genotype data with respect to organ failure scores showed the 1,1 genotype 
was significantly decreased in the OFS~1 group compared to the OFS=O group (52.2% vs 
70.6%, x2=4.0, p=0.046•), whereas the 1,2 genotype was significantly increased between 
the same groups (47.8% vs 26.5%, x2=5.49, p=0.019, Pc=0.038). The 1,1 genotype was 
significantly decreased in the OFS~ group compared to the OFS=O group (48.5% vs 
70.6%, x2=4.68, p=0.031•) while the 1,2 genotype was significantly increased between the 
same groups (51.5% vs 26.5%, x2=6.15, p=0.013, Pc=0.026). The 1,2 genotype was 
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significantly increased in the OFS~4 group compared to OFS=O group (58.3% vs 26.5%, 
x.2=4.82, p=0.028•). 
Different combi11ations of tile aetiological groups 
No significant differences in genotype frequency were found between the different 
combinations of the aetiological groups. 
Allele frequency 
Controls vs patie11ts/ controls vs patie11t subgroups/ mild group vs severe group/ OFS=O 
group vs OFS~,2,3,4 groups/ differe~tt combinations oft/re aetiological groups 
No significant differences were found between the Taq I allelic frequencies in controls and 
patients or between subdivisions of the patient group. 
* p value became non-significant following correction for the number of comparisons 
made. 
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6.1.4 IL-IRN: 
6.1.4.1 Msp I polymorphism 
Figure 6.1 illustrates the location of the Msp I polymorphism in the IL-l gene 
cluster. Msp I digestion of genomic DNA amplified with amplimers Msp I and 11 produced 
fragments of 640bp and 206bp, 434bp for alleles l and 2 respectively. Three genotypes 
were observed: 1,1; 1 ,2; 2,2. The T ~C8006 SNP creates a Msp I restriction site. 
Homozygotes for allele 1 (640bp) occur when the SNP is not present on either 
chromosome. Homozygotes for allele 2 (206bp, 434bp) occur when the SNP is present on 
both chromosomes. Heterozygotes (206bp, 434bp, 640bp) occur when the SNP is present 
on only one chromosome (Figure 6.8). 
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Figure 6.8: 3% agarose gel displaying the genotypes detected at the Msp I locus 
1 2 3 4 5 
206bp ~ 
434bp ~ 
640bp ~ 
Two alleles were detected: allele 1 (640bp), allele 2 (434bp, 206bp). 
Lanes 1,3,4,7 and 9- 1,1 
Lanes 2,5,10,11 and 12-1,2 
Lanes 6 and 8 - 2,2 
Lane 13- Molecular weight marker XIV (1 OObp ladder) 
6 7 
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Table 6.7A: Frequency ofiL-lRN Msp I genotypes in controls, patients and patient subgroups 
Mild Severe A I G 
Genotype Controls Patients AP AP OFS=O OFS~1 OFS~ OFS~ OFS~ AP AP AP 
% o;o % o;o % % % % % 0/o % o;o 
1 , 1 47.7 55.9 50.5 70.3" 53.9 59.6 61.8 68.4 66.7 52.4 66.7 51.9 
(71) (76) (50) (26) (48) (28) (21) (13) (8) (11) (24) (41) 
1,2 43.6 36 40.4 24.3 39.3 29.8 29.4 26.3 33.3 42.9 30.6 36.7 
(65) (49) (40) (9) (35) (14) (10) (5) (4) (9) (11) (29) 
2,2 8.7 8.1 9.1 5.4 6.7 10.6 8.8 5.3 0.0 4.8 2.8 11.4 
(13) (11) (9) (2) (6) (5) (3) (1) (0) (1) (1) (9) 
Total (n) 149 136 99 37 89 47 34 19 12 21 36 79 
This table shows the frequency of the 3 genotypes of the Msp I polymorphism in the IL-l RN gene in controls and patient subgroups. n represents the 
number of genotypes in each group. The number in brackets is the actual number of subjects with a particular genotype. Comparisons were made between 
the control and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for 
each genotype using the x2 test and 2 x 2 contingency tables. 
• =severe vs controls (70.3% vs 47.7%, x2=6.08, p=0.014 (ldf), Pc=0.028) 
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Table 6.7B: Frequency of IL-l RN Msp I alleles in controls, patients and patient subgroups 
Mild Severe A I G 
Allele Controls Patients AP AP OFS=O OFS~l OF~ OFS~ OFS~ AP AP AP 
% 0/o % % % % % 0/o 0/o 0/o % % 
1 69.5 73.9 70.7 82.4" 73.6 74.5 76.5 81.6 83.3 73.8 81.9b 70.3 
(207) (201) (140) (61) (131) (70) (52) (31) (20) (31) (59) (Ill) 
2 30.5 26.1 29.3 17.6" 26.4 25.5 23.5 18.4 16.7 26.2 18.1b 29.7 
(91) (71) (58) (13) (47) (24) (16) (7) (4) (11) (13) (47) 
Total (n) 298 272 198 74 178 94 68 38 24 42 72 158 
This table shows the frequency of the 2 alleles of the Msp I polymorphism in the IL-l RN gene in controls and patient subgroups. n represents the number 
of alleles in each group. The number in brackets is the actual number of subjects with a particular allele. Comparisons were made between the control 
and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for each 
allele using the x2 test and 2 x 2 contingency tables. 
a= severe vs controls (Allele 1: 82.4% vs 69.5%, x2=4.95, p=0.026 (ldf), Pc=0.026; Allele 2: 17.6% vs 30.5%, x2=4.95, p=0.026 (1df), Pc=0.026) 
b= idiopathic vs controls (Allele 1: 81.9% vs 69.5%, x2=4.47, p=0.034 (1df), Pc=0.034; Allele 2: 18.1% vs 30.5%, X2=4.47, p=0.034 {1df), Pc=0.034) 
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Summary of the results obtained at the M so I locus 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Genotype frequency 
Co11trols vs patie11ts 
No significant differences were found in the Msp I genotype frequencies between controls 
and patients. 
C011trols vs patient subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology, and comparisons made between the different subgroups and the controls, the I, I 
genotype was found to be significantly increased in the severe group compared to controls 
(70.3% vs 47.7%, x2=6.08, p=O.OI4, Pc=0.028), while the I,2 genotype was significantly 
decreased between the two groups (24.3 o/o VS 43.6%, x2=4.6I, p=0.032*). In addition, the 
I, I genotype was significantly increased in the idiopathic group compared to controls 
(66.7% vs 47.7%, x2 = 4.2, p=0.04I•). 
Mild group vs severe group 
Analysis of the genotypes with respect to severity showed the I, I, genotype was 
significantly increased in the severe group compared to the mild group (70.3% vs 50.5%, 
x2=4.27, p=0.039•). 
OFS=O group vs OFS~,2,3,4 groups/different combinations of the aetiological groups 
There were no significant differences in Msp I genotype frequencies between the OFS=O 
group and OFS2I,2,3,4 groups or between the different combinations of the aetiological 
groups. 
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Allele frequency 
Controls vs patients 
No significant differences were found in the Msp I allelic frequencies between controls and 
patients. 
Controls vs patient subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with the controls, allele I was found to be 
significantly increased in the severe group compared to controls (82.4% vs 69.5% :x,2=4.95, 
p=0.026, Pc=0.026), while allele 2 was significantly decreased between the same two 
groups (17 .6% vs 30.5%, :x,2=4.95, p=0.026, Pc=0.026). In addition, allele 1 was 
significantly increased in the idiopathic group compared to controls (81.9% vs 69.5%, 
:x,2=4.47, p=0.034, Pc=0.034) while allele 2 was significantly decreased between the same 
groups (18.1% vs 30.5 %, :x,2=4.47, p=0.034, Pc=0.034). 
Mild group vs severe group 
Analysis of the data with respect to severity showed allele 1 was significantly increased in 
the severe group compared to the mild group (82.4% vs 70.7%, x2=3.84, p=0.05*) whereas 
allele 2 was significantly decreased between the 2 groups (17.6% vs 29.3%, :x,2=3.84, 
p=0.05*). 
OFS=O group vs OFS~,2,3,4 groups, different combinations oft/le aetiological groups 
No significant differences in allele frequency were found when the mild group was 
compared with the severe group, OFS=O group was compared with the OFS~1.2,3,4 groups 
or between different combinations of the aetiological groups. 
* p value became non-significant following correction for the number of comparisons 
made. 
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6.1.4.2 VLP polymorphism 
Figure 6.1 illustrates the location of the VLP polymorphism in the ll.-1 gene 
cluster. Three alleles (alleles l-3) were detected in this study corresponding to l.55kb, 
1.45kb and 1.3kb fragments. Six genotypes were observed. Intermediate sized products of 
l.4kb and l.Skb were detected in 2,3 and 1,3 heterozygotes respectively. These artefacts 
were also present in the study by Steinkasserer et al, 1991 (Figure 6.9). 
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Figure 6.9: 2% agarose gel illustrating the genotypes observed at the VLP locus. 
1 2 3 4 5 6 7 
1.3kb 
=t 1.45kb 1.55kb 
Three different alleles were detected: allele 1 (1.55kb), allele 2 (1.45kb), allele 3 (1.3kb). 
Lanes 1 and 9- 3,3 
Lanes 2,4 and 10 - 2,3 
Lanes 3,6,8 and 12- 2,2 
Lanes 5 and 11- 1,3 
Lane 7- 1,2 
Lane 13- Molecular weight marker Vll (0.37kbp-8.0kbp) 
Lane 14- Molecular weight marker ill (0.12kbp-21.2kbp) 
8 9 10 11 12 13 14 
+---- 992bp (lane I 3) 
+---- 1164bp (lane I 3) 
+---- 1375bp (lane 14) 
+---- 1584bp (lane 14) 
Intermediate sized artefacts of 1.4kb and 1.5kb were detected in 2,3 and 1,3 heterozygotes respectively. These were also present in the study by Steinkasserer 
et al, 1991. 
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Table 6.8A: Frequency ofiL-lRN VLP genotypes in controls, patients and patient subgroups 
Mild Severe A I G 
Genotype Controls Patients AP AP OFS=O OFS~ OFS~ OF~ OF~4 AP AP AP 
0/o % % % 0/o % % 0/o 0/o 0/o % % 
1 ' 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
1,2 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(8) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
1,3 2.7 1.5" 2 0.0 2.2 0.0 0.0 0.0 0.0 4.8 0.0 1.3 
(4) (2) (2) (0) (2) (0) (0) (0) (0) (1) (0) (1) 
2,2 42.5 55.9 50.5 70.3b 53.9 59.6 61.8 68.4 66.7 52.4 66.7" 51.9 
(62) (76) (50) (26) (48) (28) (21) (13) (8) (11) (24) (41) 
2,3 41.8 33.8 37.4 24.3 36 29.8 29.4 26.3 33.3 38.1 27.8 35.4 
(61) (46) (37) (9) (32) (14) (10) (5) (4) (8) (10) (28) 
3,3 7.5 8.8 10.1 5.4 7.9 10.6 8.8 5.3 0 4.8 5.6 11.4 
(11) (12) (10) (2) (7) (5) (3) (1) (0) (1) (2) (9) 
Total (n) 146 136 99 37 89 47 34 19 12 21 36 79 
This table shows the frequency of the 6 genotypes of the VLP polymorphism in the IL-1RN gene in controls and patient subgroups. n represents the number 
of genotypes in each group. The number in brackets is the actual number of subjects with a particular genotype. Comparisons were made between the 
control and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for 
each genotype using the x2 test and 2 x 2 contingency tables. 
a(sum total of 1,1;1,2;1,3)= patients VS controls (1.5% VS 8.2%, X2=6.8, p=0.009 {ldf), Pc=0.027) 
b = severes vs controls (70.3% vs 42.5%, x2=9.14, p=0.002 (ldf), Pc=0.006) 
c =idiopathies vs controls (66.7% vs 42.5%, x2=6.79, p=0.009 (ldf), Pc=0.027) 
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Table 6.8B: Frequency of IL-l RN VLP alleles in controls, patients and patient subgroups 
Mild Severe A I G 
Allele Controls Patients AP AP OFS=O OF~1 OFS~ OF~ OF~ AP AP AP 
•;. 0/o 0/o % % % % % % % % % 
1 4.1 0.7" 1.0 0.0 1.1 0.0 0.0 0.0 0.0 2.4 0.0 0.6 
(12) (2) (2) (0) (2) (0) (0) (0) (0) (1) (0) (1) 
2 66.1 72.8 69.2 82.4b 71.9 74.5 76.5 81.6 83.3 71.4 80.6c 69.6 
(193) (198) (137) (61) (128) (70) (52) (31) (20) (30) (58) (110) 
3 29.8 26.5 29.8 17.6 27.0 25.5 23.5 18.4 16.7 26.2 19.4 29.7 
(87) (72) (59) (13) (48) (24) (16) (7) (4) (11) (14) (47) 
Total (n) 292 272 198 74 178 94 68 38 24 42 72 158 
This table shows the frequency of the 3 alleles of the VLP polymorphism in the IL-l RN gene in controls and patient subgroups. n represents the number 
of alleles in each group. The number in brackets is the actual number of subjects with a particular allele. Comparisons were made between the control 
and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for each 
allele using the x2 test and 2 x 2 contingency tables. 
n= patients vs controls (0.7% VS 4.1 %, 1(2 = 6.62, p=O.Ol(ldf), Pc=0.02) 
b =severe vs controls (82.4% vs 66.1 %, x2 = 7.42, p=0.006 (ldf), Pc=O.Ol2} 
c =idiopathies vs controls (80.6% vs 66.1% x2=5.64, p=0.018 (I elf), Pc=0.036) 
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Summary of tbe results obtained at tbe VLP locus 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Genotype frequency 
To make the genotype analysis easier, the genotypes were divided into 2,2; 2,3; 3,3 and 
"other" (1,1+1,2+1,3). 
Controls vs patients 
Comparisons of the VLP genotype frequencies between patients and controls showed that 
the 2,2 genotype was significantly increased in patients compared to controls (55.9% vs 
42.5%, x2=5.07, p=0.024•), whereas the 'other' genotype (1 ,I+ 1 ,2+ I ,3) was significantly 
decreased between the same groups (1.5% vs 8.2%, x2=6.8, p=0.009, Pc=0.027). 
Controls vs patient subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with controls, the 'other' genotype ( 1, I+ I ,2+ I ,3) 
was significantly decreased in mild patients compared to controls (2.0% vs 8.2%, x2=4.21, 
p=0.04•). The 2,2 genotype was significantly increased in the severe group compared to 
controls (70.3% vs 42.5%, x2=9.14, p=0.002, Pc=0.006). The 2,2 genotype was 
significantly increased in the OFS~l group compared to controls (59.6% vs 42.5%, 
x2=4.18, p=0.041•). The 'other' genotype (1,1+1,2+1,3) was significantly decreased in the 
OFS~1 group compared to controls (0.0% vs 8.2%, x2=4.12, p=0.042•). The 2,2 genotype 
was significantly increased in the OFS~3 group compared to controls (68.4% vs 42.5 %, 
x2=4.57, p=0.033•). The 2,2 genotype was significantly increased in the idiopathic group 
compared to controls (66.7% vs 42.5%, x2=6.79, p=0.009, Pc=0.027). The 'other' 
genotype (1,1+1,2+1,3) was significantly decreased in the gallstone group compared to 
controls (1.3% vs 8.2%, x2=4.55, p=0.033•). 
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Mild group vs severe group 
Analysis of the data with respect to severity showed the 2,2 genotype was significantly 
increased in the severe group compared to the mild group (70.3% vs 50.5%, x2=4.27, 
p=0.039*). 
OFS=O group vs OFS2:1,2,3,4 groups/different combinati01rs oft/re aetiological groups 
No significant differences in genotype frequency were observed when the OFS=O group 
was compared with OFS~1,2,3,4 groups or when the different combinations of the 
aetiological groups were compared. 
Allele frequency 
Controls vs patients 
Comparisons of the VLP allelic frequencies between patients and controls showed allele 1 
was significantly decreased in patients compared to controls (0. 7% vs 4.1 %, x2=6.62, 
p=0.01, Pc=0.02). 
C01rtrols vs patient subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with controls allele I was significantly decreased in 
the mild group compared to controls ( 1.0% vs 4.1 %, x2=4.08, p=0.043• ). Allele 2 was 
significantly increased in the severe group compared to controls (82.4% vs 66.1 %, x2 
=7.42, p=0.006, Pc=0.012) whereas allele 3 was significantly decreased between the same 
two groups (17 .6% vs 29.8%, x2=4.44, p=0.035• ). Allele 1 was significantly decreased in 
the OFS~l group compared to controls (0.0% vs 4.1%, x2=3.99, p=0.046•). Allele 2 was 
significantly increased in the idiopathic group compared to controls (80.6% vs 66.1 %, 
x2=5.64, p=0.018, Pc=0.036). Allele 1 was significantly decreased in the gallstone group 
compared to controls (0.6% vs 4.1 %, x2=4.42, p=0.036• ). 
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Mild group vs severe group 
Analysis of the data with respect to severity allele 2 was significantly increased in the 
severe group compared to the mild group (82.4% vs 69.2%, x2=4.77, p=0.029•) whereas 
allele 3 was significantly decreased between the same groups (17.6% vs 29.8%, x2=4.14, 
p=0.042•). 
OFS=O group vs OFS:?!1,2,3,4 groups/different combinations of the aetiological groups 
No significant differences in allele frequency were found between the OFS=O group and 
OFS~l,2,3,4 groups or between different combinations of the aetiological groups. 
* p value became non-significant following correction for the number of comparisons 
made. 
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6.1.4.3. VNTR86 polymorphism 
Figure 6.1 illustrates the location of the VNTR 86 polymorphism in the IL-l gene 
cluster. Three different alleles (alleles 1-3) were observed corresponding to 4 (410bp), 2 
(240bp) and 5 (500bp) copies of the 86bp repeat sequence. Five genotypes were detected. 
Alleles 4 and 5 corresponding to 3 (325bp) and 6 (595bp) copies of the repeat sequence 
were not detected (Figure 6.1 0). 
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Figure 6.10: 2% agarose gel showing the genotypes detected at the IL-1RN VNTR86 locus. 
1 2 3 4 5 6 7 8 9 10 11 12 13 
._ 
._ 
240bp 
__. ._ 
410bp ~ 
._ 
500bp 
Three different alleles (alleles 1-3) were observed corresponding to 4 (410bp), 2 (240bp) and 5 (500bp) copies of the 86bp repeat sequence. 
Alleles 4 and 5 corresponding to 3 (325bp) and 6 (595bp) copies of the repeat sequence were not detected. 
Lanes 1,4,6, 8 and 12- 1,1 
Lanes 2,5 and 11 - 1 ,2 
Lanes 3 and 1 0 - 2,2 
Lane 7 and 9- 1,3 
Lane 13 - Molecular weight marker XIV (1 OObp ladder) 
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Table 6.9A: Frequency ofiL-lRN VNTR86 genotypes in controls, patients and patient subgroups 
Mild Severe A I G 
Genotype Controls Patients AP AP OFS=O OFS~ OFS~ OF~ OFS~4 AP AP AP 
% 0/o % % 0/o % % % % % % % 
1 '1 42.0 54.3 47.5 69.4" 50.0 60.~ 63.6c 68.4 66.7 44.4 67.6d 50.0 
(63) (63) (38) (25) (35) (28) (21) (13) (8) (8) (23) (32) 
1,2 38.0 35.3 40.0 25.0 40.0 28.3 27.3 26.3 33.3 44.4 29.4 35.9 
(57) (41) (32) (9) (28) (13) (9) (5) (4) (8) (10) (23) 
2,2 12.0 10.3 12.5 5.6 10.0 10.9 9.1 5.3 0.0 11.1 2.9· 14.1 
(18) {12) (10) (2) (7) (5) (3) (1) (0) (2) (1) (9) 
1,3 4.0 0.0 0.0 0.0 0.0 0.0 0.0 o.o 0.0 0.0 0.0 0.0 
(6) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
2,3 4.0 0.0 0.0 0.0 0.0 0.0 0.0 o.o 0.0 0.0 0.0 0.0 
(6) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
Total (n) 150 116 80 36 70 46 33 19 12 18 34 64 
This table shows the frequency of the 5 genotypes ofthe VNTR86 polymorphism in the IL-1RN gene in controls and patient subgroups. n represents the 
number of genotypes in each group. The number in brackets is the actual number of subjects with a particular genotype. Comparisons were made between 
the control and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS;::l,2,3,4 groups and different patient aetiologies for 
each genotype using the x.2 test and 2 x 2 contingency tables. 
a= severe vs controls (69.4% vs 42.0%, x.2 =8.77, p=0.003 (ldf), Pc=0.006) 
b = OFS~l vs controls (60.9% vs 42.0%, x.2=5.04, p=0.025 (ldf), Pc<O.OS) 
c = OFS~ vs controls (63.6% vs 42.0%, x.2=5.1, p=0.024 (ldf), Pc=0.048) 
d =idiopathies vs controls (67.6% vs 42.0%, x.2 = 7.32, p=0.007 {ldf), Pc=O.Ol4) 
e (sum total of2,2;1,3;2,3) =idiopathies vs controls (2.9% vs 20.0%, x.2=5.76, p=0.016 (ldf), Pc=0.032) 
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Table 6.9B: Frequency of IL-l RN VNTR86 alleles in controls, patients and patient subgroups 
Mild Severe A I G 
Allele Controls Patients AP AP OFS=O OFS~1 OFS<!:Z OFS~ OFS~4 AP AP AP 
% % 0/o 0/o % 0/o 0/o 0/o % % % % 
1 63.0 72.0 67.5 81.9cj 70.0 75.0 77.3 81.61 83.3 66.7 82.4g 68.0 
(189) (167) (108) (59) (98) (69) (51) (31) (20) (24) (56) (87) 
2 33.0 28.0 32.5 18.1 dj 30.0 25.0 22.7 18.4 16.7 33.3 17.6b 32.0 
(99) (65) (52) (13) (42) (23) (15) (7) (4) (12) (12) (41) 
3 4.0 o.o· o.ob 0.0 o.o• 0.0 0.0 0.0 0.0 0.0 0.0 o.o• 
(12) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
Total (n) 300 232 160 72 140 92 66 38 24 36 68 128 
This table shows the frequency of the 3 alleles of the VNTR86 polymorphism in the IT...-1RN gene in controls and patient subgroups. n represents the number 
of al1eles in each group. The number in brackets is the actual number of subjects with a particular allele. Comparisons were made between the control and 
patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS;::l,2,3,4 groups and different patient aetiologies for each allele 
using the x2 test and 2 x 2 contingency tables. 
3 
=patients VS controls (0.0% vs 4.0%, X2=9.49, p=0.002 (ldf): Pc=0.004) 
b =mild vs controls (0.0% vs 4.0%, x2=6.57, p=O.Ol (ldf), Pc=0.02) 
c =severe vs controls (81.9% vs 63.0%, x2=9.38, p=0.002 (ldf), Pc=0.004) 
d =severe vs controls (18.1% vs 33.0%, x2=6.16, p=0.013 (1df), Pc=0.026) 
·= OFS=O vs controls (0.0% vs 4.0%, x2=5.76, p=0.016 (1df), Pc=0.032) 
r = OFS~3 vs controls (81.6% vs 63.0%, x2=5.12, p=0.024 (1df), Pc=0.048) 
s= idiopathies vs controls (82.4% vs 63.0%, x2 =9.33, p=0.002 (1df), Pc=0.004) 
h =idiopathies vs controls (17.6% vs 33.0%, x2=6.2, p=0.013 (1df), Pc=0.026) 
i =gallstones vs controls (0.0% vs 4.0%, x2=5.27, p=0.022 (ldf), Pc=0.044) 
i =severe vs mild (Allele 1: 81.9% vs 67.5%, x2=5.14, p=0.023 (ldf), Pc=0.046; Allele 2: 18.1% vs 32.5%, x2=5.14, p=0.023 (1df), Pc=0.046) 
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Summary of the results obtained at the IL-l RN VNTR86 locus 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Genotype frequency 
To make the genotype analysis easier, the genotypes were divided into I, 1; I ,2 and "other" 
(2,2+ 1 ,3+ 2,3). 
Controls vs patients 
Comparisons of the IL-1RN VNTR86 genotype frequencies between patients and controls 
showed the 1,1 genotype was significantly increased in patients compared to controls 
(54.3% vs 42.0%, :x2=3.98, p=0.046*) while the 'other' genotype (2,2+1,3+2,3) was 
significantly decreased between the groups (10.3% vs 20.0%, :x2=4.59, p=0.032*). 
Controls vs patie11t subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with controls, the I, I genotype was significantly 
increased in the severe group compared to controls (69.4% vs 42.0%, :x2=8.77, p=0.003, 
Pc=0.006) while the 'other' genotype (2,2+ I ,3+ 2,3) was significantly decreased between 
the two groups (5.6% vs 20.0%, :x2=4.25, p=0.039*). The 1,1 genotype was significantly 
increased in the OFS~1 group compared to controls (60.9% vs 42.0%, :x2=5.04, p=0.025, 
Pc<0.05). The 1,1 genotype was significantly increased in the OFS~2 group compared to 
controls (63.6% vs 42.0%, :x2=5.1, p=0.024, Pc=0.048). The 1,1 genotype was significantly 
increased in the idiopathic group compared to controls (67.6% vs 42.0%,:x2=7.32, p=0.007, 
Pc=0.014) whereas the 'other' group (2,2+ 1,3+2,3) was significantly decreased between the 
groups (2.9% vs 20.0%, :x2=5.76, p=0.016, Pc=0.032). 
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Mild group vs severe group 
Analysis of the data with respect to severity showed the 1,1 genotype was significantly 
increased in the severe group compared to the mild group (69.4% vs 47.5%, x2=4.82, 
p=0.028•). 
OFS=O group vs OFS8,2,3,4 groups 
When the data was analysed with respect to organ failure scores, the 1,1 genotype was 
significantly increased in the OFS:?!3 group compared to the OFS=O group (68.4 % vs 
50.0%, x2=4.76, p=0.029•). 
Different combinations oft/re aetiological groups 
No significant differences in IL-lRN VNTR86 genotype frequency were found between the 
different combinations of the aetiological groups. 
Allele frequency 
Controls vs patients 
Comparisons of the IL-lRN VNTR86 allelic frequencies between patients and controls 
showed allele 1 was significantly increased in the patient group compared to control group 
(72.0% vs 63.0%,x2 =4.77, p=0.029•), whereas allele 3 was significantly decreased 
between the groups (0.0% vs 4.0%,x2=9.49, p=0.002, Pc=0.004). 
Controls vs patient subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and compared with controls, allele 3 was significantly decreased in the mild 
group compared to controls (0.0% vs 4.0%,x2=6.57, p=0.01, Pc=0.02). Allele I was 
significantly increased in the severe group compared to controls (81.9% vs 63.0%, 
:x;2=9.38, p=0.002, Pc=0.004) whereas allele 2 was significantly decreased between the 
same two groups (18.1% vs 33.0%, x2=6.16, p=0.013, Pc=0.026). Allele 3 was 
significantly decreased in OFS=O group compared to controls (0.0% vs 4.0%, :x;2=5.76, 
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p=0.016, Pc=0.032). Allele 1 was significantly increased in the OFS~1 group compared to 
controls (75.0% vs 63.0%, x2=4.51, p=0.034•). Allele 1 was significantly increased in the 
OFS~ group compared to controls (77.3% vs 63.0%, x2=4.88, p=0.027•). Allele I was 
significantly increased in the OFS~3 group compared to controls (81.6% vs 63.0%, 
x2=5.12, p=0.024, Pc=0.048). Allele 1 was significantly increased in the OFS~4 group 
compared to controls (83.3% vs 63.0%, x2=4.01, p=0.045•). Allele I was significantly 
increased in the idiopathic group compared to controls (82.4% vs 63.0%, x2=9.33, 
p=0.002, Pc=0.004). Allele 2 was significantly decreased in the idiopathic group compared 
to controls (17.6% vs 33.0%,x2=6.2, p=0.013, Pc=0.026). Allele 3 was significantly 
decreased in the gallstone group compared to controls (0.0% vs 4.0%, x2=5.27, p=0.022, 
Pc=0.044). 
Mild vs severe 
Analysis of the allele data with respect to severity showed allele 1 was significantly 
increased in the severe group compared to mild group (81.9% vs 67.5%, x2=5.14, p=0.023, 
Pc=0.046) whereas allele 2 was significantly decreased between the same groups (18.1% vs 
32.5%,x2=5.14, p=0.023, Pc=0.046). 
OFS=O group vs OFS~,2,3,4 groups 
No significant differences in allele frequency were seen when comparing OFS=O group 
with OFS~ I ,2,3,4 groups. 
Different combinations of the aetiological groups 
When the data was analysed with respect to aetiology, allele 1 was significantly increased 
in the idiopathic group compared to the gallstone group (82.4% vs 68.0%, x2=4.66, 
p=0.031•) whereas allele 2 was significantly decreased between the same groups ( 17.6% vs 
32.0%, x2=4.66, p=0.031• ). • p value became non-significant following correction for the 
number of comparisons made. 
193 
6.1.4.4 Ssp I polymorpllism 
Figure 6.1 illustrates the location of t;he Ssp I polymorphism in the IL-l gene 
cluster. Ssp I digestion of the fragment amplified with amplimers Ssp I and II identified 
allele I of 379bp and allele 2 of 11 Obp, 269bp. Three genotypes were observed: 1,1; 1,2;2,2. 
The A~T9589 SNP creates a Ssp I restriction site. Homozygotes for allele 1 (379bp) occur 
when the SNP is not present on either chromosome. Homozygotes for allele 2 (llObp, 
269bp) occur when the SNP is present on both chromosomes. Heterozygotes (110bp, 
269bp, 379bp) occur when the SNP is present on only one chromosome (Figure 6.11). 
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Figure 6.11: 3% agarose gel displaying the genotypes observed at the Ssp I locus. 
1 2 3 4 5 
liObp 
---+ 
269bp 
---+ 
379bp ---+ 
Two alle1es were detected: allele 1 (379bp), allele 2 (269bp,110bp). 
Lanes 1,4,7,8 and 11 - 1,2 
Lane 2-2,2 
Lanes 3,5,6,9,10 and 12- 1,1 
Lane 13 - Molecular weight marker XIV (1 OObp ladder) 
6 7 
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8 9 10 11 12 13 
+--- 500bp 
~ IOOObp 2642bp 
Table 6.10A: Frequency of IL-l RN Ssp I genotypes in controls, patients and patient subgroups 
Mild Severe A I G 
Genotype Controls Patients AP AP OFS=O OFS:?:1 OFS:?:2 OFS:?:J OFS:?:4 AP AP AP 
% 0/o 0/o 0/o 0/o % % % % % % % 
1 '1 46.2 55.1 49.5 70.3" 52.8 59.6 61.8 68.4 66.7 52.4 63.9 51.9 
(67) (75) (49) (26) (47) (28) (21) (13) (80 (11) (23) (41) 
1,2 46.2 37.5 42.4 24.3b 41.6 29.8 29.4 26.3 33.3 42.9 36.1 36.7 
(67) (51) (42) (9) (37) (14) (10) (5) (4) (9) (13) (29) 
2,2 7.6 7.4 8.1 5.4 5.6 10.6 8.8 5.3 0.0 4.8 0.0 11.4 
(11) (10) (8) (2) (5) (5) (3) (1) (0) (1) (0) (9) 
Total (n) 145 136 99 37 89 47 34 19 12 21 36 79 
This table shows the frequency of the 3 genotypes of the Ssp I polymorphism in the IL-l RN gene in controls and patient subgroups. n represents the number 
of genotypes in each group. The number in brackets is the actual number of subjects with a particular genotype. Comparisons were made between the 
control and patient group, control and patient subgroups, mild and severe groups, OFS=O and OFS~l,2,3,4 groups and different patient aetiologies for 
each genotype using the x2 test and 2 x 2 contingency tables. 
a= severe vs controls (70.3% vs 46.2%, x2=6.83, p=0.009 (ldf), Pc=0.018) 
b= severe vs controls (24.3% vs 46.2%, x2 =5.8, p=0.016 (ldf), Pc=0.032) 
196 
Table 6.10B: Frequency ofiL-lRN Ssp I alleles in controls, patients and patient subgroups 
Mild Severe A I G 
Allele Controls Patients AP AP OFS=O OFS~ OFS~ OFS~ OFS~ AP AP AP 
0/o % % 0/o % % 0/o 0/o % 0/o 0/o % 
1 69.3 73.9 70.7 82.4" 73.6 74.5 76.5 81.6 83.3 73.8 81.9b 70.3 
(201) (201) (140) (61) (131) (70) (52) (31) (20) (31) (59) (111) 
2 30.7 26.1 29.3 17.68 26.4 25.5 23.5 18.4 16.7 26.2 18.1b 29.7 
(89) (71) (58) (13) (47) (24) (16) (7) (4) (11) (13) (47) 
Total (n) 290 272 198 74 178 94 68 38 24 42 72 158 
This table shows the frequency of the 2 alleles of the Ssp I polymorphism in the IL-l RN gene in controls and patient subgroups. n represents the number 
of alleles in each group. The number in brackets is the actual number of subjects with a particular allele. Comparisons were made between the controls 
and patient subgroups for each allele using the x2 test and 2 x 2 contingency tables. 
a= severe vs controls (Allele 1: 82.4% vs 69.3%, x2 =5.03, p=0.025 (ldf), Pc=0.025, Allele 2: 17.6 vs 30. 7%, x2 =5.03, p=0.025 (1df), Pc=0.025) 
b =idiopathies VS controls (Allele 1: 81.9% VS 69.3%, x2 =4.55, p=0.033 (ldf), Pc=0.033; Allele 2: 18.1% vs 30.7%, x2 =4.55, p=0.033 (1df), Pc=0.033) 
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Summary of the results obtained at the Sso I locus 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Genotype frequency 
Controls vs patients 
No significant differences in genotype frequency were seen between controls and patients. 
Controls vs patient subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with controls, the 1,1 genotype was significantly 
increased in the severe group compared to controls (70.3% vs 46.2%, x2=6.83, p=0.009, 
Pc=0.018), whereas the 1,2 genotype was significantly decreased between the same groups 
(24.3% vs 46.2%, x2=5.8, p=O.Ol6, Pc=0.032). The 1,2 genotype was significantly 
decreased in the OFS~l group compared to controls (29.8% vs 46.2%, x2=3.92, 
p=0.048•). 
Mild group vs severe group 
Analysis of the genotype data with respect to severity showed the 1, I genotype was 
significantly increased in the severe group compared to the mild group (70.3 %vs 49.5%, 
x2=4.7, p=0.03•). 
OFS=O group vs OFS~,2,3,4 groups 
No significant differences in genotype frequency were found between the OFS=O group 
and the OFS~l,2,3,4 groups. 
Different combinations of the aetiological groups 
When the data was analysed with respect to aetiology, the 2,2 genotype was significantly 
decreased in the idiopathic group compared to the gallstone group (0.0% vs 11.4%, 
x2=4.45, p=0.035*). 
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Allele frequency 
Controls vs patients 
No significant differences in allele frequency were found between controls and patients. 
Controls vs patie11t subgroups 
When the patient group was subdivided according to severity, organ failure scores and 
aetiology and the subgroups compared with controls, al\ele 1 was significantly increased in 
the severe group compared to controls (82.4% vs 69.3%, x2=5.03, p=0.025, Pc=0.025) 
whereas allele 2 was significantly decreased in the severe group compared to controls 
(17.6% vs 30.7%, x2=5.03, p=0.025, Pc=0.025). Allele 1 was significantly increased in the 
idiopathic group compared to controls (81.9% vs 69.3%, x2=4.55, p=0.033, Pc=0.033) 
while allele 2 was significantly decreased between the same groups (18.1% vs 30.7%, 
x2=4.55, p=0.033, Pc=0.033). 
Mild group vs severe group 
Analysis of the data with respect to severity showed allele 1 was significantly increased in 
the severe group compared to the mild group (82.4% vs 70.7%, x2=3.84, p=O.OS*) whereas 
allele 2 was significantly decreased between the 2 groups (17.6% vs 29.3%, x2=3.84, 
p=O.OS*). 
OFS=O group vs OFS~,2,3,4 groups/differellt combi11ations of tile aetiological groups 
No significant differences in allele frequency were observed between the mild and severe 
group, OFS=O group and OFS~l,2,3,4 groups or between different combinations of the 
aetiological groups. 
* p value became non-significant following correction for the number of comparisons 
made. 
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6.1.5 Haplotype Analysis 
In addition to analysing the genotypes of each polymorphism between controls, 
patients and patient subgroups, the genotypes of the different genes were combined to give 
haplotypes and analysed to determine whether the genes studied were linked and hence 
influence each others expression. Only 2 genes were compared at any one time since the 
combination of more than 2 genes would make the number of subjects too small following 
removal of the double heterozygotes that no significant data could be obtained. The 
haplotype analysis compared the total controls and total patient population only. All of the 
significant data are discussed, however, only the data that are significant following 
correction for the number of comparisons involved are included in the tables. With the 
exception of the (X)n haplotypes, the data in each of the following tables is displayed with 
the most significant result at the top and least significant at the bottom of the table. 
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Table 6.11A: Frequency of(AC)n-VNTR46 haplotype in the control population 
(AC)n-VNTR46 observed frequency expected frequency 12 
Haplotype (n) (%) (n) (%) 
2-2 22 15.7 6.9 4.9 33.04 a 
2-1 7 5.0 24.9 17.8 12.87 b 
1-2 3 2.1 11.4 8.1 6.19 
2-6 3 2.1 0.8 0.6 6.05 
2-4 2 1.4 0.5 0.4 4.50 
4-2 1 0.7 5.2 3.7 3.39 
4-1 26 18.6 18.7 13.4 2.85 
1-3 8 5.7 4.7 3.4 2.32 
1-1 48 34.3 40.8 29.1 1.27 
5-1 8 5.7 5.5 3.9 1.14 
3-3 I 0.7 0.4 0.3 0.90 
0-1 2 1.4 1.4 1.0 0.26 
8-1 2 1.4 1.4 1.0 0.26 
2-3 2 1.4 2.8 2.0 0.23 
6-1 I 0.7 0.7 0.5 0.13 
3-1 3 2.1 3.5 2.5 0.07 
3-2 1 0.7 1.0 0.7 0.00 
0-3 0 0.0 
5-2 0 0.0 
X-X 0 0.0 9.4 6.7 9.40c 
This table shows the frequency and actual (observed) number of copies of the (AC)n-
VNTR46 haplotype detected within the control population. The X-X haplotype represents 
the sum of the haplotypes that were not detected. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected (AC)n-VNTR46 haplotypes 
and x2 values were determined. The x2 test was used to estimate linkage disequilibrium 
between the loci. 
"2-2(15.7% vs 4.9%, x2=33.04, p<O.OOOOOOI (ldf), Pc<0.000002) 
b 2-1 (5.0% vs 17.8%, x2=12.87, p=0.0003 (ldf), Pc=0.005) 
c X-X(O.O% VS 6.7% x2= 9.40, p=0.002 (1df), Pc=0.03) 
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Table 6.11B Frequency of (AC)n-VNTR46 haplotype in tbe patient population 
(AC)n-VNTR46 observed frequency expected frequency '1..2 
Haplotype (n) (%) (n) (%) 
2-2 17 13.7 5.9 4.8 20.88" 
2-1 9 7.3 23.8 19.2 9.20b 
1-2 1 0.8 8.4 6.8 6.52 
2-6 3 2.4 0.9 0.7 4.90 
4-1 21 16.9 14.2 11.5 3.26 
0-3 1 0.8 0.2 0.2 3.20 
4-2 1 0.8 3.5 2.8 1.79 
1-3 12 9.7 8.8 7.1 1.16 
1-1 39 31.5 33.5 27.0 0.90 
3-1 4 3.2 2.6 2.1 0.75 
6-1 3 2.4 1.9 1.5 0.64 
2-3 8 6.5 6.2 5.0 0.52 
5-1 4 3.2 3.2 2.6 0.20 
5-2 1 0.8 0.8 0.6 0.05 
0-1 0 0.0 
2-4 0 0.0 
3-2 0 0.0 
3-3 0 0.0 
8-1 0 0.0 
X-X 0 0.0 10.1 8.1 10.10c 
This table shows the frequency and actual (observed) number of copies of the (AC)n-
VNTR46 haplotype detected within the patient population. The X-X haplotype represents 
the sum of the haplotypes that were not detected. Haplotypes were assigned in those 
subjects who were homozygous at one or both loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected (AC)n-VNTR46 haplotypes 
and 1..2 values were determined. The 1..2 test was used to estimate linkage disequilibrium 
between the loci. 
8 2-2 (13.7% VS 4.8%, x2=20.88, p=0.000005 (ldf), Pc=0.00007) 
b 2-1 (7.3% vs 19.2%, x2=9.20, p=0.002 (ldf), Pc=0.03) 
c X-X(O.O% VS 8.1% x2=10.10, p=0.001 (1df), Pc=0.01) 
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Summary oftbe results obtained for analysis of the (AC}n-VNTR46 baplotypes 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Tables 6.11A and 6.11B show that the (AC)n-VNTR46 polymorphisms of the IL-IA gene 
are linked. In both control and patient groups, the most common haplotype was found to be 
l-1 with an observed frequency of 34.3% in controls and 31.5% in patients. 
Controls 
Significantly more of the 2-2 (15.7% vs 4.9%, x2=33.04, p<0.0000001, Pc<0.000002), 2-6 
(2.1% vs 0.6%, x2 =6.05, p=0.01*) and 2-4 (1.4% vs 0.4%, x2 =4.50, p=0.03*) haplotypes 
and significantly less of the 2-1 (5.0% vs 17.8%, x2=12.87, p=0.0003, Pc=0.005), X-X 
(0.0% VS 6.7%, x2=9.40, p=0.002, Pc=0.03) and l-2 (2.1% vs 8.1%, x2 =6.19, p=O.Ol*) 
haplotypes were observed in controls than expected. 
Patients 
There were significantly more of the 2-2 (13.7% vs 4.8%, x2 = 20.88, p=0.000005, 
Pc=0.00007) and 2-6 (2.4% vs 0.7%, x2 = 4.90, p=0.03*) haplotypes than expected in the 
patient group and a significant reduction in the number of the X-X (0.0% vs 8.1 %, x2 
=10.10, p=0.001, Pc=0.01), 2-l (7.3% vs 19.2%, x2 =9.20, p=0.002, Pc=0.03) and l-2 
(0.8% vs 6.8%, x2 = 6.52, p=O.Ol *) haplotypes. 
* p value became non-significant following correction for the number of comparisons 
made. 
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Table 6.12A: Frequency of Aval-Aiul-Taql haplotype in the control population 
Aval-Aiul-Taql observed frequency expected frequency ·l 
Haplotype (n) (%) (n) (%) 
2-2-1 40 33.9 11.4 9.7 71.75a 
2-1-1 0 0.0 22.2 18.8 22.20b 
1-2-1 0 0.0 22.2 18.8 22.20c 
1- 1- 2 19 16.1 8.3 7.0 13.79d 
1 - 1 - 1 59 50.0 43.3 36.7 5.69e 
2-1-2 0 0.0 4.3 3.6 4.30 
1- 2- 2 0 0.0 4.3 3.6 4.30 
2-2-2 0 0.0 2.2 1.9 2.20 
This table shows the frequency and actual (observed) number of copies of the Aval-Aiul-
Taql haplotype detected within the control population. Haplotypes were assigned in those 
subjects who were homozygous at two or more loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected Aval-Alul-Taql haplotypes 
and x.2 values were determined. The x.2 test was used to estimate linkage disequilibrium 
between the loci. 
a 2-2-1 (33.9% vs 9.7%, x.2 =71.75, p<0.0000001 (1df), Pc<0.0000002) 
b 2-1-1 (0.0% vs 18.8%, x.2=22.20, p=0.000002 (1df), Pc=0.000004) 
c 1-2-1 (0.0% VS 18.8%, X,2=22.20, p=0.000002 (1df), Pc=0.000004) 
d 1-1-2 (16.1% vs 7.0%, x.2=13. 79, p=0.0002 (1df), Pc=0.0004) 
e 1-1-1 (50.0% vs 36.7%, x.2=5.69, p=0.02 (1df), Pc=0.04) 
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Table 6.12B: Frequency of Aval-Alul-Taql haplotypes in the patient population 
Aval-Aiul-Taql observed frequency expected frequency 'X2 
Haplotype (n) (%) (n) (%) 
2-2-1 17 14.9 2.9 2.5 68.56" 
2-1-1 0 0.0 12.3 10.8 12.30 b 
1-2-1 1 0.9 13.8 12.1 11.87 c 
2-2-2 3 2.6 0.9 0.8 4.90 
2-1-2 0 0.0 3.8 3.3 3.80 
1-2-2 0.9 4.3 3.8 2.53 
1 - 1 - 1 69 60.5 57.9 50.8 2.13 
1-1-2 23 20.2 18.0 15.8 1.39 
This table shows the frequency and actual (observed) number of copies of the Aval-Alul-
Taql haplotype detected within the patient population. Haplotypes were assigned in those 
subjects who were homozygous at two or more loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected Aval-Alul-Taql haplotypes 
and x_2 values were determined. The x_2 test was used to estimate linkage disequilibrium 
between the loci. 
"2-2-1 (14.9% vs 2.5%, x_2=68.56, p<0.0000001 (1df), Pc<0.0000005) 
b 2-1-1 (0.0% vs 10.8%, x_2=12.30, p=0.0005 (1df), Pc=0.003) 
c 1-2-1 (0.9% vs 12.1%, x_2=11.87, p=0.0006 (1df), Pc=0.003) 
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Summary of the results obtained for analysis of the Aval-Aiul-Taql haplotypes 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Tables 6.12A and 6.12B indicate that the Aval-Alu/-Taq/ polymorphisms of the IL-l B gene 
are linked. In both control and patient groups, the most common haplotype was found to be 
1-1-1 with an observed frequency of 50.0% in controls and 60.5% in patients. 
Controls: 
Significantly more of the 2-2-1 (33.9% vs 9.7%, x.2 =71.75, p<O.OOOOOOl, Pc<0.0000002), 
1-1-2 (16.1% vs 7.0%, x2 =13.79, p=0.0002, Pc=0.0004) and 1-1-1 (50.0% vs 36.7%, x2 
=5.69, p=0.02, Pc=0.04) haplotypes and significantly less of the 2-1-1 (0.0% vs 18.8%, x2 
=22.20, p=0.000002, Pc=0.000004), 1-2-1 (0.0% vs 18.8%, X2 = 22.20, p=0.000002, 
Pc=0.000004), 1-2-2 (0.0% vs 3.6%, x2 =4.30, p=0.04•) and 2-1-2 (0.0% vs 3.6%, x2 
=4.30, p=0.04•) haplotypes were observed in controls than expected. 
Patients: 
There was significantly more of the 2-2-1 (14.9% vs 2.5%, x2 =68.56, p<0.0000001, 
Pc<0.0000005) and 2-2-2 (2.6% vs 0.8%, x2 = 4.90 p=0.03•) haplotypes than expected in 
the patient group with a significant reduction in the number of 2-1-1 (0.0% vs 1 0.8%, x2 
=12.30, p=0.0005, Pc=0.003) and 1-2-1 (0.9% vs 12.1 %, X2 = 11.87, p=0.0006, Pc=0.003) 
haplotypes. 
* p value became non-significant following correction for the number of comparisons 
made. 
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Table 6.13A Frequency of Mspl-VLP-VNTR86-Sspl haplotype in the control 
population 
Mspl-VLP-VNTR86 -Sspl observed frequency expected frequency 
·l 
Haplotype (n) (%) (n) (%) 
2-3-2-2 16 15.7 0.1 0.1 2528.10" 
1-2-1-1 86 84.3 51.5 50.5 23.11 b 
1-2-2-1 0 0.0 9.6 9.4 9.60c 
1-2-1-2 0 0.0 9.6 9.4 9.60d 
2-3-2-1 0 0.0 0.3 0.3 0.30 
X-X-X-X 0 0.0 30.9 30.3 30.90e 
This table shows the frequency and actual (observed) number of copies of the Mspl-V LP-
VNTR86-Ssp/ haplotype detected within the control population. The X-X-X-X haplotype 
represents the sum of the haplotypes that were not detected. Haplotypes were assigned in 
those subjects who were homozygous at three or more loci. The expected haplotype 
frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more 
than one locus). Comparisons were made between the observed and expected Msp/-VLP-
VNTR 86 -Ss pi haplotypes and x2 values were determined. The x2 test was used to estimate 
linkage disequilibrium between the loci. 
a 2-3-2-2 (15.7% VS 0.1 %, x2=2528.10, p<0.0000001 (ldf), Pc<0.0000001) 
b 1-2-1-1 (84.3% vs 50.5%, x2=23.11, p=0.000001 (1df), Pc=0.000001) 
c 1-2-2-1 (0.0% VS 9.4%, x2=9.60, p=0.002 (1df), Pc=0.002) 
d 1-2-1-2(0.0% vs 9.4%, x2=9.60, p=0.002 (ldf), Pc=0.002) 
e X-X-X-X (0.0% vs 30.3%, x2=30.90, p<0.0000001 (ldf), Pc<0.0000001) 
207 
Table 6.13B Frequency of Mspl-VLP-VNTR86-Sspl haplotype in the patient 
population 
Msp/-VLP-VNTR86 -Sspl observed frequency expected frequency 1.2 
Haplotype (n) (%) (n) (%) 
2-3-2-2 2I I4.0 O.I O.I 4368.10" 
1-2-1-1 I26 84.0 78.9 52.6 28.I2 b 
1-2-2-1 I 0.7 I4.2 9.5 12.27 c 
1-2-1-2 I 0.7 I3.6 9.1 11.67 d 
2-3-2-1 I 0.7 0.4 0.3 0.90 
X-X-X-X 0 0.0 42.8 28.5 42.80° 
This table shows the frequency and actual (observed) number of copies of the Msp/-VLP-
VNTR86-Ssp/ haplotype detected within the patient population. The X-X-X-X haplotype 
represents the sum of the haplotypes that were not detected. Haplotypes were assigned in 
those subjects who were homozygous at three or more loci. The expected haplotype 
frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more 
than one locus). Comparisons were made between the observed and expected Msp/-VLP-
VNTR86-Ssp/haplotypes and x2 values were determined. The x2 test was used to estimate 
linkage disequilibrium between the loci. 
• 2-3-2-2 (14.0% vs 0.1 %, x2=4368.l0, p<O.OOOOOOI (Idf), Pc<0.0000004) 
b 1-2-I-1 (84.0% VS 52.6%, x2=28.I2, p<O.OOOOOOI (1df), Pc<0.0000004) 
c 1-2-2-1 (0.7% vs 9.5%, x2=12.27, p=0.0005 (Idf), Pc=0.002) 
d I-2-I-2 (0.7% VS 9.1 %, x2=I1.67, p=0.0006 (Idf), Pc=0.002) 
e X-X-X-X (0.0% vs 28.5%, x2=42.80, p<O.OOOOOOI (Id f), Pc<0.0000004) 
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Summary of the results obtained for analysis of the Msol-VLP-VNTR86-Sspl 
haplotvpes 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Tables 6.13A and 6.13B suggest that the Mspl-VLP-VNTR 86 -Sspl polymorphisms of the 
IL-1RN gene are linked. The most common haplotype in both control and patient 
populations was found to be 1-2-1-1 that occurred with an observed frequency of 84.3% in 
the control group and 84.0% in the patient group. 
Controls: 
Significantly more of the 2-3-2-2 (15.7% vs 0.1%, x2 =2528.11, p<O.OOOOOOl, 
Pc<O.OOOOOOl) and 1-2-1-1 (84.3% vs 50.5%, x2 =23.11, p=0.000001, Pc=O.OOOOOl) 
haplotypes were observed in the control population than expected. 1n addition, there was a 
significant reduction in the X-X-X-X (0.0% vs 30.3%, x2=30.90, p<O.OOOOOOI, 
Pc<0.0000001), 1-2-2-1 (0.0% vs 9.4%, x2 =9.60, p=0.002, Pc=0.002) and 1-2-1-2 (0.0% 
VS 9.4%, x2 =9.60, p=0.002, Pc=0.002) haplotypes. 
Patients: 
There were significantly more 2-3-2-2 (14.0% vs 0.1 %, x2 =4368.1 0, p<0.0000001, 
Pc<0.0000004) and 1-2-1-1 (84.0% VS 52.6%, x2 =28.12, p<0.0000001, Pc<0.0000004) 
haplotypes than expected in the patient population. Significantly less X-X-X-X (0.0% vs 
28.5%, x2 =42.80, p<O.oooooo1, Pc<0.0000004), 1-2-2-1 (0.7% vs 9.5%, x2 =12.27, 
p=O.OOOS, Pc=0.002) and 1-2-1-2 (0.7% VS 9.1%, x2 =11.67, p=0.0006, Pc=0.002) 
haplotypes were also found in this group. 
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Table 6.14A Frequency of Pstl-(AC)n-VNTR46 haplotype in tbe control population 
Haplotype observed frequency expected frequency ·l 
Pstl-(AC)n-VNTR46 (n) (%) (n) (%) 
2-2-2 12 14.3 3.7 4.4 18.62 a 
1-2-6 2 2.4 0.2 0.2 16.20 b 
2-2-1 3 3.6 12.2 14.5 6.94 
2-2-4 2 2.4 0.4 0.5 6.40 
2-1-2 1 1.2 5.4 6.4 3.59 
1-3-1 2 2.4 0.6 0.7 3.27 
2-3-3 1 1.2 0.2 0.2 3.20 
1-2-2 3 3.6 1.2 1.4 2.70 
1-0-1 I 1.2 0.3 0.4 1.63 
2-1-1 23 27.4 17.8 21.2 1.52 
2-4-1 11 13.1 7.6 9.0 1.52 
1-4-1 4 4.8 2.4 2.9 1.07 
2-5-1 2 2.4 1.0 1.2 1.0 
2-8-1 2 2.4 1.0 1.2 1.0 
2-1-3 3 3.6 1.9 2.3 0.64 
1 -1 -1 7 8.3 5.6 6.7 0.35 
1-1-3 1 1.2 0.6 0.7 0.27 
2-3-2 1 1.2 0.6 0.7 0.27 
2-2-6 1 1.2 0.7 0.8 0.13 
2-2-3 1 1.2 1.3 1.5 0.07 
2-0-1 1 1.2 1.0 1.2 0.00 
2-0-3 0 0.0 
1-2-1 0 0.0 
1-2-3 0 0.0 
2-3-1 0 0.0 
2-6-1 0 0.0 
X-X-X 0 0.0 18.3 21.8 18.30 c 
This table shows the frequency and actual (observed) number of copies of the Pstl-(AC)n-
VNTR46 haplotype detected within the control population. The X-X-X haplotype represents 
the sum of the haplotypes that were not detected. Haplotypes were assigned in those 
subjects who were homozygous at two or more loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected Pstl-(AC)n-VNTR46 
haplotypes and x.2 values were determined. The x2 test was used to estimate linkage 
disequilibrium between the loci. 
a 2-2-2 (14.3% VS 4.4%, X2 =18.62, p=0.00002 (1dt), Pc=0.0004) 
b 1-2-6 (2.4% vs 0.2%, x2=16.20, p=0.00006 (ldt), Pc=0.001) 
c X-X-X(O.O% vs 21.8%, x2=18.30, p=0.00002 (1dt), Pc=0.0004) 
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Table 6.14B Frequency of Pst/-(AC)n-VNTR46 haplotype in the patient population 
Haplotype observed frequency expected frequency 
·l 
Pst/-(AC)n-VNTR46 (n) (%) (n) (%) 
2-2-2 10 12.2 3.0 3.7 16.33 8 
2-2-1 3 3.7 14.1 17.2 8.74b 
2-2-6 2 2.4 0.5 0.6 4.50 
2-4-1 12 14.6 7.0 8.5 3.57 
2-0-3 1 1.2 0.2 0.2 3.20 
1-2-2 1 1.2 0.2 0.2 3.20 
2-1-3 10 12.2 6.9 8.4 1.39 
2-5-1 4 4.9 2.4 2.9 1.07 
1-2-3 1 1.2 0.4 0.5 0.90 
2-3-1 3 3.7 1.8 2.2 0.80 
1-2-1 2 2.4 1.1 1.3 0.74 
2-6-1 2 2.4 1.2 1.5 0.53 
2-1-1 24 29.3 21.2 25.9 0.37 
1- 1 -1 2 2.4 1.7 2.1 0.05 
2-2-3 5 6.1 4.6 5.6 0.03 
1-0-1 0 0.0 
2-0-1 0 0.0 
2-1-2 0 0.0 
1-1-3 0 0.0 
2-2-4 0 0.0 
1-2-6 0 0.0 
1-3-1 0 0.0 
2-3-2 0 0.0 
2-3-3 0 0.0 
1-4-1 0 0.0 
2-8-1 0 0.0 
X-X-X 0 0.0 15.7 19.1 15.70 c 
This table shows the frequency and actual (observed) number of copies of the Pst/-(AC)n-
VNTR46 haplotype detected within the patient population. The X-X-X haplotype represents 
the sum of the haplotypes that were not detected. Haplotypes were assigned in those 
subjects who were homozygous at two or more loci. The expected haplotype frequencies 
were obtained from the individual allelic frequencies. (The haplotype frequency analysis 
does not take into account individuals who were heterozygous at more than one locus). 
Comparisons were made between the observed and expected Pstl-(AC)n-VNTR46 
haplotypes and x2 values were determined. The x2 test was used to estimate linkage 
disequilibrium between the loci. 
a 2-2-2 (12.2% VS 3.7%, x2=16.33, p=0.00005 (1df), Pc=0.0007) 
b 2-2-1 (3.7% vs 17.2%, x2=8.74, p=0.003 (ldf), Pc=0.04) 
c X-X-X(O.O% vs 19.1%, x2=15.70, p=0.00007 (1df), Pc=0.001) 
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Summary of the results obtained for analysis of the Psti-(AC)n-VNTR46 haplotvpes 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Tables 6.14A and 6.14B suggest that the Pst I polymorphism of the IL-lR gene and (AC)n-
VNTR46 polymorphisms of the IL-IA gene are linked. The most common haplotype was 2-
1-1 that occurred with an observed frequency of27.4% in controls and 29.3% in patients. 
Controls: 
There were significantly more of the 2-2-2 (14.3% vs 4.4%, x2 =18.62, p=0.00002, 
Pc=0.0004), 1-2-6 (2.4% vs 0.2%, x2 =16.20, p=0.00006, Pc=O.OOl) and 2-2-4 (2.4% vs 
0.5%, x2=6.40 p=0.01 *) haplotypes than expected in controls and a significant reduction in 
the number of the X-X-X (0.0% vs 21.8%, x2=18.30, p=0.00002, Pc=0.0004) and 2-2-1 
(3.6% VS 14.5%, x2=6.94, p=0.008*) haplotypes. 
Patients: 
Significantly more of the 2-2-2 (12.2% vs 3.7%, x2=16.33, p=0.00005, Pc=0.0007) and 2-
2-6 (2.4% vs 0.6%, x2 =4.50, p=0.03*) haplotypes were found than expected whereas the 
number of X-X-X (0.0% vs 19.1%, x2=15.70, p=0.00007, Pc=0.001) and 2-2-1 (3.7% vs 
17.2%, x2=8.74, p=0.003, Pc=0.04) haplotypes were significantly reduced. 
* p value became non-significant following correction for the number of comparisons 
made. 
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Table 6.15A: Frequency of Pstl-Aval-Alul-Taqlhaplotype in tbe control population 
Pstl-Aval-Aiul-Taql observed frequency expected frequency '1..2 
Haplotype (n) (%) (n) (%) 
2-2-2-1 26 27.7 9.1 9.7 31.39 a 
1-2-2-1 10 10.6 3.1 3.3 15.36 b 
2-1-2-1 0 0.0 14.6 15.5 14.60 c 
2-2-1-1 0 0.0 14.6 15.5 14.60 d 
2-1-1-2 9 9.6 3.1 3.3 11.23 e 
2-1-1-1 35 37.2 23.5 25.0 5.63 
1-1-2-1 0 0.0 5.0 5.3 5.00 
1-2-1-1 0 0.0 5.0 5.3 5.00 
2-1-2-2 0 0.0 1.9 2.0 1.90 
2-2-1-2 0 0.0 1.9 2.0 1.90 
1-1-1-1 12 12.8 8.1 8.6 1.88 
2-2-2-2 0 0.0 1.2 1.3 1.20 
1 - 1 - 1 - 2 2 2.1 1.1 1.2 0.74 
1-1-2-2 0 0.0 0.7 0.7 0.70 
1-2-1-2 0 0.0 0.7 0.7 0.70 
1-2-2-2 0 0.0 0.4 0.4 0.40 
This table shows the frequency and actual (observed) nwnber of copies of the Pstl-Aval-
Alul-Taql haplotype detected within the control population. Haplotypes were assigned in 
those subjects who were homozygous at three or more loci. The expected haplotype 
frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more 
than one locus). Comparisons were made between the observed and expected Pstl-Aval-
Alul-Taql haplotypes and '1..2 values were determined. The x_2 test was used to estimate 
linkage disequilibriwn between the loci. 
a 2-2-2-1 (27.7% VS 9.7%, x2=31.39, p<0.0000001 (1df), Pc<0.0000005) 
b 1-2-2-1 (10.6% VS 3.3%, x2=15.36, p=0.00009 (1df), Pc=0.0005) 
c 2-1-2-1 (0.0% vs 15.5%, x2=14.60, p=0.0001 (ldf), Pc=0.0005) 
d 2-2-1-1 (0.0% VS 15.5%, x2=14.60, p=O.OOOl (1df), Pc=0.0005) 
e 2-1-1-2 (9.6% VS 3.3%, x2=11.23, p=0.0008 (1df), Pc=0.004) 
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Table 6.15B: Frequency of Pstl-Aval-Alui-Taql haplotype in the patient population 
Pstl-Aval-Aiul-Taql observed frequency expected frequency 12 
Haplotype (n) (%) (n) (%) 
2-2-2-1 12 12.5 1.9 2.0 53.69 8 
2-1-2-1 0 0.0 9.7 10.1 9.70b 
1-2-2-1 2 2.1 0.3 0.3 9.63 c 
2-2-1-1 0 0.0 9.0 9.4 9.00d 
2-2-2-2 2 2.1 0.5 0.5 4.50 
2-2-1-2 0 0.0 2.4 2.5 2.40 
1-1-2-1 0 0.0 1.5 1.6 1.50 
2-1-1-2 16 16.7 11.8 12.3 1.49 
1-2-1-1 0 0.0 1.4 1.5 1.40 
1-1-1-1 10 10.4 7.0 7.3 1.29 
2-1-1-1 52 54.2 45.1 47.0 1.06 
2-1-2-2 1 1.0 2.5 2.6 0.90 
1-1-2-2 0 0.0 0.4 0.4 0.40 
1-2-1-2 0 0.0 0.4 0.4 0.40 
1-1-1-2 1 1.0 1.8 1.9 0.36 
1-2-2-2 0 0.0 0.1 0.1 0.10 
This table shows the frequency and actual (observed) number of copies of the Pstl-Aval-
Alul-Taql haplotype detected within the patient population. Haplotypes were assigned in 
those subjects who were homozygous at three or more loci. The expected haplotype 
frequencies were obtained from the individual allelic frequencies. (The haplotype 
frequency analysis does not take into account individuals who were heterozygous at more 
than one locus). Comparisons were made between the observed and expected Pstl-Aval-
Alul-Taql haplotypes and xz values were determined. The X) test was used to estimate 
linkage disequilibrium between the loci . 
• 2-2-2-1 (12.5% VS 2.0%, x2=53.69, p<0.0000001 (1df), Pc<0.0000007) 
b 2-1-2-1 (0.0% vs 10.1%, X2=9.70, p=0.002 (ldf), Pc=O.Ol) 
c l-2-2-1 (2.1% vs 0.3%, x2=9.63, p=0.002 (ldf), Pc=O.Ol) 
d 2-2-1-1 (0.0% vs 9.4%, x2=9.00, p=0.003 (Idf), Pc=0.02) 
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Summary of the results obtained for analysis of the Pstl-Aval-Aiul-Taql haplotvpes 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Tables 6.15A and 6.15B indicate that the Pst I polymorphism of the IL-lR gene and Aval-
Alul-Taql polymorphisms of the IL-1B gene are also linked. The most common haplotype 
was found to be 2-1-1-1 with an observed frequency of 37.2% in controls and 54.2% in 
patients. 
Controls: 
Significantly more of the 2-2-2-1 (27.7% vs 9.7%, x2 =31.39, p<O.OOOOOOl, 
Pc<0.0000005), 1-2-2-1 (10.6% VS 3.3%, x2 =15.36, p=0.00009, Pc=0.0005), 2-1-1-2, 
(9.6% vs 3.3%, x2 =11.23, p=0.0008, Pc=0.004) and 2-1-1-1 (37.2% vs 25.0%, x.2 =5.63, 
p=0.02•) haplotypes were observed in controls than expected, whereas the number of 2-1-
2-1, (0.0% vs 15.5%, x2 =14.60, p=0.0001, Pc=0.0005), 2-2-I-1, (O.O% vs 15.5%, x2 
=14.60, p=0.0001, Pc=0.0005) 1-1-2-1 (0.0% vs 5.3%, x.2 =5.0, p=0.03•) and 1-2-1-1 
(0.0% vs 5.3%, x_2 =5.0, p=0.03•) haplotypes were found to be significantly decreased. 
Patients: 
There were significantly more of the 2-2-2-1 (12.5% vs 2.0%, x_2=53.69, p<0.0000001, 
Pc=0.0000007), 1-2-2-1, (2.1% vs 0.3%, x_2 =9.63, p=0.002, Pc=0.01) and 2-2-2-2 (2.1% 
vs 0.5%, x_2 =4.50, p=0.03•) haplotypes than expected in the patient group, however, there 
were less ofthe 2-1-2-1, (0.0% vs 10.1%, x2 =9.70, p=0.002, Pc=0.01) and 2-2-1-1, (0.0% 
vs 9.4%, x_2 =9.00, p=0.003, Pc=0.02) haplotypes than expected. 
* p value became non-significant following correction for the number of comparisons 
made. 
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Table 6.16A Frequency of Pstl-Mspl-VLP-VNTR86-Sspl haplotype in the control 
population 
Pstl-Mspl-VLP-VNTR86 -Sspl observed frequency expected frequency 
·l 
Haplotype (n) (%) (D) (%) 
2-1-2-1-1 58 59.2 33.4 34.1 18.12 a 
1 - 1 - 2 - 1 - 1 24 24.5 14.7 15.0 5.88 
2-2-3-2-2 10 10.2 0.0 
1-2-3-2-2 6 6.1 0.0 
2-1-2-2-1 0 0.0 0.0 
X-X-X-X-X 0 0.0 49.9 50.9 49.90 b 
This table shows the frequency and actual (observed) number of copies of the Pst!-Mspl-
VLP-VNTR86-Sspl haplotype detected within the control population. The X-X-X-X-X 
haplotype represents the sum of the haplotypes that were not detected. Haplotypes were 
assigned in those subjects who were homozygous at four or more loci. The expected 
haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were heterozygous 
at more than one locus). Comparisons were made between the observed and expected Pstl-
Msp!-VLP-VNTR 86 -Ss pi haplotypes and x2 values were determined. The x2 test was used 
to estimate linkage disequilibrium between the loci. 
a 2-1-2-1-1 {59.2% VS 34.1%, x2=18.12, p=0.00002 (1dt), Pc=0.00006) 
b X-X-X-X-X (0.0% vs 50.9%, x2=49.90, p<O.OOOOOOI {ldt), Pc<0.0000003) 
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Table 6.168 Frequency of Pstl-Mspl-VLP-VNTR86-Sspl haplotype in the patient 
population 
Pstl-Mspl-VLP-VNTR86 -Sspl observed frequency expected frequency 
·l 
Haplotype (n) (%) (n) (%) 
2-1-2-1-1 103 71.5 68.6 47.6 17.25 3 
2-1-2-2-1 1 0.7 10.4 7.2 8.50b 
1-1-2-1-1 22 15.3 15.2 10.6 3.04 
2-2-3-2-2 14 9.7 0 
1-2-3-2-2 4 2.8 0 
X-X-X-X-X 0 0.0 49.8 34.6 49.80c 
This table shows the frequency and actual (observed) number of copies of the Pstl-Mspl-
VLP-VNTR86-Sspl haplotype detected within the patient population. The X-X-X-X-X 
haplotype represents the sum of the haplotypes that were not detected. Haplotypes were 
assigned in those subjects who were homozygous at four or more loci. The expected 
haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were heterozygous 
at more than one locus). Comparisons were made between the observed and expected Pstl-
Mspl-VLP-VNTR86-Ssp!haplotypes and x2 values were determined. The x2 test was used 
to estimate linkage disequilibrium between the loci. 
0 2-1-2-1-1 (71.5% VS 47.6%, x2=17.25, p=0.00003 (1df), Pc=0.0001) 
b 2-1-2-2-1 (0.7% vs 7.2%, x2=8.50, p=0.004 (1df), Pc=0.02) 
c X-X-X-X-X(O.O% vs 34.6%, x2=49.80, p<O.oooooo1 (1df), Pc<0.0000004) 
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Summary of the results obtained for analysis of the Pstl-Msol-VLP-VNTR86-Sspl 
haplotypes 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Data in tables 6.16A and 6.16B suggest that linkage occurs between Psi/polymorphism of 
the IL-1RI gene and the Mspl-VLP-VNTR 86 -Sspl polymorphisms of the IL-l RN gene. The 
most common haplotype was found to be 2-l-2-1-1 with an observed frequency of 59.2% 
in controls and 71.5% in patients. 
Controls 
Significantly more of the 2-1-2-1-1 (59.2% vs 34.1%, x.2 =18.12 p=0.00002, Pc=0.00006) 
and 1-1-2-1-1 (24.5% vs 15.0%, x2 =5.88, p=0.02•) haplotypes and significantly less of 
the X-X-X-X-X haplotype were found (0.0% vs 50.9%, x.2 =49.90 p<O.OOOOOOI, 
Pc<0.0000003) in controls than expected. 
Patients 
There were significantly more of the 2-1-2-1-l (71.5% vs 47.6%, x.2 =17.25, p=0.00003, 
Pc=0.0001) than expected in the patient group. Significantly less of the X-X-X-X-X (0.0% 
VS 34.6%, x2 =49.80, p<O.OOOOOOl, Pc<0.0000004) and 2-1-2-2-1 (0.7% VS 7.2%, x.2 
=8.50, p=0.004, Pc=0.02) haplotypes were found than expected. 
* p value became non-significant following correction for the number of comparisons 
made. 
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Table 6.17 A: Frequency of (AC)n-VNTR46 -Aval-Alul-Taql haplotype in tbe control 
population 
Haplotype observed frequency expected frequency 
·l 
IL-IA-IL-18 (n) (%) (n) (%) 
2-2-2-2-1 6 13.0 0.2 0.4 168.20" 
2-6-2-2-1 3 6.5 0.1 0.2 84.10 b 
1-1-1-1-2 5 10.9 0.6 1.3 32.27 c 
4-1-1-1-1 10 21.7 3.5 7.6 12.07d 
5-1-1-1-1 5 10.9 1.5 3.3 8.17 
3-1-1-1-1 3 6.5 0.9 2.0 4.90 
1-1-2-2-1 2 4.3 0.7 1.5 2.41 
2-1-1-1-1 I 2.2 3.8 8.3 2.06 
4-1-1-1-2 2.2 0.5 1.1 0.50 
4-1-2-2-1 1 2.2 0.7 1.5 0.13 
1-1-1-1-1 4 8.7 3.8 8.3 0.01 
1-2-1-1-1 1 2.2 1.1 2.4 0.01 
2-2-1-1-1 2 4.3 1.1 2.4 0.74 
1-3-2-2-1 1 2.2 0.0 0.00 
2-4-2-2-1 1 2.2 0.0 0.00 
1-1-1-2-2 0 0.0 
1-1-2-2-2 0 0.0 
1-3-1-1-1 0 0.0 
2-3-1-1-1 0 0.0 0.00 
2-3-2-2-1 0 0.0 0.00 
6-1-1-1-1 0 0.0 0.00 
X-X-X-X-X 0 0.0 27.5 59.8 27.5o• 
This table shows the frequency and actual (observed) number of copies of the (AC)n-
VNTR46-Ava/-Alu/-Taq/ haplotype detected within the control population. The X-X-X-X-
X haplotype represents the sum of the haplotypes that were not detected. Haplotypes were 
assigned in those subjects who were homozygous at four or more loci. The expected 
haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were heterozygous 
at more than one locus). Comparisons were made between the observed and expected 
(AC)n-VNTR46-Ava/-Alu/-Taq/ haplotypes and x.2 values were determined. The x2 test 
was used to estimate linkage disequilibrium between the loci. 
a 2-2-2-2-1 (13.0% VS 0.4%, x2=168.20, p<0.0000001 {ldt), Pc<0.000001) 
b 2-6-2-2-1 (6.5% VS 0.2%, x2=84.10, p<O.OOOOOOOl (1dt), Pc<O.OOOOOl) 
c l-l-1-1-2 (10.9% vs 1.3%, x.2=32.27, p<0.0000001 (1dt), Pc<0.000001) 
d 4-1-1-1-1 (21.7% vs 7.6%, x.2=12.07, p=0.0005 {ldt), Pc=0.007) 
e X-X-X-X-X (0.0% VS 59.8%, x2=27.50, p<0.0000001 (1dt), Pc<0.0000001) 
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Table 6.17B: Frequency of (AC)n-VNTR46-Aval-Alul-Taql polymorphism haplotype 
in the patient population 
Haplotype observed frequency expected frequency .,; 
IL-IA-IL-18 (n) (%) (n) (%) 
1-1-1-1-2 3 8.3 0.5 1.4 12.50 a 
1-1-1-2-2 1 2.8 0.1 0.3 8.10 
4-1-1-1-1 9 25.0 3.9 10.8 6.67 
3-1-1-1-1 3 8.3 1.3 3.6 2.22 
5-1-1-1-1 2 5.6 0.9 2.5 1.34 
2-2-1-1-1 2 5.6 1.0 2.8 1.00 
2-1-1-1-1 3 8.3 5.2 14.4 0.93 
6-1-1-1-1 1 2.8 0.4 1.1 0.90 
1-3-1-1-1 1 2.8 0.4 1.1 0.90 
2-3-1-1-1 1 2.8 0.6 1.7 0.27 
1-1-1-1-1 4 11.1 3.9 10.8 0.00 
2-2-2-2-1 3 8.3 0.0 0.00 
2-6-2-2-1 2 5.6 0.0 0.00 
2-3-2-2-1 1 2.8 0.0 0.00 
1-1-2-2-1 0 0.0 
1-1-2-2-2 0 0.0 
1-3-2-2-1 0 0.0 
2-4-2-2-1 0 0.0 
4-1-1-1-2 0 0.0 
4-1-2-2-1 0 0.0 
X-X-X-X-X 0 0.0 17.8 49.4 17.80 b 
This table shows the frequency and actual (observed) number of copies of the (AC)n-
VNTR46-Aval-Aiul-Taqlhaplotype detected within the patient population. The X-X-X-X-X 
haplotype represents the sum of the haplotypes that were not detected. Haplotypes were 
assigned in those subjects who were homozygous at four or more loci. The expected 
haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were heterozygous 
at more than one locus). Comparisons were made between the observed and expected 
(AC)n-VNTR46-Aval-Aiul-Taql haplotypes and x.2 values were determined. The x.2 test 
was used to estimate linkage disequilibrium between the loci. 
• 1-1-1-1-2 (8.3% vs 1.4%, x.2=12.50, p=0.0004 (ldf), Pc=0.005) 
b X-X-X-X-X (0.0% vs 49.4%, x.2=17.80, p=0.00002 (ldf), Pc=0.0003) 
220 
Summary of the results obtained for analysis of the (AC)n-VNTR46-Aval-Alul-Taql 
haplotvpes 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
Tables 6.17 A and 6.17B show that the (AC)n-VNTR46 polymorphisms of the IL-l A gene 
and Aval-Alul-Taql polymorphisms of the IL-IB gene are also linked. The most common 
haplotype was 4-1-1-1-l that occurred with an observed frequency of21.7% in controls and 
25.0% in patients. 
Controls: 
There were significantly more of the 2-2-2-2-1 (13.0% vs 0.4%, J) =168.20, p<O.OOOOOOl, 
Pc<O.OOOOOI), 2-6-2-2-l (6.5% vs 0.2%, x.2=84.10, p<O.OOOOOOl, Pc<O.OOOOOI), l-l-l-1-
2 (10.9% vs 1.3%, x.2=32.27, p<O.OOOOOOl, Pc<0.000001), 4-1-l-l-l (21.7% vs 7.6%, 
x.2=12.07, p=0.0005, Pc=0.007), 5-1-1-1-l (10.9% vs 3.3%, x.2=8.17, p=0.004•) and 3-1-
l-1-l (6.5% vs 2.0%, x.2=4.90, p=0.03•) haplotypes than expected in the control group. 
The X-X-X-X-X haplotype was significantly reduced in controls compared to expected 
(0.0% vs 59.8%, x.2=27.50, p<O.OOOOOOI, Pc<O.OOOOOI). 
Patients: 
Significantly more of the l-l-l-l-2 (8.3% vs 1.4%, x.2=l2.50, p=0.0004, Pc=0.005), l-1-l-
2-2 (2.8% VS 0.3%, x.2=8.10, p=0.004*) and 4-l-l-l-1 (25.0% VS 10.8%, x.2=6.67, 
p=O.Ol *) haplotypes and significantly less of the X-X-X-X-X haplotype (0.0% vs 49.4%, 
x.2=17.80, p=0.00002, Pc=0.0003) were observed in patients compared to expected. 
• p value became non-significant following correction for the number of comparisons 
made. 
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Table 6.18A: Frequency of (AC)n-VNTR46-MspJ-VLP-VNTR86..SspJ haplotype in the 
control population 
Haplotype observed frequency expected frequency ·i 
IL-lA-IL-lRN (n) (%) (n) (%) 
2-2-1-2-1-1 6 12.5 0.5 1.0 60.5o• 
4-1-1-2-1-1 13 27.1 6.2 12.9 7.46 
1-1-1-2-1-1 15 31.3 7.8 16.3 6.65 
2-1-1-2-1-1 1 2.1 2.9 6.0 1.24 
8-1-1-2-1-1 1 2.1 0.4 0.8 0.90 
5-1-1-2-1-1 3 6.3 2.1 4.4 0.39 
1-2-1-2-1-1 1 2.1 1.3 2.7 0.07 
1-1-2-3-2-2 3 6.3 0.0 
4-1-2-3-2-2 2 4.2 0.0 
5-1-2-3-2-2 2 4.2 0.0 
3-1-2-3-2-2 1 2.1 0.0 
0-3-1-2-1-1 0 0.0 
1-3-1-2-1-1 0 0.0 
2-1-2-3-2-2 0 0.0 
2-2-2-3-2-2 0 0.0 
2-3-1-2-1-1 0 0.0 
2-6-2-3-2-2 0 0.0 
3-1-1-2-1-1 0 0.0 
4-2-1-2-1-1 0 0.0 
5-2-1-2-1-2 0 0.0 
6-1-1-2-1-1 0 0.0 
X-X-X-X-X-X 0 0.0 26.8 55.8 26.80 b 
This table shows the frequency and actual (observed) number of copies of the (AC)n-
VNTR46-Msp/-VLP-VNTR86-Ssp/ haplotype detected within the control population. The 
X-X-X-X-X-X haplotype represents the sum of the haplotypes that were not detected. 
Haplotypes were assigned in those subjects who were homozygous at five or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
(The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ haplotypes and x.2 values were 
determined. The x.2 test was used to estimate linkage disequilibrium between the loci. 
"2-2-1-2-1-1 (12.5% vs 1.0%, x.2=60.50, p<0.0000001 (1df), Pc<0.000001) 
b X-X-X-X-X-X(O.O% vs 55.8%, x.2=26.80, p<O.OOOOOOl (1df), Pc<O.OOOOOl) 
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Table 6.18B Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ haplotype in the 
patient population 
Haplotype observed frequency expected frequency '1.2 
IL-IA-IL-l RN (n) (%) (n) (%) 
2-2-1-2-1-1 11 12.5 2.8 3.2 24.01 a 
4-1-1-2-1-1 14 15.9 6.0 6.8 10.67 b 
1-3-1-2-1-1 10 11.4 4.0 4.5 9.ooc 
1-1-1-2-1-1 24 27.3 13.4 15.2 8.39 
0-3-1-2-1-1 I 1.1 0.1 0.1 8.10 
5-2-1-2-1-2 1 1.1 0.1 0.1 8.10 
2-1-1-2-1-1 5 5.7 10.1 11.5 2.58 
3-1-1-2-1-1 2 2.3 0.8 0.9 1.80 
6-1-1-2-1-1 2 2.3 0.8 0.9 1.80 
2-3-1-2-1-1 5 5.7 3.0 3.4 1.33 
4-2-1-2-1-1 1 1.1 1.7 1.9 0.29 
5-1-1-2-1-1 2 2.3 1.5 1.7 0.17 
2-6-2-3-2-2 3 3.4 0.0 
1-1-2-3-2-2 2 2.3 0.0 
2-2-2-3-2-2 2 2.3 0.0 
2-1-2-3-2-2 1 1.1 0.0 
4-1-2-3-2-2 I 1.1 0.0 
5-1-2-3-2-2 I 1.1 0.0 
3-1-2-3-2-2 0 0.0 
8-1-1-2-1-1 0 0.0 
1-2-1-2-1-1 0 0.0 
X-X-X-X-X-X 0 0.0 43.7 49.7 43.70d 
This table shows the frequency and actual (observed) number of copies of the (AC)n-
VNTR46-Msp/-VLP-VNTR86-Ssp/haplotype detected within the patient population. The X-
X-X-X-X-X haplotype represents the sum of the haplotypes that were not detected. 
Haplotypes were assigned in those subjects who were homozygous at five or more loci. 
The expected haplotype frequencies were obtained from the individual allelic frequencies. 
{The haplotype frequency analysis does not take into account individuals who were 
heterozygous at more than one locus). Comparisons were made between the observed and 
expected (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ haplotypes and x_2 values were 
determined. The x_2 test was used to estimate linkage disequilibrium between the loci. 
a 2-2-I-2-1-1 (I2.5% vs 3.2%, x_2 =24.01, p=O.OOOOOI (Idf), Pc=0.00002) 
h 4-I-I-2-1-I (15.9% vs 6.8%, x2=I0.67, p=O.OOI (Idf), Pc=0.02) 
c I-3-1-2-I-1 (11.4% vs 4.5%, X 2=9.00, p=0.003 (Idf), Pc<0.05) 
d X-X-X-X-X-X (0.0% vs 49.7%, x_2=43.70, p<O.OOOOOOI {ldf), Pc<0.000002) 
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Summap; of the results obtained for analysis of the (AC)n-VNTR46-Msp/-VLP-
VNTR8 -Sspl haplotypes 
All of the significant data are discussed, however, only the data that are significant 
following correction for the number of comparisons involved are included in the tables. 
The data in tables 6.18A and 6.18B indicate that the (AC)n-VNTR46 polymorphisms of the 
IL-l A gene and Msp/-VLP-VNTR86-Ssp/ polymorphisms of the IL-lRN gene are linked. 
The most common haplotype was 1-1-1-2-1-1 that occurred with an observed frequency of 
31.3% in controls and 27.3% in patients. 
Controls: 
There were significantly more of the 2-2-1-2-1-1 (12.5% vs 1.0%, :x,2=60.50, p<O.OOOOOOI, 
Pc<0.000001), 4-1-1-2-1-1 (27.1% vs 12.9%, :x,2=7.46, p=0.006*) and 1-1-1-2-1-1 (31.3% 
vs 16.3%, x.2=6.65, p=0.01•) haplotypes and significantly less of the X-X-X-X-X-X 
haplotype (0.0% vs 55.8%, x.2= 26.80, p<0.0000001, Pc<0.000001) than expected in 
controls. 
Patients: 
Significantly more of the 2-2-1-2-1-1 (12.5% vs 3.2%, x.2=24.01, p=O.OOOOOI, 
Pc=0.000002), 4-1-1-2-1-1 (15.9% vs 6.8%, x.2 =10.67, p=O.OOl, Pc=0.02), 1-3-1-2-1-1 
(11.4% VS 4.5%, :x,2=9.00, p=0.003, Pc<0.05) 1-1-1-2-1-1 (27.3% VS 15.2%, :x,2=8.39, 
p=0.004*), 0-3-1-2-1-1 (1.1% VS 0.1%, :x,2=8.10, p=0.004*) and 5-2-1-2-1-2 (1.1% VS 
0.1 %, x.2 =8.1 0, p=0.004•) haplotypes were found than expected while the X-X-X-X-X-X 
haplotype was significantly decreased (0.0% vs 49.7%, x.2=43.70, p<O.OOOOOOI, 
Pc<0.000002) in patients compared to expected. 
* p value became non-significant following correction for the number of comparisons 
made. 
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Table 6.19A Frequency of Aval-Alui-Taql-Mspl-VLP-VNTR86-Sspl haplotype in the 
control population 
Haplotype observed frequency expected frequency 'X.2 
IL-18-IL-lRN (n) (%) (n) (%) 
2-2-1-1-2-1-1 16 24.2 2.6 3.9 69.06 a 
1-1-2-1-2-1-1 11 16.7 3.0 4.5 21.33 b 
1-1-1-1-2-1-1 29 43.9 13.6 20.6 17.44° 
1-2-1-1-2-1-1 0 0.0 5.9 8.9 5.90 
1-1-1-1-2-1-2 0 0.0 2.4 3.6 2.40 
1-2-2-1-2-1-1 0 0.0 1.3 2.0 1.30 
2-2-2-1-2-1-1 0 0.0 0.6 0.9 0.60 
1-1-1-2-3-2-2 5 7.6 0.0 0.0 
2-2-1-2-3-2-2 4 6.1 0.0 0.0 
1-1-2-2-3-2-2 1.5 0.0 0.0 
2-2-2-2-3-2-2 0 0.0 0.0 0.0 
X-X-X-X-X-X-X 0 0.0 36.6 55.5 36.60d 
This table shows the frequency and actual (observed) number of copies of the Aval-Alul-
Taql-Mspl-VLP-VNTR86-Ssplhap1otype detected within the control population. The X-X-
X-X-X-X-X haplotype represents the sum of the haplotypes that were not detected. 
Haplotypes were assigned in those subjects who were homozygous at six or more loci. The 
expected haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were heterozygous 
at more than one locus). Comparisons were made between the observed and expected Aval-
Alul-Taql-Mspl-VLP-VNTR 86 -Ss pi haplotypes and x2 values were determined. The x2 test 
was used to estimate linkage disequilibrium between the loci. 
"2-2-1-l-2-1-1 (24.2% vs 3.9%, x2=69.06, p<0.0000001 (1df), Pc<0.0000005) 
b 1-1-2-1-2-1-1 (16.7% VS 4.5%, x2=21.33, p=0.000004 (1df}, Pc=0.00002) 
c 1-1-1-1-2-1-1 (43.9% vs 20.6%, x2=17.44, p=0.00003 (ldf), Pc=0.0002) 
d X-X-X-X-X-X-X (0.0% vs 55.5%, x2=36.60, p<0.0000001 (1df), Pc<0.0000005) 
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Table 6.19B Frequency of Aval-Alul-Taql-Mspl-VLP-VNTR86-Sspl haplotype in the 
patient population 
Haplotype observed frequency expected frequency '1..2 
IL-lB-11..-lRN (n) (%) (n) (%) 
1-1-1-1-2-1-1 48 54.5 25.5 29.0 19.85 a 
1-1-2-1-2-1-1 21 23.9 9.6 10.9 13.54 b 
2-2-1-1-2-1-1 3 3.4 0.8 0.9 6.05 
1-2-1-1-2-1-1 1 l.l 4.8 5.5 3.01 
1-1-1-1-2-1-2 1 l.l 4.4 5.0 2.63 
2-2-2-1-2-1-1 1 l.l 0.3 0.3 1.63 
1-2-2-1-2-1-1 1 1.1 1.8 2.0 0.36 
1-1-1-2-3-2-2 4 4.5 0.0 
2-2-1-2-3-2-2 7 8.0 0.0 
2-2-2-2-3-2-2 1 1.1 0.0 
1-1-2-2-3-2-2 0 0.0 0.0 
X-X-X-X-X-X-X 0 0.0 40.8 46.4 40.80c 
This table shows the frequency and actual (observed) number of copies of the Aval-Alul-
Taql-Mspl-VLP-VNTR 86 -Ss pi haplotype detected within the patient population. The X-X-
X-X-X-X-X haplotype represents the sum of the haplotypes that were not detected. 
Haplotypes were assigned in those subjects who were homozygous at six or more loci. The 
expected haplotype frequencies were obtained from the individual allelic frequencies. (The 
haplotype frequency analysis does not take into account individuals who were heterozygous 
at more than one locus). Comparisons were made between the observed and expected Aval-
Alul-Taql-Mspl-VLP-VNTR 86 -Ss pi haplotypes and X2 values were determined. The x2 test 
was used to estimate linkage disequilibrium between the loci. 
• 1-1-1-1-2-1-1 (54.5% vs 29.0%, x2=19.85, p=0.000008 (ldf), Pc=0.00007) 
b 1-1-2-1-2-1-1 (23.9% VS 10.9%, x2=13.54, p=0.0002 (1df), Pc=0.002) 
c X-X-X-X-X-X-X (0.0% vs 46.4%, x2=40.80, p<O.OOOOOOl (1df), Pc<0.0000009) 
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Summary of the results obtained for analysis of the Aval-Alul-Taql-Mspl-VLP-
VNTR86 -Sspl baplotypes 
All of the significant data are discussed, however, only the data that are significant 
following correction for the nwnber of comparisons involved are included in the tables. 
The information shown in tables 6.19A and 6.19B suggests that the Aval-Alul-Taql 
polymorphisms of the IL-l B gene and Mspl-VLP-VNTR 86 -Ss pi polymorphisms of the IL-
IRN gene are linked. The most common haplotype was found to be 1-1-1-1-2-1-1 with an 
observed frequency of 43.9% in controls and 54.5% in patients. 
Controls: 
Significantly more of the 2-2-1-1-2-1-1 (24.2% vs 3.9%, :x.2=69.06, p<O.OOOOOOI, 
Pc<0.0000005), 1-1-2-1-2-1-1 (16.7% vs 4.5%, :x,2=21.33 p=0.000004, Pc=0.00002) and 1-
1-1-1-2-1-1 (43.9% vs 20.6%, :x.2=17.44 p=0.00003, Pc=0.0002) haplotypes were observed 
in the controls than expected, whereas the number of the X-X-X-X-X-X-X (0.0% vs 
55.5%, :x.2 =36.60, p<O.OOOOOOI, Pc<0.0000005) and 1-2-1-1-2-1-1 (0.0% vs 8.9%, :x.2 
=5.90, p=0.02•) haplotypes were found to be significantly decreased. 
Patients: 
There were significantly more of the 1-1-1-1-2-1-1 (54.5% vs 29.0%, :x.2=19.85, 
p=0.000008, Pc=0.00007), 1-1-2-1-2-1-1, (23.9% vs 10.9%, :x.2=13.54, p=0.0002, 
Pc=0.002) and 2-2-1-1-2-1-1 (3.4% vs 0.9%, :x.2=6.05, p=0.01•) haplotypes than expected 
in the patient population, while the X-X-X-X-X-X-X haplotype (0.0% vs 46.4%, :x.2 
=40.80, p<0.0000001, Pc<0.0000009) was significantly reduced. 
* p value became non-significant following correction for the nwnber of comparisons 
made. 
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6.1.6 Combined Genotype Analysis 
Because the numbers of subjects are so small in the patient subgroups when the 
double heterozygotes are removed, there are not enough subjects to obtain significance for 
the haplotype analysis. In view of this, the genotypes of the polymorphisms were combined 
to determine whether there was preferential association of the markers within controls, 
patients and patient subgroups to determine whether a particular group expressed 
preferential association of genotypes. The results obtained from this analysis are shown in 
Appendix 2. 
6.2 Protein studies 
Studies were also performed to determine whether there was an association between 
the polymorphisms and protein levels. The most significant results obtained for the genetic 
studies in the IL-IA, IL-18 and IL-IRN genes were used as a basis for patient selection for 
the protein studies. Patients were recalled according to their genotype and depending on the 
hypothesis. For example, in the case of the IL-lB study, the 2,2 genotype of the Alu I 
polymorphism was found to be associated with susceptibility to acute pancreatitis, 
therefore patients with the 2,2 and 1,1 genotype were recalled to represent the 2 extremes 
of the genotype. Before the protein studies were performed the supematants obtained in the 
optimisation experiment (Appendix 1) were used to determine the secretory profile of each 
protein over a 120 hour period. The same lO Caucasian adults were used as controls for 
each of the following protein studies. These were 4 males and 6 females with an age range 
of 24-48 years and a median age of 27 years. 
C0= unstirnulated controls 
P0= unstimulated patients 
A 1 °= unstimulated subjects with allele I 
A2°= unstimulated subjects with allele 2 
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C5= stimulated controls 
P5= stimulated patients 
A1 5= stimulated subjects with allele 1 
A25= stimulated subjects with allele 2 
6.2.1 Interleukin-1 alpha protein 
6.2.1.1 lllterleukin-1 alpha time course experime11t 
The IL-la time course experiment showed that the peak IL-la protein secretion 
occurred at 24 hours (Figure 6.12). 
6.2.1.2 l11terleukin-1 alpha protein experime11t 
The most significant results in the polymorphism studies of the IL-IA gene were 
obtained from the (AC)n repeat polymorphism. The 2,4 genotype of this polymorphism 
was significantly increased in the alcoholic patients compared to controls (33.3% vs 12.0%, 
x)= 6.72, p=O.Ol, Pc<0.05) and significantly decreased in patients with gallstone disease 
compared to patients with alcoholic disease (7.5% vs 33.3%, x2=9.9, p=0.002, Pc=O.Ol). 
"Hypothesis: the 2,4 genotype of the (AC)n polymorphism may be associated with 
susceptibility to alcoholic acute pancreatitis." 
Patients with gallstone and alcoholic disease with the 2,4 genotype were recalled 
and the amount ofiL-la protein secreted from their PBMCs stimulated with 0-5f.1g/ml LPS 
for 0-72 hours was compared with that secreted from PBMCs taken from healthy controls. 
Unfortunately, only 3 patients with gallstone disease and 1 with alcohol-induced acute 
pancreatitis agreed to donate a blood sample for this study. In addition, because there are 
many different alleles in the polymorphism giving rise to may different genotypes, only 1 
of the 10 controls had a 2,4 genotype and therefore it was not possible to compare 2,4 
patients with 2,4 genotype controls so the hypothesis could not be tested. 
Instead the amount of IL-la protein secreted was compared between controls and 
patients so the samples that had been prepared would not be wasted. The genotypes, 
protein levels (individual and median) stimulated with 0 and 5 f.!g/ml LPS for 0-72 hours in 
controls and patients are shown in Tables 6.20A and 6.20B respectively. 
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Figure 6.12: IL-l alpha protein secreted from PBMCs cultured at lx106 cells per ml and stimulated with Suglml 
LPS for 0-120 hours 
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Table 6.20A: IL-Ia protein (pg/ml) secreted by PBMCs cultured at lxl06 cells per ml 
and stimulated witb 0-SJ.I.g/ml LPS for 0-72 boors in controls (C0 and C5) 
Time (boors) Gff 0 24 48 72 0 24 48 72 
LPS (Jlgfml) 0 0 0 0 5 5 5 5 
Control I 2,3 0 0 0 0 7 440 400 150 
Control2 1,1 2 I 2 2 0 540 490 370 
Control3 4,4 3 2 2 I 3 350 300 260 
Control4 1,7 2 54 57 55 2 560 490 430 
ControlS 1,4 3 4 8 13 0 490 410 250 
Control6 1,1 0 0 16 0 0 490 440 270 
Control? 0,2 0 0 8 0 2 600 540 530 
ControlS 1,1 19 0 21 0 0 690 530 450 
Contro19 1,3 I 3 5 7 0 1130 980 690 
ControllO 2,4 I I 3 0 0 370 350 160 
n 10 10 10 10 10 lO 10 10 
Median 1.5 1.0 6.5 0.5 0.0 515 465 320 
Range 0-19 0-54 0-57 0-55 0-7 350- 300- 150-
1130 980 690 
i.q.r. 0-3 0-3 2-16 0-7 0-2 440- 400- 250-
600 530 450 
Table 6.20B: IL-Ia protein (pg/ml) secreted by PBMCs cultured at lxl06 cells per ml 
and stimulated witb 0-SJ.I.g/ml LPS for 0-72 boors in patients witb acute pancreatitis 
(P0 and pS) 
Time (boors) Gff 0 24 48 72 0 24 48 72 
LPS (Jlg/ml) 0 0 0 0 5 5 5 5 
Patient 1 2,4 0 83 90 90 0 620 480 310 
Patient2 2,4 0 215 253 235 0 1020 640 460 
Patient 3 2,4 0 512 574 619 0 1690 1250 1090 
Patient 4 2,4 172 260 186 0 730 390 330 
n 4 4 4 4 4 4 4 4 
Median 0.0 193.5' 256.5b 2!0S 0.0 875d 560 395 
Range 0-1 83-512 90-574 90-619 0-0 620- 390- 310-
1690 1250 1090 
i.q.r. 0-0.5 127.5- 171.5- 138- 0-0 675- 435- 320-
363.5 417.0 427 1355 945 775 
G/T = genotype 
i.q.r. = interquartile range 
• =patients vs controls 0 LPS, 24 hours: 193.5 (127 .5-363.5)pg/rnl vs 1.0 (0.0-3.0)pg/ml, p=O.OOS 
b =patients vs controls 0 LPS, 48 hours: 256.5 (171.5-417.0)pg/ml vs 6.5 (2.0-16.0)pg/ml, p=0.006 
c=patients vs controls 0 LPS, 72 hours: 210.5 (138-427)pg/rnl vs 0.5 (0-7)pg/ml, p=0.005 
d=patients vs controls 5 LPS, 24 hours: 875 (675-1355)pg/rnl vs 515 (440-600)pg/ml, p=0.028 
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The IL-la protein levels for the individual controls and patients are shown in Figure 6.13. 
The protein secreted from all subjects peaked at 24 hours as in the time course study, 
however, the amount of protein produced varied in each case. 
Figure 6.14 shows the median IL-la protein levels m controls and patients 
separated according to whether the cells were unstimulated or stimulated with LPS (C0 vs 
P0 and C5 vs P\ The IL-la protein levels were significantly increased in the unstimulated 
patients (P0) compared to the unstimulated controls (C0) at the following time points. 
Values are median (interquartile range): 24 hours: 193.5 (127.5-363.5) pg/ml vs 1.0 (0.0-
3.0) pg/ml, p=0.005; 48 hours: 256.5 (171.5-417.0) pg/ml vs 6.5 (2.0-16.0) pg/ml, p=0.006; 
72 hours: 210.5 (138-427) pg/ml vs 0.5 (0-7) pg/ml, p=0.005. The IL-l a protein level was 
also significantly increased in the stimulated patients (P5) compared to the stimulated 
controls (C5) at 24 hours. Values are median (interquartile range): 875 (675-1355) pg/ml vs 
515(440-600) pg/ml, p=0.028. No other significant differences in protein levels were 
found. 
C0= unstimulated controls 
P0= unstimulated patients 
C5= stimulated controls 
P5= stimulated patients 
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Figure 6.13: IL-l alpha protein secreted from PBMCs cultured at lx106 cells per ml and stimulated with 0-
Sug/ml LPS for 0-72 hours in controls and patients with acute pancreatitis 
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Figure 6.14: Median IL-l alpha protein secreted from PBMCs cultured at lx106 cells per ml for 0-72 hours in 
controls and patients with acute pancreatitis separated according to whether the PBMCs were unstimulated or 
stimulated with 5ug/ml LPS 
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6.2.2 lnterleukin-1 beta protein 
6.2.2.1 Inter/eukin-1 beta time course experime11t 
The 120 hour time course experiment showed that the peak IL-l P protein secretion 
occurred at 24 hours (Figure 6.15). 
6.2.2.2 Interleukin-1beta protein experime11t 
The most significant results in the polymorphism studies of the IL-l B gene were 
obtained from the Alu I polymorphism. The 2,2 genotype was found to be significantly 
decreased in patients compared to controls (9.7% vs 19.5%, x2=5.60, p=O.Ol8, Pc=0.036). 
"Hypothesis: the 2,2 genotype of the IL-JB Alu I polymorphism may be associated with 
susceptibility to acute pancreatitis." 
Patients with 1,1 and 2,2 genotypes were recalled for this study and the amount of 
IL-lP protein secreted from their PBMCs stimulated with 0-5J.tg/ml LPS for 0-72 hours 
was compared with IL-l P secreted from PBMCs taken from healthy controls. The 
genotypes, protein levels (individual and median) stimulated with 0 and 5J.tg/ml LPS for 0-
72 hours in controls and patients are shown in Tables 6.21A and 6.2IB respectively. The 
IL-lP protein levels for the individual controls and patients are shown in Figure 6.16. The 
protein secreted from all subjects peaked at 24 hours as in the time course study, however, 
the amount of protein produced varied in each case. 
Figure 6.17 shows the median IL-l P protein levels in controls and patients 
separated according to whether the cells were unstimulated or stimulated with LPS (C0 vs 
C0= unstimulated controls 
C5= stimulated controls 
P0= unstimulated patients 
P5= stimulated patients 
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Figure 6.15: llr 1 beta protein secreted from PBMCs cultured at lx106 cells per ml and stimulated with Sug/ml 
LPS for 0-120 hours 
1- 5uglm1 LPS I 
0 24 48 72 96 120 
Time (hours) 
236 
Table 6.21A: IL-lfi protein (pg/ml) secreted by PBMCs cultured at lx106 cells per ml 
and stimulated with 0-5J.lg/ml LPS for 0-72 hours in controls (C0 and C5) 
Time (hours) Gff 0 24 48 72 0 24 48 72 
LPS (J.Lg/ml) 0 0 0 0 s s s s 
Control I 2,2 10 0 16 7 0 4200 3760 3580 
Control2 1,1 14 13 21 11 9 5150 4780 4410 
Control3 1,1 15 11 13 14 20 3430 3320 2990 
Control4 1,1 5 681 605 614 2 5780 5470 5250 
ControlS 1,1 15 0 9 2 9 3440 3250 2650 
Control6 1,2 8 5 11 0 7 4300 3340 3070 
Control7 2,2 3 6 11 2 6 6180 5870 5610 
ControlS 1,1 10 84 108 102 19 10190 9350 9040 
Control9 1,1 0 53 36 43 2 4260 3770 3700 
ControiiO 1,2 I 14 13 15 2 3070 2990 2780 
n 10 10 10 10 10 10 10 10 
Median 9 12 14.5 12.5 6.5 4280 3765 3640 
Range 0-15 0-681 9-605 0-614 0-20 3070- 2990- 2650-
10190 9350 9040 
i.q.r. 3-14 5-53 11-36 2-43 2-9 3440- 3320- 2990-
5780 5470 5250 
Table 6.21B: IL-lfi protein (pg/ml) secreted byPBMCs cultured at lx106 cells per ml 
and stimulated with 0-5J.lg/ml LPS for 0-72 hours in patients with acute pancreatitis 
(P0 and P5) 
Time (hours) Gff 0 24 48 72 0 24 48 72 
LPS (J.Lg/ml) 0 0 0 0 s s s s 
Patient I 2,2 2 507 508 442 2 3040 2740 2460 
Patient 2 2,2 2 598 593 608 3 4780 4770 4240 
Patient 3 2,2 0 728 647 483 I 4860 3560 2510 
Patient 4 1,1 0 782 1080 771 0 4090 3920 3880 
PatientS 1,1 0 1032 1253 931 0 4680 4010 3630 
Patient 6 1,1 0 433 570 422 0 2570 2030 1720 
n 6 6 6 6 6 6 6 6 
Median o• 663b 620° 545.5d 0.5" 4385 3740 3070 
Range 0-2 433- 508- 422- 0-3 2570- 2030- 1720-
1032 1253 931 4860 4770 4240 
i.q.r. 0-2 507- 570- 442- 0-2 3040- 2740- 2460-
782 1080 771 4780 4010 3880 
G/T= genotype 
i.q.r. = interquartile range 
• =patients vs controls 0 LPS, 0 hours: 0 (0-2)pg/ml vs 9 (3-14)pg/ml, p=0.010 
b=patients vs controls 0 LPS, 24 hours: 663 (507-782)pg/ml vs 12 (5-53)pg/ml, p=0.004 
c =patients vs controls 0 LPS, 48 hours: 620 (570-1080)pg/ml vs 14.5 (11-36)pg/ml, p=0.004 
d =patients vs controls 0 LPS, 72 hours: 545.5 (442-77l)pg/ml vs 12.5 (2-43)pg/ml, p=0.006 
• =patients vs controls 5 LPS, 0 hours: 0.5 (0-2)pg/ml vs 6.5 (2-9)pg/ml, p=0.024 
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Figure 6.16: IL-lbeta protein secreted from PBMCs cultured at lx106 cells per ml and stimulated with 0-Sug/ml 
LPS for 0-72 hours in controls and patients with acute pancreatitis 
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Figure 6.17: Median IL-l beta protein secreted from PBMCs cultured at lx106 cells per ml for 0-72 hours in 
controls and patients with acute pancreatitis separated according to whether the PBMCs were unstimulated or 
stimulated with Sug/ml LPS 
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The IL-l~ protein levels were significantly increased in the unstimulated patients (P0) 
compared to the unstimulated controls (C0) at the following time points. Values are median 
(interquartile range): 24 hours: 663 (507-782) pg/ml vs 12 (5-53) pg/ml, p=0.004; 48 
hours: 620 (570-1080) pg/ml vs 14.5 (11-36) pg/ml, p=0.004; 72 hours: 545.5 (442-771) 
pg/ml vs 12.5 (2-43) pg/ml, p=0.006. The IL-l~ protein level was significantly decreased 
in the unstimulated patients (P0) compared to the unstimulated controls (C~ at 0 hours: 0 
(0-2) pg/ml vs 9 (3-14) pg/ml, p=O.OIO. The IL-l~ protein level was also significantly 
decreased in the stimulated patients (P5) compared to stimulated controls (C5) at 0 hours: 
0.5 (0-2) pg/ml vs 6.5 (2-9) pg/ml, p=0.024. No other significant differences in protein 
levels were found. 
In order to determine whether particular alleles corresponded to protein levels, the 
subjects were separated according to whether their genotypes contained allele I ( l, l and 
1,2) or allele 2 (2,2 and 1,2). The data are shown in Tables 6.21C and 6.21D. Figure 6.18 
shows the median IL-l~ protein levels in subjects with allele I and subjects with allele 2 
separated according to whether the cells were unstimulated or stimulated with LPS (A 1° vs 
A2° and A 15 vs A25). No significant differences in IL-l~ protein secretion were found 
between subjects with allele I or allele 2 at any time point for unstimulated or stimulated 
cells. 
A I 0= unstimulated subjects with allele I 
Al 5= stimulated subjects with allele I 
A2°= unstimulated subjects with allele 2 
A25= stimulated subjects with allele 2 
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Table 6.21C: IL-113 protein (pglml) secreted by PBMCs cultured at lx106 cells per mJ 
and stimulated with 0-SJ.Lg/ml LPS for 0-72 hours from subjects with allele 1 (A1 ° and 
A1) 
Time (hours) GIT 0 24 48 72 0 24 48 72 
LPS (Jig/ml) 0 0 0 0 5 5 5 5 
Subject 1 1,1 12 1033 2354 4210 93 14900 32860 26240 
Subject 2 1,1 7 304 305 311 63 10140 16230 12320 
Subject 3 1,1 97 2480 1562 813 118 20290 28790 27430 
Subject 4 1,1 7 464 488 1263 125 10850 22820 19640 
Subject 5 1,1 150 1321 3727 4610 173 9950 15340 12000 
Subject 6 1,1 0 1735 2864 3322 217 7080 9820 8820 
Subject 7 1,2 8 5 11 0 7 4300 3340 3070 
Subject 8 1,2 1 14 13 15 2 3070 2990 2780 
Subject 9 1,1 0 782 1080 771 0 4090 3920 3880 
Subject 10 1,1 0 433 570 422 0 2570 2030 1720 
Subject 11 I, I 0 1032 1253 931 0 4680 4010 3630 
n 11 11 11 11 11 11 11 11 
Median 7 782 1080 813 63 7080 9820 8820 
Range 0-150 5-2480 11- 0-4610 0-217 2570- 2030- 1720-
3727 20290 32860 27430 
l.q.r. 0-12 304- 305- 311- 0-125 4090- 3340- 3070-
1321 2354 3322 10850 22820 19640 
Table 6.210: IL-113 protein (pglml) secreted by PBMCs cultured at lx106 cells per ml 
and stimulated with 0-SJ.Lg/ml LPS for 0-72 hours from subjects with allele 2 (A2° and 
A2) 
Time (hours) GIT 0 24 48 72 0 24 48 72 
LPS (J!g/ml) 0 0 0 0 5 5 5 5 
Subject 1 2,2 396 3108 3789 3836 354 12310 14190 13960 
Subject 2 2,2 3 6 11 2 6 6180 5870 5610 
Subject3 1,2 8 5 11 0 7 4300 3340 3070 
Subject4 1,2 1 14 13 15 2 3070 2990 2780 
Subject 5 2,2 2 598 593 608 3 4780 4770 4240 
Subject 6 2,2 2 507 508 442 2 3040 2740 2460 
Subject7 2,2 0 728 647 483 1 4860 3560 2510 
n 7 7 7 7 7 7 7 7 
Median 2 507 508 442 3 4780 3560 3070 
Range 0-396 5-3108 11- 0-3836 1-354 3040- 2740- 2460-
3789 12310 14190 13960 
i.q.r. 1-8 6-728 11-647 2-608 2-7 3070- 2990- 2510-
6180 5870 5610 
GIT= genotype 
i.q.r. = interquartile range 
No significant differences in IL-l p protein secretion were found when unstimulated and 
stimulated cells from subjects with allele 1 were compared with those from subjects with 
allele 2 at any time point. 
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Figure 6.18: Median IL-l beta protein secreted from PBMCs cultured at lx106 cells per ml in subjects with allele 
1 and allele 2 separated according to whether the PBMCs were unstimulated or stimulated with Suglml LPS 
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6.2.3 Interleukin-1 receptor antagonist protein 
6.2.3.1 lnterleukin-1 receptor a11tagonist time course experiment 
The 120 hour time course experiment showed that the peak IL-l ra protein secretion 
occurred at 48 hours (Figure 6.19) 
6.2.3.2 lnterleukin-1 receptor antagonist protein experiment 
The most significant results in the polymorphism studies of the IL-l RN gene were 
obtained from the VNTR86 polymorphism. Allele 1 was significantly increased in the 
severe group of patients compared to controls (81.9% vs 63.0%, x2=9.38, p=0.002; 
Pc=0.004) and in the idiopathic patients compared to controls (82.4% vs 63.0%, x2=9.33, 
p=0.002; Pc=0.004). 
"Hypothesis: allele 1 may be associated with severity of acute pancreatitis and also 
susceptibility to idiopathic acute pancreatitis." 
Patients with idiopathic disease with the I, I and I ,2 genotype were recalled for this 
study and the amount of IL-lra protein secreted from their PBMCs stimulated with 0-
51J.g/ml LPS for 0-72 hours was compared with IL-l ra secreted from PBMCs taken from 
healthy controls. The genotypes, protein levels (individual and median) stimulated with 0 
and 51J.g/ml LPS for 0-72 hours in controls and patients are shown in Tables 6.22A and 
6.22B respectively. The protein levels for the individual controls and patients are shown in 
Figure 6.20. The protein secreted from all subjects peaked at 48 hours as in the time course 
study, however, the amount of protein produced varied in each case. 
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Figure 6.19: IL-lra protein secreted from PBMCs cultured at lx106 cells per ml and stimulated with Sug/ml LPS 
for 0-120 hours 
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Table 6.22A: IL-lra protein (pglml) secreted by PBMCs cultured at lx106 cells per 
ml and stimulated with 0-SJ.lg/ml LPS for 0-72 hours in controls (C0 and Cs) 
Time (hours) Grr 0 24 48 72 0 24 48 72 
LPS (j.Lg/ml) 0 0 0 0 5 5 5 5 
Control I 1,2 396 3108 3789 3836 354 12310 14190 13960 
Control2 1,1 12 1033 2354 4210 93 14900 32860 26240 
Control3 1,2 7 304 305 311 63 10140 16230 12320 
Control4 1,2 97 2480 1562 813 118 20290 28790 27430 
ControlS I, I 7 464 488 1263 125 10850 22820 19640 
Control6 1,1 52 637 587 1035 86 12110 21520 16330 
Contro17 1,1 149 759 1137 2430 112 13890 18640 17170 
ControlS 1,2 150 1321 3727 4610 173 9950 15340 12000 
Control9 I, I 0 1735 2864 3322 217 7080 9820 8820 
Control tO I, I 108 164 159 345 44 7000 10440 9590 
n 10 10 10 10 10 10 10 10 
Median 74.5 896 1349.5 1846.5 115 11480 17435 15145 
Range 0-396 164- 159- 311- 44-354 7000- 9820- 8820-
3108 3789 4610 20290 32860 27430 
i.q.r. 7-149 464- 488- 813- 86-173 9950- 14190- 12000-
1735 2864 3836 13890 22820 19640 
Table 6.22B: IL-lra protein (pglml) secreted by PBMCs cultured at lx106 cells per ml 
and stimulated with 0-StJ.g/ml LPS for 0-72 hours in patients with acute pancreatitis 
(P0 and Ps) 
Time (hours) Gff 0 24 48 72 0 24 48 72 
LPS (j.Lg/ml) 0 0 0 0 5 5 5 5 
Patient 1 I, I 0 241 288 344 0 2750 3140 2000 
Patient 2 I, I 397 984 1373 1342 203 6610 11040 8870 
Patient 3 1, I 17 5539 8092 6547 0 14480 24960 20520 
Patient4 I, I 237 1713 2780 2256 0 1140 3170 2520 
Patient 5 I, I 21 209 268 293 16 20010 24340 19330 
Patient 6 1,2 378 4802 6028 6079 385 19690 23860 21220 
Patient 7 1,2 215 7766 10890 12010 0 20910 37820 33210 
Patient 8 1,2 28 507 703 595 18 11730 15030 13130 
n 8 8 8 8 8 8 8 8 
Median 121.5 1348.5 2076.5 1799 8 13105 19445 16230 
Range 0-397 209- 268- 293- 0-385 1140- 3140- 2000-
7766 10890 12010 20910 37820 33210 
i.q.r. 19- 374- 495.5- 469.5- 0- 4680- 7105- 5695-
307.5 5170.5 7060 6313 110.5 19850 24650 20870 
G/T= genotype 
i.q.r.= interquartile range 
There were no significant differences in IL-lra protein secretion between controls and 
patients at any time point for unstimulated or stimulated cells. 
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Figure 6.20: IL-lra protein secreted from PBMCs cultured at lx106 cells per ml and stimulated with 0-Sug/ml 
LPS for 0-72 hours in controls and patients with acute pancreatitis 
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Figure 6.21 shows the median IL-1ra protein levels separated according to whether the cells 
were unstimulated or stimulated with LPS (C0 vs P0 and C5 vs P5). No significant 
differences in protein levels were found between unstimulated cells in controls (C0) and 
patients (P0) or between stimulated cells in controls (C5) and patients (P5). 
In order to determine whether particular alleles corresponded to protein levels, the 
subjects were separated according to whether their genotypes contained allele I (I, I) and 
allele 2 (1 ,2). (The 2,2 genotype was rare and therefore subjects willing to take part in the 
study could not be found). The data are shown in Tables 6.22C and 6.220. Figure 6.22 
shows the median IL-lra protein levels in subjects with allele 1 and subjects with allele 2 
separated according to whether the cells were unstimulated or stimulated with LPS (A 1° vs 
A2° and A 15 vs A2\ No significant differences in IL-l ra protein secretion were found 
between subject groups with allele 1 or allele 2 at any time point for unstimulated cells or 
stimulated cells. 
C0= unstimulated controls 
C5= stimulated controls 
AI 0= unstimulated subjects with allele 1 
A2°= unstimulated subjects with allele 2 
P0= unstimulated patients 
P5= stimulated patients 
A 15= stimulated subjects with allele I 
A25= stimulated subjects with allele 2 
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Figure 6.21: Median IL-lra protein secreted from PBMCs cultured at lx106 cells per ml for 0-72 hours in 
controls and patients separated according to whether the PBMCs were unstimulated or stimulated with 5uglml 
LPS 
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Table 6.22C: IL-lra protein (pglml) secreted by PBMCs cultured at lx106 cells per ml 
and stimulated witb 0-SJJg/ml LPS for 0-72 boors from subjects wltb allele 1 (AI 0 and 
A15) 
Time (hours) Gff 0 24 48 72 0 24 48 72 
LPS(111lfml) 0 0 0 0 s s s s 
Subject 1 1,1 12 1033 2354 4210 93 14900 32860 26240 
Subject 2 1,1 7 464 488 1263 125 10850 22820 19640 
Subject3 I, I 52 637 587 1035 86 12110 21520 16330 
Subject 4 1,1 149 759 1137 2430 112 13890 18640 17170 
SubjectS 1,1 0 1735 2864 3322 217 7080 9820 8820 
Subject 6 1,1 108 164 159 345 44 7000 10440 9590 
Subject 7 1,1 0 241 288 344 0 2750 3140 2000 
Subject 8 1,1 397 984 1373 1342 203 6610 11040 8870 
Subject 9 I, 1 17 5539 8092 6547 0 14480 24960 20520 
Subject 10 1,1 237 1713 2780 2256 0 1140 3170 2520 
Subject 11 1,1 21 209 268 293 16 20010 24340 19330 
n 11 11 11 11 11 11 11 11 
Median 21 759 1137 1342 86 10850 18640 16330 
Range 0-397 164- 159- 293- 0-217 1140- 3140- 2000-
5539 8092 6547 20010 32860 26240 
i.q.r. 7-149 241- 288- 345- 0-125 6610- 9820- 8820-
1713 2780 3322 14480 24340 19640 
Table 6.22D: IL-lra protein (pglml) secreted by PBMCs cultured at lx106 cells per ml 
and stimulated witb 0-SJJg/ml LPS for 0-72 boors from subjects witb allele 2 (A2° and 
A25) 
Time (hours) Gff 0 24 48 72 0 24 48 72 
LPS(111lfml) 0 0 0 0 s s s s 
Subject 1 1,2 396 3108 3789 3836 354 12310 14190 13960 
Subject 2 1,2 7 304 305 311 63 10140 16230 12320 
Subject 3 1,2 97 2480 1562 813 118 20290 28790 27430 
Subject 4 1,2 150 1321 3727 4610 173 9950 15340 12000 
SubjectS 1,2 378 4802 6028 6079 385 19690 23860 21220 
Subject 6 1,2 215 7766 10890 12010 0 20910 37820 33210 
Subject 7 1,2 28 507 703 595 18 11730 15030 13130 
n 7 7 7 7 7 7 7 7 
Median 150 2480 3727 3836 118 12310 16230 13960 
Range 7-396 304- 305- 311- 0-385 9950- 14190- 12000-
7766 10890 12010 20910 37820 33210 
i.q.r. 28-378 507- 703- 595- 18-354 10140- 15030- 12320-
4802 6028 6079 20290 28790 27430 
GIT= genotype 
i.q.r.= interquartile range 
No significant differences in IL-lra protein secretion were found when unstimulated and 
stimulated cells from subjects with allele 1 were compared with those from subjects with 
allele 2 at any time point. 
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Figure 6.22: Median IL-lra protein secreted from PBMCs cultured at lx106 cells per ml for 0-72 hours in 
subjects with allele 1 and allele 2 separated according to whether the PBMCs were unstimulated or stimulated 
with Suglml LPS 
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Summary of the Interleukin-1 alpha, Interleukin-1 beta and lnterleukin-1 receptor 
antagonist protein protein studies 
Correlation of the (AC)n polymorphism witll IL-l aprotei11 levels. 
IL-l a. protein levels peaked at 24 hours in all subjects, but there was inter-
individual variation in the amount secreted. Comparison of the median IL-l a. protein levels 
between unstimulated patients (P0) and unstimulated controls (C0) showed that the levels 
were significantly increased in patients compared to controls. Significant differences in 
median IL-Ia. protein levels were found at 24 hours (193.5 (127.5-363.5) pg/ml vs 1.0 (0.0-
3.0) pg/ml, p=0.005), 48 hours (256.5 (171.5-417.0) pg/ml vs 6.5 (2.0-16.0) pg/ml, 
p=0.006) and at 72 hours (210.5 (138-427) pg/ml vs 0.5 (0-7) pg/ml, p=0.005). 
Comparison of the median IL-l a. protein levels between stimulated patients (Ps) and 
stimulated controls (Cs) showed that the levels were also increased in patients compared to 
controls, however, a significant difference was only found at 24 hours (875 (675-1355) 
pg/ml vs 515 (440-600) pg/ml, p=0.028). No genotype-protein correlation was performed 
for the (AC)n polymorphism of the IL-IA gene due to lack of subjects with the 2,4 
genotype. 
Correlation of the Alu 1 polymorphism witlllL-Jpproteill levels. 
IL-1P protein levels peaked at 24 hours in all subjects, but there was inter-
individual variation in the amount secreted. Comparison of the median IL-l p protein levels 
between unstimulated patients (PC) and unstimulated controls (C0) showed that the levels 
were significantly increased in patients compared to controls. Significant differences in 
median IL-IP protein were found at 24 hours (663 (507-782) pg/ml vs 12 (5-53) pg/ml, 
p=0.004), 48 hours (620 (570-1080) pg/ml vs 14.5 (11-36) pg/ml, p=0.004) and at 72 hours 
(545.5 (442-771) pg/ml vs 12.5 (2-43) pg/ml, p=0.006). Comparison of the median IL-l P 
protein levels between unstimulated patients (P0) and unstimulated controls (C0) at time 0 
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hours showed that the levels were significantly decreased in patients compared to controls: 
0(0-2) pg/ml vs 9(3-14) pg/ml, p=O.OlO). 
Comparison of the median IL-l p protein levels between stimulated patients (P5) 
and stimulated controls (C5) showed that the levels were decreased in patients compared to 
controls, however, a significant difference was only found at 0 hours (0.5 (0-2) pg/ml vs 
6.5 (2-9) pg/ml, p=0.024). No significant differences in the median IL-l P levels were 
found when the subjects were separated according to those with genotypes containing allele 
I or 2 (AI 0 vs A2° and Al 5 vs A25). 
Correlation of the VNTK6 polymorphism with IL-lra protein levels 
IL-l ra protein levels peaked at 48 hours in all subjects, but there was inter-
individual variation in the amount secreted. No significant differences were found when 
comparing the median IL-lra protein levels between unstimulated patients (P0) and 
unstimulated controls (C0) or between stimulated patients (P5) and stimulated controls (C5). 
No significant differences in the median IL-Ira levels were found when the subjects were 
separated according to those with genotypes containing allele 1 or 2 (A 1° vs A2° and A 15 
VS A25). 
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CHAPTER 7: GENERAL DISCUSSION 
This is the first genetic study to characterise the IL-l gene cluster in patients with 
acute pancreatitis and therefore the results can only be compared with other diseases in 
which the polymorphisms have been studied. Figure 7.1 illustrates a map of the IL-l gene 
cluster and IL-l receptor genes and summarises the results obtained from the thesis. 
Although many results were found, only the most important are discussed. Strong 
associations were found with polymorphisms in the IL-IRN gene (Msp I, VLP, VNTR86, 
Ssp I). Weak or no associations were found with polymorphisms in the IL-IRI (Pst I), IL-
IA ((AC)n, VNTR46) and IL-IB (Ava I, Alu /, Taq I) genes. The strong associations will be 
discussed first, followed by the weak associations. 
Interestingly, a study of polymorphisms in the genes for other pro-inflammatory 
TNFa (TNFa, TNFb, TNFc, TNF-308) and anti-inflammatory cytokines IL-l 0 (IL-l O.G, -
1117, -854, -627) on the same group of patients with acute pancreatitis showed no 
association with disease susceptibility or severity (Sargen et al, 2000). 
7.1 DNA Studies 
7.1.1 Genotype Analysis 
7.1.1.1 IL-lRN gene 
Msp I polymorphism 
The association of the 1,1 genotype and allele 1 (640bp) with severe patients 
suggests that the Msp I polymorphism may be a severity marker for acute pancreatitis. An 
association was also found between allele 1 and idiopathic patients. This implies that the 
polymorphism may also be a susceptibility marker for idiopathic acute pancreatitis and 
suggests that genetic heterogeneity exists within the disease. This supports studies that 
show genetic heterogeneity exists within hereditary pancreatitis (Ferec et al, 1999). 
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Figure 7.1: Map of the IL-l gene cluster and IL-l receptor genes with a summary of the results 
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To date, there have been no studies reporting an association of the Msp I polymorphism 
with disease or with functional protein levels. If allele 1 was found to correlate with low 
IL-l ra protein levels, 1, 1 homozygotes would have reduced IL-l ra protein compared to 
individuals with 1,2 or 2,2 genotypes and would therefore be more at risk of developing 
acute pancreatitis or a more severe form of the disease. 
Variable le11gt/1 polymorpl1ism 
The 2,2 genotype and allele 2 (1.45kb) were significantly increased in idiopathic 
patients compared to controls. These results suggest that the variable length polymorphism 
may be a susceptibility marker for acute pancreatitis and in particular idiopathic disease. 
The frequencies of the 2,2 genotype and allele 2 were also significantly increased in severe 
group compared to controls implying that the polymorphism may also be a marker of 
disease severity. As yet, there have been no studies reporting an association of the variable 
length polymorphism with disease or with functional protein levels. The results suggest 
that allele 2 may be associated with decreased IL-l ra production since this allele and the 
2,2 genotype were significantly increased in patients with acute pancreatitis and in patients 
with severe disease. 
VNTR86 polymorphism 
The VNTR86 polymorphism is the most extensively studied polymorphism of the 
IL-lRN gene and of the IL-l gene cluster. In this study, the 1,1 genotype and allele l (4 x 
86bp repeats) were significantly increased in the severe group compared to controls 
implying that this polymorphism may act as a severity marker for acute pancreatitis. The 
1,1 genotype and allele I were also significantly increased in the idiopathic group 
compared to controls. These observations suggest that the VNTR86 polymorphism may be a 
susceptibility marker for idiopathic acute pancreatitis. 
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To date, only one other group based in Edinburgh has studied the VNTR86 polymorphism 
in patients with acute pancreatitis. In their study, no association was found between the 
genotype or allele frequencies suggesting that this polymorphism is neither a marker of 
susceptibility or severity for the disease (Powell et at, 2001). The possible reasons for the 
difference in results obtained between the two studies are discussed later. 
Studies regarding an association between this polymorphism and functional IL-l ra 
protein levels are conflicting. One study suggests that allele 2 (2 x 86bp repeats) correlates 
with low IL-lra protein level. The 86bp repeat sequence is comprised of 3 protein-binding 
sites: an a-interferon silencer A, a ~-interferon silencer B and an acute phase response 
element. The activity of the enhancer sequences and hence the transcription of the IL-l RN 
gene may depend on the number of tandem copies present in the gene - the less 86bp 
repeats, the less protein-binding sites and the less IL-l ra protein is produced. Allele 2 
homozygotes with 2 x 86bp repeats would therefore have reduced levels of IL-l ra protein 
compared to allele l homozygotes with 4 x 86bp repeats (Tarlow et al, 1993). Interestingly 
a similar VNTR polymorphism in the IL-IA gene which consists of 46bp repeating units 
has been found to have an inverse correlation with IL-la production- the more repeats the 
less IL-l a is produced (Bailly et al, 1996). In contrast, a subsequent study has reported that 
allele 2 (2 x 86bp repeats) corresponds to high IL-lra protein levels (Danis et al, 1995). If 
allele 2 corresponds to high IL-l ra secretion as suggested by Danis et al, then allele l may 
correspond to low IL-l ra secretion. This hypothesis has been supported by data from 
Mandrup-Poulsen et al, who found that the 1,1 genotype was associated with low plasma 
IL-l ra levels in type l diabetes (Mandrup-Poulsen et al, 1994). 
The results obtained in this thesis support the studies by Danis and Mandrup-
Poulsen and imply that allele l (4 x 86bp repeats) is associated with reduced IL-lra protein 
levels. l, l homozygotes would have lower IL-lra levels compared to individuals with other 
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genotypes and are therefore at greater risk of developing acute pancreatitis or a more severe 
form of the disease. 
There have been many studies linking the VNTR86 polymorphism with disease and 
most have reported an association with allele 2. For example, increased frequency of this 
allele has been associated with susceptibility to ulcerative colitis (Mansfield et al, 1994) 
and multiple sclerosis (Crusius et al, 1995) and with severity of alopecia areata (Tarlow et 
al, 1994) and diabetic nephropathy (Blakemore et al, 1996). In contrast, increased 
frequency of allele 1 has been associated with susceptibility to hepatic fibrosis in alcoholic 
liver disease (Takamatsu et al, 1998), asthma in black South Africans (Pillay et al, 2000) 
and with severity and susceptibility to multiple sclerosis (Sciacca et al, 1999). For other 
disease associations with this polymorphism see Tables 4.2A-C. 
Ssp I polymorphism 
The association between the 1,1 genotype and allele I (379bp) in severe patients 
implies that the Ssp I polymorphism may be a severity marker for acute pancreatitis. 
Furthermore, an association was also found between allele 1 and the idiopathic patients. 
This suggests that the polymorphism may be a susceptibility marker for idiopathic acute 
pancreatitis and suggests genetic heterogeneity within the disease. To date, there have been 
no studies reporting an association of the Ssp I polymorphism with disease or with 
functional protein levels. As with the Msp I polymorphism, if allele 1 was found to 
correspond with low IL-l ra protein levels, then 1,1 homozygotes would have reduced IL-
lra protein compared to individuals with 1,2 or 2,2 genotypes and would therefore be more 
at risk of developing acute pancreatitis or a more severe form of the disease. It is 
interesting to note that all 4 of the polymorphisms studied in the IL-IRN gene confer 
susceptibility to idiopathic acute pancreatitis and with severity of the disease. 
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7.1.1.2 IL-lRI, IL-IA and IL-lB genes 
Pst I Polymorphism 
An association was found between the allele frequencies of the Pst I polymorphism 
in the IL-1RI gene and acute pancreatitis, but not the genotype frequencies. Allele 2 (97bp, 
252bp) was significantly increased in patients compared to controls and in patients with 
gallstone disease compared to controls. This suggests that allele 2 may be a marker of 
disease susceptibility to acute pancreatitis and in particular patients with gallstone disease. 
The lack of an association with idiopathic or alcoholic disease again implies that there may 
be genetic heterogeneity within acute pancreatitis. Allele 2 was also significantly increased 
in the OFS~ 1 group compared to controls, implying that the Pst I polymorphism may also 
be a marker of disease severity. However, since there was no association with the 
OFS~,3,or 4 groups that are progressively more severe forms of the disease, this 
association with disease severity is questionable. The lack of an association between the 
other organ failure score groups may have been due to the lower number of patients within 
these groups that meant the figures could not reach significance. 
The Pst I polymorphism which was originally identified as a restriction fragment 
length polymorphism (RFLP) consisting of 2 fragments: a more common fragment (1.2kb) 
and a less common fragment (3.2kb) (Pociot et al, 1992) has been associated with 
susceptibility to IDDM in both Dutch (Pociot et al, 1994; Bergholdt et al, 1995) and British 
(Metcalfe et a!, 1996) populations. The studies involving the Dutch population showed an 
association with genotype frequencies only, whereas the British study showed an 
association with both the Pst I genotype and allele frequencies. The 1,1 genotype and allele 
1 (362bp) were significantly increased in patients compared to controls while the 2,2 
genotype and allele 2 (256bp, I 06bp) were significantly decreased between the same 2 
groups. These trends in allele frequency are opposite to those found in this study for acute 
pancreatitis and may be due to the fact that IDDM is an auto immune disease whereas acute 
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pancreatitis is an inflammatory disease. This suggests that the 2 alleles may act differently 
according to the disease pathogenesis. 
Since the Pst I polymorphism is located in the promoter region of the gene, the 
T ~c nucleotide substitution may affect the transcription. If allele 2 corresponded with 
increased IL-l RI expression it would cause an increase in the activity of IL-l resulting in 
an augmented inflammatory response. Conversely, if allele 2 corresponded with decreased 
IL-lRI expression it would cause a decrease in IL-l activity resulting in an attenuated 
inflammatory response. There is no evidence to date to suggest that this polymorphism has 
functional significance; however, it may be in linkage disequilibrium with another 
polymorphism in the IL-lRI gene that has not yet been identified. The haplotype analysis 
performed in this study suggests that the Pst I polymorphism is in linkage disequilibrium 
with other genes in the IL-l gene complex. The functional effect of this polymorphism 
could be tested using reporter gene assays similar to those used in the study to determine 
the effect of the -174 (G~C) Nlaiii polymorphism in the promoter region of the IL-6 gene 
(Fishman et al, 1998). 
(AC)11 repeat polymorphism 
The 2,4 genotype of this polymorphism was significantly increased in the alcoholic 
group compared to controls and significantly decreased in the gallstone group compared to 
the alcoholic group. This suggests that the (AC)n repeat polymorphism may act as a marker 
for disease susceptibility to acute pancreatitis in particular alcoholic disease. It may also 
determine aetiologies most at risk whereby gallstone patients with 2,4 genotype are at less 
risk than alcoholic patients with 2,4 genotype. In addition, the I ,2 genotype was 
significantly increased in OFS~2 group compared to controls and in the OFS~2 group 
compared to the OFS=O group. This suggests that the (AC)n polymorphism may act also 
act as a marker of severity for acute pancreatitis, however, since no significance was 
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obtained for OFS~3 or OFS~4 groups which are more severe forms of the disease, the link 
between severity is doubtful. Again, this may be due to the lower number of subjects 
within these groups. 
Lack of an association was found between this (AC)n repeat polymorphism 
polymorphism and rheumatoid arthritis (Gomolka et a!, 1995), juvenile chronic arthritis 
(Donn et a!, 1999) and Tuberculosis (Bellamy et a!, 1998). Polymorphisms located within 
introns of a gene can still affect protein levels (Beenken et al, 1991 ), however, as yet there 
have been no reports of an association between this polymorphism and functional IL-Ia 
protein levels. Even if this dinucleotide repeat is not functional itself, the polymorphism 
may be in linkage disequilibrium with other polymorphisms in the gene. This is supported 
by the results from this thesis that imply the (AC)n repeat polymorphism is strongly linked 
with the VNTR46 polymorphism in intron 6 and with polymorphisms in other genes of the 
IL-l cluster. 
VNTR46 polymorphism 
No significant differences in genotype or allele frequencies were found between 
controls, patients or patient subgroups for the VNTR46 polymorphism suggesting that it is 
not a susceptibility or severity marker for acute pancreatitis. The involvement of this 
polymorphism in acute pancreatitis should not be totally disregarded, however, because as 
previously discussed it appears to be in linkage disequilibrium with the (AC)n repeat 
polymorphism that may be a susceptibility and/or severity marker for the disease. 
Lack of an association was also found between this polymorphism and rheumatoid 
arthritis (Bailly et al, 1995). Each 46bp repeat contains 3 potential transcription factor-
binding sites: SPI, viral enhancer element and glucocorticoid-responsive element (GRE) 
(Bailly et al, 1993). The presence of these transcription factor-binding sites implies that the 
polymorphism may be involved in IL-1a gene regulation. A recent study has shown that 
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there was an inverse relationship between the number of repeats and IL-la production, 
suggesting that the polymorphism has a negative regulatory role on IL-l a gene expression 
(Bailly et al, 1996). 
Ava I polymorphism 
The lack of an association between this polymorphism and patients with acute 
pancreatitis suggests that Ava I polymorphism is not associated with susceptibility to or 
severity of the disease. However, it may be in linkage disequilibrium with another 
polymorphism that is associated with the disease. fu fact the haplotype analysis performed 
in this study suggests that this polymorphism is strongly linked with the Alu I and Taq I 
polymorphisms of the IL-l B gene and with polymorphisms in other genes of the IL-l gene 
cluster. 
The Ava I polymorphism is located in the promoter region of the gene and may 
therefore affect transcription. This has been confirmed by a recent study which showed that 
allele 2 (717bp) was associated with high IL-lP secretion (Nemetz et al, 1999). The 
polymorphism has also been linked with a number of diseases. fucreased carriage of allele 
2 has been associated with susceptibility to alcoholic liver disease (Takamatsu et al, 2000) 
and gastric cancer (El-Omar et al, 2000) and with severity of ulcerative colitis, Crohn's 
disease (Nemetz et al, 1999) and rheumatoid arthritis (Di Giovine et al, 1992). For other 
associations see Tables 4.2A-C. 
Alu I polymorphism 
The association of the 2,2 genotype with patients implies that this polymorphism 
may be a susceptibility marker for acute pancreatitis. No significant differences in genotype 
or allele frequencies were found between the groups when they were separated according to 
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severity, organ failure scores or aetiology, suggesting that the Alu I polymorphism is not a 
susceptibility marker for a particular aetiology or a severity marker for acute pancreatitis. 
A positive association has recently been found between this polymorphism and 
gastric cancer (El-Omar et al, 2000). The Alu I polymorphism is also located within the 
promoter region of the IL-l B gene and therefore may affect the expression of the gene, 
however, to date, no studies have demonstrated an association between this polymorphism 
and functional protein levels. Without these functional studies, it is only possible to 
speculate as to the effect of the Alu I polymorphism. If for example, allele 2 was found to 
be associated with low IL-IB protein levels, then 2,2 homozygotes would have low IL-IB 
levels and would be "protected". Since this low IL-l 8 genotype was decreased in patients 
compared to controls, the patients would be more susceptible to inflammation. 
Taq I polymorphism 
The Taq I polymorphism is the most extensively studied polymorphism of the IL-
18 gene. The 1,2 genotype was significantly increased in the OFS~2 group compared to 
controls, which implies that the polymorphism may be a susceptibility marker for acute 
pancreatitis. However, since no association was found between patients and controls or 
between different aetiological groups and controls, this link with susceptibility is unlikely. 
Furthermore, the same genotype was significantly increased in the OFS~ 1 group compared 
to the OFS=O group and was even more significantly increased in the OFS~2 group 
compared to the OFS=O group suggesting that the polymorphism may be a marker of 
severity. However, since there was no association with the OFS~3 or OFS~4 groups that 
are progressively more severe forms of the disease, this association with disease severity is 
questionable and probably represents a spurious result. As previously mentioned, the lack 
of an association between the other organ failure score groups may be due to the lower 
number of subjects within these groups. 
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Allele 2 (740bp) of the Taq I polymorphism of the ll..-1B gene has been associated with 
high ll..-113 protein production (Pociot et al, 1992). The Taq I polymorphism has been 
studied in a variety of diseases. Increased carriage of allele 2 has been associated with 
susceptibility to myasthenia gravis (Huang et al, 1998) and pancreatic cancer (Barber et al, 
2000) and with the severity of periodontitis (Galbraith et al, 1999a) and multiple sclerosis 
(Kantarci et al, 2000). For other associations see Tables 4.2A-C. 
Variability between different genetic studies 
Many of the studies involving the ll..-1 gene polymorphisms are not reproducible in 
different ethnic populations or within ethnic populations and often provide conflicting 
results. For example, the Ava I polymorphism was associated with rheumatoid arthritis in a 
British population (Di Giovine et al, 1992) but not in a French population (Cantagrel et al, 
1999). The Taq I polymorphism polymorphism was associated with multiple sclerosis in an 
American population (Kantarci et al, 2000) but not in a Dutch population (Schrijver et al, 
1999). The VNTR86 polymorphism was associated with diabetic nephropathy in a British 
(Biakemore et al, 1996) but not in Danish population (Tamow et al, 1997). Furthermore, 
Crusius et al found an association with multiple sclerosis in a Dutch population (Crusius et 
al, 1995) that could not be replicated by Schrijver et al in a similar cohort (Schrijver et al 
1999). 
A similar difference in result was obtained for the VNTR86 and Taq I 
polymorphisms in acute pancreatitis (Powell et al, 2001) compared to this study. The 
reasons for no (or weak) associations may be related to a number of factors. The 
epidemiology of acute pancreatitis is known to vary between different geographical regions 
within the same country, therefore it might be expected that different subjects (controls and 
patients) taken from opposite ends of Britain might produce different results. This may 
represent a true difference in incidence or may be due to better diagnostic procedures in a 
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particular area of the country. Furthermore, population stratification may occur in areas 
such as Cornwall and Devon whereby because of the high percentage of Celtic population, 
the subjects do not represent a random selection. Also, the defining criteria that are to a 
certain extent subjective in nature may not be consistent with those used in this study. It is 
evident that the proportions of patients used in this thesis were different to those reported 
in other studies: 58% gallstones (80/137), 26% idiopathic (36/137) and 15% alcoholics 
(21/137) as compared to 40% gallstones, 30% idiopathic and 20% alcoholics reported by 
Lankisch et al (Lankisch et al, 1997). Another explanation is that there are different 
numbers of subjects in the cohorts. A small cohort of subjects might have a borderline non-
significant value that would become significant in a larger cohort. Finally, there appears to 
be no universal method for correction ofp values. 
Whilst acknowledging that standards were not used on a day to day basis thus 
introducing the possibility of errors and differences in results between studies, in the case 
of the restriction digestion reactions, there were always samples which showed the 3 
extremes of a restriction digestion reaction on a gel to show that the enzyme was working 
adequately (i.e. homozygotes for both alleles and heterozygotes). The optimum conditions 
for each enzyme were determined on test samples prior to the experiments on subjects and 
if on a particular day all subjects appeared to be heterozygotes, suggesting only partial 
digestion by the enzyme, the experiment was repeated. The allele frequencies of the 
polymorphisms studied in the thesis obeyed the Hardy-Weinberg equilibrium showing that 
the polymorphisms conformed to normal distribution within the population. Furthermore, 
the control allele frequencies for the studies involving the restriction digestion reactions 
were similar to those reported in other studies involving Caucasian controls. For example, 
in this Ava I study the allele frequencies were: A1=62.2%, A2=37.8% as compared with 
A1=59.0%, A2=41.0% (Di Giovine et al, 1992), whilst in this Taq I study the allele 
frequencies were: Al= 83.2%, A2=16.8% as compared with Al=79.8%, A2=20.2% 
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(Loughrey et al, 1998). The control allele frequencies of other polymorphisms such as the 
VNTR86 and VLP were also similar to those reported in other studies. For example, in this 
VNTR86 study the allele frequencies were: Al=63.0%, A2=33.0%, A3=4.0% as compared 
with Al=68.0%, A2=28.0%, A3+A4=4.0% (Danis et al, 1994) and in this VLP study the 
allele frequencies were: A 1 =4.1 %, A2=66.1 %, A3=29.8% as compared with A I =4.0%, 
A2=65.0%, A3=30.0% (Steinkasserer et al, 1991). 
7.1.2 Haplotype Analysis 
Recent haplotype studies in other diseases have shown that it is not simply a matter 
of correlating a particular polymorphism with certain protein level, since polymorphisms of 
the different genes within the IL-l gene complex are often linked and coordinately regulate 
each others expression. Linkage disequilibrium is expected since the genes of the IL-l 
cluster occupy a relatively short distance ( 430kb) on the long arm of chromosome 2. Cox et 
al, have recently shown that some of the IL-l gene cluster polymorphisms are in significant 
linkage disequilibrium, indicating that specific groups of alleles are inherited together. The 
disequilibrium was strong for 3 markers in the IL-IA gene (222/223, gz5/gz6 and Ncoi889) 
but was weaker in the IL-lB gene (Taq f 3953 and Ava /"511 ) (Cox et a!, 1998). A study by 
Guasch et al, also showed weak disequilibrium within the IL-lB gene between Taq I and 
Alu I (Guasch et al, 1996). Two studies have shown that the linkage between 
polymorphisms in the IL-l RN gene is very strong (Clay et al, 1996; Guasch et al, 1996). 
Several different haplotype patterns have been identified and linked with disease. 
Recently, a haplotype consisting of Ncoi889 (A2t -Taqt3953 (A2t has been associated 
with susceptibility to severe adult periodontitis. It was named the "periodontitis-associated 
genotype (P AG) or "periodontitis susceptibility trait (PST)" (Kornman et al, 1997; Gore et 
al, 1998) and was found to be associated with increased IL-l production (Engebretson et al, 
1999). The same haplotype is associated with increased risk of Alzheimers' disease (Nicoll 
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et al, 2000). Another haplotype consisting of Ava .f511 (A2t- IL-l RN +2018 (A2t is 
associated with susceptibility to cardiovascular diseases. The IL-l ~2018 polymorphism is 
in strong linkage disequilibrium with VNTR86 (K.ornrnan et al, 1999). The VNTR86(A2)+-
TaqF395\A2)" haplotype has been associated with ulcerative colitis (Bioque et al, 1995; 
Heresbach et al, 1997) and with the progression of multiple sclerosis (Schrijver et al, 
1999). The VNTR86(A2)" - Taqi +3953 (A2t haplotype has been associated with 
susceptibility to myasthenia gravis (Huang et al, 1998). The VNTR86(A2)"- Taq I+3953 {Al) 
+ haplotype (VNTR86(A2)"-TaqF3953(A2)" haplotype) is associated with Tuberculous 
pleurisy (Wilkinson et al, 1999) and found to be protective against Epstein-Barr Virus 
(Hurrne and Helminen, l998a). The Ava .f511 (A2l- Taqi +3953 (A l t haplotype is 
associated with the development of alcoholic liver cirrhosis (Takamatsu et al, 2000). 
Finally, the Ava .f511{Alt-Nco.f889(A2l-VNTR86{Alt haplotype was significantly 
increased in patients with Schizophrenia compared to controls (K.atila et al, l999).The 
results obtained from the haplotype analysis in this study provide further evidence for 
linkage in the IL-l gene cluster. 
Since it is the polymorphisms of the IL-l RN gene that are strongly associated with 
acute pancreatitis, only the haplotypes containing these polymorphisms will be discussed. 
The other haplotypes involving different combinations of polymorphisms in the IL-l RI, IL-
l A and IL-1B genes can be explained in a similar way with respect to those polymorphisms 
that are known to be functional, however, in each case the effect of the other 
polymorphisms on protein levels remains unknown. i.e. haplotypes containing the VNTR46 
polymorphism produce IL-1a protein which is inversely proportional to the number of 
repeats in the allele (Bailly et al, 1996), whilst those containing Ava I allele 2 (Nemetz et 
al, 1999) or Taq I allele 2 (Pociot et al, 1992) are high IL-l P secretors. 
The genotype studies showed an association of the IL-l RN gene with severe and 
idiopathic acute pancreatitis. It would have been useful to test the IL-l RN haplotypes in the 
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severe and idiopathic groups in order to detennine whether there is a particular haplotype 
for susceptibility or severity, however, the study was limited by the number of subjects in 
each group. In view of this, the haplotypes were compared only in the total controls and 
total patient groups. 
Mspl-VLP-VNTR86 -Sspl haplotypes 
The 2-3-2-2 and 1-2-1-1 haplotypes were significantly increased in controls and 
patients, while the 1-2-2-1, 1-2-1-2 and X-X-X-X haplotypes were significantly decreased 
between the same 2 groups. It is expected that if one particular haplotype increases, then 
another will decrease to compensate and that if the polymorphisms are in linkage 
disequilibrium they will be linked in both controls and patients. Since the X-X-X-X 
haplotype represents the sum of all other haplotypes not detected in the study, it is not 
possible to comment on which of the undetected haplotypes is significantly decreased. One 
particular haplotype or all of the undetected haplotypes may be decreased and this applies 
to all of the haplotype analyses. 
As previously discussed, there is controversy as to whether allele 2 of the VNTR 86 
polymorphism corresponds to high IL-1ra protein (Danis et a!, 1995) or low IL-1ra protein 
(Tarlow et a!, 1993). To date there are no functional studies for the Msp I, VLP or Ssp I 
polymorphisms. The 2-3-2-2 haplotype contains the high IL-1ra VNTR86 allele according 
to Danis et a! (low IL-lra VNTR 86 allele according to Tarlow et al), the 1-2-1-1 haplotype 
contains the low IL-lra VNTR86 allele according to Danis et al (high IL-lra VNTR86 allele 
according to Tarlow et al), whereas the 1-2-2-1 and 1-2-1-2 haplotypes contain the high 
and low alleles respectively according to Danis et al. Since these haplotypes were increased 
in controls and patients, they are unlikely to be susceptibility haplotypes, but may be linked 
with other susceptibility haplotypes. 
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Pst/-Msp/-VLP-VNTR86 -Sspl haplotypes 
The 2-1-2-1-1 haplotype was significantly increased while the X-X-X-X-X 
haplotype was significantly decreased in both controls and patients (although more 
pronounced in the controls). This haplotype contains the low IL-lra VNTR86 allele 
according to Danis et at (high IL-l ra VNTR 86 allele according to Tar low et al). Because 
these haplotypes were increased and decreased in both controls and patients they are 
unlikely to be susceptibility haplotypes but again may be in linkage with others. The 2-1-2-
2-1 haplotype was also significantly decreased in patients but not controls suggesting 
susceptibility to disease. It contains the high IL-lra VNTR86 allele according to Danis et al 
(low IL-lra VNTR86 allele according to Tar low et a!). A decrease in this high IL-l ra allele 
in patients, may cause acute pancreatitis to occur. This explanation does not however take 
into account the influence of the Pst I, Msp I, VLP or Ssp I polymorphisms whose 
functional status remains unknown. 
(A C)n-VNTR46 -Mspl-VLP-VNTR86 -Sspl haplotypes 
The 2-2-1-2-1-1 haplotype was significantly increased in controls and patients 
while the X-X-X-X-X-X haplotype was significantly decreased between other groups. 
Since the same results were found in controls and patients, these particular haplotypes are 
unlikely to determine susceptibility but they may be linked with other haplotypes. 
Interestingly the 4-1-1-2-1-1 and 1-3-1-2-1-1 haplotypes were also significantly increased 
in the patient group but not in the control group suggesting that these may be susceptibility 
haplotypes. The 4-1-1-2-1-1 haplotype contains the VNTR46 high IL-1a allele (allele 1:9 
repeats) (Bailly et a!, 1996) and low IL-lra VNTR86 allele (allele I) according to Danis et 
al (high IL-lra VNTR86 allele according to Tarlow et a!). High IL-Ia and low IL-lra could 
therefore predispose to acute pancreatitis. The 1-3-1-2-1-1 haplotype contains another 
VNTR46 high IL-l a allele (allele 3: 8 repeats) with the low IL-lra VNTR86 allele (allele I) 
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according to Danis et a! (high IL-1ra VNTR86 allele according to Tarlow et a!). Again high 
IL-la and low IL-1ra could lead to acute pancreatitis. This explanation does not however 
take into account the influence of the (AC)n, Msp I, VLP and Ssp I polymorphisms whose 
functional status remains unknown. 
Avai-Alu-1-Taql-Mspl- VLP-VNTK6 -Sspl haplotypes. 
The 1-1-2-1-2-1-1 and 1-1-1-1-2-1-1 haplotypes were significantly increased in 
both controls and patients whereas the X-X-X-X-X-X-X haplotype was significantly 
decreased between the 2 groups. Because the same haplotypes were increased or decreased 
in controls and patients, these are probably not susceptibility haplotypes but may be in 
linkage with other haplotypes. Interestingly, the 2-2-1-1-2-1-1 haplotype was also 
significantly increased in the control group but not the patient group, suggesting that this 
may be "protective". This haplotype contains the Ava I high IL-IP allele (Nemetz et al, 
1999), Taq Ilow IL-lP allele (Pociot et al, 1992) and low IL-lra VNTR86 allele according 
to Danis et al (high IL-lra VNTR86 allele according to Tarlow et al). If eo-dominant, the 
high and low IL-l P alleles may cancel to give a moderate amount of IL-l p and despite 
having the low IL-l ra allele may still be protective because the IL-l ra: IL-l ratio may still 
be large enough to prevent acute pancreatitis. Again, this explanation does not take into 
account the influence of the Alu I, Msp I, VLP and Ssp I polymorphisms whose functional 
status remains unknown. 
7.1.3 Combined Genotype Analysis 
The combined genotype data showed that in general, different combinations of 
genotypes are more common in controls than in patients with acute pancreatitis e.g. l ,4-1 ,2 
of the (AC)n-VNTR46 combined genotype is more common in controls whereas the 1,2-1,2 
combination is more common in patients. In addition, the majority of patient subgroups 
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shared the same most common combined genotype, regardless of whether they were 
categorised according to severity, organ failure scores or aetiology. In cases where a 
particular group or groups varied from the majority, the most common genotype in the 
majority of groups was the second or third most common genotype in the varied group and 
was only less common by I or 2 patients e.g. for the (AC)n-VNTR46 combined haplotype, 
the most common combined genotype in the majority of groups (total patients, mild, 
severe, OFS~l, OFS~. OFS~3. OFS~4. idiopathic and gallstone groups) was 1,2-1,2 that 
occurred at frequencies of 16.9%, 15.2%, 25.0%, 29.8%, 33.3%, 31.6%, 33.3%, 24.2% and 
17.2% respectively. The OFS=O and alcoholic group varied from this trend whereby the 
most common combined genotype was 2,4-1,2 that occurred at frequencies of 11.2% and 
22.2% respectively. The 1-2,1-2 combined genotype that was the most common combined 
genotype in the majority of patient groups was the second most common genotype in the 
OFS=O group and third most common in the alcoholic group occurring at frequencies of 
10.1% and 11.1% respectively. The presence of the 2,4-1,2 combined genotype in the 
OFS=O group, but its absence in OFS~1,2,3 and 4 groups suggests that this combination 
could act as a disease severity marker. 
Although no statistical analysis could be performed, the data gives an indication of 
the most common combined genotype in a particular group of patients. If a larger cohort 
was used, more numbers would be present in the groups and statistical analysis could be 
applied to determine whether the differences in distribution of the most common combined 
genotypes were significant between controls and patients. 
7.2 Protein Studies 
It is well recognised that polymorphisms in the promoter and intron regions of 
cytokine genes such as IL-6 (Fishman et a!, 1998), IL-10 (Eskdale et al, 1996; Turner et al, 
1997), IL-13 (Van der Pouw Kraan et al, 1999), TNFa. (Wilson et al, 1997; Huang et al, 
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1999) and IFNy (Pravica et al, 1999) can have an effect on the expression of the gene. In 
view of this, the polymorphisms in genes such as IL-l RN studied in this thesis may also 
have a functional effect on the protein. The IL-l ra protein may be affected by 
polymorphisms in two main ways: 
a) altered expression of protein levels 
If there is an increase in IL-l ra expression, there would be a decrease in inflammation. 
Conversely, an increase in IL-lra expression would cause an increase in inflammation. 
b) altered structure of the protein 
A change in the structure of the protein may affect the affinity of the IL-l ra for the IL-l 
receptor. An increased affinity would decrease the inflammation, whereas a decreased 
affinity would increase the inflammation. Whether there is altered expression or structure 
of the protein depends on whether the polymorphism is in a coding, non-coding or 
promoter region of the gene. 
When considering the Msp I-VLP-VNTR 86 -Ssp I haplotype, the VLP, VNTR 86 and 
Ssp I polymorphisms are located in introns 2 and 3 and therefore may affect the IL-l ra 
mRNA or protein levels, whereas the Msp I polymorphism is located in exon 2 and may 
affect the structure of the IL-l ra protein. At present, it is not known whether the T --)-C SNP 
which creates the Msp I restriction site alters an amino acid sequence, however, a method 
of testing this would be to sequence cDNAs. There may also be variability between 
subjects i.e. environmental factors such as alcohol consumption. Just because an individual 
has a particular IL-lra phenotype, they may not necessarily develop acute pancreatitis, 
however, they may be more predisposed to the disease compared to an individual with an 
alternative IL-lra phenotype. 
To date, there are no studies of IL-l RN gene transgenic "knockout" mice in acute 
pancreatitis. It would be expected that these "knockout" mice would have increased 
severity since there would be no antagonist to block the action of IL-l. Conversely, if the 
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expression of IL-l ra was increased there would be reduced severity of the disease in much 
the same way as administering recombinant IL-lra {Tanaka et a!, 1995; Norman et a!, 
1995a). 
Polymorphisms in the IL-IA and IL-lB genes may also affect the proteins they 
encode. It is not known whether the polymorphisms are located on the same chromosome 
or on different chromosomes. If they are located on the same chromosome, they may cause 
a cis effect resulting in the formation of normal protein, however, if they are located on 
separate chromosomes, they may cause a trans effect resulting in a mutated protein. IL-l 
requires 2 receptor-binding sites to bind to the IL-l receptor in order to initiate a signal. 
The binding ofiL-1 to the receptor causes a structural change in the cytoplasmic domain of 
the receptor which allows the IL-lR-AcP to form a high affinity heterodimer complex with 
the initiation of signal transduction. A mutated protein may have only one receptor-binding 
site so that it binds to the receptor but does not result in a structural change of the receptor 
or formation of a high affinity complex and hence no signal transduction. In this way, the 
mutated protein would competitively inhibit the action of IL-l in the same way as IL-l ra. 
7.2.1 Secretion of Interleukin-1 alpha, Interleukin-1beta and Interleukin-1receptor 
antagonist 
In order to determine whether the polymorphisms had a functional effect, protein 
studies were performed using LPS to induce the production of IL-l a, IL-l p and IL-l ra 
from PBMCs in vitro. IL-l a is the intracellular form of IL-l that is only secreted by 
monocytes following cleavage by membrane-bound calpains or as a result of damaged cell 
membranes. Since the viability of the cells was confirmed using trypan blue at each time 
point, the IL-Ia found in the supematants must have been secreted following cleavage by 
calpain and not as a result of damaged cell membranes. IL-l p is the secretory form of IL-l 
that is released from the cell following cleavage by interleukin-1 beta converting enzyme 
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(ICE) while the secretory fonn ofiL-lra possesses a leader sequence and is readily secreted 
from the cell without enzymatic cleavage. 
7.2.1.1 Protein levels peak at particular time points 
The 120 hour time-course experiments showed that in vitro secretion of IL-l a and 
IL-l~ protein levels from PBMCs peaked at 24 hours, whereas the IL-l ra protein levels 
peaked at 48 hours. These findings were continued by all of the subjects in the main IL-l a, 
IL-l~ and IL-l ra protein studies. 
The time of peak protein secretion appears to vary greatly between studies. One 
study has reported that IL-l protein peaks at 2 hours, whereas IL-l ra peaks at 4 hours in 
vitro (V annier et al, 1992). In contrast, another 5 day time-course study showed that IL-l~ 
levels from monocytes stimulated in vitro by LPS were high at day 1 of culture, gradually 
decreased to day 3 and rose again to day 5 (McKay et al, 1996). This is different to the IL-
l~ cytokine profile obtained from this study which showed that IL-l~ protein levels 
continued to decrease and level off after 24 hours. A medline search was unable to find 
studies that demonstrated similar time-course experiments of 5 days or more for IL-l a and 
IL-lra. 
Although both IL-l and IL-lra protein levels peaked later in this study compared to 
that reported by V annier et al, the expression kinetics were consistent. The IL-l protein 
peaked in half the time of IL-l ra protein (24 hours (IL-l) compared to 48 hours (IL-l ra) 
and 2 hours (IL-l) compared to 4 hours (IL-l ra)). These findings are consistent with the IL-
l biology since IL-l gene expression is known to occur before IL-l ra. The main functions 
of IL-l during the inflammatory process are to cause: the increased expression of other 
cytokines that activate and attract leucocytes to the site of injury, upregulation of cell 
adhesion molecules involved in leucocyte migration and increased NO and prostaglandins 
production that cause increased vascular penneability and vasodilatation. The transcription 
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of IL-lra is induced later by IL-l itself as a compensatory mechanism to counteract the 
effects of IL-l and limit the inflammatory process. 
In further support of the results obtained for IL-lra secretion in this thesis, it has 
been reported that within the first 24 hours following stimulation, monocytes use the 
secretory promoter to transcribe siL-lra. After 48 hours, the monocyte exhibits a 
macrophage phenotype and switches on the intracellular promoter so that it starts to 
transcribe iciL-lra (Dinarello, 1996). In view of this, it would be expected that siL-Ira 
would rise between 24-48 hours and then gradually decline after 48 hours as the iciL-1 ra 
levels increase. 
The differences in the IL-l a, IL-l p and IL-l ra cytokine profiles between studies 
may be due to a number of reasons. The various studies measured cytokine secretion from 
different cell populations: monocytes, PBMCs or neutrophils. PBMCs (mixed cell 
population comprised mainly of monocytes and lymphocytes) were used in this study since 
these cells are known to interact with one another and a mixed culture may therefore more 
accurately reflect actions in vivo compared to isolated monocytes. In addition, the studies 
use different ELISA kits. Some use "in house" ELISA kits which are more likely to 
introduce variation due to human error when preparing reagents whilst others use 
commercially prepared "ready to use" kits. Cell concentrations also vary between studies. 
High concentrations of cells cultured in well plates with a small well surface area may lead 
to "contact inhibition" when the cells become confluent and this may affect the results. A 
study comparing LPS, GM-CSF and TNFa-induced IL-l and IL-lra stimulation found that 
the cytokine profile also varied depending on the stimulant (Malyak et al, 1994). Other 
studies using uromodulin, Streptococcus pneumoniae and alpha CD3 to stimulate IL-l p 
secretion from PBMCs showed that the protein level peaked at 6-12, 24 and 72 hours 
respectively (Su and Yeh, 1999; Arva and Andersson, 1999; Ruschen et a!, 1992). 
Moreover, certain stimulants preferentially stimulate the secretion of particular cytokines. 
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For example, LPS is more effective at inducing IL-l, IL-6 and TNFa production whereas 
phytohemaglutinin (PHA) is better at stimulating IL-2, IFNy and GM-CSF production (De 
Groote et al, 1992). Different strains of LPS also produce different results. It has been 
shown that LPS from Actinobacillus actinomycetemcomitans was a more potent stimulant 
of IL-l p from PBMCs than LPS from E. coli 026:B6 (Schytte Blix et al, 1999). The studies 
also vary in the concentrations of LPS used. Sf.lg/ml of LPS from E. coli 0127:B8 was 
added to the cells in this study and this was a very high dose in comparison to others. 
Although this concentration was a potent stimulator of protein, other studies have shown 
that high concentrations ofLPS may inhibit cytokine secretion. This is further supported by 
the results from the optimisation experiment (Figures Al.3-Al.6) that showed that LPS 
reduced IL-l ra protein secretion in a dose dependent manner. Although Sf.lg/ml was the 
lowest LPS concentration used in the optimisation experiment, with hindsight it may have 
been better to use an even lower LPS concentration (lng/ml) that was more physiologically 
relevant. This raises the question as to whether the in vitro adequately reflects the events in 
vivo. 
7.1.1.1 Inter-individual variability of protein levels 
Although the protein from all the subjects consistently peaked at the same time in 
each study, 24 hours for IL-l a or IL-l p and 48 hours for IL-l ra, the amount of protein 
varied between individuals. This inter-individual variation has been demonstrated with 
other cytokine protein levels (IL-2, IL-4, IL-10 and IFNy) (Kaminski et al, 1995; 
Cartwright et al, 1999). 
Since cytokines interact in a network, other cytokines may influence the levels of 
IL-l and IL-lra. IL-4, IL-10 and IFNy increase IL-lra levels while simultaneously 
decreasing IL-l levels. As with IL-l, the genes for these cytokines contain polymorphisms 
that may cause variation in the levels of these cytokines between individuals. If e.g. IL-1 0 
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levels are low in an individual this could cause lower IL-l ra levels than in an individual 
with higher IL-10 levels. Conversely low IL-10 levels would lead to increased IL-l levels 
compared to an individual with high IL-10. A study investigating the effect of IL-10 on 
LPS-induced IL-l and IL-lra levels showed that IL-l 0 inhibited IL-l production but 
stimulated IL-lra production in monocytes (Jenkins et al, 1994). Furthermore, IL-l has 
been shown to induce IL-l ra production, so low IL-l levels may also lead to low IL-l ra 
levels in a particular individual (Marsh and Wewers et al 1994). The effect ofiL-1ra on IL-
l levels has also been studied. Recombinant human IL-l ra administered to cultures was 
found to decrease LPS-induced IL-1mRNA and decrease IL-l protein (Conti et al, 1992). 
An individual that produces high levels of IL-l ra in vitro may have lower IL-l levels in the 
supematant as compared to individuals with lower IL-lra levels. Furthermore, IL-l 
stimulates its own production and this stimulation may be more efficient in some 
individuals than in others, which means that these individuals may have more IL-l protein 
present in the supematant compared to individuals with a less efficient stimulation ofiL-1. 
7.2.1.3 Correlation of the (AC)11 a11d Alu I polymorphism with protei11 levels. 
The median IL-l a and IL-l P protein levels from unstimulated cells were 
significantly increased in patients compared to controls (P0 vs C0). This enhanced release of 
IL-la and IL-lP by unstimulated cells from patients with acute pancreatitis suggests that 
these cells may be "primed" following an episode of the disease. Following stimulation by 
LPS, the median amount ofiL-1a was significantly higher in patients than in controls (P5 
vs C5) at 24 hours, while the median amount of IL-l p was significantly lower in patients 
than in controls (P5 vs C5) at 0 hours. No significant differences in the median IL-l p levels 
were found when the subjects were separated according to those with genotypes containing 
allele 1 or 2 (A1 ° vs A2° and A1 5 vs A25). This suggests that despite being located in the 
promoter region of the IL-lB gene, the Alu I polymorphism is not functional. Results from 
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this thesis and the study by Guasch et at, suggest that it may be in linkage disequilibrium 
with the Taq I polymorphism, which is functional (Guasch et at, 1996). 
Although conclusions were drawn from the protein data, they were based on a 
relatively small number of subjects and hence a small number of alleles, which would 
affect the statistical analysis. The protein studies were originally designed to show whether 
the disease itself may influence the protein levels and therefore patients with a particular 
genotype were taken and compared with controls of the same genotype. Unfortunately, 
problems were encountered when recalling patients, so it was difficult to obtain blood from 
patients with the required genotype. Furthermore, the controls used in the genotype study 
were taken from a bank of cord bloods, which had been collected previously and these 
individuals were not available to obtain blood samples for protein studies. This meant that 
controls from the laboratory had to be used and their genotypes were not always the 
required genotype. This limited availability of subjects resulted in selected patients being 
compared with unselected controls, which are not directly comparable. Any significant 
differences noted could be simply due to the different genotypes and therefore the results 
obtained here are probably spurious. No genotype-protein correlation could be performed 
for the (AC)n polymorphism of the IL-IA gene due to lack of subjects with the 2,4 
genotype. Since neither of these polymorphisms have previously been associated with 
functional protein levels it is not possible to compare with other studies. 
7.2.1.4 Correlatio11 of the VNTRa6 polymorphism with protei11 levels 
No significant differences were found in median IL-l ra protein levels between 
controls and patients for unstimulated (C0 vs P0) or stimulated (C5 vs P5) cells. This 
VNTR86 polymorphism has been previously associated with functional protein levels. 
Danis et at, found allele 2 was associated with high IL-l ra (Danis et at, 1995), whereas 
Tarlow et at, found it was associated with low IL-l ra (Tar low et at, 1993). This thesis 
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could not reproduce the results of either study since on separating the subjects according to 
alleles, allele I appeared to produce a similar amount of IL-l ra as allele 2 (A I 0vs A2° and 
AI 5 vs A25). In contrast to Danis and Tarlow, this suggests that the polymorphism is not 
functional but may be in linkage with other polymorphisms that are functional. Again as 
with the IL-l a and IL-l~ studies, this study involved the comparison of selected patients 
and unselected controls and a small number of alleles, which would affect the statistical 
analysis. In view of this, the results obtained here are probably spurious. 
To my knowledge only 2 studies have investigated the LPS-induced cytokine 
secretion from cells taken from patients with acute pancreatitis. One study compared the 
cytokine secretion of TNFa, IL-6 and IL-8 (but not IL-l~) from PBMCs taken from 6 
controls and 16 patients (De Beaux et a!, 1996). The second study compared the cytokine 
secretion of IL-l~. TNFa, IL-6 and IL-8 from monocytes taken from 26 patients. This 
study compared protein levels between mild cases with severe cases, but did not compare 
against controls. No association was found between IL-l~ levels and disease severity 
(McKay et al, 1996). Because the first study did not investigate IL-l a, IL-l~ or IL-l ra 
protein levels and the second investigated only IL-l~ protein levels with respect to 
severity, these studies are not directly comparable to those performed in this thesis. 
The in vitro production of IL-l and IL-lra protein has been studied in other 
diseases. IL-lra levels were decreased in unstimulated and LPS-stimulated neutrophils 
obtained from patients with active SLE compared to non-active SLE and controls (Hsieh et 
a!, 1995). LPS-stimulated IL-l~ production was increased in PBMCs cultured from 
patients with chronic fatigue syndrome (Chao et a!, 1991 ), Parkinsons' Disease (Bessler et 
a!, 1999) and multiple sclerosis compared with controls (Sarchielli et al, 1997). 
Interestingly, the LPS-induced stimulation of IL-la and IL-l~ from PBMCs and 
monocytes were decreased in 2 studies of sepsis implying that a regulatory mechanism 
downregulates the production of IL-l during sepsis (Munoz et al, 1991; Kremer et al, 
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1996). Since acute pancreatitis is considered to be a model of sepsis (Wilson et al, 1998), 
this may also be the case in this disease. 
7 .2.2 Limitations of the protein studies 
This project was originally designed as a genetic study in 1996. In view of this, 
blood was collected from all patients for DNA extraction and the serum was discarded. 
With hindsight the serum from this blood should have been removed, aliquoted and frozen 
for future use. This would have avoided the need to recall patients, a process that proved to 
be fraught with problems (see below). Disadvantages of this method are that the protein 
may start to degrade over time and the measurement of cytokine levels in the serum may 
not adequately reflect the cytokine producing potential of immune cells because of the 
short half-life and presence of inhibitors in the human sera. An alternative method to this is 
the in vitro stimulation of cells that was used in this study, however, even this raises the 
question of tissue variability because cultures of PBMCs stimulated with LPS may not 
adequately reflect the events that occur in the pancreas during acute pancreatitis. 
Numerous problems were encountered when attempting to recall patients for blood 
donations. These included: death since the original admission 5 years ago and non-reply to 
the requesting letter. Some of the patients who did agree to donate blood proved to be not 
suitable since they lived too far from hospital to give a fresh blood sample that is required 
for cell culture experiments or they had recently received a vaccination and were therefore 
immune-compromised. Other patients who agreed to give blood samples were unable to 
attend outpatient appointments due to employment or holiday commitments. One elderly 
patient attended her appointment but due to her "poor" veins was unable to donate blood. 
Other patients, in particular the alcoholics, agreed to donate blood but failed to attend their 
outpatient appointment. In total 52 patients were recalled, however, only 18 donated blood 
(35%). Rewriting to the patients for a second time did not improve this recall rate. Patients 
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that did not donate blood following the frrst request were unlikely to donate following a 
second. 
Studies that correlate genotypes with functional protein levels limit the number of 
subjects that can be used since only those individuals with the appropriate genotype can be 
studied. Gender and age may also have influenced the results obtained in the study since 
the controls used were mainly young and female. Elderly patients are known to produce 
more IL-l ra whilst females produce more IL-l in the luteal phase of their menstrual cycle 
(Dinarello, 1996). 
The protein experiments could be improved in a number of ways. More subjects 
would increase the number of alleles and improve the statistical analyses. They could be 
performed on controls only since the genotype should have the same functional effect 
regardless of whether controls or patients are used. In the case of the IL-l A study for 
example, where the 2,4 genotype was implicated, protein levels from controls with the 2,4 
genotype could be compared with protein levels from controls without the 2,4 genotype. 
Also triplicate ELISA samples should be used to improve accuracy, however, this 
technique is limited by expense. The use of one large ELISA microplate (as yet not 
commercially available) would have prevented the use a number of different plates and so 
limited inter-plate variability. This would also have meant that analysis of all samples 
could be performed on the same day so ensuring ambient conditions e.g. room temperature 
are constant. Furthermore, the author acknowledges that internal standards should also 
have been used on a day to day basis to show that the results obtained from each protein 
study were consistent with those obtained on other days. 
Methods such as ELISA are sensitive to temperature changes since they are based 
on antigen-antibody binding. Comparison of "R square values", a measure of the daily 
accuracy as determined by the ELISA plate reader showed that hot days (>23°C) resulted in 
non-linear standard curves and inaccurate results. Only the results from ELISA plates with 
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linear standard curves with "R square values" close to 1 were used in the study. ELISA are 
expensive to repeat and are limited by the amount of supernatant available. Alternative 
methods of quantifying protein levels include radioimmunoassay {RlA), western blotting 
and ELispot (for intracellular protein). 
7.3 Further studies 
Further studies to arise from this work include: 
1) Correlation ofiL-1 mRNA levels with protein levels 
Polymorphisms in the DNA can have an affect on mRNA and protein levels. It is not 
enough to measure just protein levels or just mRNA levels since protein levels do not 
necessarily correspond to mRNA levels. For example, a low protein level could 
indicate a low mRNA level, when actually mRNA levels may be high but protein is 
being metabolised rapidly by the cell. Similarly a high protein level does not 
necessarily mean that mRNA levels will be high, since mRNA is unstable and may 
degrade too rapidly to be measured effectively. A preliminary experiment was 
performed using RNA stat 60 to extract mRNA from PBMCs, however, not enough 
cells were present to detect an adequate amount of mRNA. At least 20x l 06 cells 
(10xl06 for unstimulated and 10xl06 for stimulated) requiring 20mls of blood were 
required to obtain a reasonable amount of mRNA. Since these patients were already 
donating 30mls for the protein study it was not ethical to collect a further 20mls from 
them for the mRNA study. 
2) Investigation of other IL-l gene cluster polymorphisms in acute pancreatitis since new 
polymorphisms are continually being reported or in the ICE, type II receptor or 
interleukin-1 accessory protein which are involved in IL-l processing and signal 
transduction 
3) Investigation of other pro-inflammatory cytokines and chemokines in acute pancreatitis 
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4) Investigation of the IL-l polymorphisms in patients with chronic pancreatitis 
particularly the (AC)n repeat polymorphism which showed an association with 
alcoholic acute pancreatitis since most chronic pancreatitis are alcohol-induced. 
5) Although not a genetic study, for completeness it would be interesting to compare IL-
l a, IL-l~. IL-l ra protein levels and IL-l receptor expression in specimens of pancreas 
obtained from patients with acute pancreatitis and healthy controls using techniques 
such as immunohistochemistry. This type of study is however limited by specimen 
availability. Pancreatic specimens are difficult to obtain from acute pancreatitis patients 
because the pancreas is rarely resected and control specimens would also be difficult to 
obtain unless donated by for example, road traffic accident victims. 
7.4 Concluding Points 
The main conclusions from this thesis are: 
1) Pst I polymorphism of the IL-l RI gene may be associated with susceptibility to acute 
pancreatitis 
2) (AC)n repeat polymorphism of the IL-IA gene may be associated with susceptibility to 
alcoholic acute pancreatitis (suggesting genetic heterogeneity in acute pancreatitis) 
3) Alu I polymorphism of the IL-lB gene may be associated with susceptibility to acute 
pancreatitis 
4) Msp I, VLP, VNTR86 and Ssp lpolymorphisms of the IL-lRN gene may be associated 
with idiopathic acute pancreatitis and with severity of the disease 
5) Polymorphisms within genes of the IL-l gene cluster appear to be m linkage 
disequilibrium 
6) IL-l RI, IL-IA, IL-lB and IL-lRN genes appear to be in linkage disequilibrium 
7) There appears to be preferential combinations of genotypes in controls and patients. 
8) There appears to be inter-individual variation in IL-l a, IL-l~ and IL-l ra protein levels 
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,, 
9) Nnsfirilulat(:d 1P~MCs f!om tpatients' with acute pancreatitis· (P0) secrete signi fican:tly 
rn<m: n;~ a andi II£:,.:1 p: pr~tein.levels b1Jt the,same amount of IL-lra· protein compared 
.with unstimulatedl PBM~s from controls (C~, There is no :significant: difference in 1IL-
'I a, 11J.:,d P' or. IL:clnl1 !:JeCrCAti(.)n :from 'PBMCs:stimulated'with I{.:PS ~betWeen ,controls (C5) 
lO}The (AC)n; Alu I and' VNfR86 pol)'morphisms do not' appear to :correspondi ,to 
differences rin: functional protein J)evels 
I 
I. 
,. 
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APPENDIX! 
Experiment to determine the optimum conditions for maximum protein secretion 
Part/ 
An optimisation experiment was performed to determine the optimum cell culture 
conditions for peak protein secretion. IL-lra was the first protein to be studied and this was 
used to determine optimum cell culture conditions for all 3 proteins. 
20mls of peripheral venous blood were collected in a sodium heparin vacutainer 
(Becton Dickinson, Oxford, UK) from a healthy control. The PBMCs were then extracted 
using "Lymphoprep™" (Gibco GRL, Paisley, UK) by the method described in Section 5.9 
to give 20 X I 06 cells. The cell concentration was then adjusted to I xI 06 cells per ml. Next 
Iml of the cell suspension was added to 20 wells on a 24 well flat-bottomed culture plate 
(Fischer Scientific, Loughborough, UK). Different amounts of LPS (0-20J..tg/ml 
LPS)(Sigma Chemicals, Poole, UK) were then added to each wells in rows 1-5 (Figure 
Al. I). The cells were stimulated for 1,6,12 and 24 hours at 37°C 5% C02 in a humidified 
container. Twenty-four hours was the maximum time chosen since previous studies have 
shown that IL-lra protein expression peaks at 4 hours and IL-l peaks at 2 hours in vitro 
(V annier et al, 1992). The supematant was removed after each time interval using a I ml 
Gilson Pipetman and transferred to a 1.5ml Eppendorf. The supematant was then 
centrifuged in a Heraeus Sepatech microcentrifuge (Heraeus, Germany) to pellet out the 
cells and the supematant was then transferred to a clean Eppendorf and stored at -20°C 
ready for batch cytokine assay by ELISA. Exactly the same method was carried out on 
cells plated at 5x105 and lxl05 cells per ml. The various cell concentrations were used to 
determine whether contact inhibition would affect the level of protein secreted. 
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Figure Al.l: Layout of the 24 well cell-culture plate used in Part I of the optimisation 
experiment 
0 5 10 15 20 X 
I hour I hour 1 hour 1 hour 1 hour 
0 5 10 15 20 X 
6 hours 6 hours 6 hours 6 hours 6 hours 
0 5 10 15 20 X 
12 hours 12 hours 12 hours 12 hours 12 hours 
0 5 10 15 20 X 
24 hours 24 hours 24 hours 24 hours 24 hours 
0, 5, 10, 15 and 20jlg/ml LPS 
X = unused well 
Figure Al.2: Layout of the 24 well cell-culture plate used in Part 11 of the 
optimisation experiment 
0 5 0 5 0 5 
0 hour 0 hour 24 hours 24 hours 48 hours 48 hours 
0 5 0 5 0 5 
72 hours 72 hours 96 hours 96 hours 120 hours 120 hours 
X X X X X X 
X X X X X X 
0 and 5jlg/ml LPS 
X = unused well 
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Part II 
Data obtained from the Part I of the optimisation experiment showed that the optimum cell 
culture conditions, i.e. those that produced the maximum protein yield were: lxl06 cells 
per well stimulated with 5j.1g/ml. The optimum time for peak protein secretion could not be 
determined, however, because at 24 hours the curves were still increasing so maximum 
protein secretion must occur after 24 hours. In view of this a second part of the experiment 
was carried out which involved plating cells at lx106 and stimulating half with 5J.lg/ml 
LPS for 0, 24, 48, 72, 96 and 120 hours. The other half of the cells remained unstimulated 
(Figure Al.2). Cells were not cultured any later than 5 days because cell viability would 
become compromised after this time. The supematant from each well was removed after 
each time point using a 1 ml Gilson Pipetman and transferred into an Eppendorf where it 
was centrifuged in a Heraeus Sepatech microcentrifuge to pellet out the cells. The 
supematant was then transferred to a clean Eppendorf and stored at -20°C for batch 
cytokine assay. After each time point, the cell viability was checked using 20j.1l trypan blue 
to determine whether the cell membranes were still intact. This showed that the protein 
was being secreted and not released due to cell membrane rupture dying cells. The 
cell/trypan blue mixture was added to a Neubauer Haemocytometer and observed under a 
microscope. The cells were considered to be still viable if at least 95% of cell membranes 
remained intact. The data are shown in Tables Al.lA to Al.lD and illustrated in Figures 
Al.3 to Al.6. 
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Table Al.lA: IL-lra protein (pglml) secreted from lx106 PBMCs stimulated with 0-
20f.1.g/ml LPS for 1-24 hours 
LPS (Jlg!ml) 
Time 0 s 10 lS 20 
660 600 920 120 600 
1470 5300 3190 2080 2900 
920 8500 7620 6250 7520 
1170 20060 16240 13620 11510 
Table A1.1B: IL-1ra protein (pglml) secreted from Sx105 PBMCs stimulated with 0-
20f.1.g/ml LPS for 1-24 hours 
Time 
I2 
24 
0 
0 
120 
228 
377 
s 
21 
952 
2I91 
4743 
LPS (J1g/ml) 
IO IS 20 
131 36 9 
1243 1218 694 
2116 1874 1709 
3938 3440 3032 
Table A1.1C: IL-1ra protein (pglml) secreted from lx105 PBMCs stimulated with 0-
20f.l.g/ml LPS for 1-24 hours 
LPS (Jlg!ml) 
Time 0 s 10 IS 20 
6 70 111 47 20 
83 708 263 183 118 
242 1296 520 335 260 
190 1714 890 861 454 
Table A1.1D: IL-1ra protein (pglml) secreted from lx106 PBMCs stimulated with 0-
Sf.l.g/ml LPS for 0-120 hours 
LPS (Jlg!ml) LPS (J1g/ml) 
Time 0 s 
0 290 189 
24 356 14870 
48 452 24440 
72 437 19450 
96 461 14200 
I20 381 14330 
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Figure A1.3: IL-lra protein secreted from PBMCs cultured at lx106 cells per ml and stimulated with 0-20uglml 
LPS for 1-24 hours 
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Figure A1.4: IL-lra protein secreted from PBMCs cultured at 5x105 cells per ml and stimulated with 0-20ug/ml 
LPS for 1-24 hours 
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Figure A1.5: ll..-lra protein secreted from PBMCs cultured at lx105 cells per ml and stimulated with 0-20uglml 
LPS for 1-24 hours 
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Figure A1.6: IL-lra protein secreted from PBMCs cultured at lx106,5x105 and lx105 cells per ml and stimulated 
with 0-20uglml LPS for 1-24 hours 
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APPENDIX2 
Combined Genotype Analysis 
The results of the combined genotype analyses are presented in the following format: 
Table A2.XA: Frequency of the combined genotypes in the control population 
Table A2.XB: Frequency of the combined genotypes in the patient population 
Table A2.XC: Frequency of the combined genotypes in the mild group of patients 
Table A2.XD: Frequency of the combined genotypes in the severe group of patients 
Table A2.XE: Frequency of the combined genotypes in the OFS=O group of patients 
Table A2.XF: Frequency of the combined genotypes in the OFS~l group of patients 
Table A2.XG: Frequency ofthe combined genotypes in the OFS~ group of patients 
Table A2.XH: Frequency of the combined genotypes in the OFS~3 group of patients 
Table A2.XI: Frequency ofthe combined genotypes in the OFS~4 group of patients 
Table A2.XJ: Frequency of the combined genotypes in the alcoholic group of patients 
Table A2.XK: Frequency of the combined genotypes in the idiopathic group of patients 
Table A2.XL: Frequency of the combined genotypes in the gallstone group of patients 
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Table A2.1A: Frequency of (AC)n-VNTR46 combined genotypes in the control 
population 
(AC)n-VNTR46 Number (n) Frequency(%) 
1,4-1,1 16 12.7 
1,2-1,2 12 9.5 
2,4-1,2 10 7.9 
2,2-2,2 8 6.3 
1,1-1,1 8 6.3 
Y-Y 72 57.1 
Total 126 99.8 
This table shows the (AC)n-VNTR46 combined genotype in the control population. n represents the 
number of subjects with each genotype combination. The most common combined genotype is 
shown at the top of the table and the least common is shown at the bottom. Y-Y represents the sum 
total of the combined genotypes that occurred at a frequency of less than 5%. The most common 
combined genotype was 1,4-1,1 that occurred at a frequency of 12.7%. 
Table Al.lB: Frequency of (AC)n-VNTR46 combined genotypes in the patient 
population 
(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2 23 16.9 
2,4-1,2 12 8.8 
1,4-1,1 10 7.4 
1,2-2,3 10 7.4 
1,1-1,3 8 5.9 
1,1-1,1 8 5.9 
Y-Y 65 47.8 
Total 136 100.1 
This table shows the (AC)n-VNTR46 combined genotype in the patient population. n represents the 
number of subjects with each genotype combination. The most common combined genotype is 
shown at the top of the table and the least common is shown at the bottom. Y-Y represents the sum 
total of the combined genotypes that occurred at a frequency of less than 5%. The most common 
combined genotype was 1,2-1,2 that occurred at a frequency of 16.9%. 
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Table A2.1C: Frequency of (AC)n-VNTR46 combined genotypes in the mild group of 
patients 
(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2 12 15.2 
2,4-1,2 9 11.4 
1,4-1,1 6 7.6 
1,2-2,3 6 7.6 
1,1-1,3 4 5.1 
1,1-1,1 4 5.1 
Y-Y 38 48.1 
Total 79 100.1 
This table shows the (AC)n-VNTR46 combined genotype in the mild group of patients. n represents 
the number of subjects with each genotype combination. The most common combined genotype is 
shown at the top ofthe table and the least common is shown at the bottom. Y-Y represents the sum 
total of the combined genotypes that occurred at a frequency of less than 5%. The most common 
combined genotype was 1,2-1,2 that occurred at a frequency of 15.2%. 
Table A2.1D: Frequency of (AC)n-VNTR46 combined genotypes in the severe group 
of patients 
(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2 9 25.0 
1,1-1,3 3 8.3 
1,2-2,3 3 8.3 
2,2-2,3 2 5.6 
2,2-1,2 2 5.6 
1,1-1,1 2 5.6 
Y-Y 15 41.7 
Total 36 100.1 
This table shows the (AC)n-VNTR46 combined genotype in the severe group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2 that occurred at a frequency of25.0%. 
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Table A2.1E: Frequency of (AC)n-VNTR46 combined genotypes in the OFS=O group 
of patients 
(AC)n-VNTR46 Number (n) Frequency(%) 
2,4-1,2 10 11.2 
1,2-1,2 9 10.1 
1,4-1,1 8 9.0 
1,1-1,1 7 7.9 
1,2-2,3 7 7.9 
1,1-1,3 6 6.7 
1,4-1,3 5 5.6 
Y-Y 37 41.6 
Total 89 100.0 
This table shows the (AC)n-VNTR46 combined genotype in the OFS=O group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,4-1,2 that occurred at a frequency of 11.2%. 
Table A2.1F: Frequency of (AC)n-VNTR46 combined genotypes in the OFS~1 group 
of patients 
(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2 14 29.8 
1,2-2,3 3 6.4 
1,5-1,3 3 6.4 
Y-Y 27 57.4 
Total 47 100.0 
This table shows the (AC)n-VNTR46 combined genotype in the OFS;?;I group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2 that occurred at a frequency of29.8%. 
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Table A2.1G: Frequency of (AC)n-VNTR46 combined genotypes in the OFS~ group 
of patients 
(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2 11 33.3 
2,2-1,2 2 6.1 
1,2-2,3 2 6.1 
1,1-1,3 2 6.1 
1,5-1,3 2 6.1 
Y-Y 14 42.4 
Total 33 100.1 
This table shows the (AC)n-VNTR46 combined genotype in the OFS~ group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2 that occurred at a frequency of 33.3%. 
Table A2.1H: Frequency of (AC)n-VNTR46 combined genotypes in the OFS~ group 
of patients 
(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2 6 31.6 
1,2-2,3 2 10.5 
1,1-1,3 2 10.5 
Y-Y 9 47.4 
Total 19 100.0 
This table shows the (AC)n-VNTR46 combined genotype in the OFS~3 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was I ,2-1 ,2 that occurred at a frequency of 31.6%. 
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Table A2.11: Frequency of (AC)n-VNTR46 combined genotypes in tbe OFS~4 group 
of patients 
(AC)n-VNTR46 Number(n) Frequency(%) 
1,2-1,2 4 33.3 
1,1-1,3 2 16.7 
2,2-2,3 1 8.3 
4,6-1,1 1 8.3 
1,2-2,3 8.3 
1,4-1,1 1 8.3 
1,5-1,1 1 8.3 
1,1-3,3 1 8.3 
Total 12 99.8 
This table shows the (AC)n-VNTR46 combined genotype in the OFS::2:4 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was 1,2-1,2 that occurred at a frequency of 33.3%. 
Table A2.1J: Frequency of (AC)n-VNTR46 combined genotypes in tbe alcoholic group 
of patients 
(AC)n-VNTR46 Number(n) Frequency(%) 
2,4-1,2 4 22.2 
1,1-1,3 3 16.7 
1,2-1,2 2 11.1 
3,4-1,1 2 11.1 
Y-Y 7 38.9 
Total 18 100.0 
This table shows the (AC)n-VNTR46 combined genotype in the alcoholic group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,4-1,2 that occurred at a frequency of 22.2%. 
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Table A2.1K: Frequency of (AC)n-VNTR46 combined genotypes in the idiopathic 
group of patients 
(AC)n-VNTR46 Number(n) Frequency(%) 
1,2-1,2 8 24.2 
2,2-2,3 3 9.1 
2,4-1,2 3 9.1 
2,2-1,2 2 6.1 
2,7-1,2 2 6.1 
1,2-2,3 2 6.1 
1,4-1,1 2 6.1 
Y-Y 11 33.3 
Total 33 100.1 
This table shows the (AC)n-VNTR46 combined genotype in the idiopathic group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was I ,2-1 ,2 that occurred at a frequency of 24.2%. 
Table A2.1L: Frequency of (AC)n-VNTR46 combined genotypes in the gaUstone 
group of patients 
(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2 11 17.2 
1,2-2,3 7 10.9 
1,1-1,1 5 7.8 
1,4-1,1 5 7.8 
Y-Y 36 56.3 
Total 64 100.0 
This table shows the (AC)n-VNTR46 combined genotype in the gallstone group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was I ,2-1 ,2 that occurred at a frequency of 17 .2%. 
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Table A2.2A: Frequency of Aval-Alui-Taql combined genotypes in the control 
population 
Avai-Alui-Taq/ Number (n) Frequency(%) 
1,1-1,1-1,1 22 25.6 
2,2-2,2-1,1 20 23.3 
1,1-1,1-1,2 15 17.4 
1,2-1,2-1,1 13 15.1 
1,2-1,2-1,2 12 14.0 
Y-Y-Y 4 4.7 
Total 86 100.1 
This table shows the Avaf-Alul-Taql combined genotype in the control population. n represents the 
number of subjects with each genotype combination. The most common combined genotype is 
shown at the top of the table and the least common is shown at the bottom. Y-Y-Y represents the 
sum total of the combined genotypes that occurred at a frequency of less than 5%. The most 
common combined genotype was 1,1-1,1-1,1 that occurred at a frequency of25.6%. 
Table A2.2B: Frequency of Aval-Alul-Taql combined genotypes in the patient 
population 
Aval-Alul-Taql Number (n) Frequency(%) 
1,2-1,2-1,1 39 34.5 
1,1-1,1-1,1 24 21.2 
1,1-1,1-1,2 20 17.7 
1,2-1,2-1,2 17 15.0 
2,2-2,2-1,1 7 6.2 
Y-Y-Y 6 5.3 
Total 113 99.9 
This table shows the Avaf-Alu/-Taql combined genotype in the patient population. n represents the 
number of subjects with each genotype combination. The most common combined genotype is 
shown at the top of the table and the least common is shown at the bottom. Y-Y-Y represents the 
sum total of the combined genotypes that occurred at a frequency of less than 5%. The most 
common combined genotype was l ,2-l ,2-1, I that occurred at a frequency of 34.5%. 
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Table A2.2C: Frequency of Aval-Alul-Taql combined genotypes in tbe mild group of 
patients 
Aval-Alul-Taql Number (n) Frequency(%) 
1,2-1,2-1,1 27 34.6 
1,1-1,1-1,1 18 23.1 
1,1-1,1-1,2 12 15.4 
1,2-1,2-1,2 11 14.1 
2,2-2,2-1,1 6 7.7 
Y-Y-Y 4 5.1 
Total 78 100.0 
This table shows the Aval-Aiul-Taql combined genotype in the mild group of patients. n represents 
the number of subjects with each genotype combination. The most common combined genotype is 
shown at the top of the table and the least common is shown at the bottom. Y-Y-Y represents the 
sum total of the combined genotypes that occurred at a frequency of less than 5%. The most 
common combined genotype was I ,2-1 ,2-1, I that occurred at a frequency of 34.6%. 
Table A2.2D: Frequency of Aval-Aiul-Taql combined genotypes in tbe severe group 
of patients 
Aval-Alul-Taql Number (n) Frequency(%) 
1,2-1,2-1,1 12 34.3 
1,1-1,1-1,2 8 22.9 
1,2-1,2-1,2 6 17.1 
1,1-1,1-1,1 6 17.1 
Y-Y-Y 3 8.6 
Total 35 100.0 
This table shows the Aval-Aiul-Taql combined genotype in the severe group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2-1,1 that occurred at a frequency of34.3%. 
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Table A2.2E: Frequency of Aval-Aiul-Taql combined genotypes in the OFS=O group 
of patients 
Aval-Aiul-Taql Number (n) Frequency(%) 
1,2-1,2-1,1 22 32.4 
1,1-1,1-1,1 20 29.4 
1,2-1,2-1,2 9 13.2 
1,1-1,1-1,2 8 11.8 
2,2-2,2-1,1 5 7.4 
Y-Y-Y 4 5.9 
Total 68 100.1 
This table shows the Aval-Aiul-Taqf combined genotype in the OFS=O group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was I ,2-1,2-l,l that occurred at a frequency of 32.4%. 
Table A2.2F: Frequency of Aval-Aiul-Taql combined genotypes in the OFS~l group 
of patients 
Aval-Aiui-Taql Number (n) Frequency(%) 
1,2-1,2-1,1 17 37.8 
1,1-1,1-1,2 12 26.7 
1,2-1,2-1,2 8 17.8 
1,1-1,1-1,1 4 8.9 
Y-Y-Y 4 8.9 
Total 45 100.1 
This table shows the Aval-Aiul-Taqf combined genotype in the OFS~l group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2-1,1 that occurred at a frequency of37.8%. 
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Table A2.2G: Frequency of Aval-Aiul-Taql combined genotypes in the OFS~ group 
of patients 
Avai-Aiul-Taql Number (n) Frequency(%) 
1,2-1,2-1,1 10 31.3 
1,1-1,1-1,2 8 25.0 
1,2-1,2-1,2 8 25.0 
1,1-1,1-1,1 4 12.5 
Y-Y-Y 2 6.3 
Total 32 100.1 
This table shows the Aval-Alul-Taql combined genotype in the OFS~2 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2-1,1 that occurred at a frequency of 31.3%. 
Table A2.2H: Frequency of Aval-Aiul-Taql combined genotypes in the OFS~ group 
of patients 
Aval-Alui-Taql Number(n) Frequency(%) 
1,2-1,2-1,1 6 33.3 
1,1-1,1-1,2 4 22.2 
1,2-1,2-1,2 3 16.7 
1,1-1,1-1,1 2 11.1 
1,2-1,2-1,2 2 11.1 
2,2-2,2-1,1 5.6 
Total 18 100.0 
This table shows the Aval-Aiul-Taql combined genotype in the OFS~3 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was 1,2-1,2-1,1 that occurred at a frequency of 33.3%. 
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Table A2.21: Frequency of Aval-Alui-Taql combined genotypes in the OFS~4 group 
of patients 
Aval-Alul-Taql Number (n) Frequency(%) 
1,2-1,2-1,1 4 33.3 
1,1-1,1-1,2 4 33.3 
1,2-1,2-1,2 3 25.0 
1,1-1,1-1,1 1 8.3 
Total 12 99.9 
This table shows the Avaf-Alul-Taql combined genotype in the OFS~4 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotypes were I ,2-1 ,2-1, I and 1,1-1, 1-1 ,2 that each occurred at a frequency of 
33.3%. 
Table A2.2J: Frequency of Avai-Alui-Taql combined genotypes in the alcoholic group 
of patients 
Aval-Aiui-Taql Number (n) Frequency(%) 
1,2-1,2-1,1 8 44.4 
1,1-1,1-1,1 4 22.2 
1,2-1,2-1,2 3 16.7 
1,1-1,1-1,2 2 11.1 
1,1-1,2-1,1 5.6 
Total 18 100.0 
This table shows the Aval-Alul-Taql combined genotype in the alcoholic group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was I ,2-1,2-1, 1 that occurred at a frequency of 44.4%. 
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Table A2.2K: Frequency of Aval-Aiui-Taql combined genotypes in the idiopathic 
group of patients 
Avai-Aiui-Taq/ Number (n) Frequency (%) 
1,2-1,2-1,1 10 31.3 
1,1-1,1-1,2 9 28.1 
1,1-1,1-1,1 6 18.8 
1,2-1,2-1,2 4 12.5 
2,2-2,2-1,1 2 6.3 
Y-Y-Y 1 3.1 
Total 32 100.1 
This table shows the Ava/-Alu/-Taql combined genotype in the idiopathic group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was I ,2-1,2-1, I that occurred at a frequency of 31.3%. 
Table A2.2L: Frequency of Avai-Aiui-Taql combined genotypes in tbe gallstone 
group of patients 
Avai-Alu/-Taql Number (n) Frequency(%) 
1,2-1,2-1,1 21 33.3 
1,1-1,1-1,1 14 22.2 
1,2-1,2-1,2 10 15.9 
1,1-1,1-1,2 9 14.3 
2,2-2,2-1,1 5 7.9 
Y-Y-Y 4 6.3 
Total 63 99.9 
This table shows the Aval-Alul-Taq/ combined genotype in the gallstone group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2-l,l that occurred at a frequency of 33.3%. 
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Table A2.3A: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in the 
control population 
Mspl-VLP-VNTR86 -Ss pi Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 43 42.2 
1,2-2,3-1,2-1,2 38 37.3 
2,2-3,3-2,2-2,2 8 7.8 
Y-Y-Y-Y 13 12.7 
Total 102 100.0 
This table shows the Mspl-VLP-VNTR86-Sspl combined genotype in the control population. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was I, 1-2,2-1,1-1, I that occurred at a frequency of 42.2%. 
Table A2.3B: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in the 
patient population 
Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 62 53.9 
1,2-2,3-1,2-1,2 39 33.9 
2,2-3,3-2,2-2,2 10 8.7 
Y-Y-Y-Y 4 3.5 
Total 115 100.0 
This table shows the Mspl-VLP-VNTR86-Sspl combined genotype in the patient population. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was l, l-2,2-l, 1-l, l that occurred at a frequency of 53 .9%. 
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Table A2.3C: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in the mild 
group of patients 
Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 37 46.8 
1,2-2,3-1,2-1,2 30 38.0 
2,2-3,3-2,2-2,2 8 10.1 
Y-Y-Y-Y 4 5.1 
Total 79 100.0 
This table shows the Mspl-VLP-VNTR86 -Sspl combined genotype in the mild group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was I, l-2,2-1, 1-l, l that occurred at a frequency of 46.8%. 
Table A2.3D: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in the 
severe group of patients 
Mspl-VLP-VNTR86 -Sspl Number(n) Frequency(%) 
1,1-2,2-1,1-1,1 25 69.4 
1,2-2,3-1,2-1,2 9 25.0 
2 5.6 
Total 36 100.0 
This table shows the Msp/-VLP-VNTR86-Ssp/ combined genotype in the severe group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was l,l-2,2-l,l-1,1 that occurred at a frequency of 69.4%. 
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Table A2.3E: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in the 
OFS=O group of patients 
Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 34 49.3 
1,2-2,3-1,2-1,2 26 37.7 
2,2-3,3-2,2-2,2 5 7.2 
Y-Y-Y-Y 4 5.8 
Total 69 100.0 
This table shows the Mspl-VLP-VNTR86-Sspl combined genotype in the OFS=O group of patients. 
n represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was l,l-2,2-1,1-1,1 that occurred at a frequency of 49.3%. 
Table A2.3F: Frequency of Msp/-VLP-VNTR86-Ssp/ combined genotypes in the 
OFS~1 group of patients 
Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 28 60.9 
1,2-2,3-1,2-1,2 13 28.3 
5 10.9 
Total 46 100.1 
This table shows the Mspl-VLP-VNTR86-Sspl combined genotype in the OFS~I group of patients. 
n represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was l,l-2,2-l,l-1,1 that occurred at a frequency of 60.9%. 
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Table A2.3G: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in tbe 
OFS~ group of patients 
Mspl-VLP-VNTR86 -Ss pi Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 21 63.6 
1,2-2,3-1,2-1,2 9 27.3 
2,2-3,3-2,2-2,2 3 9.1 
Total 33 100.0 
This table shows the Mspl-VLP-VNrR.86-Sspl combined genotype in the OFS:<::2 group of patients. 
n represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,1-2,2-1,1-1,1 that occurred at a frequency of 63.6%. 
Table A2.3H: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in the 
OFS:8 group of patients 
Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 13 68.4 
1,2-2,3-1,2-1,2 5 26.3 
2,2-3,3-2 2-2,2 1 5.3 
Total 19 100.0 
This table shows the Mspl-VLP-VNfR86-Sspl combined genotype in the OFS:<::3 group of patients. 
n represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was I, 1-2,2-1,1-1,1 that occurred at a frequency of68.4%. 
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Table A2.31: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in the 
OFS~4 group of patients 
Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 8 66.7 
1,2-2,3-1 2-1,2 4 33.3 
Total 12 100.0 
This table shows the Mspi-VLP-VNTR86-SspJ combined genotype in the OFS~4 group of patients. 
n represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was I, 1-2,2-l, 1-1, I that occurred at a frequency of 66. 7%. 
Table A2.3J: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in the 
alcoholic group of patients 
Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 8 44.4 
1,2-2,3-1,2-1,2 8 44.4 
2,2-3,3-2,2-2,2 1 5.6 
1,2-1,3-2,2-1,2 1 5.6 
Total 18 100.0 
This table shows the MspJ-VLP-VNTR86-SspJ combined genotype in the alcoholic group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
The most common combined genotypes were l, 1-2,2-l, 1-1, I and I ,2-2,3-1,2-1 ,2 that each 
occurred at a frequency of 44.4%. 
309 
Table A2.3K: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in tbe 
idiopathic group of patients 
Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 22 66.7 
1,2-2,3-1,2-1,2 8 24.2 
Y-Y-Y-Y 3 9.1 
Total 33 100.0 
This table shows the Mspi-VLP-VNfR86-Sspl combined genotype in the idiopathic group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of less 
than 5%. The most common combined genotype was 1,1-2,2-1,1-1,1 that occurred at a frequency 
of66.7%. 
Table A2.3L: Frequency of Mspl-VLP-VNTR86-Sspl combined genotypes in tbe 
gallstone group of patients 
Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-2,2-1,1-1,1 32 50.0 
1,2-2,3-1,2-1,2 23 35.9 
2,2-3,3-2,2-2 2 9 14.1 
Total 64 100.0 
This table shows the Mspi-VLP-VNfR86-Sspl combined genotype in the gallstone group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
The most common combined genotype was l,l-2,2-l,l-1,1 that occurred at a frequency of 50.0%. 
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Table A2.4A: Frequency of Pst/-(AC)n-VNTR46 combined genotypes in the control 
population 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,4-1,1 8 6.7 
2,2-1,2-1,2 8 6.7 
2,2-1,4-1,1 8 6.7 
1,2-2,4-2,2 6 5.0 
Y-Y-Y 89 74.8 
Total 119 99.9 
This table shows the Pst/-(AC)n-VNTR46 combined genotype in the control population. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotypes were 1,2-1,4-1,1, 2,2-1 ,2-1 ,2 and 2,2-1,4-1,1 that each 
occurred at a frequency of6.7%. 
Table A2.4B: Frequency of Pst/-(AC)n-VNTR46 combined genotypes in the patient 
population 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
2,2-1,2-1,2 10 8.8 
1,2-1,2-1,2 10 8.8 
2,2-1,2-2,3 9 7.9 
2,2-2,4-1,2 7 6.1 
2,2-1,1-1,3 6 5.3 
Y-Y-Y 72 63.2 
Total 114 100.1 
This table shows the Psti-(AC)n-VNTR46 combined genotype in the patient population. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotypes were 2,2-1,2-1,2 and 1,2-1,2-1,2 that each occurred at a 
frequency of 8.8%. 
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Table A2.4C: Frequency of Pstl-(AC)n-VNTR46 combined genotypes in the mild 
group of patients 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
2,2-2,4-1,2 7 9.0 
2,2-1,2-1,2 6 7.7 
2,2-1,2-2,3 6 7.7 
1,2-1,2-1,2 5 6.4 
2,2-1,1-1,1 4 5.1 
2,2-1,4-1,1 4 5.1 
Y-Y-Y 46 59.0 
Total 78 100.0 
This table shows the Pstl-(AC)n-VNTR46 combined genotype in the mild group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-2,4-1,2 that occurred at a frequency of 9.0%. 
Table A2.4D: Frequency of Pst/-(AC)n-VNTR46 combined genotypes in the severe 
group of patients 
Psti-(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2-1,2 5 13.9 
2,2-1,2-1,2 4 ll.l 
2,2-1,2-2,3 3 8.3 
2,2-1,1-1,3 3 8.3 
2,2-2,2-2,3 2 5.6 
Y-Y-Y 19 52.8 
Total 36 100.0 
This table shows the Pst/-(AC)n-VNTR46 combined genotype in the severe group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2-1,2 that occurred at a frequency of 13.9%. 
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Table A2.4E: Frequency of Pst/-(AC)n-VNTR46 combined genotypes in tbe OFS=O 
group of patients 
Pst/-(A~)n-VNTR46 Number (n) Frequency(%) 
2,2-2,4-1,2 8 9.1 
2,2-1,2-2,3 7 8.0 
2,2-1,1-1,1 6 6.8 
2,2-1,2-1,2 5 5.7 
1,2-1,4-1,3 5 5.7 
Y-Y-Y 57 64.8 
Total 88 100.1 
This table shows the Pstl-(AC)n-VNTR46 combined genotype in the OFS=O group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-2,4-1,2 that occurred at a frequency of 9.1 %. 
Table A2.4F: Frequency of Pst/-(AC)n-VNTR46 combined genotypes in tbe OFS:2!:1 
group of patients 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2-1,2 8 17.4 
2,2-1,2-1 ,2 6 13.0 
2,2-1,2-2,3 3 6.5 
Y-Y-Y 29 63.0 
Total 46 99.9 
This table shows the Pstl-(AC)n-VNTR46 combined genotype in the OFS~l group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was I ,2-1,2-1 ,2 that occurred at a frequency of 17 .4%. 
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Table A2.4G: Frequency of PstJ-(AC)n-VNTR46 combined genotypes in the OFS~ 
group of patients 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2-1,2 6 18.2 
2,2-1,2-1,2 5 15.2 
2,2-1,5-1,3 2 6.1 
2,2-1,2-2,3 2 6.1 
2,2-1,1-1,3 2 6.1 
Y-Y-Y 16 48.5 
Total 33 100.2 
This table shows the Pstl-(AC)n-VNTR46 combined genotype in the OFS~2 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2-1,2 that occurred at a frequency of 18.2%. 
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Table A2.4H: Frequency of Pst/-(AC)n-VNTR46 combined genotypes in the OFS;8 
group of patients 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2-1,2 5 26.3 
2,2-1,2-2,3 2 10.5 
2,2-1,1-1,3 2 10.5 
2,2-2,2-2,3 1 5.3 
2,2-4,6-1 ,1 1 5.3 
2,2-1,5-1,3 1 5.3 
2,2-1,1-1,1 5.3 
2,2-2,2-6,6 1 5.3 
1,2-1,4-1,1 1 5.3 
2,2-1,5-1,1 5.3 
2,2-1,1-3,3 1 5.3 
1,2-2,4-1,1 5.3 
2,2-1,2-1 2 1 5.3 
Total 19 100.3 
This table shows the Pstl-(AC)n-VNTR46 combined genotype in the OFS~3 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was 1,2-1,2-1,2 that occurred at a frequency of 26.3%. 
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Table A2.41: Frequency of Psd-(AC)n-VNTR46 combined genotypes in the OFS~4 
group of patients 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2-1,2 3 25.0 
2,2-1,1-1,3 2 16.7 
2,2-2,2-2,3 1 8.3 
2,2-4,6-1,1 1 8.3 
2,2-1,2-2,3 1 8.3 
1,2-1,4-1,1 1 8.3 
2,2-1,5-1,1 1 8.3 
2,2-1,1-3,3 1 8.3 
2,2-1 2-1 2 1 8.3 
Total 12 99.8 
This table shows the Pstl-(AC)n-VNTR46 combined genotype in the OFS~4 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was I ,2-1,2-1 ,2 that occurred at a frequency of 25 .0%. 
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Table A2.4J: Frequency of Pstl-(AC)n-VNTR46 combined genotypes in tbe alcoholic 
group of patients 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
2,2-2,4-1,2 3 I6.7 
1,2-1,1-1,3 2 Il.l 
1,2-1,2-1,2 2 Il.l 
2,2-3,4-1,1 2 Il.l 
1,2-2,4-2,2 I 5.6 
2,2-1,1-1,3 I 5.6 
2,2-2,4-1,1 5.6 
1,2-1,4-1,3 5.6 
2,2-1,5-1,1 5.6 
2,2-1,2-3,3 I 5.6 
1,2-2,4-1,2 5.6 
2,2-4,5-1,1 I 5.6 
1,1-1 2-11 5.6 
Total IS I00.4 
This table shows the Pstl-(AC)n-VNTR46 combined genotype in the alcoholic group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was 2,2-2,4-1,2 that occurred at a frequency of 16. 7%. 
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Table A2.4K: Frequency of Pst/-(AC)n-VNTR46 combined genotypes in the idiopathic 
group of patients 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2-1,2 5 15.2 
2,2-1,2-1,2 3 9.1 
2,2-2,2-2,3 2 6.1 
1,2-2,7-1,2 2 6.1 
2,2-2,4-1,2 2 6.1 
2,2-1,2-2,3 2 6.1 
Y-Y-Y 17 51.5 
Total 33 100.2 
This table shows the Pstl-(AC)n-VNTR46 combined genotype in the idiopathic group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2-1,2 that occurred at a frequency of 15.2%. 
Table A2.4L: Frequency of Pst/-(AC)n-VNTR46 combined genotypes in tbe gallstone 
group of patients 
Pstl-(AC)n-VNTR46 Number (n) Frequency(%) 
1,2-1,2-1,2 7 11.1 
2,2-1,2-2,3 7 11.1 
2,2-1,1-1,1 4 6.3 
Y-Y-Y 45 71.4 
Total 63 99.9 
This table shows the Pstl-(AC)n-VNTR46 combined genotype in the gallstone group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotypes were 1,2-1,2-1,2 and 2,2-1,2-2,3 that each occurred at a 
frequency of 11.1 %. 
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Table A2.SA: Frequency of Pstl-Aval-Aiul-Taql combined genotypes in the control 
population 
Pstl-Aval-Alul-Taql Number (n) Frequency(%) 
2,2-2,2-2,2-1,1 11 14.1 
2,2-1,1-1,1-1,1 11 14.1 
1,2-1,2-1,2-1,2 7 9.0 
1,2-1,2-1,2-1,1 7 9.0 
2,2-1,1-1,1-1,2 7 9.0 
1,2-1,1-1,1-1,1 6 7.7 
1,2-1,1-1,1-1,2 5 6.4 
2,2-1,2-1,2-1,1 4 5.1 
1,2-2,2-2,2-1,1 4 5.1 
Y-Y-Y-Y 16 20.5 
Total 78 100.0 
This table shows the Pst/-Avai-Aiu/-Taql combined genotype in the control population. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotypes were 2,2-2,2-2,2-1,1 and 2,2-1,1-1,1-1,1 that each 
occurred at a frequency of 14.1 %. 
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Table A2.SB: Frequency of Pstl-Aval-Alul-Taql combined genotypes in the patient 
population 
Pstl-Aval-Alul-Taql Number (n) Frequency(%) 
2,2-1,2-1,2-1,1 25 22.3 
2,2-1,1-1,1-1,1 15 13.4 
2,2-1,1-1,1-1,2 14 12.5 
1,2-1,2-1,2-1,1 12 10.7 
1,2-1,2-1,2-1,2 9 8.0 
2,2-1,2-1,2-1,2 8 7.1 
1,2-1,1-1,1-1,1 8 7.1 
1,2-1,1-1,1-1,2 6 5.4 
Y-Y-Y-Y 15 13.4 
Total 112 99.9 
This table shows the Pstl-Aval-Aiul-Taql combined genotype in the patient population. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-1,2-1,2-1, I that occurred at a frequency of 22.3%. 
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Table A2.5C: Frequency of Pstl-Aval-Aiul-Taql combined genotypes in the mild 
group of patients 
Pstl-Aval-Aiul-Taql Number (n) Frequency(%) 
2,2-1,2-1,2-1,1 18 23.4 
2,2-1,1-1,1-1,1 11 14.3 
2,2-1,1-1,1-1,2 8 10.4 
1,2-1,2-1,2-1,1 8 10.4 
2,2-1,2-1,2-1 ,2 6 7.8 
1,2-1,1-1,1-1,1 6 7.8 
1,2-1,2-1,2-1,2 5 6.5 
1,2-1,1-1,1-1,2 4 5.2 
Y-Y-Y-Y 11 14.3 
Total 77 100.1 
This table shows the Pstf-Aval-Alul-Taqf combined genotype in the mild group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-1,2-1,2-1, I that occurred at a frequency of23.4%. 
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Table A2.SD: Frequency of Pstl-Aval-Aiul-Taql combined genotypes in the severe 
group of patients 
Pstl-Aval-Aiul-Taql Number (n) Frequency(%) 
2,2-1,2-1,2-1,1 8 22.9 
2,2-1,1-1,1-1,2 5 14.3 
1,2-1,2-1,2-1,2 4 11.4 
2,2-1,1-1,1-1,1 4 11.4 
1,2-1,1-1,1-1,2 3 8.6 
1,2-1,2-1,2-1,1 3 8.6 
1,2-1,1-1,1-1,1 2 5.7 
2,2-1,2-1,2-1,2 2 5.7 
Y-Y-Y-Y 4 11.4 
Total 35 100.0 
This table shows the Pstl-Aval-Aiul-Taql combined genotype in the severe group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-1,2-1,2-1, I that occurred at a frequency of22.9%. 
322 
Table A2.5E: Frequency of Pstl-Aval-Alul-Taql combined genotypes in the OFS=O 
group of patients 
Pstl-Aval-Alul-Taql Number (n) Frequency(%) 
2,2-1,2-1,2-1,1 14 20.9 
2,2-1,1-1,1-1,1 13 19.4 
1,2-1,2-1,2-1,1 6 9.0 
1,2-1,1-1,1-1,1 6 9.0 
2,2-1 ,2-1,2-1 ,2 5 7.5 
2,2-1,1-1,1-1,2 4 6.0 
1,2-1,2-1,2-1,2 4 6.0 
1,2-1,1-1,1-1,2 4 6.0 
Y-Y-Y-Y 11 16.4 
Total 67 100.2 
This table shows the Pstl-Aval-Aiul-Taql combined genotype in the OFS=O group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-1,2-1 ,2-1, 1 that occurred at a frequency of20.9%. 
Table A2.5F: Frequency of Pstl-Aval-Alul-Taql combined genotypes in the OFS<::1 
group of patients 
Pstl-Aval-Aiul-Taql Number (n) Frequency(%) 
2,2-1,2-1,2-1,1 11 24.4 
2,2-1,1-1,1-1,2 10 22.2 
1,2-1,2-1,2-1,1 6 13.3 
2,2-1,2-1,2-1,2 3 6.7 
1,2-1,2-1,2-1,2 3 6.7 
Y-Y-Y-Y 12 26.7 
Total 45 100.0 
This table shows the Pstl-Aval-Aiul-Taql combined genotype in the OFS~1 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-1,2-1,2-1,1 that occurred at a frequency of24.4%. 
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Table A2.5G: Frequency of Pstl-Aval-Alul-Taql combined genotypes in the OFS~ 
group of patients 
Pstl-Aval-Alul-Taql Number (n) Frequency(%) 
2,2-1,2-1,2-1,1 7 21.9 
2,2-1,1-1,1-1,2 7 21.9 
1,2-1,2-1,2-1,2 5 15.6 
2,2-1,2-1,2-1,2 3 9.4 
1,2-1,2-1,2-1,1 3 9.4 
1,2-1,1-1,1-1,1 2 6.3 
2,2-1,1-1,1-1,1 2 6.3 
Y-Y-Y-Y 3 9.4 
Total 32 100.2 
This table shows the Pstl-Aval-Aluf-Taql combined genotype in the OFS<':2 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotypes were 2,2-1,2-1,2-1,1 and 2,2-1,1-1,1-1 ,2 that both occurred 
at a frequency of21.9%. 
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Table A2.5H: Frequency of Pstl-Aval-Aiul-Taql combined genotypes in the OFS<!:3 
group of patients 
Pstl-Aval-Alul-Taql Number(n) Frequency(%) 
2,2-1,2-1,2-1,1 5 27.8 
1,2-1,2-1,2-1,2 3 16.7 
1,2-1,2-1,2-1,1 2 11.1 
2,2-1,2-1,2-1,2 2 11.1 
2,2-1,1-1,1-1,2 2 11.1 
2,2-1,1-1,1-1,1 1 5.6 
2,2-2,2-2,2-1,1 1 5.6 
1,2-1,1-1,1-1,2 1 5.6 
1,2-1,1-1,1-1,1 1 5.6 
Total 18 100.2 
This table shows the Pstl-Aval-Aiul-Taql combined genotype in the OFS~3 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was 2,2-1,2-1,2-1,1 that occurred at a frequency of27.8%. 
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Table A2.51: Frequency of Pstl-Aval-Aiul-Taql combined genotypes in the OFS~4 
group of patients 
Psti-Aval-Aiul-Taql Number (n) Frequency(%) 
2,2-1,1-1,1-1,2 3 25.0 
2,2-1,2-1,2-1,1 2 I6.7 
1,2-1,2-1,2-1,1 2 I6.7 
2,2-1,2-1,2-1,2 2 I6.7 
2,2-1,1-1,1-1,1 I 8.3 
1,2-1,1-1,1-1,2 I 8.3 
1,2-1,2-1,2-1,2 I 8.3 
Total I2 IOO.O 
This table shows the Pstf-Aval-Alul-Taql combined genotype in the OFS~4 group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was 2,2-1,1-1,1-1,2 that occurred at a frequency of25.0%. 
Table A2.5J: Frequency of Pstl-Aval-Aiui-Taql combined genotypes in the alcoholic 
group of patients 
Pstl-Aval-Aiul-Taql Number (n) Frequency(%) 
2,2-1,2-1,2-1,1 6 33.3 
1,2-1,2-1,2-1,2 3 I6.7 
2,2-1,1-1,1-1,1 3 16.7 
2,2-1,1-1,1-1,2 2 11.1 
1,2-1,1-1,2-1,1 I 5.6 
1,2-1,1-1,1-1,1 5.6 
1,1-1,2-1,2-1,1 1 5.6 
1,2-1,2-1,2-1,1 1 5.6 
Total 18 I00.2 
This table shows the Pstl-Aval-Alul-Taql combined genotype in the alcoholic group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. The most 
common combined genotype was 2,2-1,2-1,2-1, I that occurred at a frequency of 33 .3%. 
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Table A2.5K: Frequency of Pstl-Aval-Aiul-Taql combined genotypes in the idiopathic 
group of patients 
Pstl-Aval-Aiul-Taql Number (n) Frequency(%) 
2,2-1,1-1,1-1,2 5 15.6 
2,2-1,2-1,2-1,1 5 15.6 
1,2-1,1-1,1-1,2 4 12.5 
1,2-1,2-1,2-1,1 4 12.5 
1,2-1,2-1,2-1,2 3 9.4 
2,2-1,1-1,1-1,1 3 9.4 
1,2-1,1-1,1-1,1 3 9.4 
1,2-2,2-2,2-1,1 2 6.3 
Y-Y-Y-Y 3 9.4 
Total 32 100.1 
This table shows the Pstl-Ava!-Aiul-Taql combined genotype in the idiopathic group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotypes were 2,2-1,1-1,1-1,2 and 2,2-1,2-1,2-1, I that each 
occurred at a frequency of 15.6%. 
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Table A2.5L: Frequency of Pstl-Aval-Aiui-Taql combined genotypes in the gallstone 
group of patients 
Pstl-Aval-Alul-Taql Number(n) Frequency(%) 
2,2-1,2-1,2-1,1 14 22.6 
2,2-1,1-1,1-1,1 9 14.5 
2,2-1,1-1,1-1,2 7 11.3 
1,2-1,2-1,2-1,1 7 11.3 
2,2-1,2-1,2-1,2 7 11.3 
1,2-1,1-1,1-1,1 4 6.5 
2,2-2,2-2,2-1,1 4 6.5 
Y-Y-Y-Y 10 16.1 
Total 62 100.1 
This table shows the Pstl-Ava/-Alul-Taql combined genotype in the gallstone group of patients. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-1,2-1,2-l, l that occurred at a frequency of22.6%. 
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Table A2.6A: Frequency of Pstl-Mspl-VLP-VNTR86-Sspl combined genotypes in the 
control population 
Pstl-Mspl-VLP-VNTR86 -Sspl Number (n} Frequency(%) 
2,2-1,1-2,2-1,1-1,1 20 21.3 
1,2-1,1-2,2-1,1-1,1 18 19.1 
2,2-1,2-2,3-1,2-1,2 17 18.1 
1,2-1,2-2,3-1,2-1,2 14 14.9 
Y-Y-Y-Y-Y 25 26.6 
Total 94 100.0 
This table shows the Pstl-Mspf-VLP-VNTR86-Sspf combined genotype in the control population. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top ofthe table and the least common is shown at the bottom. Y-Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-1,1-2,2-1,1-1,1 that occurred at a frequency of 
21.3%. 
Table A2.6B: Frequency of Pstl-Mspl-VLP-VNTR86-Sspl combined genotypes in the 
patient population 
Pstl-Mspl-VLP-VNTR86 -Sspl Number(n) Frequency(%} 
2,2-1,1-2,2-1,1-1,1 39 34.2 
2,2-1,2-2,3-1,2-1,2 23 20.2 
1,2-1,1-2,2-1,1-1,1 22 19.3 
1,2-1,2-2,3-1,2-1,2 14 12.3 
Y-Y-Y-Y-Y 16 14.0 
Total 114 100.0 
This table shows the Pstf-Mspf-VLP-VNTR86-Sspf combined genotype in the patient population. n 
represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 2,2-1,1-2,2-1,1-1,1 that occurred at a frequency of 
34.2%. 
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Table A2.6C: Frequency of Pstl-Mspl-VLP-VNTR86-Sspl combined genotypes in the 
mild group of patients 
Pstl-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
2,2-1,1-2,2-1,1-1,1 23 29.5 
2,2-1,2-2,3-1,2-1,2 19 24.4 
1,2-1,1-2,2-1,1-1,1 13 16.7 
1,2-1,2-2,3-1,2-1,2 10 12.8 
2,2-2,2-3,3-2,2-2,2 4 5.1 
Y-Y-Y-Y-Y 9 11.5 
Total 78 100.0 
This table shows the Pstl-Mspl-VLP-VNTR86-Sspl combined genotype in the mild group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotype was 2,2-1,1-2,2-1,1-1,1 that occurred at a 
frequency of29.5%. 
Table A2.6D: Frequency of Pstl-Mspl-VLP-VNTR86-Sspl combined genotypes in the 
severe group of patients 
Pstl-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
2,2-1,1-2,2-1,1-1,1 17 47.2 
1,2-1,1-2,2-1,1-1,1 8 22.2 
2,2-1,2-2,3-1,2-1,2 4 11.1 
1,2-1,2-2,3-1,2-1,2 4 ll.l 
Y-Y-Y-Y-Y 3 8.3 
Total 36 99.9 
This table shows the Pstl-Mspl-VLP-VNTR86-Sspl combined genotype in the severe group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotype was 2,2-1,1-2,2-1,1-1, I that occurred at a 
frequency of 4 7 .2%. 
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Table A2.6E: Frequency of Pstl-Mspl-VLP-VNTR86-Sspl combined genotypes in the 
OFS=O group of patients 
Pstl-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
2,2-1,1-2,2-1,1-1,1 22 32.4 
2,2-1,2-2,3-1,2-1,2 15 22.1 
1,2-1,1-2,2-1,1-1,1 11 16.2 
1,2-1,2-2,3-1,2-1,2 9 13.2 
Y-Y-Y-Y-Y 11 16.2 
Total 68 100.1 
This table shows the Pstl-Mspl-VLP-VNrR86-Sspl combined genotype in the OFS=O group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotype was 2,2-1,1-2,2-1,1-1,1 that occurred at a 
frequency of 32.4%. 
Table A2.6F: Frequency of Pstl-Mspl-VLP-VNTR86-Sspl combined genotypes in the 
OFS~1 group of patients 
Pstl-Mspl-VLP-VNTR86 -Sspl Number(n) Frequency(%) 
2,2-1,1-2,2-1,1-1,1 19 41.3 
1,2-1,1-2,2-1,1-1,1 9 19.6 
2,2-1,2-2,3-1,2-1,2 8 17.4 
1,2-1,2-2,3-1,2-1,2 5 10.9 
2,2-2,2-3,3-2,2-2,2 3 6.5 
Y-Y-Y-Y-Y 2 4.3 
Total 46 100.0 
This table shows the Pstl-Mspl-VLP-VNrR86-Sspl combined genotype in the OFS~1 group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotype was 2,2-1,1-2,2-1,1-1,1 that occurred at a 
frequency of 41.3%. 
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Table A2.6G: Frequency of Pstl-Mspi-VLP-VNTR86-Sspl combined genotypes in the 
OFS~ group of patients 
Psti-Mspl-VLP-VNTR86 -Sspl Number Frequency 
n % 
2,2-1,1-2,2-1,1-1,1 15 45.5 
1,2-1,1-2;2-1,1-1,1 6 18.2 
2,2-1,2-2,3-1,2-1,2 5 15.2 
1,2-1,2-2,3-1,2-1,2 4 12.1 
1,2-2,2-3,3-2,2-2,2 2 6.1 
Y-Y-Y-Y-Y 1 3.0 
Total 33 100.1 
This table shows the Pstl-Msp/-VLP-VNTR86-Ssp/ combined genotype in the OFS~2 group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotype was 2,2-1,1-2,2-1,1-1,1 that occurred at a 
frequency of 45.5%. 
Table A2.6H: Frequency of Pstl-Mspl-VLP-VNTR86-Sspl combined genotypes in the 
OFS~ group of patients 
Psti-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
2,2-1,1-2,2-1,1-1,1 9 47.4 
1,2-1,1-2,2-1,1-1,1 4 21.1 
1,2-1,2-2,3-1,2-1,2 3 15.8 
2,2-1,2-2,3-1,2-1,2 2 10.5 
2,2-2,2-3,3-2,2-2,2 5.3 
Total 19 100.1 
This table shows the Pstl-Msp/-VLP-VNTR86-Sspl combined genotype in the OFS~3 group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
The most common combined genotype was 2,2-1, 1-2,2-1,1-1, I that occurred at a frequency of 
47.4%. 
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Table A2.61: Frequency of Pstl-Mspi-VLP-VNTR86-Sspl combined genotypes in tbe 
OFS~4 group of patients 
Pstl-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
2,2-1,1-2,2-1,1-1,1 7 58.3 
1,2-1,2-2,3-1,2-1,2 3 25.0 
1,2-1,1-2,2-1,1-1,1 1 8.3 
2,2-1,2-2,3-1,2-1,2 1 8.3 
Total 12 99.9 
This table shows the Psti-Mspl-VLP-VNTR86-Sspl combined genotype in the OFS::::4 group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
The most common combined genotype was 2,2-1,1-2,2-1,1-1,1 that occurred at a frequency of 
58.3%. 
Table A2.6J: Frequency of Pstl-Mspi-VLP-VNTR86-Sspl combined genotypes in tbe 
alcoholic group of patients 
Pstl-Mspl-VLP-VNTR86 -Ss pi Number (n) Frequency(%) 
2,2-1,2-2,3-1,2-1,2 5 27.8 
1,2-1,1-2,2-1,1-1,1 4 22.2 
2,2-1,1-2,2-1,1-1,1 4 22.2 
1,2-1,2-2,3-1,2-1,2 2 11.1 
2,2-1,2-1,3-2,2-1,2 1 5.6 
2,2-2,2-3,3-2,2-2,2 1 5.6 
1 1-1,2-2,3-1 2-1,2 1 5.6 
Total 18 100.1 
This table shows the Pstl-Mspl-VLP-VNTR86-Sspl combined genotype in the alcoholic group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
The most common combined genotype was 2,2-1,2-2,3-1,2-1,2 that occurred at a frequency of 
27.8%. 
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Table A2.6K: Frequency of Pstl-Mspl-VLP-VNTR86-Sspl combined genotypes in the 
idiopathic group of patients 
Pstl-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
2,2-1,1-2,2-1,1-1,1 13 39.4 
1,2-1,1-2,2-1,1-1,1 9 27.3 
1,2-1,2-2;3-1,2-1,2 5 15.2 
2,2-1,2-2,3-1,2-1,2 2 6.1 
Y-Y-Y-Y-Y 4 12.1 
Total 33 100.1 
This table shows the Pstl-Mspl-VLP-VNTR86-Sspl combined genotype in the idiopathic group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotype was 2,2-1,1-2,2-1,1-1,1 that occurred at a 
frequency of39.4%. 
Table A2.6L: Frequency of Psd-Mspl-VLP-VNTR86-Sspl combined genotypes in the 
gallstone group of patients 
Pstl-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
2,2-1,1-2,2-1,1-1,1 24 38.1 
2,2-1,2-2,3-1,2-1,2 16 25.4 
1,2-1,2-2,3-1,2-1.2 7 11.1 
1,2-1,1-2,2-1,1-1,1 7 11.1 
1,2-2,2-3,3-2,2-2,2 4 6.3 
2,2-2,2-3,3-2,2-2,2 4 6.3 
Y-Y-Y-Y-Y I 1.6 
Total 63 99.9 
This table shows the Psll-Mspl-VLP-VNTR86-Sspl combined genotype in the gallstone group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotype was 2,2-1,1-2,2-1,1-1,1 that occurred at a 
frequency of 38.1 %. 
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Table A2.7A: Frequency of (AC)n-VNTR46-Aval-Alul-Taq/ combined genotypes in 
the control population 
(AC)n-VNTR46 -Aval-Aiul-Taql Number (n) Frequency(%) 
1,4-1,1-1,1-1,1-1,2 5 6.3 
2,4-1,2-1,2-1,2-1,1 4 5.0 
1,2-1,2-2,2-2,2-1,1 4 5.0 
Y-Y-Y-Y-Y 67 83.8 
Total 80 100.1 
This table shows the (AC)n-VNTR46-Aval-Aiul-Taql combined genotype in the control population. 
n represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top of the table and the least common is shown at the bottom. Y-Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,4-1,1-1,1-1,1-1,2 that occurred at a frequency of 
6.3%. 
Table A2.7B: Frequency of (AC)n-VNTR46-Ava/-Alul-Taql combined genotypes in 
the patient population 
46 (AC)n-VNTR -Aval-Aiul-Taql Number (n) Frequency(%) 
1,2-1,2-1,2-1,2-1,2 8 7.1 
1,2-1,2-1,2-1,2-1,1 6 5.3 
1,2-1,2-1,1-1,1-1,2 6 5.3 
1,4-1,1-1,1-1,1-1,2 6 5.3 
y- y- y- Y- y 87 77.0 
Total 113 100.0 
This table shows the (AC)n-VNTR46-Aval-Alul-Taql combined genotype in the patient population. 
n represents the number of subjects with each genotype combination. The most common combined 
genotype is shown at the top ofthe table and the least common is shown at the bottom. Y-Y-Y-Y-Y 
represents the sum total of the combined genotypes that occurred at a frequency of less than 5%. 
The most common combined genotype was 1,2-1,2-1,2-1,2-l,2 that occurred at a frequency of 
7.1%. 
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Table A2.7C: Frequency of (AC)n-VNTR46-Aval-Alul-Taql combined genotypes in 
the mild group of patients 
46 (AC)n-VNTR -Avai-Aiul-Taql Number (n) Frequency(%) 
1,2-1,2-1,2-1,2-1,2 5 6.4 
1,4-1,1-1,1-1,1-1,2 5 6.4 
2,4-1,2-1,2-1,2-1,1 5 6.4 
y- y- y- Y- y 63 80.8 
Total 78 100.0 
This table shows the (AC)n-VNTR46-Aval-Alul-Taql combined genotype in the mild group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotypes were I ,2-1,2-1,2-1,2-1 ,2, I ,4-1,1-1, 1-l, 1-l ,2 
and 2,4-1 ,2-1,2-1 ,2-l, I that each occurred at a frequency of 6.4%. 
Table A2.7D: Frequency of (AC)n-VNTR46-Aval-Alul-Taql combined genotypes in 
the severe group of patients 
46 (AC)n-VNTR -Avai-Aiul-Taql Number(n) Frequency(%) 
1,2-1,2-1,2-1,2-1,2 3 8.6 
1,2-1,2-1,2-1,2-1,1 3 8.6 
1,2-2,3-1,2-1,2-1,1 3 8.6 
1,2-1,2-1,1-1,1-1,2 3 8.6 
Y-Y-Y-Y-Y 23 65.7 
Total 35 100.1 
This table shows the (AC)n-VNTR46-Aval-Alul-Taql combined genotype in the severe group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotypes were I ,2-1 ,2-l ,2-l ,2-1 ,2, l ,2-1 ,2-l ,2-l ,2-l, 1, 
I ,2-2,3-1,2-1,2-1, I and I ,2-1 ,2-1,1-1,1-1 ,2 that all occurred at a frequency of 8.6%. 
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Table A2.7E: Frequency of (AC)n-VNTR46-Aval-Alul-Taql combined genotypes in 
the OFS=O group of patients 
46 (AC)n-VNTR -Avai-Afui-Taql Number (n) Frequency(%) 
1,2-1,2-1,2-1,2-1,2 4 5.9 
1,4-1,1-1,1-1,1-1,2 4 5.9 
2,4-1,2-1,2-1,2-1,1 4 5.9 
Y-Y-Y-Y-Y 56 82.4 
Total 68 100.1 
This table shows the (AC)n-VNTR46-Aval-Alul-Taql combined genotype in the OFS=O group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotypes were 1,2-1,2-1,2-1,2-1,2, 1,4-1,1-I,l-l,I-1,2 
and 2,4-1,2-1,2-1,2-1, I that each occurred at a frequency of 5 .9%. 
Table A2.7F: Frequency of (AC)n-VNTR46-Aval-Alul-Taql combined genotypes in 
the OFS<!:1 group of patients 
46 (AC)n-VNTR -Ava/-Afu/-Taql Number (n) Frequency(%) 
1,2-1,2-1,1-1,1-1,2 5 11.1 
1,2-1,2-1,2-1,2-1,2 4 8.9 
1,2-1,2-1,2-1,2-1,1 4 8.9 
1,2-2,3-1,2-1,2-1,1 3 6.7 
1,5-1,3-1,2-1,2-1,1 3 6.7 
Y-Y-Y-Y-Y 26 57.8 
Total 45 100.1 
This table shows the (AC)n-VNTR46-Aval-Alul-Taql combined genotype in the OFS~l group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotype was 1,2-1,2-I,l-l,l-1,2 that occurred at a 
frequency of 11.1 %. 
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Table A2.7G: Frequency of (AC)n-VNTR46-Aval-Aiul-Taql combined genotypes in 
the OFS~ group of patients 
46 (AC)n-VNTR -Aval-Aiul-Taql Number (n) Frequency(%) 
1,2-1,2-1,2-1,2-1,2 4 12.5 
1,2-1,2-1,1-1,1-1,2 3 9.4 
1,2-1,2-1,2-1,2-1,1 3 9.4 
1,5-1,3-1,2-1,2-1,1 2 6.3 
1,2-2,3-1,2-1,2-1,1 2 6.3 
y- y- y- Y- y 18 56.3 
Total 32 100.2 
This table shows the (AC)n-VNfR46-Aval-Alui-Taql combined genotype in the OFS~2 group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotype was I ,2-1,2-1 ,2-1 ,2-1 ,2-that occurred at a 
frequency of 12.5%. 
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Table A2.7H: Frequency of (AC)n-VNTR46-Aval-Alul-Taql combined genotypes in 
tbe OFS~ group of patients 
46 (AC)n-VNTR -Aval-Aiul-Taql Number(n) Frequency(%) 
1,2-1,2-1,2-1,2-1,2 3 16.7 
1,2-1,2-1,2-1,2-1,1 2 11.1 
1,2-2,3-1,2-1,2-1,1 2 11.1 
2,2-2,3-1,2-1,2-1,1 5.6 
4,6-1,1-1,1-1,1-1,1 5.6 
1,5-1,3-1,2-1,2-1,1 5.6 
2,2-6,6-2,2-2,2-1,1 5.6 
1,4-1,1-1,1-1,1-1,2 5.6 
1,5-1,1-1,1-1,1-1,2 5.6 
1,1-3,3-1,2-1,2-1,2 5.6 
2,4-1,1-1,1-1,1-1,1 1 5.6 
1,2-1,2-1,1-1,1-1,2 5.6 
1,1-1,3-1,2-1,2-1,2 1 5.6 
1,2-1,3-1,1-1,1-1 2 1 5.6 
Total 18 100.5 
This table shows the (AC)n-VNTR46-Aval-Alul-Taql combined genotype in the OFS<':3 group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
The most common combined genotype was 1,2-1,2-1,2-1,2-1,2 that occurred at a frequency of 
16.7%. 
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Table A2.71: Frequency of (AC)n-VNTR46-Ava/-Alul-Taql combined genotypes in tbe 
OFS~4 group of patients 
46 (AC)n-VNTR -A val-Aiul-Taql Number(n) Frequency(%) 
1,2-1,2-1,2-1,2-1,1 2 16.7 
2,2-2,3-1,2-1,2-1,1 1 8.3 
4,6-1,1-1,1-1,1-1,1 1 8.3 
1,2-2,3-1,2-1,2-1,1 1 8.3 
1,4-1,1-1,1-1,1-1,2 1 8.3 
1,5-1,1-1,1-1,1-1,2 1 8.3 
1,1-3,3-1,2-1,2-1,2 1 8.3 
1,2-1,2-1,1-1,1-1,2 1 8.3 
1,1-1,3-1,2-1,2-1,2 1 8.3 
1,1-1,3-1,1-1,1-1,2 1 8.3 
1,2-1,2-1,2-1,2-1,2 1 8.3 
Total 12 99.7 
This table shows the (AC)n-VNfR46-Aval-Aiul-Taql combined genotype in the OFS::.e:4 group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
The most common combined genotype was 1,2-1,2-1,2-1,2-1,1 that occurred at a frequency of 
16.7%. 
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Table A2.7J: Frequency of(AC)n-VNTR46-Aval-Aiui-Taql combined genotypes in the 
alcoholic group of patients 
46 (AC)n-VNTR -Aval-Alul-Taql Number (n) Frequency(%) 
2,4-1,2-1,2-1,2-1,1 3 16.7 
1,2-1,2-1,2-1,2-1,2 2 11.1 
3,4-1,1-1,1-1,1-1,1 2 11.1 
2,4-2,2-1,1-1,2-1,1 1 5.6 
1,1-1,3-1,2-1,2-1,2 1 5.6 
1,1-1,3-1,2-1,2-1,1 1 5.6 
1,1-1,3-1,1-1,1-1,2 1 5.6 
2,4-1,1-1,2-1,2-1,1 1 5.6 
1,4-1,3-1,2-1,2-1,1 1 5.6 
1,5-1,1-1,1-1,1-1,2 5.6 
1,2-3,3-1,2-1,2-1,1 1 5.6 
2,4-1,2-1,1-1,1-1,1 5.6 
4,5-1,1-1,1-1,1-1,1 1 5.6 
1,2-1,1-1,2-1,2-1,1 1 5.6 
Total 18 100.5 
This table shows the (AC)n-VNTR46-Aval-Aiul-Taql combined genotype in the alcoholic group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
The most common combined genotype was 2,4-l ,2-1,2-1,2-1, 1 that occurred at a frequency of 
16.7%. 
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Table A2.7K: Frequency of (AC)n-VNTR46-Aval-Aiul-Taql combined genotypes in 
the idiopathic group of patients 
46 (AC)n-VNTR -Aval-Aiul-Taql Number (n) Frequency(%) 
1,2-1,2-1,2-1,2-1,2 3 9.4 
1,2-1,2-1,1-1,1-1,2 3 9.4 
1,2-1,2-1,2-1,2-1,1 2 6.3 
1,4-1,1-1,1-1,1-1,2 2 6.3 
Y-Y-Y-Y-Y 22 68.8 
Total 32 100.2 
This table shows the (AC)n-VNfR46-Avaf-Aiuf-Taqf combined genotype in the idiopathic group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotypes were 1,2-1,2-1 ,2-1 ,2-1 ,2 and I ,2-1 ,2-1,1-1, I-
I ,2 that each occurred at a frequency of 9 .4%. 
Table A2.7L: Frequency of (AC)n-VNTR46-Aval-Alul-Taql combined genotypes in 
the gallstone group of patients 
46 (AC)n-VNTR -Aval-Aiul-Taq/ Number (n) Frequency(%) 
1,2-1,2-1,2-1,2-1,1 4 6.3 
1,4-1,1-1,1-1,1-1,2 4 6.3 
1,2-2,3-1,2-1,2-1,1 4 6.3 
Y-Y-Y-Y-Y 51 81.0 
Total 63 99.9 
This table shows the (AC)n-VNTR46-Ava!-A/uf-Taqf combined genotype in the gallstone group of 
patients. n represents the number of subjects with each genotype combination. The most common 
combined genotype is shown at the top of the table and the least common is shown at the bottom. 
Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a frequency of 
less than 5%. The most common combined genotypes were 1,2-1,2-1,2-1,2-1, I, 1,4-1,1-1,1-1, 1-1 ,2 
and 1,2-2,3-1,2-1,2-1,1 that each occurred at a frequency of6.3%. 
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Table A2.8A: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the control population 
{AC)n-VNTR46-Mspl-VLP-VNTR86-Sspl Number{n) Frequency{%) 
1,4-1,1-1,1-2,2-1,1-1,1 8 8.5 
2,4-1,2-1,1-2,2-1,1-1,1 5 5.3 
Y-Y-Y-Y-Y-Y 81 86.2 
Total 94 100.0 
This table shows the (AC)n-VNTR46-Msp/-VLP-VNTR86-&p/ combined genotype in the control 
population. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was I ,4-1,1-1,1-2,2-1,1-1, I that 
occurred at a frequency of 8.5%. 
Table A2.8B: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the patient population 
{AC)n-VNTR46 -Mspl-VLP-VNTR86 -Sspl Number(n) Frequency(%) 
1,2-1,2-1,2-2,3-1,2-1,2 10 8.7 
1,2-1,2-1,1-2,2-1,1-1,1 10 8.7 
1,1-1,3-1,1-2,2-1,1-1,1 7 6.1 
2,4-1,2-1,2-2,3-1,2-1,2 7 6.1 
1,4-1,1-1,1-2,2-1,1-1,1 7 6.1 
Y-Y-Y-Y-Y-Y 74 64.3 
Total 115 100.0 
This table shows the (AC)n-VNTR46-Mspl-VLP-VNTR86-Sspl combined genotype in the patient 
population. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotypes were 1,2-1,2-1,2-2,3-1,2-l,2 
and 1,2-1,2-1, 1-2,2-1,1-1, I that each occurred at a frequency of 8.7%. 
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Table A2.8C: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the mild group of patients 
(AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ Number(n) Frequency(%) 
2,4-1,2-1,2-2,3-1,2-1,2 7 8.9 
1,2-1,2-1,2-2,3-1,2-1,2 6 7.6 
1,4-1,1-1,1-2,2-1,1-1,1 6 7.6 
1,2-1,2-1,1-2,2-1,1-1,1 5 6.3 
1,1-1,3-1,1-2,2-1,1-1,1 4 5.1 
1,2-2,3-1,2-2,3-1,2-1,2 4 5.1 
Y-Y-Y-Y-Y-Y 47 59.5 
Total 79 100.1 
This table shows the (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined genotype in the mild 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was 2,4-1,2-1,2-2,3-1,2-1,2 that 
occurred at a frequency of 8.9%. 
Table A2.8D: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the severe group of patients 
(AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ Number (n) Frequency(%) 
1,2-1,2-1,1-2,2-1,1-1,1 5 13.9 
1,2-1,2-1,2-2,3-1,2-1,2 4 11.1 
1,2-2,3-1,1-2,2-1,1-1,1 3 8.3 
1,1-1,3-1,1-2,2-1,1-1,1 3 8.3 
2,2-2,3-1,1-2,2-1,1-1,1 2 5.6 
1,1-1,1-1,1-2,2-1,1-1,1 2 5.6 
Y-Y-Y-Y-Y-Y 17 47.2 
Total 36 100.0 
This table shows the (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined genotype in the severe 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was 1,2-1,2-1,1-2,2-1,1-1,1 that 
occurred at a frequency of 13.9%. 
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Table A2.8E: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the OFS=O group of patients 
(AC)n-VNTR46-Msp/-VLP-VNTR86-Sspl Number(n) Frequency(%) 
2,4-1,2-1,2-2,3-1,2-1,2 6 8.7 
1,2-1,2-1,2-2,3-1,2-1,2 5 7.2 
1,1-1,3-1,1-2,2-1,1-1,1 5 7.2 
1,4-1,1-1,1-2,2-1,1-1,1 5 7.2 
1,2-2,3-1,2-2,3-1,2-1,2 4 5.8 
Y-Y-Y-Y-Y-Y 44 63.8 
Total 69 99.9 
This table shows the (AC)n-VNTR46-Mspl-VLP-VNTR86-Sspl combined genotype in the OFS=O 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was 2,4-1,2-1,2-2,3-1,2-1,2 that 
occurred at a frequency of 8. 7%. 
Table A2.8F: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the OFS~1 group of patients 
(AC)n-VNTR46 -Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,2-1,2-1,1-2,2-1,1-1,1 9 19.6 
1,2-1,2-1,2-2,3-1,2-1,2 5 10.9 
y- y- y- y- Y- y 32 69.6 
Total 46 100.1 
This table shows the (AC)n-VNTR46-Mspl-VLP-VNTR86-Sspl combined genotype in the OFS~I 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency ofless than 5%. The most common combined genotype was I ,2-1,2-1,1-2,2-1, 1-1, I that 
occurred at a frequency of 19 .6%. 
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Table A2.8G: Frequency of (AC)n-VNTR46-MspJ-VLP-VNTR86-SspJ combined 
genotypes in the OFS~ group of patients 
(AC)n-VNTR46 -Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,2-1,2-1,1-2,2-1,1-1,1 7 21.2 
1,2-1,2-1,2-2,3-1,2-1,2 4 12.1 
2,2-1,2-1,1-2,2-1,1-1,1 2 6.1 
1,5-1,3-1,2-2,3-1,2-1,2 2 6.1 
1,2-2,3-1,1-2,2-1,1-1,1 2 6.1 
1,1-1,3-1,1-2,2-1,1-1,1 2 6.1 
Y-Y-Y-Y-Y-Y 14 42.4 
Total 33 100.1 
This table shows the (AC)n-VNTR46-Mspl-VLP-VNTR86-SspJ combined genotype in the OFS~2 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was 1,2-1,2-1,1-2,2-1,1-1, I that 
occurred at a frequency of 21.2%. 
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Table A2.8H: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the OFS~ group of patients 
(AC)n-VNTR46 -Mspl-VLP-VNTR86 -Ssp/ Number (n} Frequency(%} 
1,2-1,2-1,2-2,3-1,2-1,2 3 15.8 
1,2-1,2-1,1-2,2-1,1-1,1 3 15.8 
1,2-2,3-1,1-2,2-1,1-l,1 2 10.5 
1,1-1,3-1,1-2,2-1,1-1,1 2 10.5 
2,2-2,3-1,1-2,2-1,1-1,1 5.3 
4,6-1,1-1,1-2,2-1,1-1,1 1 5.3 
1,5-1,3-1,2-2,3-1,2-1,2 5.3 
1,1-1,1-1,1-2,2-1,1-1,1 5.3 
2,2-6,6-2,2-3,3-2,2-2,2 5.3 
1,4-1,1-1,1-2,2-1,1-1,1 5.3 
1,5-1,1-1,2-2,3-1,2-1,2 5.3 
1,1-3,3-1,1-2,2-1,1-1,1 5.3 
5.3 
Total 19 100.3 
This table shows the (AC)n-VNTR46-Mspl-VLP-VNTR86-Sspl combined genotype in the OFS~3 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. The most common combined genotypes were 1,2-1,2-1,2-2,3-1,2-1,2 and 1,2-1,2-1,1-2,2-
1,1-1,1 that both occurred at a frequency of 15.8%. 
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Table A2.81: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the OFS~4 group of patients 
(AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ Number(n) Frequency(%) 
1,2-1,2-1,2-2,3-1,2-1,2 3 25.0 
1,1-1,3-1,1-2,2-1,1-1,1 2 16.7 
2,2-2,3-1,1-2,2-1,1-1,1 1 8.3 
4,6-1,1-1,1-2,2-1,1-1,1 1 8.3 
1,2-2,3-1,1-2,2-1,1-1,1 8.3 
1,4-1,1-1,1-2,2-1,1-1,1 1 8.3 
1,5-1,1-1,2-2,3-1,2-1,2 l 8.3 
1,1-3,3-1,1-2,2-1,1-1,1 1 8.3 
1,2-1,2-1,1-2,2-1,1-1,1 1 8.3 
Total 12 99.8 
Tilis table shows the (AC)n-VNTR46-Msp/-VLP-VNTR86-&p/ combined genotype in the OFS2:4 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. The most common combined genotype was 1,2-1,2-1,2-2,3-1,2-l,2 that occurred at a 
frequency of 25 .0%. 
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Table A2.8J: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the alcoholic group of patients 
(AC)n-VNTR46 -Mspl-VLP-VNTR86 -Sspl Number(n) Frequency(%) 
2,4-1,2-1,2-2,3-1,2-1,2 4 22.2 
1,1-1,3-1,1-2,2-1,1-1,1 3 16.7 
2,4-2,2-1,1-2,2-1,1-1,1 1 5.6 
1,2-1,2-1,1-2,2-1,1-1,1 1 5.6 
2,4-1,1-1,1-2,2-1,1-1,1 5.6 
1,4-1,3-1,1-2,2-1,1-1,1 1 5.6 
1,5-1,1-1,2-2,3-1,2-1,2 5.6 
1,2-3,3-1,2-1,3-2,2-1,2 1 5.6 
4,5-1,1-2,2-3,3-2,2-2,2 1 5.6 
1,2-1,1-1,2-2,3-1,2-1,2 5.6 
3,4-1,1-1,1-2,2-1,1-1,1 1 5.6 
3,4-1,1-1,2-2,3-1,2-1,2 1 5.6 
1,2-1,2-1,2-2,3-1,2-1,2 1 5.6 
Total 18 100.5 
This table shows the (AC)n-VNTR46-Mspf-VLP-VNTR86-Sspf combined genotype in the alcoholic 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. The most common combined genotype was 2,4-1,2-1,2-2,3-1,2-1,2 that occurred at a 
frequency of22.2%. 
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Table A2.8K: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the idiopathic group of patients 
(AC)n-VNTR46 -Mspl-VLP-VNTR86 -Sspl Number(o) Frequency(%) 
1,2-1,2-1,1-2,2-1,1-1,1 5 15.2 
1,2-1,2-1,2-2,3-1,2-1,2 3 9.1 
2,2-2,3-1,1-2,2-1,1-1,1 3 9.1 
1,2-2,3-1,1-2,2-1,1-1,1 2 6.1 
1,4-1,1-1,1-2,2-1,1-1,1 2 6.1 
Y-Y-Y-Y-Y-Y 18 54.5 
Total 33 100.1 
This table shows the (AC)n-VNTR46-Msp/-VLP-VNTR86-&p/ combined genotype in the idiopathic 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was I ,2-1,2-1,1-2,2-1,1-1, I that 
occurred at a frequency of 15.2%. 
Table A2.8L: Frequency of (AC)n-VNTR46-Msp/-VLP-VNTR86-Ssp/ combined 
genotypes in the gallstone group of patients 
(AC)n-VNTR46 -Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,2-1,2-1,2-2,3-1,2-1,2 6 9.4 
1,4-1,1-1,1-2,2-1,1-1,1 5 7.8 
1,2-1,2-1,1-2,2-1,1-1,1 4 6.3 
1,2-2,3-1,2-2,3-1,2-1,2 4 6.3 
Y-Y-Y-Y-Y-Y 45 70.3 
Total 64 100.1 
This table shows the (AC)n-VNTR46-Msp/-VLP-VNTR86-&p/ combined genotype in the gallstone 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was I ,2-1,2-1,2-2,3-1,2-1 ,2 that 
occurred at a frequency of 9.4%. 
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Table A2.9A: Frequency of Aval-Alul-Taql-Mspi-VLP-VNTR86-Sspl combined 
genotypes in the control population 
Ava/-Aiu/-Taql-Msp/-VLP-VNTR86 -Ssp/ Number(n) Frequency(%) 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 10 12.5 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 9 11.3 
2,2-2,2-1,1-1,1-2,2-1,1-1,1 8 10.0 
2,2-2,2-1,1-1,2-2,3-1,2-1,2 7 8.8 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 6 7.5 
1,2-1,2-1,2-1,2-2,3-1,2-1,2 6 7.5 
Y-Y-Y-Y-Y-Y-Y 34 42.5 
Total 80 100.1 
This table shows the Aval-Aiul-Taql-Mspl-VLP-VNTR86-Sspl combined genotype in the control 
population. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was I, 1-1,1-1,1-1,1-2,2-1, 1-1, I 
that occurred at a frequency of 12.5%. 
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Table A2.9B: Frequency of Aval-Alul-Taql-Mspl-VLP-VNTR86-Sspl combined 
genotypes in tbe patient population 
Aval-Aiul-Taql-Mspl-VLP-VNTR86 -sspl Number(n) Frequency(%) 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 19 16.8 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 18 15.9 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 14 12.4 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 13 11.5 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 10 8.8 
1,2-1,2-1,2-1,2-2,3-1,2-1,2 7 6.2 
1,1-1,1-1,1-1,2-2,3-1,2-1,2 7 6.2 
Y-Y-Y-Y-Y-Y-Y 25 22.1 
Total 113 99.9 
This table shows the Aval-Aiu/-Taql-Mspi-VLP-VNTR86-Sspl combined genotype in the patient 
population. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was 1,2-1,2-l,l-1,2-2,3-l,2-l,2 
that occurred at a frequency of 16.8%. 
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Table A2.9C: Frequency of Aval-Alul-Taql-Mspl-VLP-VNTR86-Sspl combined 
genotypes in the mild group of patients 
Ava/-Aiul-Taql-Mspl-VLP-VNTR86 -Sspl Number(n) Frequency(%) 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 13 16.7 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 11 14.1 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 8 10.3 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 8 10.3 
1,1-1,1-1,1-1,2-2,3-1,2-1,2 7 9.0 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 6 7.7 
1,2-1,2-1,2-1,2-2,3-1,2-1,2 5 6.4 
Y-Y-Y-Y-Y-Y-Y 20 25.6 
Total 78 100.1 
This table shows the Aval-Aiul-Taql-Mspl-VLP-VNTR86-Sspl combined genotype in the mild 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was 1,2-1,2-1,1-1,2-2,3-1,2-1,2 
that occurred at a frequency of 16.7%. 
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Table A2.9D: Frequency of Aval-Aiul-Taql-Mspl-VLP-VNTR86-Sspl combined 
genotypes in the severe group of patients 
Aval-A/ul-Taqi-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 7 20.0 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 6 17.1 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 5 14.3 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 5 14.3 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 4 11.4 
1,2-1,2-1,2-1,2-2,3-1,2-1,2 2 5.7 
Y-Y-Y-Y-Y-Y-Y 6 17.1 
Total 35 99.9 
This table shows the Aval-Aluf-Taqf-Mspf-VLP-VNTR86-Sspf combined genotype in the severe 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was 1,1-1,1-1,2-1,1-2,2-1, 1-1,1 
that occurred at a frequency of20.0%. 
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Table A2.9E: Frequency of Aval-Aiui-Taql-Mspi-VLP-VNTR86-Sspl combined 
genotypes in tbe OFS=O group of patients 
Aval-A/ul-Taql-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 10 14.7 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 10 14.7 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 7 10.3 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 7 10.3 
1,1-1,1-1,1-1,2-2,3-1,2-1,2 7 10.3 
1,2-1,2-1,2-1,2-2,3-l,2-l,2 5 7.4 
1,2-1,2-1,2-1,1-2,2-l,l-1,1 4 5.9 
Y-Y-Y-Y-Y-Y-Y 18 26.5 
Total 68 100.1 
This table shows the Ava/-Aiul-Taql-Mspl-VLP-VNTR86-Sspl combined genotype in the OFS=O 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotypes were I ,2-1,2-1,1-1,2-2,3-1,2-
1,2 and 1,1-l,l-1,1-1,1-2,2-1,1-l,l that each occurred at a frequency of 14.7%. 
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Table A2.9F: Frequency of Avai-Aiul-Taql-Mspl-VLP-VNTR86-Sspl combined 
genotypes in the OFS<!::1 group of patients 
Aval-Aiul-Taq/-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 11 24.4 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 9 20.0 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 6 13.3 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 6 13.3 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 4 8.9 
Y-Y-Y-Y-Y-Y-Y 9 20.0 
Total 45 99.9 
This table shows the Aval-Alul-Taql-Mspl-VLP-VNTR86-Sspl combined genotype in the OFS;:>:l 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was I, 1-1,1-1 ,2-1,1-2,2-1,1-1, I 
that occurred at a frequency of 24.4%. 
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Table A2.9G: Frequency of Aval-Aiul-Taql-Mspl-VLP-VNTR86-Sspl combined 
genotypes in the OFS::::l group of patients 
Aval-Aiul-Taql-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 7 21.9 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 6 18.8 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 6 18.8 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 4 12.5 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 3 9.4 
1,2-1,2-1,2-1,2-2,3-1,2-1,2 2 6.3 
Y-Y-Y-Y-Y-Y-Y 4 12.5 
Total 32 100.2 
This table shows the Avaf-A/ul-Taql-Mspl-VLP-VNTR86-Sspl combined genotype in the OFS~2 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was I, 1-1,1-1,2-1,1-2,2-1,1-1,1 
that occurred at a frequency of 21.9%. 
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Table A2.9H: Frequency of Avai-Alul-Taql-Mspl-VLP-VNTR86-Ssp/ combined 
genotypes in the OFS~ group of patients 
Avai-Alul-Taql-Mspl-VLP-VNTR86-Sspl Number (n) Frequency(%) 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 4 22.2 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 3 16.7 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 3 16.7 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 3 16.7 
1,1-1,1-1,1-1,1-2,2-l,1-l,1 2 11.1 
2,2-2,2-1,1-2,2-3,3-2,2-2,2 5.6 
1,1-1,1-1,2-1,2-2,3-l,2-l,2 1 5.6 
1,2-1,2-1,2-1,2-2,3-l,2-l,2 1 5.6 
Total 18 100.2 
This table shows the Aval-Alul-Taql-Mspl-VLP-VNfR86-Sspl combined genotype in the OFS~3 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. The most common combined genotype was I ,2-1,2-1,2-1,1-2,2-1,1-1, I that occurred at a 
frequency of 22.2%. 
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Table A2.91: Frequency of Aval-Alul-Taql-Mspl-VLP-VNTR86-Sspl combined 
genotypes in the OFS~4 group of patients 
Aval-Aiul-Taql-Mspl-VLP-VNTR86 -Sspl Number(o) Frequency(%) 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 3 25.0 
1,2-1,2-1,1-1,1-2-2-1,1-1,1 2 16.7 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 2 16.7 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 2 16.7 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 I 8.3 
1,1-1,1-1,2-1,2-2,3-1,2-1,2 8.3 
1,2-1,2-1,2-1,2-2,3-1,2-1,2 8.3 
Total 12 100.0 
This table shows the Aval-Aiul-Taql-MspJ-VLP-VNfR86-Sspl combined genotype in the OFS~4 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. The most common combined genotype was I, 1-l, 1-l ,2-1, 1-2,2-l, 1-1,1 that occurred at a 
frequency of25.0%. 
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Table A2.9J: Frequency of Avai-Alul-Taqi-Mspi-VLP-VNTR86-Sspl combined 
genotypes in tbe alcoholic group of patients 
Avai-Aiul-Taql-Mspl-VLP-VNTR86-Sspl Number(n} Frequency(%} 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 4 22.2 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 3 16.7 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 2 11.1 
1,1-1,1-1,1-1,2-2,3-1,2-1,2 2 11.1 
1,1-1,2-1,1-1,1-2,2-1,1-1,1 1 5.6 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 1 5.6 
1,1-1,1-1,2-1,2-2,3-1,2-1,2 1 5.6 
1,2-1,2-1,1-1,2-1,3-2,2-1,2 1 5.6 
1,1-1,1-1,1-2,2-3,3-2,2-2,2 1 5.6 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 1 5.6 
1,2-1,2-1,2-1,2-2,3-1,2-1,2 5.6 
Total 18 100.3 
This table shows the Aval-Aiuf-Taql-Mspl-VLP-VNfR86-Sspl combined genotype in the alcoholic 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. The most common combined genotype was 1,2-1,2-1,1-1,2-2,3-1,2-1,2 that occurred at a 
frequency of 22.2%. 
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Table A2.9K: Frequency of Aval-Alul-Taql-Mspl-VLP-VNTR86-Sspl combined 
genotypes in tbe idiopathic group of patients 
Aval-Alul-Taql-Mspl-VLP-VNTR86 -Sspl Number (n) Frequency(%) 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 8 25.0 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 5 15.6 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 5 15.6 
1,2-1,2-1,1-1,2-2,3-1,2-1,2 3 9.4 
1,2-1,2-1,2-1,2-2,3-1,2-1,2 2 6.3 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 2 6.3 
Y-Y-Y-Y-Y-Y-Y 7 21.9 
Total 32 100.1 
This table shows the Avai-Alul-Taql-Mspl-VLP-VNTR86-Sspl combined genotype in the idiopathic 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was I, 1-1,1-1 ,2-1,1-2,2-1, 1-1, I 
that occurred at a frequency of25.0%. 
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Table A2.9L: Frequency of Aval-Aiul-Taql-Mspl-VLP-VNTR86-Sspl combined 
genotypes in the gallstone group of patients 
Ava/-Afu/-Taql-Mspl-VLP-VNTR86 -Sspl Number(n) Frequency(%) 
1,2-1,2-1,1-1,2-2~-1,2-1,2 12 19.0 
1,1-1,1-1,2-1,1-2,2-1,1-1,1 9 14.3 
1,1-1,1-1,1-1,1-2,2-1,1-1,1 8 12.7 
1,2-1,2-1,2-1,1-2,2-1,1-1,1 6 9.5 
1,1-1,1-1,1-1,2-2,3-1,2-1,2 5 7.9 
1,2-1,2-1,1-2,2-3,3-2,2-2,2 4 6.3 
1,2-1,2-1,2-1,2-2,3-1,2-1,2 4 6.3 
1,2-1,2-1,1-1,1-2,2-1,1-1,1 4 6.3 
2,2-2,2-1,1-2,2-3,3-2,2-2,2 4 6.3 
Y- Y- Y -Y -Y -Y -Y 7 11.1 
Total 63 99.7 
This table shows the Aval-Aiul-Taql-Mspl-VLP-VNTR86-Sspl combined genotype in the gallstone 
group of patients. n represents the number of subjects with each genotype combination. The most 
common combined genotype is shown at the top of the table and the least common is shown at the 
bottom. Y-Y-Y-Y-Y-Y-Y represents the sum total of the combined genotypes that occurred at a 
frequency of less than 5%. The most common combined genotype was I ,2-1,2-1,1-1,2-2,3-1 ,2-1 ,2 
that occurred at a frequency of 19.0%. 
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Summary o(the combi11ed gmrotvpe results 
(AC)11-VNTR46 combi11ed ge11otype 
The most common combined genotype in controls was 1 ,4-1, 1 that occurred with a 
frequency of 12.7%. The most common combined genotype in the total patients, mild, 
severe, OFS~1. OFS~2. OFS~3. OFS~4. idiopathic and gallstone groups was 1,2-1,2 that 
occurred at frequencies of 16.9%, 15.2%, 25.0%, 29.8%, 33.3%, 31.6%, 33.3%, 24.2% and 
17.2% respectively. The most common combined genotype in the OFS=O and alcoholic 
groups was 2,4-1,2 that occurred at frequencies of 11.2% and 22.2% respectively. 
Interestingly, the 2,4-1 ,2 combined genotype was the most common in the OFS=O group, 
but was absent in OFS~1,2,3,4 groups, while the 1,2-1,2 combined genotype was increased 
in these groups compared to the OFS=O group. 
Ava 1-Alu 1-Taq/ combi11ed ge11otype 
The most common combined genotype in controls was 1,1-1,1-1,1 that occurred at 
a frequency of 25.6%. The most common combined genotype in the total patient, mild, 
severe, OFS=O, OFS~1. OFS~. OFS~3, OFS~4. alcoholic, idiopathic and gallstone 
groups was 1 ,2-1,2-1, 1 that occurred at frequencies of 34.5%, 34.6%, 34.3%, 32.4%, 
37.8%, 31.3%, 33.3%, 33.3%, 44.4%, 31.3% and 33.3% respectively. The 1,1-1,1-1,2 
combined genotype was equally most common in the OFS~4 group occuning at a 
frequency of 33.3%. 
Mspl- VLP- VNTR86 -Sspl combi11ed ge11otype 
The most common combined genotype in controls was 1,1-2,2-1,1-1,1 occurring at 
a frequency of 42.2%. This was also the most common combined genotype in the total 
patient, mild, severe, OFS=O, OFS~1, OFS~. OFS~3. OFS~4, alcoholic, idiopathic and 
gallstone groups occuning at frequencies of 53.9%, 46.8%, 69.4%, 49.3%, 60.9%, 63.6%, 
68.4%, 66.7%, 44.4%, 66.7% and 50.0% respectively. The 1,2-2,3-1,2-1,2 combined 
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genotype was equally most common in the alcoholic group occurring at a frequency of 
44.4%. 
Pstl-(AC)n-VNTlt6 combined genotype 
The most common combined genotypes in the controls were 1,2-1,4-1,1, 2,2-1,2-
1,2 and 2,2-1,4-1,1 that occurred at a frequency of 6.7%. The most common combined 
genotype in the total patient, severe, OFS~1. OFS~2, OFS~3, OFS~4, idiopathic and 
gallstone groups was 1,2-1,2-1,2 that occurred at frequencies of 8.8%, 13.9%, 17.4%, 
18.2%, 26.3%, 25.0%, 15.2% and 11.1% respectively. The 2,2-1,2-1,2 combination was 
equally most common in the total patient group occurring at a frequency of 8.8%, while the 
2,2-1,2-2,3 combined genotype was equally most common in the gallstone group occurring 
at a frequency of 11.1 %. The most common combined genotype in the mild, OFS=O and 
alcoholic groups was 2,2-2,4-1,2 that occurred at frequencies of 9.0%, 9.1% and 16.7% 
respectively. Interestingly, the 2,2-2,4-1,2 combined genotype was the most common in the 
OFS=O group, but was absent in OFS~1,2,3,4 groups. 
Pstl-Aval-Alul-Taql combined genotype 
The most common combined genotypes in controls were 2,2-2,2-2,2-1,1 and 2,2-
1,1-1,1-1,1 occurring at a frequency of 14.1%. The most common combined genotypes in 
the total patient, mild, severe, OFS=O, OFS~1, OFS~,OFS~3, alcoholic, idiopathic and 
gallstone groups was 2,2-1,2-1,2-1,1 that occurred at frequencies of22.3%, 23.4%, 22.9%, 
20.9%, 24.4%, 21.9%, 27.8%, 33.3%, 15.6% and 22.6% respectively. The 2,2-1,1-1,1-1,2 
combination was equally most common in the OFS~ group occurring at a frequency of 
21.9%, while the 2,2-1,1-1,1-1,2 combination was equally most common in the idiopathic 
group occurring at 15.6%. The most common combined genotype in the OFS~4 group was 
2,2-1,1-1,1-1,2 that occurred at a frequency of 25 .0%. 
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Psti-Mspl-VLP- VNTR86 -Ss pi combined genotype 
The most common combined genotype in controls was 2,2-1,1-2,2-1,1-1,1 that 
occurred at a frequency of 21.3%. The most common combined genotype in the total 
patient, mild, severe, OFS=O, OFS~1. OFS~2. OFS~3. OFS~4. idiopathic and gallstone 
groups was 2,2-I,1-2,2-I,I-I,1 occurring at a frequencies of34.2%, 29.5%, 47.2%, 32.4%, 
41.3%, 45.5%, 47.4%, 58.3%, 39.4% and 38.1% respectively. The most common 
combined genotype in alcoholics was 2,2-I,2-2,3-I,2-I,2 that occurred at a frequency of 
27.8%. 
(AC)11-VNTr6-Aval-Aiul-Taql combined genotype 
The most common combined genotype in controls was 1 ,4-I, I-I, I-I, 1-1 ,2 that 
occurred at a frequency of 6.3%. The most common combined genotype in the total 
patient, mild, severe, OFS=O, OFS~, OFS~3 and idiopathic groups was 1,2-1 ,2-1 ,2-1 ,2-
I,2 that occurred at frequencies of 7.1%, 6.4%, 8.6%, 5.9%, 12.5%, 16.7% and 9.4% 
respectively. The I ,4-I, 1-1, 1-I, I-I,2 and 2,4-I ,2-I ,2-I ,2-1, 1 combinations were equally 
common in the mild group occurring at a frequency of 6.4%. The 1 ,2-1 ,2-1,2-1,2-1, I, I ,2-
2,3-1 ,2-I ,2-I, 1 and 1,2-1,2-1, I-I, 1-I ,2 combinations were equally most common in the 
severe group occurring at a frequency of 8.6%. The 1,4-1,1-1,1-1,1-1,2 and 2,4-1,2-1,2-
I,2-1,1 combinations were equally common in the OFS=O group occurring at a frequency 
of 5.9%. The 1,2-1,2-1,I-I,I-1,2 combination was equally as common in the idiopathic 
group occurring at a frequency of9.4%. The most common combined genotype in OFS~I 
group was 1 ,2-I ,2-1,1-1,1-1 ,2 that occurred at a frequency of 11.1 %. The most common 
combined genotype in the OFS~4 group was I ,2-1,2-1,2-1 ,2-1, I that occurred at a 
frequency of 16.7%. The most common combined genotype in the alcoholic group was 
2,4-1,2-1,2-1,2-I,I that occurred at a frequency of I6.7%. The most common combined 
genotypes in the gallstone group were I,2-I,2-I,2-1,2-1,1, 1,4-1,1-1,1-1,1-1,2 and 1,2-2,3-
1 ,2-1,2-1, 1 that occurred at a frequency of 6.3%. Interestingly, the 2,4-1,2-1,2-1,2-1, I 
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combined genotype was the most common in the OFS=O group, but was absent in 
OFS~1,2,3,4 groups. 
(A C)n-VNTR46 -Mspl-VLP-VNTR86 -Sspl combined genotype 
The most common combined genotype in the controls was 1,4-1,1-1,1-2,2-l,l-l,1 
that occurred at a frequency of 8.5%. The most common combined genotype in the total 
patient, OFS~3. OFS~4 and gallstone group was 1,2-1,2-1,2-2,3-1,2-1,2 that occurred at 
frequencies of 8.7%, 15.8%, 25.0% and 9.4% respectively. The 1,2-1,2-1,1-2,2-1,1-1,1 
combination was equally common in the total patient group occurring at a frequency of 
8.7%, while the 1,2-1,2-1,1-2,2-1,1-1,1 combination was equally most common in the 
OFS~3 group occurring at a frequency of 15.8%. The most common combined genotype in 
the mild, OFS=O and alcoholic groups was 2,4-1,2-1,2-2,3-1,2-1,2 that occurred at 
frequencies of 8.9%, 8. 7% and 22.2% respectively. The most common combined genotype 
in the severe, OFS~1. OFS~ and idiopathic groups was 1,2-1,2-1,1-2,2-1,1-l,l that 
occurred at frequencies of 13.9%, 19.6%, 21.2% and 15.2% respectively. Interestingly, the 
2,4-1,2-1,2-2,3-1,2-1,2 combined genotype was the most common in the OFS=O group, but 
was absent in OFS~1,2,3,4 groups. 
Aval-Alul-Taql-Mspl- VLP-VNTR86 -Sspl combined genotype 
The most common combined genotype in controls was 1,1-1,1-1,1-1,1-2,2-1,1-1,1 
that occurred at a frequency of 12.5%. The most common combined genotype in the total 
patient, mild, OFS=O, alcoholic and gallstone groups was 1,2-1,2-1,1-1 ,2-2,3-1,2-1 ,2 that 
occurred at frequencies of 16.8%, 16.7%, 14.7%, 22.2% and 19.0% respectively. The 1,1-
1,1-1,1-1,1-2,2-1,1-1,1 combination was equally common in the OFS=O group occurring at 
a frequency of 14.7%. The most common combined genotype in the severe, OFS~l, 
OFS~. OFS~4 and idiopathic groups was I, 1-1,1-1,2-1,1-2,2-1,1-1, I that occurred at 
frequencies of 20.0%, 24.4%, 21.9%, 25.0% and 25.0% respectively. The most common 
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Investigation of the Interleukin Gene Cluster and Its 
Association with Acute Pancreatitis 
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Summary: The interleukin I (IL-l) gene cluster has been im-
plicated in acute pancreatitis. Penta-allelic and bi-allelic poly-
morphisms exist in the IL-IRN and IL-IB genes. respectively. 
The aim of the study was to investigate these polymorphisms in 
acute pancreatitis. Genotype and allele frequencies were deter-
mined in patients (11 = 116) and healthy controls (11 = 170) 
using the polymerase chain reaction. PCR products from the 
IL-l B study were further digested with Taq I restriction endo-
nuclease. Patients were categorised according to aetiology. se-
verity. and organ-failure scores. Allele I of the IL-l RN poly-
morphism was significantly increased in patients compared 
with controls (72.0 vs. 63.0%; p = 0.029. Pc = 0.029). in 
severe cases compared with controls (81.9 vs. 63.0%; p = 
0.002. Pc = 0.004), in idiopathies compared with controls 
Acute pancreatitis is a relatively common disease with 
an annual incidence of 10-20 cases per 100,000 popula-
tion in the Western world (I). The majority of cases are 
alcohol related or due to gallstones. Whatever the cause. 
the innammatory process is triggered by ectopic intra-
pancreatic protease activation, and the disease then pro-
gresses in three phases: local innammation of the pan-
creas, a systemic innammatory response that can result 
in an organ or multiple organ failure. and finally the 
intervention of infection by translocation of bacteria 
from the gut (2). The local inllammatory response is 
amplified by changes in the microcirculation to increase 
penneability. which together with activation of leuko-
cytes leads to migration of polymorphonuclear granulo-
cytcs into the interstitium of the pancreas. A number of 
cvtokines arc known to regulate thfs local inllammatory 
I"C.\j1011S~. the lllOSI prominent hcin~ llllllOlll" llCCI"OSiS f~ll'· 
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(82.4 vs. 6J.Ofk.; I' = 0.002, Pc = 0.006). and in severe cases 
compared with mild cases (81.9 vs. 67.5%; t> = 0.023. Pc = 
0.046). Allele 2 was significantly decreased in severe cases 
compared with controls (18.1 vs. 33.0%; p = 0.013. Pc = 
0.026). in idiopathies compared with controls 117.6 vs. JJCk: I' 
= 0.0 I J. Pc = 0.039). and in severe cases compared with mild 
cases ( 18.1 vs. 32.5'7o; p = 0.023, Pc = 0.046). No significant 
differences were found for the Taq I allele or genotype fre-
quencies between controls and patients/subgroups or patients. 
IL-l RN appears to determine severity of acute pancreatitis and 
susccplibilily lo idiopalhic acule pancremilis. No associalinn 
was found between IL-l B and the disease. Key Words: Inter· 
lcukin-1 receptor antagonist (IL-l ra)-lnterleukin 1(3 (IL-
1(3)-I'olymorphism-Acute pancreatitis. 
tor alpha (TNFa), interleukin I (IL-l), and interleukin I 0 
(IL-10) (3,4). If there is an upregulated and inappropriate 
response to the initial injury, then the systemic intlam· 
matory response syndrome (SIRS) will supervene. The 
systemic manifestations are responsible for the majority 
of pancreatitis-associated morbidity and mortality and 
are due to the actions of specific innammatory cytokines. 
lt has been suggested that the clinical course of an acute 
inllanunatnry illness such as acute pancreatitis may have 
a genetic hasis because certain genetic cytokine poly-
rnorphisms may operate functional differences and hence 
the llutclllllC of the inllmnmatnry process (5). 
11.-1 and ll_-1-rcceptor antagonist (IL-Ira) arc mem· 
hers llf the IL-l gene cluster. which has hcen map11ed '" 
a 4:10-kb stretch of DNA on the Ion~ ann nf ht1111;111 
rhronwsome 2 (2ql:l-q21) (6.7). IL-l has twll ft~nm. 
IL-Io (encoded by IL-IA) and IL-IJ) kncmlc:d hv 11. 
I 11). which share a wide variety ol· hiolt~giL· "'·tiL·ities th:11 
<liT both immunologic k.g .. regulating prolife-ration ut" l 
;md 11 l'L'II!') and nonimmunnlog&c (L'.~·- rq!tdtning rol 
l:1g~n sy11thesis in fihn>hl:~sh) (.1). 11.-lra icliL'I'dcd 111 
II.-IH1\I) ai~D ha!-- lWo form~: <1 "-\..'lTl'lory t"nrlll 1 .... 11.-lr~~~ 
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produc~d by manophag~s and an intracellular form 
(iciL-ra) produced by epithelial cdls (H). IL-Ira com-
pete' with IL-l for occupancy of the IL-l cdl-surface 
rccepl<lrs. IL-l Rtl and IL·I Rill. Inn fails In initiate :m 
intracellul:u· signal. thereby acting as a competitive lll· 
hibitor of the actions of IL·I (lJ). 
11 has been suggested that an imbalance hetwecn I L· I 
and IL-l ra pr01ein levels predisposes an individual to 
disca.se (I 0,1 I). Evidence obiained from animal models 
of acute p;mcrealilis has shown that it is associalcd with 
elevated levels of IL-l. which correlate with the degree 
of pancre;uic damage ( 12). In addition. blockade of the 
cy10kine cascade at the level of the IL-l receptor using 
IL-l ra. before or soon afiCr induction of acute pancre-
atitis. inhibits the rise in the cy10kines and is associaied 
with decreased severity of pancreatitis and a reduction in 
pancreatic damage ( 13). 
Imbalances in protein levels of IL-l and IL-l ra have 
also been associated with endotoxemialsepsis ( 14 ), Lyme 
arthritis ( 15), rheumatoid arthritis ( 16), acute myeloge-
nous leukemia (17), Hodgkin's disease ( 18), and inOam-
matory bowel disease (If). Because the protein levels are 
determined by the genes that encode them, polymor-
phisms at the genetic level will result in a variation in the 
protein level. with an alteration in functional outcome. 
The IL-l genes are highly polymorphic. A bi-allelic 
polymorphism exists in the promoter region of the IL-l A 
gene and involves a C 10 T substitution. This polymor-
phism has been associated with the severity of juvenile 
rheummoid arthritis and its ocular complications ( 19). 
Similarly a bi-allelic polymorphism is known to exist in 
ex on 5 of the IL-l B gene, which involves a C to T 
substitution and which completes a Taq I restriction site. 
This polymorphism has been associated with type I dia-
betes (20). fr. addition, a polymorphism has been char-
acterised (21) in intron 2 of the IL-l RN gene in which 
there are a variable number of tandem repeal units 
(VNTR) corresponding to between two and six copies of 
an 86-base pair sequence. Associations have been found 
bel wccn this polymorphism and a variety of disc;"cs. 
Increased carriage of allele 2. in parlicular. has heeu 
linked with the severity nf type I psoriasis (22): systemic 
lupus crythenwtosus (SLE) (2J): lichen sclernsus (24 l. 
alopecia arcaw (25). and with nephropathy in diabetes 
mellitus <26). Increased carriage of the same allele als.> 
has hccn <tssociatcd with the susceptibility In certain dis-
C<tscs including ulcerative colitis (27-JO), Graves' dis-
ease (.11 ). and relapsing/remining multiple sclerosis (J2). 
The aim of this study was to investig<tle whether poly-
morphisms in the IL-l RN and IL-l B genes differentially 
affect the clinical course of acute pancreatitis. 
MATERIALS AND METIIODS 
Subjects 
After Ethical Comminee approval, 10 mL of periph-
eral blood was collected from 170 unrelated healihy 
white individuals and from 116 acute pancreatitis pa-
tients admined to Derriford Hospital in Plymouth (see 
Tables I and 2 for clinical characteristics). The patients 
were divided into groups according to aetiology (alco-
holic/idiopathic/gallstone), severity (mild/severe), and 
organ-failure score groups (OFS ~ 2, OFS ~ 3, OFS ~ 
4) according to Kingsnonh et al. (33). High-molecular-
weight DNA was prepared from all subjects using 
Nucleon DNA extraction kits (Scotlab, Coatbridge. 
U.K.). Two assays were carried out: (a) VNTR polymor-
phism of the IL-l RN gene, and (b) Taq I polymorphism 
of the IL-l B gene. 
Assays 
VNTR tmlymorplrism of the IL-l RN gene 
The variable number of tandem repeats region within 
intron 2 of the IL-l RN gene was amplified using the 
polymerase chain reaction (PCR) with the following 
primers: forward. 5'-CCC TCA GCA ACA CTC CTA 
TIG AC-3'; reverse, 5'-TCA TCTTCC TGG TCTGCA 
GOT AA-3' (MWG Biotechnology, Ebersberg, Ger-
many). 
TADLE I. Clwracteri.Hic.\· of conrro/., nnd parienrJ used in rhe IL-l RN .~ene VNTR polvmorphism srudy 
Normal AP Mild Severe A G 
comruls palienls AP AP OFS 2:2 OFS 2:) OFS 2:4 AP AP AP 
(11 = I 50)" (11 = 116)" (11 = 80) (11 = 36) (11 = JJ) (11 = 19) {11 = 12) (11 = 18) (11 = 34) (n = 64) 
Ape r>~np~: ( yr) N/A 21-86 21-86 26-78 26-84 26-78 26-76 28-62 23-84 21-86 
A'" "!!e (yr) N/A 57 54 63 64 62 61 4) 59 60 
Sex (M/Fi 77:73 53:6) )7:43 16:20 16:17 11:8 7:5 17: I 17:17 19:45 
.'\P. Antle pancrc~llilis. "·number of subjecls in each group: M. male: F. female; mild and severe disease se verily groups, m:conJing 10 the A1lan1a 
l'onvcntion dassifaca1ion: OFS. Organ-Fmlure Scores as defined by Kingsnnrlh e1 al .. 1995 ()J); A. alcoholic pam:rc;.Jtilis il daily ..:onsumption of ::::80 
g akuhol pt:r day for 6 month~: G. gallo;,toncs if radiologic or ERCP cvit.IL'm·c of cholclilhiasi~: I. idiopathic if no idcn1iriablc aeliology: NI A, age no! 
applic:Jhlc tc1 controls ""' tal\en from il h;ml. of cord blood~. 
"Ahhe~ugh I he nmlrob uml puticnt~ mC"d in the two studic ... \lr'cr~ ta~cn from I he .,amc popul:llinn\, the numhcr~ differ in cat·h ~tutly bct·ausc The 
1wo a ....... ~ ... did not nct·c..,.,arily wmJ.; for all ..;uhjects. 
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T t\ ULE 2. Clwrm:teri.'llic!i of cmrtroh mul lmlit'lll.\ u.\t•d ;, thl' IL-l /J gt'll(' Taq I polymorphism study 
Norm ill /\I' Mild Scvl'rl' A G 
cnnlrol:'ii. palicnas AP AP or-s o:2 OFS <:1 OFS 0»4 /\P AI' AP 
(11 = 170)" (11 = 114)" (11 = 78) (11 = 16) (11 = 33) (1/ = 18) (,l = 12) (rl = 18) (11 = )2) )11 = 64) 
----
1\gc r;mgc (yr) NI/\ 21-86 21-86 26-78 26-84 26-78 26-76 28-62 25-84 21-86 
Av 11gt:: (yr) NI/\ 57 54 63 lw 63 61 43 60 60 
So !M/F) 79:91 52:62 36:42 16:20 16:17 11:7 7:5 17: I 17:15 18:46 
r\P. <:~cUie pancrealitis: "·number of subjects in eilch group: M. motlc: F. female: mild and severe disease sc\·erily groups, according 10 1h~ Allanw 
l'llllvemion classilic<~lion: OFS. Organ-Failure Scores as defined by Kingsnurth t:l al.. 19~5 CJJ): A. oJkoholic pancrealitis if daily consumption of ~SO 
g alcohul per day ror 6 ltlonlhs: G. Eallslones ir rm..liologic or ERCP evidem.:e ol~cholelilhi<:~si~: I. idiopathic if no identifiable aetiology: NI A. age not 
applicable to controls ns taken from a bank of cord bloods. 
"Although the controls 1..101..1 p<llients used in the two studies were taken rrom the S;JillC populatiom.. the numbers differ in cuch study beL·ausc the 
twu ussays did not necessmily work for all subjects. 
PCR conditions consisted of 94°C for 4 minutes and 
then 30 cycles of 94°C for 30 seconds, 60°C for 2 min-
utes. and 72°C for 2 minuces. The PCR products were 
separated by electrophoresis on a 2% agarose gel, stained 
wi1h ethidium bromide, and ph01ographed to evaluate the 
presence or absence of the repeat polymorphism. 
Taq I polymorphism of the IL-l B gene 
The Taq I polymorphic site within ex on 5 of the IL-l B 
gene was amplified using the PCR with the following 
primers: forward, 5'-GAC CTG AAG CTG GAA CCC 
ATG TC-3'; reverse, 5'-CGC TCC AGC ACT CTIGTI 
TCA GC-3' (MWG Biotechnology). 
PCR conditions consisted of 94 oc for 4 minutes and 
then 30 cycles of 94°C for 30 seconds, 60°C for 2 min-
utes. and 72°C for 2 minutes. The PCR products were 
then digested with Taq I restriction endonuclease (Roche 
Diagnostic Ltd., Mannheim, Germany) at 6SOC for 3 
hours. The digestion products were analysed on a 1.5% 
agarose gel, stained with ethidium bromide. and photo-
graphed to determine whether the polymorphism was 
present. 
Statistical analysis 
The occurrence of each allele in the populations was 
expressed as a percentage of the total number of alleles 
present to give a frequency. The genotype frequency 
(i.e., the number of individuals carrying at leas1 one copy 
of a specific allele as a proportion of the total number of 
individuals) also was calculated. The / test wi1h con-
tingency lables was performed to determine the p values. 
which were !hen corrected for the number of variables 
lested (Pc). 
RESULTS 
VNTR polymorphism of the IL-lRN gene 
Only three of the five alleles reported by Tarlow et al. 
(21) were observed in this study: allele I, allele 2, and 
allele 3, corresponding to four, two, and five copies, 
respectively, of the 86-bp sequence. Five genotypes were 
detected: I, I; 1,2; 2,2; 1,3; and 2,3. The IL-l ra allelic 
and genotype frequencies are shown in Tables 3 and 4. 
I L-1 ra allelic frequencies 
The frequency of allele I was significantly increased 
in total patients compared with total controls (72.0 vs. 
63.0%; Pc = 0.029); however, the frequency of allele 3 
was found to be significantly decreased between the two 
groups (0.0 vs. 4.0%; Pc = 0.002). 
When analysing 1he patients according 10 severity, 
TABLE 3. /1_-/m allelicfr"equencieJ (%)in i><lli<'IIIJ a/1(1 wmm!J 
Normal AP 1>-111<1 Severe Alcohol tdiopmh G/stonc 
controls IMIIelll' AP /\P OFS 0»2 OFS ".1 OFS "~ AP AI' /\P 
All<le (I/ = 3!Kli )I/ = 2.\~ I Ill = 16lll ,,, = 72) (I/ = 661 I I/ = JKI 
'" 
= 2.J) (11 = .161 (I/ = 6Ki In = I~H) 
-------· ----------
61.0 no·· 67.S 81.9''' 1 77..1 K 1.1> X.1 .1 6h.7 X~..!' 68.0 
I lXI)) 111>71 ! I OXI (59) !51) t.111 1201 124) !56) (87) 
.IJ.O 1H 11 .12 5 18.1'' 11.1 IXA 11> 7 .1.U 17H .12.0 
i'IYI !65! !521 I IJI ( 151 17) 1·11 1121 1121 (411 
4.0 1111' 110'' 110 11.0 11.0 11.11 110 011 0.11 
1121 I ill I ill (()) (()) I ill ill I 101 ((I) 101 
"· mnnher ut' :dldr.:-' ll\ r.:-arll gro11p 
I':-:- (1_1129. PL· Uti21J. ··,,::: 002.\. Pl = 0.0-16: .,, = OOI.l. PL--= OOUl 
·',, = 000'2.1'L·,... 1100-1 ·,, =-: 000~. Pr = 0.1.1(1(1: 'I'= OOil. PL· ~ O.IIN 
f! = 01.102. I\· 11002. '-I' 11111. I\· ;~ 11.112 
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Nc!rlllal ,\P t\\lld S.:wrc ·\kcJIHll lditlp;cth G/,tnnc 
U1111lll\~ fl:IIIL'Ill' :\I' AP OFS ?'~ OI'S -" 1 01-S >-4 AP t\P AI' 
Gcn•''~l'h." 
'" 
~ I )ill 
'" 
= llhl 
'" 
- XIII 
'" 
= _1~) 
'" 
111 
'" 
= \l}l 
'" 
= 111 
'" 
= lXI (, = .\41 
'" 
= (c~ I 
1.1 -11.11 _)4 _ _1'' J7 .'\ lltJ.4' (JJ (l 6H.--I hfl.7 -1-l-1 h1.lt :\11.11 
16.11 16.1) L1XI 1251 ~~ 11 11.11 !HI lXI I ~-1) LL!1 
1.~ 1X 11 \) J 41Ul 2~.11 ~7 ,1 .:!h.J \1,1 4J 4 ~I}...) Jj_l} 
~~71 1411 L\~1 (~) (l)) 1)1 1-1) !XI I 1111 t:?JJ 
' ' I ~-0 111.1' 1:!.5 .'\.6 tJ.I :\J 1111 11 I :?.9'' I J.l 
11 Xi tl:?) 11111 121 t.11 ill 1111 121 ,,, ,.,, 
u 4.11 IUI 11.11 11.11 1111 Oil 1111 00 1!.11 11.0 
I hi till 1111 ill) I ill ill) 1111 ill) 1111 Ill) 
2.\ J.ll 1!.11 11.11 1!.11 11.11 11.11 11.0 11.11 11.0 11.0 
11>1 lOt ill I l{l) 1111 ill) ill I 1111 101 101 
11. m•cnhl'r of gcmnypcs in each group. 
" 1, = 11 0-1~. Pr = 0.046: 1' I' = ll 007. Pc = IJ.021: ' 1' = 0.()())_ Pr = 11.006. 
''C.:?+ 1..1 + 2..1) I' = O.ll16. Pc = ll.O.JX: ,. 12.2 + 1..1 + 2..1) 1' = O.ln2. Pr = ll.cm. 
Jhere was a significan!ly increased frequency of allele I 
(81.9 vs. 63.0%; p = 0.002, Pc = 0.004) and corre-
sponding decreased frequency of allele 2 ( 18.1 vs. 
33.0%; p = 0.013, Pc = 0.026) in the severe group 
compared with controls. The same association was found 
between the allelic frequencies of alleles I and 2 when 
comparing the severe group with the mild group (81.9 vs. 
67.5% and 18.1 vs. 32.5%; p = 0.023, Pc = 0.046). In 
addi1ion. allele 3 was found to be increased in the control 
group compared with the mild group (4.0% vs. 0.0; I' = 
0.0 I, Pc = 0.02); however, !here was no significanl 
associalion with alleles I or 2. 
There were no significanl differences be1ween !he fre-
quencies of !he alleles in comrols compared with organ-
failure score groups or in the mild group compared with 
organ-failure scores groups. 
When !he palienls were analysed according 10 aetiol-
ogy. !here was a significanl increase in !he frequency of 
allele I (82.4 vs. 63.0%; p = 0.002, Pc = 0.006), and 
corresponding decrease in !he frequency of allele 2 ( 17.6 
vs. 33.0%; p = 0.0 13, Pc = 0.039) in !he idiopalhic 
group of patients compared wilh controls; however, !here 
was no associalion wilh any olher aeliologic group and 
1he allcles. 
1/_.f m genolype frequencies 
The frequency of !he 1.1 gen01ype was found 10 be 
increased in !he lolal palienl group compared wilh !he 
lo!UI conlrol group (54.3 vs 42.0%; Pc = 0.046). 
whereas !he 2,2; I ,3; and 2,3 gen01ypes were found 10 be 
decreased beiween !he 1wo groups (I 0.3 vs. 20.0%; Pc = 
0032) 
When palienls were calcgorised according 10 scverily. 
1hcrc w;" a significamly increased frequency of ihe 1.1 
gcnolypc in !he severe group compared with the commis 
((>lJA vs. 42.0o/c; I' = 0.003. Pc = 0.006); however. no 
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genolype assoctalton was found when comparing !he 
mild group wilh !he severe group, con1rols wilh organ-
failure score groups, or !he mild group wilh !he organ-
failure score groups. 
When patienls were categorised according to aeliol-
ogy, !here was an increased frequency in the I, I geno-
lype (67.6 vs. 42.0%; p = 0.007, Pc = 0.021) and 
decreased frequency in !he 2,2; I ,3;2,3 gen01ypes (2.9 vs. 
20.0%; p = 0.016, Pc = 0.048) in idiopalhics compared 
wilh controls; however, 1here was no gen01ype associa-
lion wilh any other aetiologic group. 
Taq I polymorphism of the I L-IB gene 
Two allcles (I and 2) and ihree genotypes (I, I; I ,2; 
and 2,2) were observed in !his swdy. 
No significant differences were found bel\veen the 
Taq I allelic or gen01ype frequencies in acute pancreatitis 
palients and normal conlrols or belween subdivisions of 
!he palienl group. The Taq I allelic and genotype fre-
quencies are shown in Tables 5 and 6. 
DISCUSSION 
We describe here an associalion be!ween ihe VNTR 
polymorphism in imron 2 of !he IL-l RN gene and aculc 
pancreatilis. Only ihree of !he five alleles of !he poly-
morphism were deJecJed in !his s!Udy. According 10 Tar-
low cl al. (21 ), !he sum 1o1al of allcles 3, 4, and S ac-
counls for only 4% of !he to! a I allele frequency in a given 
population; therefore, for us 10 delecl !he rarer geno-
lypes. more subjec1s must be s!Udied. Our daw show 
significanl differences in boih allele and genolype fre-
quencies beiween the groups. Allele I (4 x 86-bp repeal 
allele) was signilicamly increased in palients compared 
with conlrols. in severe cases compared wilh conirols. in 
idinpalhic p:uicms compared with conlrols. and in severe 
cases compared with mild cases. In addilion, allele 2 (2 
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TAilLE 5. Taq I alll•lic .fi·c·qm•m·ieJ (,.k} iiiJWiil'lll.\ am/ etmtro/J 
Nurmul AP Mild Scv~r~ Alcnhol G/\IOIIC: 
c:onlrnls palicm~ AI' AP OFS <:2 OFS <:_1 OFS "=4 AP 
hJiupulh 
AP AI' 
Allele (n = _140) (n = 22R) ,, =: 156) (n = 72) 
'" 
= 0(1) 
'" 
= _16) (11 = 24) (n = .161 ''' = (H) (u = I~K) 
-~-~-
RJ.2 80.7 
(28_1) ( 184) 
2 16.8 19.) 
(57) (44) 
Alii' value!>. were nonsignificant 
''· number of allelcs in each group. 
82.7 76.4 
1129) (\51 
17.) 2.1.6 
(271 ( 17) 
x 86-bp repent allele) was found to be significantly de-
creased in severe cases compared with controls, in idio-
pathies compared with controls, and in severe cases com-
pared with mild cases. The 1,1 genotype was found to be 
significantly increased in patients compared with con-
trols, in severe cases compared with controls, and in 
idiopathies compared with controls. whereas the 2,2; 1,3; 
and 2.3 genotypes were significantly decreased in pa-
tients compared with controls and in idiopathies com-
pared with controls. These results suggest that the IL-
l RN gene could act as both a genetic marker for the 
severity of acute pancreatitis and a susceptibility marker 
for the idiopathic group. 
It has been reported that each 86-bp repeat unit of the 
VNTR polymorphism comprises three protein-binding 
sites: an Cl-interferon silencer A, a 13-interferon silencer 
B, and an acute-phase response element. These binding 
sites are believed to control IL-l ra transcription either by 
acting as promoter elements or by innuencing the splic-
ing efficiency of the IL-l ra transcripts. Individuals with 
different numbers of the repeat sequences have different 
numbers of the transcription binding sites, and this could 
have functional significance (i.e., the more repeats, the 
more protein binding sites and the more protein is pro-
duced). Allele 2 homozygotes who have 2 x 86-bp re-
peats might have reduced levels of IL-l ra m RNA and 
protein compared with allele I homozygotes who have 
4x86bp repeats (21 ). 
As previously mentioned. increased frequency of al-
74.2 
(491 
25.8 
( 17) 
75.0 70.R R6.1 78. I 80.5 
127 I ( 17) {_11) (\0) (10_1) 
25.0 29.2 IJ.9 11.9 19.5 
(9) (7) (51 ( 14) (2.11 
lcle 2 of this polymorphism has been found to be a ge-
netic marker of severity in alopecia areata, SLE. lichen 
sclerosus. and type I psoriasis, and a susceptibility 
marker for ulcerative colitis, relapsing/remitting multiple 
sclerosis, and Graves' disease. The majority of these in-
nammatory conditions are of epithelial origin. Because 
keratinocytes do not produce secretory IL-l ra (siL-l ra). 
the results obtained in these studies ;tre probably due to 
the intracellular form of IL-Irn (iclL-Irn). There has, 
however, been a lack of associalion between allele 2 of 
the polymorphism and susceptibility to nonepithelial 
conditions such as rheumatoid arthritis (25) and Crohn's 
disease (28), which are thought to involve siL-Ira. Al-
though both forms of the antagonist are produced by the 
same gene. they have different structures (iciL-1 ra lacks 
a leader sequence), so their processing may be regulated 
differently. Acute pancreatitis may also fall into the same 
category as rheumatoid arthritis and Crohn's disease be-
cause macrophages, a source of siL-l ra, are known to 
migrate into the pancreas early in the course of the dis-
ease. 
Information regarding an association between geno-
type and functional protein levels is connicting. Tarlow 
et al. (21) have suggested that allele 2 corresponds to low 
IL-l ra protein levels; however, Danis et al. (34) have 
found the reverse. If allele 2 does correspond to high 
IL-l ra secretion, as suggested by Danis et al., then allele 
I may correspond to low I L-1 ra secretion. This hypoth-
esis has been supported by data from Mandrup-Poulscn 
TA BI.E 6. Taq I gennrype ,li-ettm•nne_, t'"h I i11 fJtllit•ul\ mu/ nmtrol.\· 
Norm;ll AI' Mil~ Scv~re Aknhtll h..llttpath GJ~ttlllt' 
nmtrol., p;lliL:IIb AP AI' OFS ~! OFS .:.::.1 OFS 2:.:l AP ,,p AI' 
Cit'IHIIYill' 
'" 
= I 101 
'" 
= I 1-lJ 
'" 
= 7XJ (n = _1~1 
'" " 
li) 
'" 
= lXI 
'" 
= I~ I 
'" 
= lXI 
'" 
= _1~) 
'" 
= (,1) 
-----
1.1 h7.(1 (l l_! . 66.7 55.6 -1:-i 5 )0.0 .j 1.7 71.2 )(l ,l ll'l I 
ill.') 1721 ()~) ( 211) tlh) tlJI ()I (I_., ti:-:J 1-l" 
1.2 
·' 1.2 .1.'\ I .\1.1 ~1.7 51 \ ")() 11 :'iX.J ?7!-i -l.\ X _\!.X 
t5J) i-ll)) tJ)J 1151 (I] I t')J ill (:\1 1\-1) 1211 
' ' 
1.2 IX I.J !.X ()11 1111 ll.ll 11.0 1111 ,1 I 
12) I! I ill ill till ill( ill) (()I till I 21 
-------
-------
t\llf' \;lhlt'' \\l:ll' lltllhl!,!lllll\,,'.1111 
"· 
lllltllht•r nl ~t·notypt·, -,11 t';arh :••nup 
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cl al.(.~)). who have ftn111d th;ll the 1.1 ~elltlt)'pt: i~ 
associ;ucd with low pla'lna 11.-lra kvcl' ill type· I dia-
betes. Th~ rcsull~ obtained in our study suggc!'t that al-
lele 1 is as~ocicllcd with incrca~cU ~cverity in acu1c pan-
crcalilis hccansc of a rcd11ccd produe1ion of I L-Ira a11d 
inability 10 cmu11erac1 the ae1io11 of IL-l_ Whether allele 
1 corrc~pnnds 10 a high or low 'ccrctory phc11o1ypc will 
not be kllOWil Ulltil funnion;tl 'iudics arc carried ou1. 
These cxpcrimems will involve the in vitro stimulalion 
of monocyte cell cullurcs obwincd from acute pallcreali-
tis patients and quantiflc;uion of protein levels by tech-
niques such as Western binning_ 
The IL-l RN gene may have functional significance on 
its own, or it may be in linkage with other genes. Possible 
candidates are IL-l A, IL-l B. and IL-l Rtl, which share 
the same gene complex on the long arm of chromosome 
2 and which have previously been linked with disease. 
Analysis of lhe Taq I polymorphism in exon 5 of lhe 
IL-l B gene has found no signiflcam differences between 
patients and controls; however, other polymorphic re-
gions exist within this gene. and these must be studied 
before this gene can be eliminated. In conclusion, to our 
knowledge, this is the first repon of an association be-
tween the IL-l gene cluster and acute pancreatitis. 
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lnvestig•tion o' the IL-l ,eae cluster IDd its usoci•tion with •cute pucre~titis 
A. M. Smithi~s. K. Sargm. A, G, Demaine, A. N. Kingmorth 
Departments Molecular Medicine and Surgery, Plymouth Postgraduate Medial 
School, Plymouth PL4 8AA. UK · 
Recent studies have implicated the IL-l gene ~luster in acute pancreatitis, an 
inflammatory condition of the pancreas. A peo~-allelic polymorphism is known to 
exist in intron 2 of the D..- I ra gene in which there arc 1 variable number of tandem 
repeat units each 86bp long. In addition. 1 biallelic palymorphlsm is presenl in exon 
S of the IL-IP gene whicb involves aCto T substitution. The aim of this study wu 
to investigate these polymorphisms in acute pancrea.titis. The genocypc and allele 
frequencies were determined in patients (o~I2S) and bcalthy controls (n-1 SO) using 
the polymerase chain reaction. Patients were categorised according to aetiology 
(alcohol, idiopathic, gallstone), severity (mildfsevcrc) and organ failure scores 
(OFS~>2, OFS~J. O,FS~4). There was an increased frequency of allele I of the IL-
lra polymorphism in idiopathies compared to controls (82.4% vs 63%, p<O.OI). No 
association was found with any other aetiological group. The frequency of allele I 
was also significantly increased in severe cases compared to mild cases (81.~/, vs 
68.2%, p<O.O.S), however, the increase did nOI correspond to the Or-gan failure 
scores. IL-l ra may determine severity of acute pancreatitis and susceptibility to 
idiopathic acute pancreatitis. No association was foWid between IL-l P and the 
disease. 
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Association between the IL-1 Gene Cluster and Acute 
Pancreatitis 
A.M. Smithies•. A. G. Demaine•. A.N. Kingsnorth" 
Departmenls of • Molecular Medicine and" Surgery, Poslgradualc 
Medical School, Universily of Plymoulh. UK 
Introduction: The IL-l (inlerleukin-1) gene clus1cr has been implicalcd 1n. 
acule pancrealilis. Bi-allclic polymorph isms e~isl in I he IL-l 8 and IL-l RII 
genes which eilher generale or dcslroy restriction endonuclease si1es (Tagl. 
Aval. Alul, Psll). 
Aim: The aim of the study was to investigate these polymorphisms in acute 
pancrea1 it is. 
Method: The genotype and allele frequencies were determined in pa1ien1s (n = 
114) and heallhy controls (n = 170) using the polymerase chain reaction, fol-
lowed by digestion with I he appropriate restriction endonuclease. Patienls were 
categorised according to etiology, severity and organ failure scores. 
Results: llr I 8: There were no significant differences in the allele frequencies 
between controls and patients/subgroups of patients, however, the Alu I 2,2 
genotype and Ava I 2,2 genotype was significantly decreased in patients vs con-
trols (9.7% vs 19.5%: pc= 0.018 and 9.6% vs 18.0%, pc= 0.03 respectively). 
No other significant differences were found. IL-l Rtl: Allele I was significantly 
decreased and allele 2 significantly increased in patients vs controls (21.3% vs 
28.7%, pc= 0.037 and 78.7% vs 71.3%, pc= 0.037 respectively). No other 
significant differences were found. 
Conclusion: Si-allelic polymorph isms in the Ilr I 8 and llr I Rtl genes appear 
to be associaled wilh susceptibility to acute pancreatitis, bul nol wilh severily 
oflhe disease. 
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TRYPSINOGEi\ GENE MUTATIONS IN .4.LCOIIOLIC A.'\0 
IDIOPATHIC CHRONIC PA.'iCREA TITIS. 
D.A Q'~clilxl). B.M. Ycng 1• A.M. Sm1th1c~l. J.E. Crcightonl, A.G 
Dcrn.ainc' A.N Kin2snonh 1. Ocpanmcnu or 1 S~cry, 1Mokcular 
Medicine, Dcrri ford Hos;:>it.al. Pl)mouth and Dcpmmcnt or 
Suraery, Freeman Ho,;:iul, t\c· .. •cJ..Stlc, U.K. 
Bacqrou nd: Mu~.aliom of the trypsinogen ~:ene ha vc been 
identified in pattenu with hcrtditlt) pancreatitis. A mutau.:>n in 
exon ) (R 117H) produc~ an Arg (CGC) to His (CAC) sub~tirut;on 
rtlulting in an inactivation-resisuntti)7Sin. Aim: To investigate the 
relevance of thts mutation in patienu with alcoholic and idiopathic 
chronic pU~crutitis (CP). Methods: DNA wu extracted from blood 
samples of 27 paticnu with al.:oholic CP. ll with idiormhic CP. 21) 
a.lcoholiu without p&ncreuitl• u:d 20 nomul controls. The R 117H 
mutation wu ·examined by restf.ction ondonucleuc (Ail Ill) 
diaution of polymcre.se chain r:IICtion amplification products. 
RauiiJ: The R 111H mutation wu ckt«:tcd in 2 of the alcoholic CP 
pat.ienu. 1t wu not dct«:tc4 in the idiopathic CP group or in the 
controls. Coacluslona: 1lili is the first reported ft.nding of a 
trypsinogen ~ne mut.ation in alcoholic CP. The prevalence of this 
muution should be de1ennin.ed and the need to screen this ~up of 
patients llld their famiiics LUe~. 
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Association of the IL-IA Cene and Susccplihilily 
lo and Scn:rily or A rule l'anrrealilis 
A M Smithies,;\ (; /Jemnine. A N h'ingsnnrth 
lh·f'III'/IIIC'II/1" o( /l·lofC'C·IIIur Mc·dicilll' Ullcl SlltXI'IT. 
l'w1gl'(l(lllttlc' Ml'llicul Sc1utol. l'lnllolllh. UK 
lntrodurtion.l{eccnt studio:~ h;11·c 1n1plic;ncd the ll.-1 gene 
clu,ln in acute pancreatitis. 1\n ( 1\C)II rcpe;ll and variahlc 
lllllnh..:r 111' liiiH.km repeat ( VNTI{ l polymorphism exist within 
1111rons .'i and (J of the IL-11\ g..:nc. 
Aims. The <lilll of this study w;1s to i111-cstiga1e these poly-
mPrphisms in a<:llle pancre;ll it is. 
1'1'1 cl hods. Genotype and a lie le frequen<: ies were detcrm i nl'll 
in patients (11 = 1.16) and healthy controls (11 = IX7) using the 
polymerase chain rea<:! ion. Patients were categori1.cd acu tnl-
ing to etiology (alcoholic. idiop;llhic. gallstone) severity 
!mild/severe), and organ failure scores (01-S ~ 2. OFS ~ J. 
or:s ~ 41. 
Results. (1\C)n repeal study: ;dlde -1 was .~ignifil'ilntly 
d..:cn:a.,ed in ~even: pati~ills l'lllnp;n·<·d 10 mild patients l7.1J'ir 
1·s. 20.7';1. l'c = 0.02..JJ ;1nd in Ill'S> 2 patienh Cllmpared Ill 
1nild patient~ (7.1 'lr vs. ~0. 7'1t. I'L· = ll.tl.li. The 2.4 )!l'nlll)')l<' 
,,.,,, 'i!!nificantly incrca,nl in all'nhnlil·~ l·omparcd Ill Clllllr"l' 
1 .1.1 . .\'t, ''· 12.0'/,. Pc= 0.0.11 ;n1d d<'lTL'it'L'd in )!idlslltn<.: nun-
pared to aknholics ( 7.)'/, ,.,_ .1.1.Y;I. Pc= 0.006). In addition. 
the 1.2 genotype was signilicantly increased in OFS ~ 2 com-
pared wi I h controls ( 45. 7'/f I'S. 2.1 .. Yk. P<: = 0.024 ). V NTR study: 
nosignili<:ant dillerenc..:s in allele or genntype frequencies were 
found between controls ;uu.J patients or subgroups of pi!li..:nh. 
Condusions. The CACln repeal polymorphism of lhr 
IL-IA gene is associated with susceplihilily lo and severity 
or acule pancrealilis. 
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ln,,·,tig;tliton ur Tryp.,inug1·n I ;,·tu· J\lulalion~ 
in l'alil'nl.' wilh ('hronir l'atll'l'l'alili~ 
/1 l£111g 1, /) O'Ueilly' ·' ... 1 .\111ithicx' . 
./ Cright1111 1, A /Je111ninl< ,\ A'ing.Hwrth 1 
Mult'!'lil/11' Ml'tlicinc Rt'.\'£'cm1t (;I'I>IIJI1 1 (///tl Oc'fiCII'IIIII'I/1 
n( S"':t.:en·-'. PPMS. Ullit't'r.\lt\ nfl'lnllouth. UK 
Mutation~ of the trypsinogen gene have been identirted in 
patients with hereditary pancreatitis (HP). A mutation in exon 
J (R 117H) produces an Arg (CGC) to His (CAC) substitution 
resulting in an inactivation resislanttrypsinogen. Furthermore. 
neutral single C toT transilions in exons 4 and 5 at position 
I JJ807 and 134359, respectively. were also identified in the 
trypsinogen gene. The aim is to investigate the relevance of the 
RI 17 Hand the polymorphisms in ex on 4 in patienls with chronic 
pancreatitis (CP). DNA was extracted from blood samples of 
.\.~patient~ with alcoholic CP. I.\ with idiopathic CP. 20 alco-
holic control~. and .18 normal control~ (NC). The R 117H mula· 
· 1 ion w a~ ex a 111 i ned by rest ricl ion endonuclease (Ajllll) d i ges1 ion 
of polymerase chain reaction ( PCR l products and the positive 
~a1nplcs were confirmed hy direct sequencing. Direct scquenc-
ing of the PCR produCis was used to detect polymorphism in 
e.xon4. The R 1171-1 mutation was dett::ctcd in I of the alcoholic 
CP patit::tlls. The allelic frequency oft heT oi'C( 1.\J807)T poly-
ntorphism was 0.52 (NCl and 0.29 (CPl. The allelic frequen-
l·ie~ between CP and NC was signil.tcant (X~ =6.28. f1 < 0.02). 
Thi~ is first report ul' a R 1171-l mutation in alcoholic CP. Fur-
ther studic~ arc now required to l'lucidatL' these polymorphisms 
in chronic pancreatitis. 
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POL YMORPHlSMS IN THE IL-l RN GENE ARE ASSOCIATED 
WITH SUSCEPTiBILITY TO IDIOPATHIC ACUTE 
PANCREATITIS AND WITH SEVERITY OF TilE DISEASE. 
A.M. Smithies1 A.G. Demaine 1• A.N. Kingsnorth2. Departments of 
Molecular Medicine 1 and Surgery2, Postgraduate Medical School, 
Plymouth, UK. 
The IL-l (interleukin-1) gene cluster has been implicated in acute 
pancreatitis. Mspl, variable length (VLP) and Sspl polymorphisms 
exist within exon I, introns 2 and J respectively of the IL-l RN 
gene. The aim was to investigate these polymorphisms in acute 
pancreatitis. Genotype and allele frequencies were determined in 
patients (n= 136) and controls (n=I49) using DNA amplification and 
digestion with the appropriate enzyme. Patients were catego,.:~ed 
according to severity, organ failure scores and aetiology. Mspl and 
Sspl loci: The I ,I genotype was significantly increased in the 
severe group compared to controls (70.3% vs 47.7%, p=0.014 and 
70.3% vs 46.2%, p=0.009 respectively). Allele I was significantly 
increased in the severe group compared to controls (82.4% vs 
69.5%, p'""0.026 and 82.4% vs 69.3% p=0.025 respectively) and in 
the idiopathic group compared to controls (81.9% vs 69.5%, 
p=0.034 and 81.9% vs 69.3%, p=O.OJ3 respectively). VLP locus: 
The 2,2 genotype frequency was significantly increased in the 
severe group compared to controls (70.3% vs 42.5%, p=0.002) and 
in the idiopathic group compared to controls (66.7% vs 42.5%, 
p=0.009), and . this was reflected in the allelic frequencies. 
Polymorphisms in the IL-l RN gene are . assoc:ated with 
susceptibility to idiopathic acute pancreatitis and with severity of 
the disease. 
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